Any feedback?
Information on EC 2.7.11.22 - cyclin-dependent kinase
for references in articles please use BRENDA:EC2.7.11.22Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.7.11.22 cyclin-dependent kinaseIUBMB Comments
Activation of cyclin-dependent kinases requires association of the enzyme with a regulatory subunit referred to as a cyclin. It is the sequential activation and inactivation of cyclin-dependent kinases, through the periodic synthesis and destruction of cyclins, that provides the primary means of cell-cycle regulation.
Specify your search results
Word Map
- 2.7.11.22
- cyclins
- p27kip1
- retinoblastoma
-
mitosis
-
cell-cycle
-
checkpoint
- histone
- tumorigenesis
- tumour
- bcl-2
- p16ink4a
-
s-phase
-
hyperphosphorylation
- leukemia
- prostate
- chromatin
- epidermal
-
exit
-
antiproliferative
- mapks
- caspase-3
-
mitogen
- tau
- xenopus
- spindle
- c-myc
-
interphase
-
quiescent
- oocyte
- pcna
-
fission
- alzheimer
- proteasome
- microtubule
- analysis
- medicine
- cdc25c
- pharmacology
- letrozole
-
cycle-dependent
-
polo-like
- chk1
-
p53-independent
- drug development
-
cytokinesis
- centrosome
-
prophase
-
postmitotic
-
receptor-positive
-
cycle-related
-
anaphase
-
aurora
-
metaphase
-
her2-negative
The enzyme appears in viruses and cellular organisms
Reaction Schemes
+
a [protein]-(L-serine/L-threonine)
=
+
a [protein]-(L-serine/L-threonine) phosphate
Synonyms
cyclin-dependent kinase, cdk, p34cdc2, cdkl5, cdc2 kinase, cyclin-dependent kinase 5, cyclin-dependent kinase 2, cdc28, cyclin-dependent kinase 4, cyclin-dependent kinase 1, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
Cyclin-dependent kinase pef1
-
-
-
-
PHO85 homolog
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
phospho group transfer
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
ATP:cyclin phosphotransferase
Activation of cyclin-dependent kinases requires association of the enzyme with a regulatory subunit referred to as a cyclin. It is the sequential activation and inactivation of cyclin-dependent kinases, through the periodic synthesis and destruction of cyclins, that provides the primary means of cell-cycle regulation.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
150428-23-2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
additional information
?
-
CDK4 amplification might contribute to oncogenesis
-
-
?
additional information
?
-
-
CDK4 amplification might contribute to oncogenesis
-
-
?
additional information
?
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
?
additional information
?
-
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
?
additional information
?
-
CDK4 gene is a melanoma-predisposing gene
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
additional information
?
-
CDK4 amplification might contribute to oncogenesis
-
-
?
additional information
?
-
-
CDK4 amplification might contribute to oncogenesis
-
-
?
additional information
?
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
?
additional information
?
-
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
?
additional information
?
-
CDK4 gene is a melanoma-predisposing gene
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
-
4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]-N-(2-methoxyethyl)benzenesulfonamide
-
4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide
-
4-[(4-imidazo[1,2-b]pyridazin-3-ylpyrimidin-2-yl)amino]-N-methylbenzenesulfonamide
-
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(4-[[3-(1,3-oxazetidin-3-yl)propyl]sulfonyl]phenyl)pyrimidin-2-amine
-
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
-
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(propylsulfonyl)phenyl]pyrimidin-2-amine
-
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl]pyrimidin-2-amine
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)-N-methylbenzenesulfonamide
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-[3-(1-methylethoxy)propyl]benzenesulfonamide
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
-
4-[[4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
4-[[4-(1-cyclopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
-
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(2-methylpropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
-
N-(2-methoxyethyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
-
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-amine
-
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
-
N-[2-(1-aminohydrazino)ethyl]-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
-
N-[2-(dimethylamino)ethyl]-4-[(4-imidazo[1,2-b]pyridazin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide
-
N-[4-(benzylsulfonyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
-
N-[4-[(2-methoxyethyl)sulfonyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
GPR68 Contributes to Persistent Acidosis-Induced Activation of AGC Kinases and Tyrosine Phosphorylation in Organotypic Hippocampal Slices.
Acquired Immunodeficiency Syndrome
Characterization of isoform diversity among smooth muscle and nonmuscle myosin heavy chains.
Acquired Immunodeficiency Syndrome
Emerging Roles for Ciz1 in Cell Cycle Regulation and as a Driver of Tumorigenesis.
Acquired Immunodeficiency Syndrome
Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.
Acquired Immunodeficiency Syndrome
miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
Acquired Immunodeficiency Syndrome
Role of Cdc42p in pheromone-stimulated signal transduction in Saccharomyces cerevisiae.
Acute Kidney Injury
Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure.
Acute Kidney Injury
Cyclin-dependent kinase inhibitor p18INK4c is involved in protective roles of heme oxygenase-1 in cisplatin-induced acute kidney injury.
Acute Kidney Injury
Lack of a functional p21WAF1/CIP1 gene accelerates caspase-independent apoptosis induced by cisplatin in renal cells.
Acute Kidney Injury
Overexpression of p18INK?C in LLC-PK1 cells increases resistance to cisplatin-induced apoptosis.
Acute Kidney Injury
Role of the increase in p21 in cisplatin-induced acute renal failure in rats.
Acute Radiation Syndrome
Blocking cyclin-dependent kinase 4/6 during single dose vs. fractionated radiation therapy leads to opposite effects on acute gastrointestinal toxicity in mice.
Adenocarcinoma
Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.
Adenocarcinoma
Antiproliferative activity of the dietary isothiocyanate erucin, a bioactive compound from cruciferous vegetables, on human prostate cancer cells.
Adenocarcinoma
CDK5 positively regulates Notch1 signaling in pancreatic cancer cells by phosphorylation.
Adenocarcinoma
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Adenocarcinoma
Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
Adenocarcinoma
Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis.
Adenocarcinoma
Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.
Adenocarcinoma
Dysregulation of CDK Inhibitors and p53 in HPV-negative Endocervical Adenocarcinoma.
Adenocarcinoma
Effects of the environmental mammary carcinogen 6-nitrochrysene on p53 and p21(Cip1) protein expression and cell cycle regulation in MCF-7 and MCF-10A cells.
Adenocarcinoma
Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas.
Adenocarcinoma
Expression and prognostic significance of cyclin-dependent kinase inhibitor 1A in patients with resected gastric adenocarcinoma.
Adenocarcinoma
Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity.
Adenocarcinoma
Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas.
Adenocarcinoma
Expression of cyclin B1, D1 and K in non?small cell lung cancer H1299 cells following treatment with sulforaphane.
Adenocarcinoma
Expression of p16 protein in gallbladder carcinoma and its precancerous conditions.
Adenocarcinoma
Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression.
Adenocarcinoma
Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Adenocarcinoma
Expression patterns and prognostic values of the cyclin-dependent kinase 1 and cyclin A2 gene cluster in pancreatic adenocarcinoma.
Adenocarcinoma
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas.
Adenocarcinoma
Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110.
Adenocarcinoma
Helicobacter pylori inhibits activity of cdc2 kinase and delays G2/M to G1 progression in gastric adenocarcinoma cell line.
Adenocarcinoma
IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential.
Adenocarcinoma
Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.
Adenocarcinoma
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Adenocarcinoma
Immunohistochemical expression of TGF-beta1, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas: a clinicopathologic study.
Adenocarcinoma
IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.
Adenocarcinoma
Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma.
Adenocarcinoma
Inhibition of pRB Pathway Differentially Modulates Apoptosis in Esophageal Cancer Cells.
Adenocarcinoma
Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma.
Adenocarcinoma
Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma.
Adenocarcinoma
Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
Adenocarcinoma
Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels.
Adenocarcinoma
Mutational analysis of the P16-binding domain of cyclin-dependent kinase 4 in tumors in the head region of the pancreas.
Adenocarcinoma
p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
Adenocarcinoma
Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK inhibitor using MRI texture: a feasibility study.
Adenocarcinoma
Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage.
Adenocarcinoma
Prognostic value of p27 expression in adenocarcinoma of the pancreatic head region.
Adenocarcinoma
Pulmonary fibroblasts stimulate the proliferation of cell lines from human lung adenocarcinomas.
Adenocarcinoma
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Adenocarcinoma
Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy.
Adenocarcinoma
Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma.
Adenocarcinoma
Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.
Adenocarcinoma
The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
Adenocarcinoma
The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
Adenocarcinoma in Situ
IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.
Adenocarcinoma of Lung
Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.
Adenocarcinoma of Lung
Association of lncRNA polymorphisms with triglyceride and total cholesterol levels among myocardial infarction patients in Chinese population.
Adenocarcinoma of Lung
Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
Adenocarcinoma of Lung
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Adenocarcinoma of Lung
Elevated nuclear CDK6 is associated with an unfavorable prognosis in lung adenocarcinoma patients.
Adenocarcinoma of Lung
Knockdown of PFTK1 Expression by RNAi Inhibits the Proliferation and Invasion of Human Non-Small Lung Adenocarcinoma Cells.
Adenocarcinoma of Lung
Knockdown of SMAD3 inhibits the growth and enhances the radiosensitivity of lung adenocarcinoma via p21 in vitro and in vivo.
Adenocarcinoma of Lung
miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma.
Adenocarcinoma of Lung
Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V.
Adenocarcinoma of Lung
Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells.
Adenocarcinoma of Lung
The lncRNA ALMS1-IT1 may promote malignant progression of lung adenocarcinoma via AVL9-mediated activation of the cyclin-dependent kinase pathway.
Adenoma
Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon.
Adenoma
CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis.
Adenoma
Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients.
Adenoma
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Adenoma
Differential gene expression in pituitary adenomas by oligonucleotide array analysis.
Adenoma
Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity.
Adenoma
Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression.
Adenoma
Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein.
Adenoma
Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism.
Adenoma
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Adenoma
Targeted inactivation of p27kip1 is sufficient for large and small intestinal tumorigenesis in the mouse, which can be augmented by a Western-style high-risk diet.
Adenoma
Uncontrolled insulin secretion from a childhood pancreatic beta-cell adenoma is not due to the functional loss of ATP-sensitive potassium channels.
Adenoma, Islet Cell
Immunohistochemical investigation of F344/N rat islet cell tumors from national toxicology program studies.
Adenoma, Pleomorphic
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Adenoma, Pleomorphic
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.
Adenomatous Polyposis Coli
Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma.
Adenomatous Polyposis Coli
Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.
Adenomatous Polyposis Coli
CDK11 negatively regulates Wnt/?-catenin signaling in the endosomal compartment by affecting microtubule stability.
Adenomatous Polyposis Coli
Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients.
Adenomatous Polyposis Coli
DNA hypermethylation profiles in squamous cell carcinoma of the vulva.
Adenomatous Polyposis Coli
DNA methylation markers and early recurrence in stage I lung cancer.
Adenomatous Polyposis Coli
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Adenomatous Polyposis Coli
Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
Adenomatous Polyposis Coli
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Adenomatous Polyposis Coli
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Adenomatous Polyposis Coli
Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34.
Adenomatous Polyposis Coli
Promoter hypermethylation of p16 and APC in gastrointestinal cancer patients.
Adenomatous Polyposis Coli
Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas.
Adrenocortical Carcinoma
Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis.
Adrenocortical Carcinoma
Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
Agenesis of Corpus Callosum
A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness.
Aicardi Syndrome
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Aicardi Syndrome
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Aicardi Syndrome
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
AIDS-Associated Nephropathy
Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Alopecia
Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Alopecia
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
Alopecia
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Alopecia
[Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors]
Alzheimer Disease
A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer's disease.
Alzheimer Disease
A novel mechanism of non-A? component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5).
Alzheimer Disease
AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain.
Alzheimer Disease
Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration.
Alzheimer Disease
Adeno-associated virus 9-mediated Cdk5 inhibitory peptide reverses pathologic changes and behavioral deficits in the Alzheimer's disease mouse model.
Alzheimer Disease
Advances in multiplex PCR for Alzheimer's disease diagnostics targeting CDK genes.
Alzheimer Disease
Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Alzheimer Disease
Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk.
Alzheimer Disease
Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.
Alzheimer Disease
Antipodal effects of p25 on synaptic plasticity, learning, and memory--too much of a good thing is bad.
Alzheimer Disease
Association between plasma biomarkers, CDK5 polymorphism and the risk of Alzheimer's disease.
Alzheimer Disease
Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease.
Alzheimer Disease
Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice.
Alzheimer Disease
Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.
Alzheimer Disease
Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease.
Alzheimer Disease
Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration.
Alzheimer Disease
Cell cycle related signaling in neuro2a cells proceeds via the receptor for advanced glycation end products.
Alzheimer Disease
Cellular Localization of Debromohymenialdisine and Hymenialdisine in the Marine Sponge Axinella sp. Using a Newly Developed Cell Purification Protocol.
Alzheimer Disease
Clubbed thiazoles by MAOS: a novel approach to cyclin-dependent kinase 5/p25 inhibitors as a potential treatment for Alzheimer's disease.
Alzheimer Disease
Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice.
Alzheimer Disease
Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.
Alzheimer Disease
Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model.
Alzheimer Disease
Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer's Disease.
Alzheimer Disease
Cyclin-dependent kinase 5 activator p25 is generated during memory formation and is reduced at an early stage in Alzheimer's disease.
Alzheimer Disease
Cyclin-dependent kinase 5 is associated with risk for Alzheimer's disease in a Dutch population-based study.
Alzheimer Disease
Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11alpha protein up-regulation in Alzheimer's disease.
Alzheimer Disease
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
Alzheimer Disease
Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions.
Alzheimer Disease
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
Alzheimer Disease
Designing of dual inhibitors for GSK-3? and CDK5: Virtual screening and in vitro biological activities study.
Alzheimer Disease
Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments.
Alzheimer Disease
Determination of kinetic parameters and structure-activity relationships of ginsenosides as inhibitors of cyclin-dependent kinase 5/p25 using ultra-pressure liquid chromatography with triple quadrupole tandem mass spectrometry.
Alzheimer Disease
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease.
Alzheimer Disease
Disruption of neuronal nitric oxide synthase dimerization contributes to the development of Alzheimer's disease: Involvement of cyclin-dependent kinase 5-mediated phosphorylation of neuronal nitric oxide synthase at Ser(293).
Alzheimer Disease
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Alzheimer Disease
Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3beta) and Alzheimer's disease risk.
Alzheimer Disease
Expression of p25 impairs contextual learning but not latent inhibition in mice.
Alzheimer Disease
Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease.
Alzheimer Disease
Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.
Alzheimer Disease
Fuzhisan, a chinese herbal medicine, inhibits Beta-amyloid-induced neurotoxicity and tau phosphorylation through calpain/cdk5 pathway in cultured cortical neurons.
Alzheimer Disease
G-Protein Coupled Receptors and Tau-different Roles in Alzheimer's Disease.
Alzheimer Disease
Generation of the Cdk5 activator p25 is a memory mechanism that is affected in early Alzheimer's disease.
Alzheimer Disease
Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells.
Alzheimer Disease
Hyperphosphorylation of RNA polymerase II and reduced neuronal RNA levels precede neurofibrillary tangles in Alzheimer disease.
Alzheimer Disease
Identification of non-muscle myosin heavy chain as a substrate for Cdk5 and tool for drug screening.
Alzheimer Disease
Identification of p10 as a neurotoxic product generated from the proteolytic cleavage of the neuronal Cdk5 activator.
Alzheimer Disease
Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression.
Alzheimer Disease
Increased p27, an essential component of cell cycle control, in Alzheimer's disease.
Alzheimer Disease
Indirubin Derivative 7-Bromoindirubin-3-Oxime (7Bio) Attenuates A? Oligomer-Induced Cognitive Impairments in Mice.
Alzheimer Disease
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Alzheimer Disease
Inhibition of p25/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia.
Alzheimer Disease
Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.
Alzheimer Disease
Investigation of the flexibility of protein kinases implicated in the pathology of Alzheimer's disease.
Alzheimer Disease
Is there a role of the cyclin-dependent kinase 5 activator p25 in Alzheimer's disease?
Alzheimer Disease
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Alzheimer Disease
Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect.
Alzheimer Disease
Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors.
Alzheimer Disease
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease.
Alzheimer Disease
Networking with proline-directed protein kinases implicated in tau phosphorylation.
Alzheimer Disease
Neuroprotective effects of Tongmai Yizhi Decoction () against Alzheimer's disease through attenuating cyclin-dependent kinase-5 expression.
Alzheimer Disease
No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro.
Alzheimer Disease
P21 gene variation and late-onset Alzheimer's disease in the italian population.
Alzheimer Disease
p25/cyclin-dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum-stressed neurons.
Alzheimer Disease
p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
Alzheimer Disease
Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor.
Alzheimer Disease
Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease.
Alzheimer Disease
Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora.
Alzheimer Disease
Protein interaction module-assisted function X (PIMAX) approach to producing challenging proteins including hyperphosphorylated tau and active CDK5/p25 kinase complex.
Alzheimer Disease
Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease.
Alzheimer Disease
Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.
Alzheimer Disease
Role of protein kinases in neurodegenerative disease: cyclin-dependent kinases in Alzheimer's disease.
Alzheimer Disease
Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.
Alzheimer Disease
Studying synergism of methyl linked cyclohexyl thiophenes with triazole: Synthesis and their cdk5/p25 inhibition activity.
Alzheimer Disease
Targeting MicroRNA-125b Promotes Neurite Outgrowth but Represses Cell Apoptosis and Inflammation via Blocking PTGS2 and CDK5 in a FOXQ1-Dependent Way in Alzheimer Disease.
Alzheimer Disease
Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease.
Alzheimer Disease
TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.
Alzheimer Disease
The amyloid-beta peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity.
Alzheimer Disease
The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism.
Alzheimer Disease
The mechanisms regulating cyclin-dependent kinase 5 in hippocampus during systemic inflammatory response: The effect on inflammatory gene expression.
Alzheimer Disease
Tolfenamic acid inhibits GSK-3? and PP2A mediated tau hyperphosphorylation in Alzheimer's disease models.
Alzheimer Disease
Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing.
Alzheimer Disease
Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
Ameloblastoma
Establishment of human dental epithelial cell lines expressing ameloblastin and enamelin by transfection of hTERT and cdk4 cDNAs.
Amyloidosis
Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice.
Amyotrophic Lateral Sclerosis
Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.
Amyotrophic Lateral Sclerosis
Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration.
Amyotrophic Lateral Sclerosis
Cyclin-dependent kinase 5 in Lewy body-like inclusions in anterior horn cells of a patient with sporadic amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
Amyotrophic Lateral Sclerosis
Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
Amyotrophic Lateral Sclerosis
p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
Amyotrophic Lateral Sclerosis
Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor.
Anemia
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Anemia
Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.
Anemia, Aplastic
Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer.
Anemia, Sickle Cell
Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.
Angelman Syndrome
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.
Angiomyoma
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Aortic Aneurysm, Abdominal
Upregulation of MicroRNA-15a Contributes to Pathogenesis of Abdominal Aortic Aneurysm (AAA) by Modulating the Expression of Cyclin-Dependent Kinase Inhibitor 2B (CDKN2B).
Arrhythmias, Cardiac
Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients.
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Arthritis
Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report.
Arthritis
Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritis.
Arthritis
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
Arthritis
Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis.
Arthritis
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.
Arthritis
Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints.
Arthritis
Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial.
Arthritis, Experimental
Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice.
Arthritis, Experimental
Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report.
Arthritis, Experimental
Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.
Arthritis, Experimental
SPACIA1/SAAL1 Deletion Results in a Moderate Delay in Collagen-Induced Arthritis Activity, along with mRNA Decay of Cyclin-dependent Kinase 6 Gene.
Arthritis, Rheumatoid
Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report.
Arthritis, Rheumatoid
Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6.
Arthritis, Rheumatoid
Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis.
Arthritis, Rheumatoid
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Arthritis, Rheumatoid
p16(INK4a) exerts an anti-inflammatory effect through accelerated IRAK1 degradation in macrophages.
Arthritis, Rheumatoid
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.
Arthritis, Rheumatoid
Susceptibility of cyclin-dependent kinase inhibitor 1-deficient mice to rheumatoid arthritis arising from interleukin-1?-induced inflammation.
Arthritis, Rheumatoid
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial.
Arthritis, Rheumatoid
The expression of zinc finger 804a (ZNF804a) and cyclin-dependent kinase 1 (CDK1) genes is related to the pathogenesis of rheumatoid arthritis.
Arthritis, Rheumatoid
[Determination of IgM-RF, IgA-RF, IgG-RF, IL-1RI, CDK2 and ROC evaluation in patients with rheumatoid arthritis]
Arthrogryposis
Congenital dislocation of the knee reduced spontaneously or with minimal treatment.
Asthma
Airway Smooth Muscle Hyperproliferation is Regulated by microRNA-221 in Severe Asthma.
Astrocytoma
Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells.
Astrocytoma
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas.
Astrocytoma
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.
Astrocytoma
Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human astrocytoma cells by the pyrrolo-1,5-benzoxazepine, PBOX-21.
Astrocytoma
Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53.
Astrocytoma
p16(ink4a) and retinoic acid modulate rhoA and GFAP expression during induction of a stellate phenotype in U343 MG-A astrocytoma cells.
Astrocytoma
Primary and recurrent diffuse astrocytomas: genomic profile comparison reveals acquisition of biologically relevant aberrations.
Astrocytoma
Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1.
Ataxia
A novel function of HER2/Neu in the activation of G2/M checkpoint in response to ?-irradiation.
Ataxia Telangiectasia
?-Radiation induces cellular sensitivity and aberrant methylation in human tumor cell lines.
Ataxia Telangiectasia
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Ataxia Telangiectasia
Cytosine arabinoside induces phosphorylation of histone H2AX in hippocampal neurons via a noncanonical pathway.
Ataxia Telangiectasia
Domain within the helicase subunit Mcm4 integrates multiple kinase signals to control DNA replication initiation and fork progression.
Ataxia Telangiectasia
GPR68 Contributes to Persistent Acidosis-Induced Activation of AGC Kinases and Tyrosine Phosphorylation in Organotypic Hippocampal Slices.
Ataxia Telangiectasia
Hepatitis B virus X protein activates the ATM-Chk2 pathway and delays cell cycle progression.
Ataxia Telangiectasia
HiNF-P is a bifunctional regulator of cell cycle controlled histone H4 gene transcription.
Ataxia Telangiectasia
Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients.
Ataxia Telangiectasia
RAC1 GTPase plays an important role in ?-irradiation induced G2/M checkpoint activation.
Ataxia Telangiectasia
Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection.
Ataxia Telangiectasia
Screening of gene mutations associated with bone metastasis in nonsmall cell lung cancer.
Ataxia Telangiectasia
Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
Ataxia Telangiectasia
The Crucial Role of Cyclin-Dependent Kinase-5-Ataxia-Telangiectasia Mutated Axis in ICH-Induced Neuronal Injury of Rat Model.
Ataxia Telangiectasia
Tumor suppressor function of miR-483-3p on breast cancer via targeting of the cyclin E1 gene.
Atherosclerosis
Atherosclerosis and Cell Cycle: Put the Brakes On! Critical Role for Cyclin-Dependent Kinase Inhibitors.
Atherosclerosis
Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.
Atherosclerosis
CDKN2B methylation is associated with carotid artery calcification in ischemic stroke patients.
Atherosclerosis
Coordinate control of proliferation and migration by the p27Kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts.
Atherosclerosis
Cyclin-dependent kinase 5-mediated hyperphosphorylation of sirtuin-1 contributes to the development of endothelial senescence and atherosclerosis.
Atherosclerosis
Cyclin-dependent kinase 9 may as a novel target in downregulating the atherosclerosis inflammation (Review).
Atherosclerosis
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis.
Atherosclerosis
Deficiency of cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip1) accelerates atherogenesis in apolipoprotein E-deficient mice.
Atherosclerosis
Expression of the cyclin-dependent kinase inhibitor, p21Waf-1/Cip-1/Sdi-1, in human vascular smooth muscle cells in the proliferating state.
Atherosclerosis
Inhibition of CDK9 attenuates atherosclerosis by inhibiting inflammation and phenotypic switching of vascular smooth muscle cells.
Atherosclerosis
Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression.
Atherosclerosis
The Severity of Internal Carotid Artery Stenosis is Associated with the Cyclin-Dependent Kinase Inhibitor 2A Gene Expression.
Atrial Fibrillation
Cyclin Dependent Kinase 1 (CDK1) Activates Cardiac Fibroblasts via Directly Phosphorylating Paxillin at Ser244.
Atypical Squamous Cells of the Cervix
p16(INK4a) immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities : A systematic review and meta-analysis.
Autoimmune Diseases
Posterior Reversible Encephalopathy Occurring During Treatment With Palbociclib.
Azoospermia
microRNAs in the pathogenesis of non-obstructive azoospermia: the underlying mechanisms and therapeutic potentials.
Azoospermia
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Babesiosis
Cyclin-dependent kinase inhibitors block erythrocyte invasion and intraerythrocytic development of Babesia bovis in vitro.
Bacterial Infections
Differential patterns of apoptosis in resolving and nonresolving bacterial pneumonia.
Barrett Esophagus
Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Beckwith-Wiedemann Syndrome
Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol.
Beckwith-Wiedemann Syndrome
Methylation of KvDMR1 involved in regulating the imprinting of CDKN1C gene in cattle.
Beckwith-Wiedemann Syndrome
p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance.
Bicuspid Aortic Valve Disease
Correction: Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Bicuspid Aortic Valve Disease
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Biliary Tract Neoplasms
CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells.
Biliary Tract Neoplasms
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
Blister
Cell cycle regulation and apoptotic cell death in experimental colon carcinogenesis: intervening with cyclooxygenase-2 inhibitors.
Blister
The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker.
Bloom Syndrome
Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis.
Brain Diseases
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.
Brain Diseases
A girl with early-onset epileptic encephalopathy associated with microdeletion involving CDKL5.
Brain Diseases
A male case with CDKL5-associated encephalopathy manifesting transient methylmalonic acidemia.
Brain Diseases
A maternally inherited frameshift CDKL5 variant in a male with global developmental delay and late-onset generalized epilepsy.
Brain Diseases
A new cause of developmental and epileptic encephalopathy with continuous spike-and-wave during sleep: CDKL5 disorder.
Brain Diseases
A novel CDKL5 mutation in a 47,XXY boy with the early-onset seizure variant of Rett syndrome.
Brain Diseases
A novel p.Arg970X mutation in the last exon of the CDKL5 gene resulting in late-onset seizure disorder.
Brain Diseases
Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity.
Brain Diseases
Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease.
Brain Diseases
CDKL5 deficiency disorder in males: Five new variants and review of the literature.
Brain Diseases
CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
Brain Diseases
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
Brain Diseases
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
Brain Diseases
CDKL5 Gene-Related Epileptic Encephalopathy in Estonia: Four Cases, One Novel Mutation Causing Severe Phenotype in a Boy, and Overview of the Literature.
Brain Diseases
CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life.
Brain Diseases
CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery.
Brain Diseases
CDKL5 Mutations as a Cause of Severe Epilepsy in Infancy: Clinical and Electroencephalographic Long-term Course in 4 Patients.
Brain Diseases
CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
Brain Diseases
CDKL5 variant in a boy with infantile epileptic encephalopathy: case report.
Brain Diseases
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
Brain Diseases
Cell cloning-based transcriptome analysis in cyclin-dependent kinase-like 5 mutation patients with severe epileptic encephalopathy.
Brain Diseases
Clinical features and gene mutational spectrum of CDKL5-related diseases in a cohort of Chinese patients.
Brain Diseases
Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
Brain Diseases
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Brain Diseases
Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
Brain Diseases
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Brain Diseases
Complex mosaic CDKL5 deletion with two distinct mutant alleles in a 4-year-old girl.
Brain Diseases
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Brain Diseases
Diagnostic Approach to Genetic Causes of Early-Onset Epileptic Encephalopathy.
Brain Diseases
Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Brain Diseases
Early-Onset Developmental and Epileptic Encephalopathies of Infancy: An Overview of the Genetic Basis and Clinical Features.
Brain Diseases
Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.
Brain Diseases
Epileptic encephalopathy and atypical Rett syndrome with mutations in CDKL5: clinical and molecular characterization of two Brazilian patients.
Brain Diseases
Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 gene.
Brain Diseases
Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
Brain Diseases
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
Brain Diseases
Functional and Structural Impairments in the Perirhinal Cortex of a Mouse Model of CDKL5 Deficiency Disorder Are Rescued by a TrkB Agonist.
Brain Diseases
Generation and characterization of human induced pluripotent stem cells (iPSCs) from three male and three female patients with CDKL5 Deficiency Disorder (CDD).
Brain Diseases
Genes of early-onset epileptic encephalopathies: from genotype to phenotype.
Brain Diseases
High prevalence of genetic alterations in early-onset epileptic encephalopathies associated with infantile movement disorders.
Brain Diseases
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Brain Diseases
Historic, clinical, and prognostic features of epileptic encephalopathies caused by CDKL5 mutations.
Brain Diseases
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
Brain Diseases
In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
Brain Diseases
Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice.
Brain Diseases
Microtubules: A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder?
Brain Diseases
Molecular and genetic insights into an infantile epileptic encephalopathy - CDKL5 disorder.
Brain Diseases
Molecular characterization of a cohort of 73 patients with infantile spasms syndrome.
Brain Diseases
Mutation in an alternative transcript of CDKL5 in a boy with early onset seizures.
Brain Diseases
Mutation of Ser172 in Yeast ? Tubulin Induces Defects in Microtubule Dynamics and Cell Division.
Brain Diseases
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Brain Diseases
Neurobehavioral phenotype in cyclin-dependent kinase-like 5 syndrome: Case report and review of literature.
Brain Diseases
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Brain Diseases
Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy.
Brain Diseases
Novel CDKL5 mutations were found in patients in China: retrospective investigation in cases of CDKL5-related disorders.
Brain Diseases
Novel STXBP1 Mutations in 2 Patients With Early Infantile Epileptic Encephalopathy.
Brain Diseases
Optimizing the molecular diagnosis of CDKL5 gene-related epileptic encephalopathy in boys.
Brain Diseases
Pathogenic role of the X-linked cyclin-dependent kinase-like 5 and aristaless-related homeobox genes in epileptic encephalopathy of unknown etiology with onset in the first year of life.
Brain Diseases
Phenotypic manifestations between male and female children with CDKL5 mutations.
Brain Diseases
Re: CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
Brain Diseases
Recurrent occurrences of CDKL5 mutations in patients with epileptic encephalopathy.
Brain Diseases
Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy.
Brain Diseases
Revisiting the phenotype associated with FOXG1 mutations: two novel cases of congenital Rett variant.
Brain Diseases
Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.
Brain Diseases
Somatic mosaicism for a CDKL5 mutation as an epileptic encephalopathy in males.
Brain Diseases
Somatic mosaicism of a CDKL5 mutation identified by next-generation sequencing.
Brain Diseases
Synaptic Synthesis, Dephosphorylation, and Degradation: A NOVEL PARADIGM FOR AN ACTIVITY-DEPENDENT NEURONAL CONTROL OF CDKL5.
Brain Diseases
The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.
Brain Diseases
The Efficacy of Ketogenic Diet for Specific Genetic Mutation in Developmental and Epileptic Encephalopathy.
Brain Diseases
Turkish cases of early infantile epileptic encephalopathy: two novel mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene.
Brain Diseases
Two Novel Variants Affecting CDKL5 Transcript Associated with Epileptic Encephalopathy.
Brain Diseases
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Brain Diseases
Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
Brain Diseases
Validation of high-resolution DNA melting analysis for mutation scanning of the CDKL5 gene: identification of novel mutations.
Brain Diseases
What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.
Brain Diseases
X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
Brain Diseases
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
Brain Diseases
[Clinical usefulness of serial EEG examinations in the diagnostic of hereditary epileptic encephalopathies case of severe epileptic encephalopathy type 2].
Brain Injuries, Traumatic
Comparing effects of CDK inhibition and E2F1/2 ablation on neuronal cell death pathways in vitro and after traumatic brain injury.
Brain Injuries, Traumatic
CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury.
Brain Injuries, Traumatic
CR8, a Selective and Potent CDK Inhibitor, Provides Neuroprotection in Experimental Traumatic Brain Injury.
Brain Injuries, Traumatic
Involvement of aberrant Cdk5/p25 activity in experimental traumatic brain injury.
Brain Injuries, Traumatic
p53-independent transient p21(WAF1/CIP1) mRNA induction in the rat brain following experimental traumatic injury.
Brain Injuries, Traumatic
Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma.
Brain Injuries, Traumatic
Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials.
Brain Ischemia
CDK5 inhibition protects against OGDR induced mitochondrial fragmentation and apoptosis through regulation of Drp1S616 phosphorylation.
Brain Ischemia
Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells.
Brain Ischemia
Expression of cyclin-dependent kinase 5 mRNA and protein in the human brain following acute ischemic stroke.
Brain Ischemia
Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death.
Brain Ischemia
p27Kip1 constrains proliferation of neural progenitor cells in adult brain under homeostatic and ischemic conditions.
Brain Ischemia
Rat focal cerebral ischemia induced astrocyte proliferation and delayed neuronal death are attenuated by cyclin-dependent kinase inhibition.
Brain Ischemia
[Novel actions of HMG-CoA reductase inhibitors(statins)--vascular and cerebral protection through inhibition of small GTPase Rho]
Brain Neoplasms
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
Brain Neoplasms
Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain.
Brain Neoplasms
CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Brain Neoplasms
Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications.
Brain Neoplasms
Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
Brain Neoplasms
Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.
Brain Neoplasms
Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Brain Neoplasms
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
Brain Neoplasms
Infrequent mutation of Waf1/p21 gene, a CDK inhibitor gene, in brain tumors.
Brain Neoplasms
Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1.
Breast Neoplasms
"Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells".
Breast Neoplasms
123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1).
Breast Neoplasms
4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Breast Neoplasms
?-Thujaplicin inhibits basal-like mammary tumor growth by regulating glycogen synthase kinase-3?/?-catenin signaling.
Breast Neoplasms
?-Thujaplicin modulates estrogen receptor signaling and inhibits proliferation of human breast cancer cells.
Breast Neoplasms
?EF1 upregulates CDK4 transcription via the E2-box element on the CDK4 promoter.
Breast Neoplasms
A clinical evaluation of treatments that target cell cycle machinery in breast cancer.
Breast Neoplasms
A cmap-enabled gene expression signature-matching approach identifies small-molecule inducers of accelerated cell senescence.
Breast Neoplasms
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Breast Neoplasms
A genomic approach to predict synergistic combinations for breast cancer treatment.
Breast Neoplasms
A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine.
Breast Neoplasms
A microfluidic approach to parallelized transcriptional profiling of single cells.
Breast Neoplasms
A mixed-methods study of cyclin-dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers.
Breast Neoplasms
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer.
Breast Neoplasms
A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
Breast Neoplasms
A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells.
Breast Neoplasms
A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.
Breast Neoplasms
A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention.
Breast Neoplasms
A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors.
Breast Neoplasms
A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer.
Breast Neoplasms
A Phase 1 Study of Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Japanese Patients.
Breast Neoplasms
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
Breast Neoplasms
A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy.
Breast Neoplasms
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers.
Breast Neoplasms
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
Breast Neoplasms
A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients.
Breast Neoplasms
A Splice Site Variant of CDK12 and Breast Cancer in Three Eurasian Populations.
Breast Neoplasms
Abemaciclib induces apoptosis in cardiomyocytes by activating the Hippo signaling pathway.
Breast Neoplasms
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
Breast Neoplasms
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
Breast Neoplasms
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Breast Neoplasms
Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor.
Breast Neoplasms
Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells.
Breast Neoplasms
Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.
Breast Neoplasms
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Breast Neoplasms
Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Breast Neoplasms
Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
Breast Neoplasms
Adenoviral expression of the cyclin-dependent kinase inhibitor p27Kip1: a strategy for breast cancer gene therapy.
Breast Neoplasms
Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials.
Breast Neoplasms
Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?
Breast Neoplasms
Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma.
Breast Neoplasms
Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence.
Breast Neoplasms
Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors.
Breast Neoplasms
Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer.
Breast Neoplasms
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.
Breast Neoplasms
Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
Breast Neoplasms
Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.
Breast Neoplasms
Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report.
Breast Neoplasms
An available strategy based on accurate mass by ultra high performance liquid chromatography coupled to Fourier transform ion cyclotron resonance mass spectrometry technology to characterization of metabolic profile of palbociclib in rat urine, feces and bile.
Breast Neoplasms
An evaluation of palbociclib as a breast cancer treatment option: a current update.
Breast Neoplasms
Analysis of cell growth inhibitory effects of catechin through MAPK in human breast cancer cell line T47D.
Breast Neoplasms
Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer.
Breast Neoplasms
Analysis of the resveratrol-binding protein using phage-displayed random peptide library.
Breast Neoplasms
Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges.
Breast Neoplasms
Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Breast Neoplasms
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Breast Neoplasms
Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21.
Breast Neoplasms
Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells.
Breast Neoplasms
Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer.
Breast Neoplasms
AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
Breast Neoplasms
ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Breast Neoplasms
Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4.
Breast Neoplasms
Association of cyclin-dependent kinase inhibitor 2A/B with increased risk of developing breast cancer.
Breast Neoplasms
Association of cyclin-dependent kinase inhibitor 2B antisense RNA 1 gene expression and rs2383207 variant with breast cancer risk and survival.
Breast Neoplasms
Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han women.
Breast Neoplasms
Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt.
Breast Neoplasms
Binding sites for adeno-associated virus Rep proteins within the human genome.
Breast Neoplasms
Biological effects of G1 phase arrest compound, sesquicillin, in human breast cancer cell lines.
Breast Neoplasms
Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1).
Breast Neoplasms
Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy.
Breast Neoplasms
Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.
Breast Neoplasms
Both p62/SQSTM1-HDAC6-dependent autophagy and the aggresome pathway mediate CDK1 degradation in human breast cancer.
Breast Neoplasms
Breast Cancer Special Feature: Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins.
Breast Neoplasms
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Breast Neoplasms
Bullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity.
Breast Neoplasms
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report.
Breast Neoplasms
Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy.
Breast Neoplasms
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment.
Breast Neoplasms
CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Breast Neoplasms
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
Breast Neoplasms
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.
Breast Neoplasms
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer.
Breast Neoplasms
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Breast Neoplasms
CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.
Breast Neoplasms
CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease.
Breast Neoplasms
CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.
Breast Neoplasms
CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells.
Breast Neoplasms
CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.
Breast Neoplasms
CDK11p58 inhibits ER?-positive breast cancer invasion by targeting integrin ?3 via the repression of ER? signaling.
Breast Neoplasms
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Breast Neoplasms
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Breast Neoplasms
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/? -catenin Signaling.
Breast Neoplasms
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Breast Neoplasms
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Breast Neoplasms
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion.
Breast Neoplasms
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Breast Neoplasms
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Breast Neoplasms
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
Breast Neoplasms
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.
Breast Neoplasms
CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Breast Neoplasms
CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.
Breast Neoplasms
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.
Breast Neoplasms
CDK4/6 Inhibitors: Game Changers in the Management of Hormone ReceptorPositive Advanced Breast Cancer?
Breast Neoplasms
CDK7-dependent transcriptional addiction in triple-negative breast cancer.
Breast Neoplasms
CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy.
Breast Neoplasms
CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis.
Breast Neoplasms
Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.
Breast Neoplasms
Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Breast Neoplasms
Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT.
Breast Neoplasms
Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid Models.
Breast Neoplasms
CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.
Breast Neoplasms
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Breast Neoplasms
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Breast Neoplasms
Chemotherapy patient with Stevens-Johnson Syndrome presents to the Emergency Department: A case report.
Breast Neoplasms
Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
Breast Neoplasms
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
Breast Neoplasms
Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy.
Breast Neoplasms
Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Breast Neoplasms
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Breast Neoplasms
Clinical Outcomes in Breast Cancer: Innovations and Ideas Commentary on "Expression of CDK13 was Associated with Clinical Outcomes and Expression of HIF-1 and Beclin1 in Breast Cancer Patients".
Breast Neoplasms
Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Breast Neoplasms
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer.
Breast Neoplasms
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.
Breast Neoplasms
Combined Luteolin and Indole-3-Carbinol Synergistically Constrains ER?-Positive Breast Cancer by Dual Inhibiting Estrogen Receptor Alpha and Cyclin-Dependent Kinase 4/6 Pathway in Cultured Cells and Xenograft Mice.
Breast Neoplasms
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Breast Neoplasms
Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Breast Neoplasms
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Breast Neoplasms
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
Breast Neoplasms
Constitutive CCND1/CDK2 activity substitutes for p53 loss, or MYC or oncogenic RAS expression in the transformation of human mammary epithelial cells.
Breast Neoplasms
Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?
Breast Neoplasms
Correlation of p27 protein expression with HER-2/neu expression in breast cancer.
Breast Neoplasms
Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
Breast Neoplasms
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Breast Neoplasms
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Breast Neoplasms
Critical role of CDK11(p58) in human breast cancer growth and angiogenesis.
Breast Neoplasms
Crosstalk of Cyclin-dependent kinase inhibitor 1A (CDKN1A) gene polymorphism with p53 and CCND1 polymorphism in breast cancer.
Breast Neoplasms
Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.
Breast Neoplasms
Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy.
Breast Neoplasms
Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors.
Breast Neoplasms
Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth.
Breast Neoplasms
Cyclin-dependent kinase 15 upregulation is correlated with poor prognosis for patients with breast cancer.
Breast Neoplasms
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Breast Neoplasms
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Breast Neoplasms
Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Breast Neoplasms
Cyclin-dependent kinase 4-mediated phosphorylation inhibits smad3 activity in cyclin d-overexpressing breast cancer cells.
Breast Neoplasms
Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer.
Breast Neoplasms
Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer.
Breast Neoplasms
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Breast Neoplasms
Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
Breast Neoplasms
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Breast Neoplasms
Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Breast Neoplasms
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Breast Neoplasms
Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Breast Neoplasms
Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
Breast Neoplasms
Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
Breast Neoplasms
Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances.
Breast Neoplasms
Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.
Breast Neoplasms
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Breast Neoplasms
Cyclin?dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor?positive breast cancer patients: A systematic review and meta?analysis of randomized clinical trials.
Breast Neoplasms
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.
Breast Neoplasms
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
Breast Neoplasms
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Breast Neoplasms
Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.
Breast Neoplasms
Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: Correlation with Jab1 stability and PI3K/Akt pathway.
Breast Neoplasms
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Breast Neoplasms
Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2- Advanced Breast Cancer: A Nationwide Real-World Experience.
Breast Neoplasms
Depletion of ?-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation.
Breast Neoplasms
Depletion of gamma-glutamylcyclotransferase inhibits cancer cell growth by activating the AMPK-FOXO3a-p21 axis.
Breast Neoplasms
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.
Breast Neoplasms
Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells.
Breast Neoplasms
Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Breast Neoplasms
Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Breast Neoplasms
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Breast Neoplasms
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications.
Breast Neoplasms
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Breast Neoplasms
Doenjang hexane fraction-induced G1 arrest is associated with the inhibition of pRB phosphorylation and induction of Cdk inhibitor p21 in human breast carcinoma MCF-7 cells.
Breast Neoplasms
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
Breast Neoplasms
Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.
Breast Neoplasms
Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Breast Neoplasms
Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA).
Breast Neoplasms
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Breast Neoplasms
Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
Breast Neoplasms
Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells.
Breast Neoplasms
Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer.
Breast Neoplasms
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Breast Neoplasms
Effects of 60-Hz fields, estradiol and xenoestrogens on human breast cancer cells.
Breast Neoplasms
Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.
Breast Neoplasms
Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis.
Breast Neoplasms
Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2- ABC Patients: A Systematic Review and Meta-Analysis.
Breast Neoplasms
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Breast Neoplasms
Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Breast Neoplasms
Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study.
Breast Neoplasms
Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6.
Breast Neoplasms
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.
Breast Neoplasms
Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.
Breast Neoplasms
Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
Breast Neoplasms
Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.
Breast Neoplasms
Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells.
Breast Neoplasms
Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report.
Breast Neoplasms
Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Breast Neoplasms
Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.
Breast Neoplasms
ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
Breast Neoplasms
ERINA is an estrogen-responsive lncRNA that drives breast cancer through the E2F1/RB1 pathway.
Breast Neoplasms
Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS.
Breast Neoplasms
Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells.
Breast Neoplasms
Estrogenic and DNA-damaging activity of Red No. 3 in human breast cancer cells.
Breast Neoplasms
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects.
Breast Neoplasms
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Breast Neoplasms
Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Breast Neoplasms
Expression and prognostic value of transcription-associated cyclin-dependent kinases in human breast cancer.
Breast Neoplasms
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
Breast Neoplasms
Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines.
Breast Neoplasms
Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1? and beclin1 in Breast Cancer Patients.
Breast Neoplasms
Expression of p16 and cyclin-dependent kinase 4 proteins in primary breast carcinomas.
Breast Neoplasms
Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast.
Breast Neoplasms
Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.
Breast Neoplasms
Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer.
Breast Neoplasms
Expression of the G2-M checkpoint regulators cyclin B1 and P34CDC2 in breast cancer: a correlation with cellular kinetics.
Breast Neoplasms
Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21(waf1) and p27(kip1).
Breast Neoplasms
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting.
Breast Neoplasms
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
Breast Neoplasms
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Breast Neoplasms
Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Breast Neoplasms
Fatty acid synthase regulates estrogen receptor-? signaling in breast cancer cells.
Breast Neoplasms
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Breast Neoplasms
First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Breast Neoplasms
First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta.
Breast Neoplasms
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Breast Neoplasms
Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
Breast Neoplasms
Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Breast Neoplasms
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
Breast Neoplasms
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Breast Neoplasms
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Neoplasms
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives.
Breast Neoplasms
G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells.
Breast Neoplasms
Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis.
Breast Neoplasms
Gene delivery of cyclin-dependent kinase inhibitors p21 ( Waf1 ) and p27 ( Kip1 ) suppresses proliferation of MCF-7 breast cancer cells in vitro.
Breast Neoplasms
Genetic Association of rs2237572 Cyclin-Dependent Kinase 6 Gene with Breast Cancer in Iraq.
Breast Neoplasms
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Breast Neoplasms
Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
Breast Neoplasms
Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.
Breast Neoplasms
Growth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal Luminal A breast cancer.
Breast Neoplasms
Heat shock protein B8, a cyclin-dependent kinase-independent cyclin D1 target gene, contributes to its effects on radiation sensitivity.
Breast Neoplasms
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
Breast Neoplasms
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Breast Neoplasms
High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors.
Breast Neoplasms
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Breast Neoplasms
Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Breast Neoplasms
HIV-1 Tat Peptide Immunoconjugates Differentially Sensitize Breast Cancer Cells to Selected Antiproliferative Agents That Induce the Cyclin-Dependent Kinase Inhibitor p21(WAF-1/CIP-1).
Breast Neoplasms
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.
Breast Neoplasms
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
Breast Neoplasms
HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of action, Clinical Activity, and Safety Profiles.
Breast Neoplasms
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Breast Neoplasms
Identification of key genes in glioblastoma-associated stromal cells using bioinformatics analysis.
Breast Neoplasms
Immunohistochemical study of nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 in invasive breast carcinoma of no special type.
Breast Neoplasms
In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
Breast Neoplasms
Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex.
Breast Neoplasms
Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions.
Breast Neoplasms
Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter.
Breast Neoplasms
Induction of G1 arrest and apoptosis in human jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1, and Bax proteins.
Breast Neoplasms
Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
Breast Neoplasms
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.
Breast Neoplasms
Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.
Breast Neoplasms
Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
Breast Neoplasms
Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.
Breast Neoplasms
Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2.
Breast Neoplasms
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Breast Neoplasms
Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
Breast Neoplasms
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Breast Neoplasms
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Breast Neoplasms
Inhibitory effect of mimosine on proliferation of human lung cancer cells is mediated by multiple mechanisms.
Breast Neoplasms
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.
Breast Neoplasms
Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
Breast Neoplasms
Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Breast Neoplasms
Interference with ER-? enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Breast Neoplasms
Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology.
Breast Neoplasms
Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Breast Neoplasms
Involvement of Sphingosine Kinase 2 in p53-Independent Induction of p21 by the Chemotherapeutic Drug Doxorubicin.
Breast Neoplasms
Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells.
Breast Neoplasms
Isolation and Structural Elucidation of Palbociclib's Eight Process-Related Impurities: Two Identified as New Compounds.
Breast Neoplasms
Jasmonates induce Arabidopsis bioactivities selectively inhibiting the growth of breast cancer cells through CDC6 and mTOR.
Breast Neoplasms
Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors.
Breast Neoplasms
Knockdown of FLOT1 Impairs Cell Proliferation and Tumorigenicity in Breast Cancer through Upregulation of FOXO3a.
Breast Neoplasms
Knockdown of flotillin-2 impairs the proliferation of breast cancer cells through modulation of Akt/FOXO signaling.
Breast Neoplasms
Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.
Breast Neoplasms
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Breast Neoplasms
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Breast Neoplasms
Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis.
Breast Neoplasms
Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.
Breast Neoplasms
Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors.
Breast Neoplasms
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer.
Breast Neoplasms
Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
Breast Neoplasms
Markers for Sebaceoma Show a Spectrum of Cell Cycle Regulators, Tumor Suppressor Genes, and Oncogenes.
Breast Neoplasms
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
Breast Neoplasms
Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies.
Breast Neoplasms
Metastatic hormone receptor-positive breast cancer in CDK 4/6 era: An outcome audit.
Breast Neoplasms
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Breast Neoplasms
MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment.
Breast Neoplasms
miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation.
Breast Neoplasms
miR-125a-3p inhibits ER? transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
Breast Neoplasms
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Breast Neoplasms
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
Breast Neoplasms
Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Breast Neoplasms
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Breast Neoplasms
Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose.
Breast Neoplasms
Monocillin II inhibits human breast cancer growth partially by inhibiting MAPK pathways and CDK2 Thr160 phosphorylation.
Breast Neoplasms
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Breast Neoplasms
Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas.
Breast Neoplasms
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
Breast Neoplasms
Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
Breast Neoplasms
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Breast Neoplasms
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Breast Neoplasms
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Breast Neoplasms
Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells.
Breast Neoplasms
Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient.
Breast Neoplasms
Nuclear exclusion of p53 controls DNA-synthesis through reduction in the expression of p21 inhibitor of cyclin-dependent kinase-2.
Breast Neoplasms
Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy.
Breast Neoplasms
Okadaic acid-mediated induction of the c-fos gene in estrogen receptor-negative human breast carcinoma cells utilized, in part, posttranscriptional mechanisms involving adenosine-uridine-rich elements.
Breast Neoplasms
Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
Breast Neoplasms
On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: Progress & Ongoing Challenges.
Breast Neoplasms
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.
Breast Neoplasms
Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Breast Neoplasms
Optimizing Palbociclib Therapy Across the Age Spectrum: Hypothetical, Illustrative Case Scenarios in HR+, HER2-Metastatic Breast Cancer.
Breast Neoplasms
Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.
Breast Neoplasms
Oral adverse effects of CDK4/6 inhibitors among breast cancer patients: a systematic review and meta-analysis.
Breast Neoplasms
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Neoplasms
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Breast Neoplasms
Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
Breast Neoplasms
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.
Breast Neoplasms
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Breast Neoplasms
P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
Breast Neoplasms
p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up.
Breast Neoplasms
p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression.
Breast Neoplasms
p53-GSDME Elevation: A Path for CDK7 Inhibition to Suppress Breast Cancer Cell Survival.
Breast Neoplasms
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series.
Breast Neoplasms
Palbociclib and beyond for the treatment of HR?+?HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Breast Neoplasms
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Breast Neoplasms
Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
Breast Neoplasms
Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
Breast Neoplasms
Palbociclib for the treatment of postmenopausal breast cancer - an update.
Breast Neoplasms
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
Breast Neoplasms
Palbociclib in metastatic breast cancer: current evidence and real-life data.
Breast Neoplasms
Palbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma.
Breast Neoplasms
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.
Breast Neoplasms
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Breast Neoplasms
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer.
Breast Neoplasms
Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Breast Neoplasms
Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells.
Breast Neoplasms
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Breast Neoplasms
Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.
Breast Neoplasms
Penta-O-galloyl-?-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of P21 cyclin-dependent kinase inhibitor 1A, P27 cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple-negative xenograft growth.
Breast Neoplasms
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
Breast Neoplasms
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Breast Neoplasms
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Breast Neoplasms
Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
Breast Neoplasms
Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.
Breast Neoplasms
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Breast Neoplasms
Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer.
Breast Neoplasms
POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer.
Breast Neoplasms
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
Breast Neoplasms
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
Breast Neoplasms
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
Breast Neoplasms
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
Breast Neoplasms
Preclinical discovery and development of abemaciclib used to treat breast cancer.
Breast Neoplasms
Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Breast Neoplasms
Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.
Breast Neoplasms
Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.
Breast Neoplasms
Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.
Breast Neoplasms
Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells.
Breast Neoplasms
Prevention of p53 degradation in human MCF-7 cells by proteasome inhibitors does not mimic the action of roscovitine.
Breast Neoplasms
Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene.
Breast Neoplasms
Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300.
Breast Neoplasms
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Breast Neoplasms
Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer.
Breast Neoplasms
Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
Breast Neoplasms
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Breast Neoplasms
Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report and literature overview.
Breast Neoplasms
Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
Breast Neoplasms
Pulchranin A: First report of isolation from an endophytic fungus and its inhibitory activity on cyclin dependent kinases.
Breast Neoplasms
Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting-initial results.
Breast Neoplasms
Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer.
Breast Neoplasms
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer.
Breast Neoplasms
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.
Breast Neoplasms
Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.
Breast Neoplasms
Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions.
Breast Neoplasms
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group.
Breast Neoplasms
Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors.
Breast Neoplasms
Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Breast Neoplasms
Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer.
Breast Neoplasms
Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Breast Neoplasms
Real-World Palbociclib Use in HR+/HER2- Advanced Breast Cancer in Canada: The IRIS Study.
Breast Neoplasms
Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Breast Neoplasms
Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Breast Neoplasms
Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.
Breast Neoplasms
Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
Breast Neoplasms
Regression of a nonfunctioning pituitary macroadenoma on the CDK4/6 inhibitor palbociclib: case report.
Breast Neoplasms
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Breast Neoplasms
Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
Breast Neoplasms
RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.
Breast Neoplasms
Reproductive and developmental toxicity assessment of palbociclib, a CDK4/6 inhibitor, in Sprague-Dawley rats and New Zealand White rabbits.
Breast Neoplasms
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Breast Neoplasms
Response evaluation with 18F-FDG PET/CT in metastatic breast cancer patients treated with Palbociclib: first experience in clinical practice.
Breast Neoplasms
Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
Breast Neoplasms
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.
Breast Neoplasms
Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer.
Breast Neoplasms
Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Breast Neoplasms
Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer.
Breast Neoplasms
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Breast Neoplasms
Rhomboid domain-containing protein 1 promotes breast cancer progression by regulating the p-Akt and CDK2 levels.
Breast Neoplasms
Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Breast Neoplasms
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
Breast Neoplasms
Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
Breast Neoplasms
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
Breast Neoplasms
Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Breast Neoplasms
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Breast Neoplasms
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
Breast Neoplasms
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Breast Neoplasms
RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells.
Breast Neoplasms
RNF115/BCA2 E3 Ubiquitin Ligase Promotes Breast Cancer Cell Proliferation through Targeting p21(Waf1/Cip1) for Ubiquitin-Mediated Degradation.
Breast Neoplasms
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Breast Neoplasms
Role of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells.
Breast Neoplasms
Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice.
Breast Neoplasms
Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice.
Breast Neoplasms
Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation.
Breast Neoplasms
Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Breast Neoplasms
Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-? in human ER-positive breast cancer cells.
Breast Neoplasms
Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
Breast Neoplasms
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia.
Breast Neoplasms
Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination.
Breast Neoplasms
Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature.
Breast Neoplasms
Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells.
Breast Neoplasms
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors.
Breast Neoplasms
Secretome analysis of breast cancer-associated adipose tissue to identify paracrine regulators of breast cancer growth.
Breast Neoplasms
Selective oestrogen receptor degraders in breast cancer: a review and perspectives.
Breast Neoplasms
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
Breast Neoplasms
Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.
Breast Neoplasms
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications.
Breast Neoplasms
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Breast Neoplasms
Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.
Breast Neoplasms
Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report.
Breast Neoplasms
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Breast Neoplasms
Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Breast Neoplasms
Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.
Breast Neoplasms
Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS.
Breast Neoplasms
Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC.
Breast Neoplasms
Some molecular and clinical aspects of genetic predisposition to malignant melanoma and tumours of various site of origin.
Breast Neoplasms
SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer.
Breast Neoplasms
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).
Breast Neoplasms
Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.
Breast Neoplasms
Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options.
Breast Neoplasms
Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer.
Breast Neoplasms
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Breast Neoplasms
Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.
Breast Neoplasms
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.
Breast Neoplasms
T-loop deletion of CDC2 from breast cancer tissues eliminates binding to cyclin B1 and cyclin-dependent kinase inhibitor p21.
Breast Neoplasms
Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.
Breast Neoplasms
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
Breast Neoplasms
Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances.
Breast Neoplasms
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Breast Neoplasms
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
Breast Neoplasms
Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Breast Neoplasms
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Breast Neoplasms
Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
Breast Neoplasms
Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells.
Breast Neoplasms
Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer.
Breast Neoplasms
The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
Breast Neoplasms
The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
Breast Neoplasms
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Breast Neoplasms
The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells.
Breast Neoplasms
The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells.
Breast Neoplasms
The cyclin-dependent kinase inhibitor p27 (Kip1) regulates both DNA synthesis and apoptosis in mammary epithelium but is not required for its functional development during pregnancy.
Breast Neoplasms
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers.
Breast Neoplasms
The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo.
Breast Neoplasms
The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway.
Breast Neoplasms
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.
Breast Neoplasms
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Breast Neoplasms
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease.
Breast Neoplasms
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Breast Neoplasms
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
Breast Neoplasms
The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Breast Neoplasms
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
Breast Neoplasms
The Indole-3-carbinol cyclic tetrameric derivative CTet synergizes with cisplatin and doxorubicin in triple-negative breast cancer cell lines.
Breast Neoplasms
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.
Breast Neoplasms
The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.
Breast Neoplasms
The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3) induces lethality of human carcinoma cells by generation of reactive oxygen species.
Breast Neoplasms
The Open Issues Regarding Cyclin-Dependent Kinase 4/6 Inhibitors in the Management of Advanced Breast Cancer.
Breast Neoplasms
The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer.
Breast Neoplasms
The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer.
Breast Neoplasms
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Breast Neoplasms
The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.
Breast Neoplasms
The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters.
Breast Neoplasms
Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
Breast Neoplasms
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Breast Neoplasms
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Breast Neoplasms
Trends in the early investigational drug development and areas for improvement.
Breast Neoplasms
UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation.
Breast Neoplasms
Unliganded estrogen receptor alpha inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21(WAF1)).
Breast Neoplasms
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.
Breast Neoplasms
Unraveling the complexity of endocrine resistance in breast cancer by functional genomics.
Breast Neoplasms
Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a.
Breast Neoplasms
Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate.
Breast Neoplasms
Updates on managing advanced breast cancer with palbociclib combination therapy.
Breast Neoplasms
Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer.
Breast Neoplasms
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Breast Neoplasms
Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.
Breast Neoplasms
Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer.
Breast Neoplasms
Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients.
Breast Neoplasms
Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus.
Breast Neoplasms
Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
Breast Neoplasms
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Breast Neoplasms
Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
Breast Neoplasms
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
Breast Neoplasms
[Consensus recommendations for the clinical application of CDK4/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer].
Breast Neoplasms
[Effect of CDK2-AP1 gene over-expression on proliferation and cell cycle regulation of breast cancer cell line MCF-7].
Breast Neoplasms
[Prognostic significance of cyclin-dependent kinase inhibitor p27kip1 expression in human breast cancer]
Breast Neoplasms
[Progression and future of CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer].
Breast Neoplasms
[Subcellular re-distribution of F-actin in MCF7 cells upon inducible expression of CDKN2A/p16(INK4a)].
Breast Neoplasms, Male
Male patient with metastatic stage IV breast cancer achieves complete remission on second line Abemaciclib, Fulvestrant and Leuprolide: A case report.
Breast Neoplasms, Male
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report and literature overview.
Breast Neoplasms, Male
The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer.
Bronchopulmonary Dysplasia
The effect of neonatal hyperoxia on the lung of p21Waf1/Cip1/Sdi1-deficient mice.
Burkitt Lymphoma
A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma.
Burkitt Lymphoma
Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line.
Carcinogenesis
3'-Hydroxypterostilbene Inhibits 7,12-Dimethylbenz[a]anthracene (DMBA)/12-O-Tetradecanoylphorbol-13-Acetate (TPA)-Induced Mouse Skin Carcinogenesis.
Carcinogenesis
A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.
Carcinogenesis
Absence of High-Risk Human Papillomavirus (HPV) Detection in Endocervical Adenocarcinoma with Gastric Morphology and Phenotype.
Carcinogenesis
Alteration of p16 (CDKN2) gene is associated with interleukin-2-induced tumor cell growth in adult T-cell leukemia.
Carcinogenesis
Alterations in cyclin-dependent kinase 2 function during differentiation of primary human keratinocytes.
Carcinogenesis
Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis.
Carcinogenesis
Analysis of location and integrity of the human PITSLRE (p58(cdc2L1)) genes in neuroblastoma cell genomes.
Carcinogenesis
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Carcinogenesis
c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice.
Carcinogenesis
c-Jun NH2-Terminal Kinase 1 Plays a Critical Role in Intestinal Homeostasis and Tumor Suppression.
Carcinogenesis
c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression.
Carcinogenesis
CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis.
Carcinogenesis
CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis.
Carcinogenesis
CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity.
Carcinogenesis
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Carcinogenesis
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/? -catenin Signaling.
Carcinogenesis
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
Carcinogenesis
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Carcinogenesis
CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis.
Carcinogenesis
CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis.
Carcinogenesis
CDK5 Knockdown inhibits proliferation and induces apoptosis and Cell Cycle Arrest in Human Glioblastoma.
Carcinogenesis
CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis.
Carcinogenesis
Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma.
Carcinogenesis
Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers.
Carcinogenesis
Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice.
Carcinogenesis
Chemical transformation of mouse liver cells results in altered cyclin D-CDK protein complexes.
Carcinogenesis
Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.
Carcinogenesis
ChIP-Seq analysis identifies p27(Kip1)-target genes involved in cell adhesion and cell signalling in mouse embryonic fibroblasts.
Carcinogenesis
Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development.
Carcinogenesis
Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/CASP-3 during apoptosis induced by tumor necrosis factor.
Carcinogenesis
Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.
Carcinogenesis
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Carcinogenesis
Combined cyclin D1 overexpression and zinc deficiency disrupts cell cycle and accelerates mouse forestomach carcinogenesis.
Carcinogenesis
Combined loss of p21(waf1/cip1) and p27(kip1) enhances tumorigenesis in mice.
Carcinogenesis
Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6.
Carcinogenesis
Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients.
Carcinogenesis
Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy.
Carcinogenesis
Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation.
Carcinogenesis
Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth.
Carcinogenesis
Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer.
Carcinogenesis
Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis.
Carcinogenesis
Cyclin-Dependent Kinase 5 (CDK5)-Mediated Phosphorylation of Upstream Stimulatory Factor 2 (USF2) Contributes to Carcinogenesis.
Carcinogenesis
Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis.
Carcinogenesis
Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer.
Carcinogenesis
Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma.
Carcinogenesis
Cyclin-dependent kinase inhibitor 3 promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting P27.
Carcinogenesis
Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis.
Carcinogenesis
Cyclin-dependent kinase inhibitors in restriction point control, genomic stability, and tumorigenesis.
Carcinogenesis
Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis.
Carcinogenesis
Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors.
Carcinogenesis
Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis.
Carcinogenesis
DNA methyltransferase 3A promotes cell proliferation by silencing CDK inhibitor p18INK4C in gastric carcinogenesis.
Carcinogenesis
Down-regulation of p27Kip1 expression is correlated with increased cell proliferation but not expression of p21waf1 and p53, and human papillomavirus infection in benign and malignant tumours of sinonasal regions.
Carcinogenesis
Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
Carcinogenesis
Downregulation of beta1,4-galactosyltransferase 1 inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide.
Carcinogenesis
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
Carcinogenesis
Dual effects of Ral-activated pathways on p27 localization and TGF-? signaling.
Carcinogenesis
Dysregulation of CDK Inhibitors and p53 in HPV-negative Endocervical Adenocarcinoma.
Carcinogenesis
Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia.
Carcinogenesis
EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis.
Carcinogenesis
Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
Carcinogenesis
Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer.
Carcinogenesis
Expression and mutational analysis of Cip/Kip family in early glottic cancer.
Carcinogenesis
Expression of p16(INK4A) in cervical precancerous lesions is unlikely to be preventable by human papillomavirus vaccines.
Carcinogenesis
Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma.
Carcinogenesis
Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors.
Carcinogenesis
Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma.
Carcinogenesis
Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer.
Carcinogenesis
FBXL16 is a novel E2F1-regulated gene commonly upregulated in p16INK4A- and p14ARF-silenced HeLa cells.
Carcinogenesis
FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor.
Carcinogenesis
Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Carcinogenesis
Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
Carcinogenesis
Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice.
Carcinogenesis
HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis.
Carcinogenesis
High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.
Carcinogenesis
Hypoxia-inducible factor 1 alpha is essential for hypoxic p27 induction in endometrioid endometrial carcinoma.
Carcinogenesis
Icariside II inhibits tumorigenesis via inhibiting AKT/Cyclin E/ CDK 2 pathway and activating mitochondria-dependent pathway.
Carcinogenesis
ICK1, a cyclin-dependent protein kinase inhibitor from Arabidopsis thaliana interacts with both Cdc2a and CycD3, and its expression is induced by abscisic acid.
Carcinogenesis
Immunohistochemical analysis for cell regulatory proteins in bladder carcinogenesis induced by N-methyl-N-nitrosourea-terephthalic acid.
Carcinogenesis
Immunohistochemical localization of p21(WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues.
Carcinogenesis
Inactivation of p21WAF1/cip1 enhances intestinal tumor formation in Muc2-/- mice.
Carcinogenesis
Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
Carcinogenesis
Interactions between polymorphisms in the 3'untranslated region of the cyclin dependent kinase 6 gene and the human papillomavirus infection, and risk of cervical precancerous lesions.
Carcinogenesis
Involvement of p21cip1/waf1 in the anti-proliferative effects of polyethylene glycol in colon carcinogenesis.
Carcinogenesis
JAB1-STAT3 activation loop is associated with recurrence following 5-fluorouracil-based adjuvant chemotherapy in human colorectal cancer.
Carcinogenesis
Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Carcinogenesis
Knockdown of FLOT1 Impairs Cell Proliferation and Tumorigenicity in Breast Cancer through Upregulation of FOXO3a.
Carcinogenesis
Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.
Carcinogenesis
Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Carcinogenesis
Long noncoding RNA DLEU2 affects the proliferative and invasive ability of colorectal cancer cells.
Carcinogenesis
Loss of anchorage in checkpoint-deficient cells increases genomic instability and promotes oncogenic transformation.
Carcinogenesis
Loss of expression of tumor suppressor p16(INK4) protein in human primary gastric cancer is related to the grade of differentiation.
Carcinogenesis
Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
Carcinogenesis
Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation.
Carcinogenesis
Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia.
Carcinogenesis
Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells.
Carcinogenesis
MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a.
Carcinogenesis
MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis.
Carcinogenesis
MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B.
Carcinogenesis
MicroRNAs 221 and 222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1.
Carcinogenesis
miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8.
Carcinogenesis
Molecular-cloning of the human cycg1 gene encoding a g-type cyclin - overexpression in human osteosarcoma cells.
Carcinogenesis
Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclins D1 and D2 binding to cdk4.
Carcinogenesis
NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.
Carcinogenesis
NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma.
Carcinogenesis
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.
Carcinogenesis
Overexpression of CDK7 is associated with unfavourable prognosis in oral squamous cell carcinoma.
Carcinogenesis
p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells.
Carcinogenesis
p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer.
Carcinogenesis
p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis.
Carcinogenesis
Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling.
Carcinogenesis
PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.
Carcinogenesis
Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Carcinogenesis
Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression.
Carcinogenesis
Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor.
Carcinogenesis
Promoter hypermethylation of p16 and APC in gastrointestinal cancer patients.
Carcinogenesis
Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis.
Carcinogenesis
Reduced expression of the CDK inhibitor p27(KIP1) in rat two-stage bladder carcinogenesis and its association with expression profiles of p21(WAF1/Cip1) and p53.
Carcinogenesis
Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation.
Carcinogenesis
RNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growth.
Carcinogenesis
Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice.
Carcinogenesis
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Carcinogenesis
Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.
Carcinogenesis
Sequential and progressive cyclin expression in human osteosarcoma cells - diagnostic and therapeutic implications.
Carcinogenesis
Serine 123 Phosphorylation Modulates p21 Protein Stability and Activity by Suppressing Ubiquitin-Independent Proteasomal Degradation.
Carcinogenesis
Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study.
Carcinogenesis
Steady state expression of cell-cycle regulatory genes in prostate carcinoma cell lines.
Carcinogenesis
Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization.
Carcinogenesis
Supernumerary ring chromosomes derived from the long arm of chromosome 12 as the primary cytogenetic anomaly in a rare soft tissue chondroma.
Carcinogenesis
Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
Carcinogenesis
Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery.
Carcinogenesis
The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors.
Carcinogenesis
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
Carcinogenesis
The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance.
Carcinogenesis
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Carcinogenesis
The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis.
Carcinogenesis
The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers.
Carcinogenesis
The phosphorylation of survivin Thr34 by p34cdc2 in carcinogenesis of oral submucous fibrosis.
Carcinogenesis
The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer.
Carcinogenesis
The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer.
Carcinogenesis
Transcriptional activation of CBF? by CDK11p110 is necessary to promote osteosarcoma cell proliferation.
Carcinogenesis
Transgenesis-mediated reproductive dysfunction and tumorigenesis: effects of immunological neutralization.
Carcinogenesis
Unexpected reduction of skin tumorigenesis on expression of cyclin-dependent kinase 6 in mouse epidermis.
Carcinoid Tumor
Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1.
Carcinoma
2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
Carcinoma
A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
Carcinoma
Aberrant methylation in promoter regions of cyclin-dependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland.
Carcinoma
Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Carcinoma
Absence of High-Risk Human Papillomavirus (HPV) Detection in Endocervical Adenocarcinoma with Gastric Morphology and Phenotype.
Carcinoma
Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells.
Carcinoma
Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas.
Carcinoma
Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
Carcinoma
Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
Carcinoma
Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma.
Carcinoma
Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus.
Carcinoma
An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation.
Carcinoma
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Carcinoma
Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Carcinoma
Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
Carcinoma
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Carcinoma
CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma.
Carcinoma
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Carcinoma
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
Carcinoma
CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target.
Carcinoma
CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
Carcinoma
CDK5 neutralizes the tumor suppressing effect of BIN1 via mediating phosphorylation of c-MYC at Ser-62 site in NSCLC.
Carcinoma
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
Carcinoma
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Carcinoma
Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression.
Carcinoma
Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours.
Carcinoma
Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.
Carcinoma
Cell cycle-related gene abnormalities and product expression in esophageal carcinoma.
Carcinoma
Cell shape change precedes staurosporine-induced stabilization and accumulation of p27kip1.
Carcinoma
Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line.
Carcinoma
Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter.
Carcinoma
Chemopreventive effects of green tea polyphenols correlate with reversible induction of p57 expression.
Carcinoma
Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma.
Carcinoma
Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis.
Carcinoma
Clinical significance of overexpressed cyclin-dependent kinase subunits 1 and 2 in esophageal carcinoma.
Carcinoma
Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.
Carcinoma
Cohypermethylation of p14 in combination with CADM1 or DCC as a recurrence-related prognostic indicator in stage I esophageal squamous cell carcinoma.
Carcinoma
Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma.
Carcinoma
Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma.
Carcinoma
Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells.
Carcinoma
Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.
Carcinoma
Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
Carcinoma
Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.
Carcinoma
Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients.
Carcinoma
Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma.
Carcinoma
Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells.
Carcinoma
Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions.
Carcinoma
Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
Carcinoma
Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma.
Carcinoma
Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Carcinoma
Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma.
Carcinoma
Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas.
Carcinoma
Cyclin-dependent kinase inhibitor p27(Kip1) expression in transitional cell carcinoma of renal pelvis and ureter.
Carcinoma
Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma.
Carcinoma
Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma.
Carcinoma
Depletion of the cdk inhibitor p16INK4a differentially affects proliferation of established cervical carcinoma cells.
Carcinoma
Deregulation of the cyclin D1/Cdk4 retinoblastoma pathway in rat mammary gland carcinomas induced by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Carcinoma
Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.
Carcinoma
Diagnostic value of cyclin-dependent kinase/cyclin-dependent kinase inhibitor expression ratios as biomarkers of locoregional and hematogenous dissemination risks in oral squamous cell carcinoma.
Carcinoma
Differential expression of degradome components in cutaneous squamous cell carcinomas.
Carcinoma
Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma.
Carcinoma
Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
Carcinoma
Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats.
Carcinoma
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Carcinoma
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
Carcinoma
Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.
Carcinoma
Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines.
Carcinoma
Enhanced sensitivity to cis-diamminedichloroplatinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression.
Carcinoma
Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Carcinoma
Expression and tissue distribution of human X-linked armadillo repeat containing-6.
Carcinoma
Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines.
Carcinoma
Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis.
Carcinoma
Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity.
Carcinoma
Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.
Carcinoma
Expression of cyclin-dependent kinase inhibitor 2A 16, tumour protein 53 and epidermal growth factor receptor in salivary gland carcinomas is not associated with oncogenic virus infection.
Carcinoma
Expression of Cyclin-dependent Kinase Inhibitor p21(WAF1/CIP1) in Non-small Cell Lung Carcinomas: Relationship with p53 Status and Proliferative Activity.
Carcinoma
Expression of G1 cell cycle markers and the effect of adenovirus-mediated overexpression of p21Waf-1 in squamous cell carcinoma of the esophagus.
Carcinoma
Expression of G1/S-cyclins and cyclin-dependent kinase inhibitors in actinic keratosis and squamous cell carcinoma.
Carcinoma
Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression.
Carcinoma
Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma.
Carcinoma
Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy.
Carcinoma
Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas.
Carcinoma
Expression of Skp2 and p27(kip1) proteins in hypopharyngeal squamous cell carcinoma and its clinical significance.
Carcinoma
Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions.
Carcinoma
Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in oesophageal squamous cell carcinomas.
Carcinoma
Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Carcinoma
Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase.
Carcinoma
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Carcinoma
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Carcinoma
Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.
Carcinoma
Gene expression reveals two distinct groups of anal carcinomas with clinical implications.
Carcinoma
Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma.
Carcinoma
Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.
Carcinoma
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Carcinoma
Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines.
Carcinoma
Growth inhibitory effect of interferon-beta is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 in a human gastric carcinoma cell line.
Carcinoma
H(2)O(2) scavenging inhibits G1/S transition by increasing nuclear levels of p27(KIP1).
Carcinoma
High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas.
Carcinoma
Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia.
Carcinoma
Hypermethylation of Promoter Region of LATS1 - a CDK Interacting Protein in Oral Squamous Cell Carcinomas - a Pilot Study in India.
Carcinoma
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Carcinoma
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Carcinoma
Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma.
Carcinoma
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Carcinoma
In vitro effects of 2-methoxyestradiol on cell morphology and Cdc2 kinase activity in SNO oesophageal carcinoma cells.
Carcinoma
Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx.
Carcinoma
Increased cdc2 and cdk2 kinase activity by retinoid X receptor gamma-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines.
Carcinoma
Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas.
Carcinoma
Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer.
Carcinoma
Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1).
Carcinoma
Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells.
Carcinoma
Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-? signaling.
Carcinoma
Influence of 2-methoxyestradiol on cell morphology and cdc2 kinase activity in WHCO3 esophageal carcinoma cells.
Carcinoma
Influence of the G2 cell cycle block abrogator pentoxifylline on the expression and subcellular location of cyclin B1 and p34cdc2 in HeLa cervical carcinoma cells.
Carcinoma
Inhibition of polyamine oxidase prevented cyclin-dependent kinase inhibitor-induced apoptosis in HCT 116 colon carcinoma cells.
Carcinoma
Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression.
Carcinoma
Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression.
Carcinoma
Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma.
Carcinoma
Investigating DNA methylation as a potential mediator between pigmentation genes, pigmentary traits and skin cancer.
Carcinoma
Involvement of glycogen synthase kinase-3beta signaling and aberrant nucleocytoplasmic localization of retinoblastoma protein in tumor promotion in a rat two-stage thyroid carcinogenesis model.
Carcinoma
LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
Carcinoma
LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas.
Carcinoma
Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/?-catenin signaling pathway.
Carcinoma
Long noncoding RNA MACC1-AS1 is a potential sponge of microRNA-34a in cervical squamous cell carcinoma and upregulates cyclin-dependent kinase 6.
Carcinoma
Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma.
Carcinoma
Low Expression of CyclinH and Cyclin-Dependent Kinase 7 Can Decrease the Proliferation of Human Esophageal Squamous Cell Carcinoma.
Carcinoma
Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas.
Carcinoma
microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the progression of cutaneous squamous cell carcinoma.
Carcinoma
miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Carcinoma
miR-145 downregulates the expression of cyclin-dependent kinase 6 in human cervical carcinoma cells.
Carcinoma
miR-204 enhances p27 mRNA stability by targeting Brd4 in head and neck squamous cell carcinoma.
Carcinoma
miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2.
Carcinoma
MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).
Carcinoma
miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway.
Carcinoma
Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines.
Carcinoma
Molecular cloning of PISSLRE, a novel putative member of the cdk family of protein serine/threonine kinases.
Carcinoma
Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells.
Carcinoma
Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis.
Carcinoma
Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1.
Carcinoma
On the concentrations of cyclins and cyclin-dependent kinases in extracts of cultured human cells.
Carcinoma
Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27.
Carcinoma
Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Carcinoma
Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Carcinoma
Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.
Carcinoma
p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma.
Carcinoma
P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
Carcinoma
p27/Kip1 mediates retinoic acid-induced suppression of ovarian carcinoma cell growth.
Carcinoma
p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression.
Carcinoma
p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
Carcinoma
p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma.
Carcinoma
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Carcinoma
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Carcinoma
Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma.
Carcinoma
Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck.
Carcinoma
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.
Carcinoma
Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas.
Carcinoma
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
Carcinoma
Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Carcinoma
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.
Carcinoma
Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.
Carcinoma
Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy.
Carcinoma
Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.
Carcinoma
Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx.
Carcinoma
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Carcinoma
Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas.
Carcinoma
Rapid induction of p21WAF1 but delayed down-regulation of Cdc25A in the TGF-beta-induced cell cycle arrest of gastric carcinoma cells.
Carcinoma
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma.
Carcinoma
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas.
Carcinoma
Reduced expression of p27(Kip1) protein in relation to salivary adenoid cystic carcinoma metastasis.
Carcinoma
Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma.
Carcinoma
Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells.
Carcinoma
Retinoic acid receptor beta induces terminal differentiation of squamous cell carcinoma lines in the absence of cyclin-dependent kinase inhibitor expression.
Carcinoma
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Carcinoma
S10 phosphorylation of p27 mediates atRA induced growth arrest in ovarian carcinoma cell lines.
Carcinoma
Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study.
Carcinoma
Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
Carcinoma
SIRT1 knockdown up-regulates p53 and p21/Cip1 expression in renal adenocarcinoma cells but not in normal renal-derived cells in a deacetylase-independent manner.
Carcinoma
SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells.
Carcinoma
Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.
Carcinoma
Sulforaphane Increases Cyclin-Dependent Kinase Inhibitor, p21 Protein in Human Oral Carcinoma Cells and Nude Mouse Animal Model to Induce G(2)/M Cell Cycle Arrest.
Carcinoma
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Carcinoma
Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.
Carcinoma
Suppression of survival in human SKBR3 breast carcinoma in response to metal-chelator complexes is preferential for copper-dithiocarbamate.
Carcinoma
Targeted Transferrin-Modified Polymeric Micelles: Enhanced Efficacy in Vitro and in Vivo in Ovarian Carcinoma.
Carcinoma
Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells.
Carcinoma
The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
Carcinoma
The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein.
Carcinoma
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Carcinoma
The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
Carcinoma
The cyclin-dependent kinase inhibitor p21(cip1/waf1) enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells.
Carcinoma
The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy.
Carcinoma
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
Carcinoma
The localization of p34cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity.
Carcinoma
The overexpression of cyclin-dependent kinase (CDK) 2 in laryngeal squamous cell carcinomas.
Carcinoma
The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells.
Carcinoma
The role of cyclin-dependent kinase inhibitor p27 in squamous cell carcinoma of the esophagus.
Carcinoma
The role of protein p16INK4a in non-oropharyngeal head and neck squamous cell carcinoma in Southern China.
Carcinoma
The ubiquitous transcription factor NF-Y positively regulates the transcription of human p27Kip1 through a CCAAT box located in the 5-upstream region of the p27Kip1 gene.
Carcinoma
The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Carcinoma
Transfection of p27(Kip1) threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells.
Carcinoma
TSC-box is essential for the nuclear localization and antiproliferative effect of XTSC-22.
Carcinoma
Ultraviolet radiation down-regulates expression of the cell-cycle inhibitor p21WAF1/CIP1 in human cancer cells independently of p53.
Carcinoma
Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma.
Carcinoma
Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas.
Carcinoma
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.
Carcinoma
Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells.
Carcinoma
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]
Carcinoma
[Expression of miR-145 in transfected HeLa cells and its effect on the targeted inhibition of CDK6].
Carcinoma
[Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma]
Carcinoma, Adenoid Cystic
Aberrant methylation in promoter regions of cyclin-dependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland.
Carcinoma, Adenoid Cystic
Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells.
Carcinoma, Adenoid Cystic
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Carcinoma, Adenoid Cystic
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Carcinoma, Adenoid Cystic
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Carcinoma, Basal Cell
Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions.
Carcinoma, Basal Cell
Investigating DNA methylation as a potential mediator between pigmentation genes, pigmentary traits and skin cancer.
Carcinoma, Ductal
Expression of the G2-M checkpoint regulators cyclin B1 and P34CDC2 in breast cancer: a correlation with cellular kinetics.
Carcinoma, Ductal
Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
Carcinoma, Ehrlich Tumor
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Carcinoma, Embryonal
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.
Carcinoma, Embryonal
Expression and role of p27(kip1) in neuronal differentiation of embryonal carcinoma cells.
Carcinoma, Embryonal
Human testis phosphoproteome reveals kinases as potential targets in spermatogenesis and testicular cancer.
Carcinoma, Embryonal
Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation.
Carcinoma, Embryonal
Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors.
Carcinoma, Embryonal
Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells.
Carcinoma, Hepatocellular
6-[(1-naphthylmethyl)sulfanyl]-9H-purine induces G2/M phase arrest and apoptosis in human hepatocellular carcinoma HepG2 cells.
Carcinoma, Hepatocellular
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
Carcinoma, Hepatocellular
A Novel Tetranucleotide Repeat Polymorphism Within KCNQ1OT1 Confers Risk for Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes.
Carcinoma, Hepatocellular
Activation of protein kinase C alpha is required for TPA-triggered ERK (MAPK) signaling and growth inhibition of human hepatoma cell HepG2.
Carcinoma, Hepatocellular
Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells.
Carcinoma, Hepatocellular
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
Carcinoma, Hepatocellular
CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
Carcinoma, Hepatocellular
CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients.
Carcinoma, Hepatocellular
CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.
Carcinoma, Hepatocellular
Circular RNA circSP3 promotes hepatocellular carcinoma growth by sponging microRNA-198 and upregulating cyclin-dependent kinase 4.
Carcinoma, Hepatocellular
Clinical and biological significance of Cdk10 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Clinical role and biological function of CDK5 in hepatocellular carcinoma: A study based on immunohistochemistry, RNA-seq and
Carcinoma, Hepatocellular
Coupling function of cyclin-dependent kinase 2 and Septin2 in the promotion of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Carcinoma, Hepatocellular
Cyclin-dependent kinase 1 inhibitor RO3306 promotes mitotic slippage in paclitaxel-treated HepG2 cells.
Carcinoma, Hepatocellular
Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1?: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib.
Carcinoma, Hepatocellular
Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.
Carcinoma, Hepatocellular
Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation.
Carcinoma, Hepatocellular
Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis.
Carcinoma, Hepatocellular
Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
Carcinoma, Hepatocellular
Effect of dibutyryl cyclic AMP on the cyclin-dependent kinase inhibitor p27Kip1 in the human hepatoma cells PLC/PRF/5.
Carcinoma, Hepatocellular
Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer.
Carcinoma, Hepatocellular
Effect of survivin regulation of transcription level by p21waf1 overexpression in HepG2 hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity.
Carcinoma, Hepatocellular
Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression and Significance of LncRNA-MINCR and CDK2 mRNA in Primary Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Farnesoid X receptor knockdown provides significant growth inhibition in hepatocellular carcinoma cells while it does not interfere with the proliferation of primary human hepatocyte-derived cells.
Carcinoma, Hepatocellular
Frequent Amplification of CENPF, GMNN and CDK13 Genes in Hepatocellular Carcinomas.
Carcinoma, Hepatocellular
Genistein arrests hepatoma cells at G2/M phase: involvement of ATM activation and upregulation of p21waf1/cip1 and Wee1.
Carcinoma, Hepatocellular
Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells.
Carcinoma, Hepatocellular
Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma.
Carcinoma, Hepatocellular
Ibulocydine sensitizes human cancers to radiotherapy by induction of mitochondria-mediated apoptosis.
Carcinoma, Hepatocellular
Ibulocydine, a novel prodrug Cdk inhibitor, effectively induces apoptosis in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos/c-jun, and p53 proteins.
Carcinoma, Hepatocellular
Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
Carcinoma, Hepatocellular
Integrin beta1 subunit overexpressed in the SMMC-7721 cells regulates the promoter activity of p21(CIP1) and enhances its transcription.
Carcinoma, Hepatocellular
Introduction of G1 phase arrest in Human Hepatocellular carcinoma cells (HHCC) by APMCF1 gene transfection through the down-regulation of TIMP3 and up-regulation of the CDK inhibitors p21.
Carcinoma, Hepatocellular
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.
Carcinoma, Hepatocellular
Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5.
Carcinoma, Hepatocellular
Long non-coding RNA colon cancer-associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression.
Carcinoma, Hepatocellular
Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression.
Carcinoma, Hepatocellular
MAPRE1 promotes cell cycle progression of hepatocellular carcinoma cells by interacting with CDK2.
Carcinoma, Hepatocellular
MicroRNA-1271-5p inhibits cell proliferation and enhances radiosensitivity by targeting CDK1 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B.
Carcinoma, Hepatocellular
Molecular mechanism of cell cycle blockage of hepatoma SK-Hep-1 cells by Epimedin C through suppression of mitogen-activated protein kinase activation and increased expression of CDK inhibitors p21(Cip1) and p27(Kip1).
Carcinoma, Hepatocellular
NUCKS1 Acts as a Promising Novel Biomarker for the Prognosis of Patients with Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Overexpression of cyclin E and cyclin-dependent kinase 2 is correlated with development of hepatocellular carcinomas.
Carcinoma, Hepatocellular
PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
Carcinoma, Hepatocellular
Phosphorylation of Caldesmon by PFTAIRE1 kinase promotes actin binding and formation of stress fibers.
Carcinoma, Hepatocellular
Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.
Carcinoma, Hepatocellular
Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Carcinoma, Hepatocellular
Quercetin induces cell cycle G1 arrest through elevating Cdk inhibitors p21 and p27 in human hepatoma cell line (HepG2).
Carcinoma, Hepatocellular
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Hepatocellular
Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway.
Carcinoma, Hepatocellular
Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells.
Carcinoma, Hepatocellular
Suppression of albumin and alpha-fetoprotein gene expression by butyrolactone I, a selective inhibitor of the cdk family, in HuH-7 human hepatoma cells.
Carcinoma, Hepatocellular
TGF-beta1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27(Kip1) CDK inhibitor in hepatoma cells replated on fibronectin.
Carcinoma, Hepatocellular
The centrosomal protein Tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2.
Carcinoma, Hepatocellular
The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Carcinoma, Hepatocellular
The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death.
Carcinoma, Hepatocellular
The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines.
Carcinoma, Hepatocellular
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Carcinoma, Hepatocellular
Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Carcinoma, Hepatocellular
Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.
Carcinoma, Hepatocellular
Vitamin K3 inhibits growth of human hepatoma HepG2 cells by decreasing activities of both p34cdc2 kinase and phosphatase.
Carcinoma, Hepatocellular
Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Carcinoma, Hepatocellular
[Correlations of expressions of macrophage migration inhibitor factor and cyclin D1 with tumor size and metastasis of hepatocellular carcinoma]
Carcinoma, Hepatocellular
[Effect of acupoint-injection of oxymatrine on experimental hepatic carcinoma and study on the mechanism]
Carcinoma, Hepatocellular
[Mitotic cyclins--new possibilities for examining mechanisms of neoplasm growth]
Carcinoma, Lewis Lung
miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2.
Carcinoma, Lobular
Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
Carcinoma, Mucoepidermoid
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Carcinoma, Neuroendocrine
Dramatic response to cyclin D-dependent kinase 4/6 inhibitor in refractory poorly differentiated neuroendocrine carcinoma of the breast.
Carcinoma, Neuroendocrine
Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
Carcinoma, Non-Small-Cell Lung
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
Carcinoma, Non-Small-Cell Lung
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Carcinoma, Non-Small-Cell Lung
Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling.
Carcinoma, Non-Small-Cell Lung
Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
Carcinoma, Non-Small-Cell Lung
An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Carcinoma, Non-Small-Cell Lung
Cell shape change precedes staurosporine-induced stabilization and accumulation of p27kip1.
Carcinoma, Non-Small-Cell Lung
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Carcinoma, Non-Small-Cell Lung
Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients.
Carcinoma, Non-Small-Cell Lung
Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Cyclin-dependent kinase 5 controls vasculogenic mimicry formation in non-small cell lung cancer via the FAK-AKT signaling pathway.
Carcinoma, Non-Small-Cell Lung
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Downregulation of XIAP and Induction of Apoptosis by the Synthetic Cyclin-Dependent Kinase Inhibitor GW8510 in Non-Small Cell Lung Cancer Cells.
Carcinoma, Non-Small-Cell Lung
Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment.
Carcinoma, Non-Small-Cell Lung
Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
Carcinoma, Non-Small-Cell Lung
Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Knockdown of PFTK1 Expression by RNAi Inhibits the Proliferation and Invasion of Human Non-Small Lung Adenocarcinoma Cells.
Carcinoma, Non-Small-Cell Lung
Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC.
Carcinoma, Non-Small-Cell Lung
Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Carcinoma, Non-Small-Cell Lung
miR-377 inhibited tumorous behaviors of non-small cell lung cancer through directly targeting CDK6.
Carcinoma, Non-Small-Cell Lung
Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells.
Carcinoma, Non-Small-Cell Lung
Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments.
Carcinoma, Non-Small-Cell Lung
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Non-Small-Cell Lung
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer.
Carcinoma, Non-Small-Cell Lung
RNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growth.
Carcinoma, Non-Small-Cell Lung
Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Carcinoma, Non-Small-Cell Lung
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Carcinoma, Non-Small-Cell Lung
The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens.
Carcinoma, Non-Small-Cell Lung
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
Carcinoma, Ovarian Epithelial
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers.
Carcinoma, Ovarian Epithelial
Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Overexpression of p34cdc2 protein kinase in epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells.
Carcinoma, Renal Cell
BAI, a novel Cdk inhibitor, enhances farnesyltransferase inhibitor LB42708-mediated apoptosis in renal carcinoma cells through the downregulation of Bcl-2 and c-FLIP (L).
Carcinoma, Renal Cell
Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Cyclin-Dependent Kinase Inhibitor BMI-1026 Induces Apoptosis by Downregulating Mcl-1 (L) and c-FLIP (L) and Inactivating p-Akt in Human Renal Carcinoma Cells.
Carcinoma, Renal Cell
MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).
Carcinoma, Renal Cell
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Carcinoma, Renal Cell
Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma.
Carcinoma, Renal Cell
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Carcinoma, Renal Cell
[Expression of P27(kip1) in renal cell carcinoma and its clinical significance.]
Carcinoma, Squamous Cell
A Key Role for Early Growth Response-1 and Nuclear Factor-{kappa}B in Mediating and Maintaining GRO/CXCR2 Proliferative Signaling in Esophageal Cancer.
Carcinoma, Squamous Cell
Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus.
Carcinoma, Squamous Cell
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Carcinoma, Squamous Cell
Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21.
Carcinoma, Squamous Cell
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.
Carcinoma, Squamous Cell
Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.
Carcinoma, Squamous Cell
Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma.
Carcinoma, Squamous Cell
Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions.
Carcinoma, Squamous Cell
Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas.
Carcinoma, Squamous Cell
Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.
Carcinoma, Squamous Cell
Differential expression of degradome components in cutaneous squamous cell carcinomas.
Carcinoma, Squamous Cell
Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells.
Carcinoma, Squamous Cell
Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines.
Carcinoma, Squamous Cell
Expression of G1 cell cycle markers and the effect of adenovirus-mediated overexpression of p21Waf-1 in squamous cell carcinoma of the esophagus.
Carcinoma, Squamous Cell
Expression of G1/S-cyclins and cyclin-dependent kinase inhibitors in actinic keratosis and squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of p34cdc2 protein kinase and p53 in supraglottic carcinomas.
Carcinoma, Squamous Cell
Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions.
Carcinoma, Squamous Cell
Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in oesophageal squamous cell carcinomas.
Carcinoma, Squamous Cell
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Carcinoma, Squamous Cell
G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Carcinoma, Squamous Cell
Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors.
Carcinoma, Squamous Cell
Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.
Carcinoma, Squamous Cell
Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma.
Carcinoma, Squamous Cell
Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.
Carcinoma, Squamous Cell
Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia.
Carcinoma, Squamous Cell
Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx.
Carcinoma, Squamous Cell
Increased cdc2 and cdk2 kinase activity by retinoid X receptor gamma-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines.
Carcinoma, Squamous Cell
Increased expression of the P27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1.
Carcinoma, Squamous Cell
Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-? signaling.
Carcinoma, Squamous Cell
Long noncoding RNA MACC1-AS1 is a potential sponge of microRNA-34a in cervical squamous cell carcinoma and upregulates cyclin-dependent kinase 6.
Carcinoma, Squamous Cell
Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the progression of cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
miR-204 enhances p27 mRNA stability by targeting Brd4 in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo.
Carcinoma, Squamous Cell
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Carcinoma, Squamous Cell
Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck.
Carcinoma, Squamous Cell
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.
Carcinoma, Squamous Cell
Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy.
Carcinoma, Squamous Cell
Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx.
Carcinoma, Squamous Cell
Prognostic significance of p34cdc2 expression in tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Squamous Cell
Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.
Carcinoma, Squamous Cell
Retinoic acid receptor beta induces terminal differentiation of squamous cell carcinoma lines in the absence of cyclin-dependent kinase inhibitor expression.
Carcinoma, Squamous Cell
Retinoic acid-mediated G1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin-dependent kinase 3 in human lung squamous carcinoma CH27 cells.
Carcinoma, Squamous Cell
Role of p12(CDK2-AP1) in transforming growth factor-beta1-mediated growth suppression.
Carcinoma, Squamous Cell
Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells.
Carcinoma, Squamous Cell
Suppression of DNA methyltransferase 1 levels in head and neck squamous carcinoma cells using small interfering RNA results in growth inhibition and increase in Cdk inhibitor p21.
Carcinoma, Squamous Cell
The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
Carcinoma, Squamous Cell
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
Carcinoma, Squamous Cell
The overexpression of cyclin-dependent kinase (CDK) 2 in laryngeal squamous cell carcinomas.
Carcinoma, Squamous Cell
The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth.
Carcinoma, Squamous Cell
The role of cyclin-dependent kinase inhibitor p27 in squamous cell carcinoma of the esophagus.
Carcinoma, Squamous Cell
The role of protein p16INK4a in non-oropharyngeal head and neck squamous cell carcinoma in Southern China.
Carcinoma, Squamous Cell
Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57.
Carcinoma, Squamous Cell
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]
Carcinoma, Transitional Cell
Cyclin-dependent kinase inhibitor p27(Kip1) expression in transitional cell carcinoma of renal pelvis and ureter.
Carcinoma, Transitional Cell
p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
Cardiomegaly
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Cardiomegaly
Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Facilitates the Development of Cardiac Hypertrophy.
Cardiomegaly
Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy.
Cardiomegaly
Overexpression of cdk Inhibitor p16INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy.
Cardiomegaly
Senescence as a novel mechanism involved in ?-adrenergic receptor mediated cardiac hypertrophy.
Cardiomegaly
SGK1-Sensitive Regulation of Cyclin-Dependent Kinase Inhibitor 1B (p27) in Cardiomyocyte Hypertrophy.
Cardiomegaly
The protective effect of 1,25(OH)2D3 against cardiac hypertrophy is mediated by the cyclin-dependent kinase inhibitor p21.
Cardiomyopathies
Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy.
Cardiotoxicity
Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.
Cardiovascular Diseases
Control of vascular smooth muscle cell growth by cyclin-dependent kinase inhibitory proteins and its implication in cardiovascular disease.
Cardiovascular Diseases
Effects of CDKN2B-AS1 polymorphisms on the susceptibility to coronary heart disease.
Cardiovascular Diseases
Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation.
Cardiovascular Diseases
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Cardiovascular Diseases
Single nucleotide polymorphism on chromosome 9p21 and endothelial progenitor cells in a general population cohort.
Cardiovascular Diseases
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Carotid Stenosis
The Severity of Internal Carotid Artery Stenosis is Associated with the Cyclin-Dependent Kinase Inhibitor 2A Gene Expression.
Cataract
Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.
Cataract
[Epidemiology of Bietti's keratopathy. Study of risk factors in Central Africa (Chad)]
Central Nervous System Neoplasms
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors.
Cerebral Infarction
Localization and expression of cdc2 and cdk4 in Alzheimer brain tissue.
Cerebral Infarction
Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.
Cervical Intraepithelial Neoplasia
Enzyme-linked immunosorbent assay for p16(INK4a) - a new triage test for the detection of cervical intraepithelial neoplasia?
Cervical Intraepithelial Neoplasia
Expression of CK7 and CDKN2 in Cervical Intraepithelial Neoplasia and Correlation with Clinical Outcome.
Cervical Intraepithelial Neoplasia
Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents.
Cervical Intraepithelial Neoplasia
p16(INK4a) immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities : A systematic review and meta-analysis.
Cervical Intraepithelial Neoplasia
The triage of low-grade cytological abnormalities by the immunocytological expression of cyclin-dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+.
Chemical and Drug Induced Liver Injury
Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.
Cholangiocarcinoma
ADC cut points for chronic kidney disease in pathologically-proven cholangiocarcinoma.
Cholangiocarcinoma
Adenovirus expressing mutant p27kip1 enhanced apoptosis against cholangiocarcinoma than adenovirus-p27kip1 wild type.
Cholangiocarcinoma
Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model.
Cholangiocarcinoma
Apoptosis-related protein-1 acts as a tumor suppressor in cholangiocarcinoma cells by inducing cell cycle arrest via downregulation of cyclin-dependent kinase subunits.
Cholangiocarcinoma
Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment.
Cholangiocarcinoma
CRM-1 knockdown inhibits extrahepatic cholangiocarcinoma tumor growth by blocking the nuclear export of p27Kip1.
Cholangiocarcinoma
Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Cholangiocarcinoma
Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas.
Cholangiocarcinoma
The cyclin?dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma.
Cholangiocarcinoma
Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
Cholangitis
CRM-1 knockdown inhibits extrahepatic cholangiocarcinoma tumor growth by blocking the nuclear export of p27Kip1.
Cholangitis
miRNA-21 ablation protects against liver injury and necroptosis in cholestasis.
Cholangitis
Practical value of applying cdc2 kinase shRNA to chronic proliferative cholangitis in treatment of hepatolithiasis.
Cholesteatoma
Roles of cytokines and cell cycle regulating substances in proliferation of cholesteatoma epithelium.
Cholesteatoma, Middle Ear
Expression patterns of p27Kip1 and Ki-67 in cholesteatoma epithelium.
Chondrosarcoma
Array-comparative genomic hybridization of central chondrosarcoma: identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations.
Chondrosarcoma
Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Chordoma
Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.
Chordoma
Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
Chordoma
Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.
Chordoma
Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity.
Choriocarcinoma
Immunohistochemical expression of cell cycle proteins E2F-1, Cdk-2, Cyclin E, p27(kip1), and Ki-67 in normal placenta and gestational trophoblastic disease.
Choriocarcinoma
The expression of Cdk inhibitors p27kip1 and p57kip2 in mouse placenta and human choriocarcinoma JEG-3 cells.
Choriocarcinoma
[Effect of F10 gene silencing and over-expression on cell cycle of choriocarcinoma cell line JAR and the mechanisms].
Choroid Plexus Neoplasms
Expression of proline-directed protein kinase, (p34cdc2/p58cyclin A), a novel cell proliferation marker in childhood brain tumors.
Ciliopathies
A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness.
Ciliopathies
DNA replication stress underlies renal phenotypes in CEP290-associated Joubert syndrome.
Ciliopathies
NEK8 Links the ATR-Regulated Replication Stress Response and S Phase CDK Activity to Renal Ciliopathies.
Classical Lissencephalies and Subcortical Band Heterotopias
A novel neurological mutant mouse, yotari, which exhibits reeler-like phenotype but expresses CR-50 antigen/reelin.
Cleft Palate
Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome.
Clubfoot
Congenital dislocation of the knee reduced spontaneously or with minimal treatment.
Clubfoot
Early reduction for congenital dislocation of the knee within twenty-four hours of birth.
Coinfection
Accumulation of human papillomavirus type 16 E7 protein bypasses G1 arrest induced by serum deprivation and by the cell cycle inhibitor p21.
Coinfection
Characterization of the p125 subunit of human DNA polymerase delta and its deletion mutants. Interaction with cyclin-dependent kinase-cyclins.
Colonic Neoplasms
5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells.
Colonic Neoplasms
Adiponectin Represses Colon Cancer Cell Proliferation via AdipoR1- and -R2-Mediated AMPK Activation.
Colonic Neoplasms
Antiproliferative activity of mixed-ligand dien-Cu(II) complexes with thiazole, thiazoline and imidazole derivatives.
Colonic Neoplasms
Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells.
Colonic Neoplasms
Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling.
Colonic Neoplasms
Bisimidazoacridones induce a potent cytostatic effect in colon tumor cells that sensitizes them to killing by UCN-01.
Colonic Neoplasms
Butyrate-induced G2/M block in Caco-2 colon cancer cells is associated with decreased p34cdc2 activity.
Colonic Neoplasms
C-glycosyl flavone from Urginea indica inhibits proliferation & angiogenesis & induces apoptosis via cyclin-dependent kinase 6 in human breast, hepatic & colon cancer cell lines.
Colonic Neoplasms
Caco-2 intestinal cell differentiation is associated with G1 arrest and suppression of CDK2 and CDK4.
Colonic Neoplasms
CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.
Colonic Neoplasms
Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.
Colonic Neoplasms
Common targets for a deadly duo of diabetes mellitus and colon cancer: Catching two fish with one worm.
Colonic Neoplasms
CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest.
Colonic Neoplasms
Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells.
Colonic Neoplasms
Differential cyclin-dependent kinase expression and activation in human colon cancer.
Colonic Neoplasms
Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies.
Colonic Neoplasms
Downregulation of CDK-8 inhibits colon cancer hepatic metastasis by regulating Wnt/?-catenin pathway.
Colonic Neoplasms
Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells.
Colonic Neoplasms
Fargesin Inhibits EGF-Induced Cell Transformation and Colon Cancer Cell Growth by Suppression of CDK2/Cyclin E Signaling Pathway.
Colonic Neoplasms
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Colonic Neoplasms
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Colonic Neoplasms
Gene expression network analysis of lymph node involvement in colon cancer identifies AHSA2, CDK10, and CWC22 as possible prognostic markers.
Colonic Neoplasms
HY-1 induces G(2)/M cell cycle arrest in human colon cancer cells through the ATR-Chk1-Cdc25C and Weel pathways.
Colonic Neoplasms
IGFBP-rP1, a potential molecule associated with colon cancer differentiation.
Colonic Neoplasms
In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/G1 p53-associated cell cycle arrest.
Colonic Neoplasms
Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas.
Colonic Neoplasms
Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin.
Colonic Neoplasms
Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.
Colonic Neoplasms
Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1.
Colonic Neoplasms
Inhibition of mitotic cyclin B and cdc2 kinase activity by selenomethionine in synchronized colon cancer cells.
Colonic Neoplasms
Knockdown of PFTAIRE Protein Kinase 1 (PFTK1) Inhibits Proliferation, Invasion, and EMT in Colon Cancer Cells.
Colonic Neoplasms
Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.
Colonic Neoplasms
Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway.
Colonic Neoplasms
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Colonic Neoplasms
Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/?-catenin signaling pathway.
Colonic Neoplasms
Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells.
Colonic Neoplasms
p27 Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells.
Colonic Neoplasms
Pharmacological Inhibition of CDK8 in Triple-Negative Breast Cancer Cell Line MDA-MB-468 Increases E2F1 Protein, Induces Phosphorylation of STAT3 and Apoptosis.
Colonic Neoplasms
Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and autophagy in a time-dependent manner in HCT116 colon cancer cells.
Colonic Neoplasms
Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer.
Colonic Neoplasms
Silencing of the polyamine catabolic key enzyme SSAT prevents CDK inhibitor-induced apoptosis in Caco-2 colon cancer cells.
Colonic Neoplasms
Silencing Prion Protein in HT29 Human Colorectal Cancer Cells Enhances Anticancer Response to Fucoidan.
Colonic Neoplasms
Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.
Colonic Neoplasms
SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors.
Colonic Neoplasms
Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction.
Colonic Neoplasms
Suppression of colonic polyposis by homeoprotein CDX2 through its nontranscriptional function that stabilizes p27Kip1.
Colonic Neoplasms
Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides.
Colonic Neoplasms
The anti-tumor effect of miR-539-3p on colon cancer via regulating cell viability, motility, and nude mouse tumorigenicity with CDK14 inhibition.
Colonic Neoplasms
The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
Colonic Neoplasms
The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression).
Colonic Neoplasms
The Flavonoid Apigenin Downregulates CDK1 by Directly Targeting Ribosomal Protein S9.
Colorectal Neoplasms
A molecular dynamics investigation of CDK8/CycC and ligand binding: conformational flexibility and implication in drug discovery.
Colorectal Neoplasms
A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.
Colorectal Neoplasms
A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1.
Colorectal Neoplasms
Activation of cyclin E-dependent kinase activity in colorectal cancer.
Colorectal Neoplasms
Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma.
Colorectal Neoplasms
Anti-p21 autoantibodies detected in colorectal cancer patients: A proof of concept study.
Colorectal Neoplasms
Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer.
Colorectal Neoplasms
CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
Colorectal Neoplasms
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
Colorectal Neoplasms
CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis.
Colorectal Neoplasms
CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1.
Colorectal Neoplasms
Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.
Colorectal Neoplasms
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.
Colorectal Neoplasms
Correlation between the expressions of gastrin, somatostatin and cyclin and cyclin-depend kinase in colorectal cancer.
Colorectal Neoplasms
Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells.
Colorectal Neoplasms
Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737.
Colorectal Neoplasms
Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer.
Colorectal Neoplasms
Differences in loss of p16INK4 protein expression by promoter methylation between left- and right-sided primary colorectal carcinomas.
Colorectal Neoplasms
Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
Colorectal Neoplasms
Downregulation of lncRNA NR2F2 Antisense RNA 1 Induces G1 Arrest of Colorectal Cancer Cells by Downregulating Cyclin-Dependent Kinase 6.
Colorectal Neoplasms
Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment.
Colorectal Neoplasms
Effects of epidermal growth factor and its signal transduction inhibitors on apoptosis in human colorectal cancer cells.
Colorectal Neoplasms
Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma.
Colorectal Neoplasms
Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Colorectal Neoplasms
Expressions of cell cycle regulators in human colorectal cancer cell lines.
Colorectal Neoplasms
Frequent Amplification of CENPF, GMNN and CDK13 Genes in Hepatocellular Carcinomas.
Colorectal Neoplasms
High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer.
Colorectal Neoplasms
High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.
Colorectal Neoplasms
Identification of Phosphorylated Cyclin-Dependent Kinase 1 Associated with Colorectal Cancer Survival Using Label-Free Quantitative Analyses.
Colorectal Neoplasms
Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil.
Colorectal Neoplasms
Inactivation of the kinase domain of CDK10 prevents tumor growth in a preclinical model of colorectal cancer, and is accompanied by downregulation of Bcl-2.
Colorectal Neoplasms
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.
Colorectal Neoplasms
Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.
Colorectal Neoplasms
Mechanistic Studies of Cyclin-Dependent Kinase Inhibitor 3 (CDKN3) in Colorectal Cancer.
Colorectal Neoplasms
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Colorectal Neoplasms
MicroRNA-1258 Inhibits the Proliferation and Migration of Human Colorectal Cancer Cells through Suppressing CKS1B Expression.
Colorectal Neoplasms
microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs.
Colorectal Neoplasms
microRNA-769 is downregulated in colorectal cancer and inhibits cancer progression by directly targeting cyclin-dependent kinase 1.
Colorectal Neoplasms
Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells.
Colorectal Neoplasms
Nondysplastic Ulcerative Colitis Has High Levels of the Homologous Recombination Repair Protein NUCKS1 and Low Levels of the DNA Damage Marker Gamma-H2AX.
Colorectal Neoplasms
Notch1-dependent regulation of p27 determines cell fate in colorectal cancer.
Colorectal Neoplasms
p22/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis.
Colorectal Neoplasms
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
Colorectal Neoplasms
p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma.
Colorectal Neoplasms
p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
Colorectal Neoplasms
p53-independent inhibition of proliferation and p21(WAF1/Cip1)-modulated induction of cell death by the antioxidants N-acetylcysteine and vitamin E.
Colorectal Neoplasms
Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma.
Colorectal Neoplasms
Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice.
Colorectal Neoplasms
Personalized oncology through integrative high-throughput sequencing: a pilot study.
Colorectal Neoplasms
PI3K p110? Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells.
Colorectal Neoplasms
Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization.
Colorectal Neoplasms
Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas.
Colorectal Neoplasms
Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells.
Colorectal Neoplasms
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma.
Colorectal Neoplasms
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas.
Colorectal Neoplasms
Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer.
Colorectal Neoplasms
Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells.
Colorectal Neoplasms
Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.
Colorectal Neoplasms
Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer.
Colorectal Neoplasms
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Colorectal Neoplasms
Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells.
Colorectal Neoplasms
Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells.
Colorectal Neoplasms
Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer.
Colorectal Neoplasms
Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients.
Colorectal Neoplasms
Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways.
Colorectal Neoplasms
Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
Common Cold
p27Kip1-mediated controlled proliferation technology increases constitutive sICAM production in CHO-DUKX adapted for growth in suspension and serum-free media.
Congenital Abnormalities
Congenital dislocation of the knee reduced spontaneously or with minimal treatment.
Congenital Abnormalities
Congenital dislocation of the knee: overview of management options.
Corneal Diseases
Immunohistochemical localization of D-{beta}-aspartic acid-containing proteins in climatic droplet keratopathy.
Corneal Diseases
Tissue Microarray Analysis of Cyclin-Dependent Kinase Inhibitors p21 and p16 in Fuchs Dystrophy.
Corneal Dystrophies, Hereditary
Tissue Microarray Analysis of Cyclin-Dependent Kinase Inhibitors p21 and p16 in Fuchs Dystrophy.
Coronary Artery Disease
Association between rs3088440 (G?>?A) polymorphism at 9p21.3 locus with the occurrence and severity of coronary artery disease in an Iranian population.
Coronary Artery Disease
Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs.
Coronary Artery Disease
Ex vivo antisense oligonucleotides to proliferating cell nuclear antigen and Cdc2 kinase inhibit graft coronary artery disease.
Coronary Artery Disease
Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?
Coronary Artery Disease
Inhibition of CDK9 attenuates atherosclerosis by inhibiting inflammation and phenotypic switching of vascular smooth muscle cells.
Coronary Artery Disease
The role of CDKN2B in cardiovascular risk in ethnic Saudi Arabs: A validation study.
Coronary Disease
CDKN2B-AS1 gene rs4977574 A/G polymorphism and coronary heart disease: A meta-analysis of 40,979 subjects.
Coronary Disease
Increased Risk of CHD in the Presence of rs7865618 (A allele): Tehran Lipid and Glucose Study.
Coronary Disease
New findings in the roles of Cyclin-dependent Kinase inhibitors 2B Antisense RNA 1 (CDKN2B-AS1) rs1333049 G/C and rs4977574 A/G variants on the risk to coronary heart disease.
Costello Syndrome
Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis.
COVID-19
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Cushing Syndrome
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
cyclin-dependent kinase deficiency
A framework for understanding quality of life domains in individuals with the CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain.
cyclin-dependent kinase deficiency
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
cyclin-dependent kinase deficiency
Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Age-Related Cognitive and Motor Decline in a Mouse Model of CDKL5 Deficiency Disorder is Associated with Increased Neuronal Senescence and Death.
cyclin-dependent kinase deficiency
Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
cyclin-dependent kinase deficiency
Altered network and rescue of human neurons derived from individuals with early-onset genetic epilepsy.
cyclin-dependent kinase deficiency
Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
cyclin-dependent kinase deficiency
AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Brain morphological abnormalities in children with cyclin-dependent kinase-like 5 deficiency disorder.
cyclin-dependent kinase deficiency
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer.
cyclin-dependent kinase deficiency
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
cyclin-dependent kinase deficiency
CDKL5 deficiency augments inhibitory input into the dentate gyrus that can be reversed by deep brain stimulation.
cyclin-dependent kinase deficiency
CDKL5 deficiency disorder in males: Five new variants and review of the literature.
cyclin-dependent kinase deficiency
CDKL5 Deficiency Disorder-A Complex Epileptic Encephalopathy.
cyclin-dependent kinase deficiency
CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
cyclin-dependent kinase deficiency
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
cyclin-dependent kinase deficiency
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
cyclin-dependent kinase deficiency
Cerebral visual impairment in CDKL5 deficiency disorder: vision as an outcome measure.
cyclin-dependent kinase deficiency
Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
cyclin-dependent kinase deficiency
Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
cyclin-dependent kinase deficiency
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
cyclin-dependent kinase deficiency
Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
cyclin-dependent kinase deficiency
Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.
cyclin-dependent kinase deficiency
Comprehensive behavioral analysis of the Cdkl5 knockout mice revealed significant enhancement in anxiety- and fear-related behaviors and impairment in both acquisition and long-term retention of spatial reference memory.
cyclin-dependent kinase deficiency
Computational experiments reveal the efficacy of targeting CDK2 and CKIs for significantly lowering cellular senescence bar for potential cancer treatment.
cyclin-dependent kinase deficiency
Content Validation of Clinician-Reported Items for a Severity Measure for CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.
cyclin-dependent kinase deficiency
Cyclin-dependent-like kinase 5 is required for pain signaling in human sensory neurons and mouse models.
cyclin-dependent kinase deficiency
Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
cyclin-dependent kinase deficiency
Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Evoked Potentials and EEG Analysis in Rett Syndrome and Related Developmental Encephalopathies: Towards a Biomarker for Translational Research.
cyclin-dependent kinase deficiency
Expanding the phenotype of the CDKL5 deficiency disorder: Are seizures mandatory?
cyclin-dependent kinase deficiency
Exploring genotype-phenotype relationships in the CDKL5 deficiency disorder using an international dataset.
cyclin-dependent kinase deficiency
Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Functional and Structural Impairments in the Perirhinal Cortex of a Mouse Model of CDKL5 Deficiency Disorder Are Rescued by a TrkB Agonist.
cyclin-dependent kinase deficiency
Generation and characterization of human induced pluripotent stem cells (iPSCs) from three male and three female patients with CDKL5 Deficiency Disorder (CDD).
cyclin-dependent kinase deficiency
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
cyclin-dependent kinase deficiency
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
cyclin-dependent kinase deficiency
In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
cyclin-dependent kinase deficiency
Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
cyclin-dependent kinase deficiency
Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.
cyclin-dependent kinase deficiency
Microtubules: A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder?
cyclin-dependent kinase deficiency
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
cyclin-dependent kinase deficiency
Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Pregnenolone and pregnenolone-methyl-ether rescue neuronal defects caused by dysfunctional CLIP170 in a neuronal model of CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Proof-of-concept for a gene replacement approach to CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Reflex Seizures in a Patient with CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic.
cyclin-dependent kinase deficiency
Seizures in Mouse Models of Rare Neurodevelopmental Disorders.
cyclin-dependent kinase deficiency
Site-specific abnormalities in the visual system of a mouse model of CDKL5 deficiency disorder.
cyclin-dependent kinase deficiency
Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: Findings from a multicenter cohort.
cyclin-dependent kinase deficiency
Structural Bases of Atypical Whisker Responses in a Mouse Model of CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Synaptic Synthesis, Dephosphorylation, and Degradation: A NOVEL PARADIGM FOR AN ACTIVITY-DEPENDENT NEURONAL CONTROL OF CDKL5.
cyclin-dependent kinase deficiency
The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.
cyclin-dependent kinase deficiency
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
cyclin-dependent kinase deficiency
The perceived effects of cannabis products in the management of seizures in CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Therapeutic potential of pregnenolone and pregnenolone methyl ether on depressive and CDKL5 deficiency disorders: Focus on microtubule targeting.
cyclin-dependent kinase deficiency
Treatment with a GSK-3?/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
cyclin-dependent kinase deficiency
X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
Cystitis
Cyclin-dependent kinase 1 shows to be a potential genetic target for chemical cystitis.
Cystitis, Interstitial
Oncosuppressor protein p53 and cyclin-dependent kinase inhibitor p21 regulate interstitial cystitis associated gene expression.
Cysts
Ascofuranone: A Possible Therapeutic Tool for Autosomal Dominant Polycystic Kidney Disease? - Letter.
Cysts
Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Cysts
Early Cyst Growth Is Associated with the Increased Nuclear Expression of Cyclin D1/Rb Protein in an Autosomal-Recessive Polycystic Kidney Disease Rat Model.
Cysts
High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease.
Cysts
Induction of cdc2a and cyc1At expression in Arabidopsis thaliana during early phases of nematode-induced feeding cell formation.
Cysts
Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts.
Cysts
Regulation of a Myb transcription factor by cyclin-dependent kinase 2 in Giardia lamblia.
Cysts
Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease.
Cysts
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Cytomegalovirus Infections
Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7.
Deafness
A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness.
Dehydration
Regulation of cell cycle components during exposure to anoxia or dehydration stress in the wood frog, Rana sylvatica.
Dementia
CDK5 knockdown prevents hippocampal degeneration and cognitive dysfunction produced by cerebral ischemia.
Dementia
Cell cycle proteins preceded neuronal death after chronic cerebral hypoperfusion in rats.
Dementia
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Dementia
Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer's dementia patients.
Dementia
Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity.
Dementia
The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders.
Demyelinating Diseases
Cyclin-dependent kinase inhibitor flavopiridol promotes remyelination in a cuprizone induced demyelination model.
Demyelinating Diseases
Serine/Threonine-Protein Kinase PFTK1 Modulates Oligodendrocyte Differentiation via PI3K/AKT Pathway.
Dermatitis, Phototoxic
Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro.
Developmental Dysplasia of the Hip
Early reduction for congenital dislocation of the knee within twenty-four hours of birth.
Diabetes Mellitus
Angiotensin converting-enzyme inhibitor treatment reduces glomerular p16INK4 and p27Kip1 expression in diabetic BBdp rats.
Diabetes Mellitus
Association of a cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1 (CDKAL1) polymorphism with elevated hemoglobin A?(c) levels and the prevalence of metabolic syndrome in Japanese men: Interaction with dietary energy intake.
Diabetes Mellitus
CDKAL1 gene rs7756992 A/G polymorphism and type 2 diabetes mellitus: a meta-analysis of 62,567 subjects.
Diabetes Mellitus
Common variants in TCF7L2 and CDKAL1 genes and risk of type 2 diabetes mellitus in Egyptians.
Diabetes Mellitus
Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus.
Diabetes Mellitus
Cyclin-Dependent Kinase 5/p35/p39: A Novel and Imminent Therapeutic Target for Diabetes Mellitus.
Diabetes Mellitus
Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs.
Diabetes Mellitus
Inflammation and poor response to treatment with erythropoietin in chronic kidney disease.
Diabetes Mellitus
Studies of variations of the cyclin-dependent kinase inhibitor 1C and the cyclin-dependent kinase 4 genes in relation to type 2 diabetes mellitus and related quantitative traits.
Diabetes Mellitus
The type 2 diabetes mellitus susceptibility gene CDKAL1 polymorphism is associated with depressive symptom in first-episode drug-naive schizophrenic patients.
Diabetes Mellitus
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Diabetes Mellitus, Type 1
Cyclin-dependent kinase 4 hyperactivity promotes autoreactivity in the immune system but protects pancreatic cell mass from autoimmune destruction in the nonobese diabetic mouse model.
Diabetes Mellitus, Type 1
Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes.
Diabetes Mellitus, Type 2
Association between Type 2 Diabetes and CDKN2A/B: a meta-analysis study.
Diabetes Mellitus, Type 2
Association of a cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1 (CDKAL1) polymorphism with elevated hemoglobin A?(c) levels and the prevalence of metabolic syndrome in Japanese men: Interaction with dietary energy intake.
Diabetes Mellitus, Type 2
Cdk5 Inhibitory Peptide (CIP) Inhibits Cdk5/p25 Activity Induced by High Glucose in Pancreatic Beta Cells and Recovers Insulin Secretion from p25 Damage.
Diabetes Mellitus, Type 2
CDKAL1 gene rs7756992 A/G polymorphism and type 2 diabetes mellitus: a meta-analysis of 62,567 subjects.
Diabetes Mellitus, Type 2
Common variants in TCF7L2 and CDKAL1 genes and risk of type 2 diabetes mellitus in Egyptians.
Diabetes Mellitus, Type 2
Contribution of CDKAL1 rs7756992 and IGF2BP2 rs4402960 polymorphisms in Type 2 diabetes, diabetic complications, obesity risk and hypertension in the Tunisian population.
Diabetes Mellitus, Type 2
Cyclin-Dependent Kinase 5 Promotes Pancreatic {beta}-Cell Survival via Fak-Akt Signaling Pathways.
Diabetes Mellitus, Type 2
Distinct Hepatic PKA and CDK Signaling Pathways Control Activity-Independent Pyruvate Kinase Phosphorylation and Hepatic Glucose Production.
Diabetes Mellitus, Type 2
Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs.
Diabetes Mellitus, Type 2
Expression profiling of cell cycle genes in human pancreatic islets with and without type 2 diabetes.
Diabetes Mellitus, Type 2
Genetic variants of cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1 and transcription factor 7-like 2 are not associated with polycystic ovary syndrome in Chinese women.
Diabetes Mellitus, Type 2
Pharmacogenomics of Sulfonylureas Response in Relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 Regulatory Subunit-associated Protein 1-like (CDKAL1) Gene in Iranian Type 2 Diabetes Patients.
Diabetes Mellitus, Type 2
Studies of variations of the cyclin-dependent kinase inhibitor 1C and the cyclin-dependent kinase 4 genes in relation to type 2 diabetes mellitus and related quantitative traits.
Diabetes Mellitus, Type 2
The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel.
Diabetes Mellitus, Type 2
The type 2 diabetes mellitus susceptibility gene CDKAL1 polymorphism is associated with depressive symptom in first-episode drug-naive schizophrenic patients.
Diabetic Nephropathies
CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via erk1/2/ppar? pathway.
Diabetic Nephropathies
Cyclin-dependent kinase 5 contributes to endoplasmic reticulum stress induced podocyte apoptosis via promoting MEKK1 phosphorylation at Ser280 in diabetic nephropathy.
Diabetic Nephropathies
LNCRNA CDKN2B-AS1 regulates mesangial cell proliferation and extracellular matrix accumulation via miR-424-5p/HMGA2 axis.
Diabetic Nephropathies
Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis.
Diabetic Nephropathies
p16ink4a Expression Is Increased through 12-Lipoxygenase in High Glucose-Stimulated Glomerular Mesangial Cells and Type 2 Diabetic Glomeruli.
Diabetic Nephropathies
The Expression of Intermediate Filament Protein Nestin and Its Association with Cyclin-Dependent Kinase 5 in the Glomeruli of Rats With Diabetic Nephropathy.
DNA Repair-Deficiency Disorders
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Down Syndrome
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Down Syndrome
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Down Syndrome
Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario.
Drug Resistant Epilepsy
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
Drug Resistant Epilepsy
Amelioration of intractable epilepsy by adjunct vagus nerve stimulation therapy in a girl with a CDKL5 mutation.
Drug Resistant Epilepsy
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
Drug Resistant Epilepsy
CDKL5 and Shootin1 Interact and Concur in Regulating Neuronal Polarization.
Drug Resistant Epilepsy
CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility.
Drug Resistant Epilepsy
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
Drug Resistant Epilepsy
CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons.
Drug Resistant Epilepsy
CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
Drug Resistant Epilepsy
Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
Drug Resistant Epilepsy
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
Drug Resistant Epilepsy
Impacts of caring for a child with the CDKL5 disorder on parental wellbeing and family quality of life.
Drug Resistant Epilepsy
Mutation screening of the CDKL5 gene in cryptogenic infantile intractable epilepsy and review of clinical sensitivity.
Drug Resistant Epilepsy
Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy.
Drug Resistant Epilepsy
Pathogenic role of the X-linked cyclin-dependent kinase-like 5 and aristaless-related homeobox genes in epileptic encephalopathy of unknown etiology with onset in the first year of life.
Drug Resistant Epilepsy
Re: CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
Drug Resistant Epilepsy
Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships.
Drug Resistant Epilepsy
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Drug Resistant Epilepsy
Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
Drug Resistant Epilepsy
What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.
Drug Resistant Epilepsy
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
Dry Eye Syndromes
Surface alterations, corneal hypoesthesia, and iris atrophy in patients with climatic droplet keratopathy.
Dwarfism
The Mediator kinase module acts as a positive regulator of salicylic acid accumulation and systemic acquired resistance.
Dyskinesias
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Dysplastic Nevus Syndrome
Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Dysplastic Nevus Syndrome
Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.
Encephalitis
Cell cycle inhibitor enhances the resolution of HSV-1-induced proinflammatory response in murine microglial cells.
Encephalitis
Isolated spinal cord contusion in rats induces chronic brain neuroinflammation, neurodegeneration, and cognitive impairment. Involvement of cell cycle activation.
Encephalitis
Isolated spinal cord contusion in rats induces chronic brain neuroinflammation, neurodegeneration, and cognitive impairment: Involvement of cell cycle activation.
Encephalitis, Herpes Simplex
Cell cycle inhibitor enhances the resolution of HSV-1-induced proinflammatory response in murine microglial cells.
Encephalomyelitis
CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice.
Encephalomyelitis
Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice.
Encephalomyelitis, Autoimmune, Experimental
Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis.
Endometrial Hyperplasia
Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.
Endometrial Hyperplasia
Loss of cables, a cyclin-dependent kinase regulatory protein, is associated with the development of endometrial hyperplasia and endometrial cancer.
Endometrial Hyperplasia
The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.
Endometrial Neoplasms
Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
Endometrial Neoplasms
Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-?B transcriptional signaling.
Endometrial Neoplasms
Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21(Waf1/Cip1) and p27(Kip1).
Endometrial Neoplasms
Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
Endometrial Neoplasms
Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers.
Endometrial Neoplasms
Cyclin-dependent kinase 4/6-specific activities as a biomarker for prognosis and chemosensitivity in endometrial cancer.
Endometrial Neoplasms
Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
Endometrial Neoplasms
Effect of cyclin-dependent kinase 7 silencing on cisplatin sensitivity in endometrial carcinoma cells.
Endometrial Neoplasms
Loss of cables, a cyclin-dependent kinase regulatory protein, is associated with the development of endometrial hyperplasia and endometrial cancer.
Endometrial Neoplasms
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Endometrial Neoplasms
Medroxyprogesterone acetate stimulates cdk inhibitors, p21 and p27, in endometrial carcinoma cells transfected with progesterone receptor-B cDNA.
Endometrial Neoplasms
p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein.
Endometrial Neoplasms
Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
Endometrial Neoplasms
Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
Endometrial Neoplasms
Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer.
Endometrial Neoplasms
Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
Endometrial Neoplasms
Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
Endometrial Neoplasms
The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer.
Endometrial Neoplasms
The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.
Endometrial Neoplasms
Transforming growth factor-beta, estrogen, and progesterone converge on the regulation of p27Kip1 in the normal and malignant endometrium.
Endometriosis
A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese.
Endometriosis
A potential role of cyclin-dependent kinase inhibitor 1 (p21/WAF1) in the pathogenesis of endometriosis: Directions for future research.
Endometriosis
Association of CDKN2B-AS and WNT4 genetic polymorphisms in Korean patients with endometriosis.
Endometriosis
Comprehensive characterization of endometrial competing endogenous RNA network in infertile women of childbearing age.
Endometriosis
Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Endometriosis
Expression of the cyclin-dependent kinase inhibitor p27Kip1 in eutopic endometrium and peritoneal endometriosis.
Endometriosis
[Regulatory mechanism of malignant behavior of endometriosis mediated by puerarin]
Endotoxemia
Cyclin-Dependent Kinase 9 Inhibition Suppresses Necroptosis and Pyroptosis in the Progress of Endotoxemia.
Ependymoma
Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Epilepsies, Myoclonic
Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
Epilepsies, Myoclonic
CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.
Epilepsies, Myoclonic
Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
Epilepsies, Myoclonic
Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience.
Epilepsies, Myoclonic
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Epilepsy
A case of CDKL5 disorder: improved ADL by simple treatment strategy for intractable epileptic seizures.
Epilepsy
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.
Epilepsy
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
Epilepsy
A novel p.Arg970X mutation in the last exon of the CDKL5 gene resulting in late-onset seizure disorder.
Epilepsy
Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
Epilepsy
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
Epilepsy
Analysis of Hungarian patients with Rett syndrome phenotype for MECP2, CDKL5 and FOXG1 gene mutations.
Epilepsy
Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
Epilepsy
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
Epilepsy
Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients.
Epilepsy
CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.
Epilepsy
CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
Epilepsy
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
Epilepsy
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
Epilepsy
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
Epilepsy
CDKL5 Mutations as a Cause of Severe Epilepsy in Infancy: Clinical and Electroencephalographic Long-term Course in 4 Patients.
Epilepsy
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
Epilepsy
CDKL5 PROTEIN SUBSTITUTION THERAPY RESCUES NEUROLOGICAL PHENOTYPES OF A MOUSE MODEL OF CDKL5 DISORDER.
Epilepsy
Clinical and electroencephalographic features in patients with CDKL5 mutations: two new Italian cases and review of the literature.
Epilepsy
Clinical evolution and epilepsy outcome in three patients with CDKL5-related developmental encephalopathy.
Epilepsy
Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
Epilepsy
Detection of a mosaic CDKL5 deletion and inversion by optical genome mapping ends an exhaustive diagnostic odyssey.
Epilepsy
Early-onset seizure variant of Rett syndrome: Definition of the clinical diagnostic criteria.
Epilepsy
Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in single generation families.
Epilepsy
Functional and Structural Impairments in the Perirhinal Cortex of a Mouse Model of CDKL5 Deficiency Disorder Are Rescued by a TrkB Agonist.
Epilepsy
Genetic Variants Identified from Epilepsy of Unknown Etiology in Chinese Children by Targeted Exome Sequencing.
Epilepsy
Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience.
Epilepsy
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Epilepsy
Historic, clinical, and prognostic features of epileptic encephalopathies caused by CDKL5 mutations.
Epilepsy
Identification of De Novo DNMT3A Mutations That Cause West Syndrome by Using Whole-Exome Sequencing.
Epilepsy
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
Epilepsy
Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
Epilepsy
Maternal origin of a novel C-terminal truncation mutation in CDKL5 causing a severe atypical form of Rett syndrome.
Epilepsy
Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.
Epilepsy
Neuron-Type Specific Loss of CDKL5 Leads to Alterations in mTOR Signaling and Synaptic Markers.
Epilepsy
Novel CDKL5 mutations were found in patients in China: retrospective investigation in cases of CDKL5-related disorders.
Epilepsy
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Epilepsy
Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.
Epilepsy
Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder.
Epilepsy
Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: Findings from a multicenter cohort.
Epilepsy
Targeted gene sequencing in 6994 individuals with neurodevelopmental disorder with epilepsy.
Epilepsy
The perceived effects of cannabis products in the management of seizures in CDKL5 Deficiency Disorder.
Epilepsy
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Epilepsy
White Matter Lesions Detected by Magnetic Resonance Imaging in Neonates and Children With Congenital Myotonic Dystrophy.
Epilepsy, Generalized
A maternally inherited frameshift CDKL5 variant in a male with global developmental delay and late-onset generalized epilepsy.
Epileptic Syndromes
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Epileptic Syndromes
Network for Therapy in Rare Epilepsies (NETRE): Lessons From the Past 15 Years.
Epstein-Barr Virus Infections
Investigation of differentially expressed genes in nasopharyngeal carcinoma by integrated bioinformatics analysis.
Epstein-Barr Virus Infections
MAGT1 is required for HeLa cell proliferation through regulating p21 expression, S-phase progress, and ERK/p38 MAPK MYC axis.
Epstein-Barr Virus Infections
Proteomics Analysis of Gastric Epithelial AGS Cells Infected with Epstein-Barr Virus.
Erythema Multiforme
Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions.
Esophageal Neoplasms
Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth.
Esophageal Neoplasms
CDKN2B, SLC19A3 and DLEC1 promoter methylation alterations in the bone marrow of patients with acute myeloid leukemia during chemotherapy.
Esophageal Neoplasms
Correlation between microvessel density (MVD) and multi-spiral CT (MSCT) perfusion parameters of esophageal cancer lesions and the diagnostic value of combined CtBP2 and P16INK4A.
Esophageal Neoplasms
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Esophageal Neoplasms
Induction of differentiation-dependent apoptosis in human esophageal squamous cell carcinoma by adenovirus-mediated p21sdi1 gene transfer.
Esophageal Neoplasms
Inhibition of pRB Pathway Differentially Modulates Apoptosis in Esophageal Cancer Cells.
Esophageal Neoplasms
Negative regulation of CDK6 expression by microRNA-126-5p and its influence on the proliferation and invasion of esophageal cancer cells.
Esophageal Neoplasms
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
Esophageal Squamous Cell Carcinoma
CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target.
Esophageal Squamous Cell Carcinoma
Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
Esophageal Squamous Cell Carcinoma
Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas.
Esophageal Squamous Cell Carcinoma
Low Expression of CyclinH and Cyclin-Dependent Kinase 7 Can Decrease the Proliferation of Human Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis.
Esophageal Squamous Cell Carcinoma
Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma.
Exanthema
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
Exfoliation Syndrome
[Epidemiology of Bietti's keratopathy. Study of risk factors in Central Africa (Chad)]
Exostoses
Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population.
Fanconi Anemia
Construction of a high-resolution physical and transcription map of chromosome 16q24.3: a region of frequent loss of heterozygosity in sporadic breast cancer.
Fanconi Anemia
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.
Fanconi Anemia
Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor.
Fanconi Anemia
The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2.
Fatty Liver
Significant lethality following liver resection in A20 heterozygous knockout mice uncovers a key role for A20 in liver regeneration.
Febrile Neutropenia
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Fibroma
Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions.
Fibromatosis, Aggressive
Analysis of p27KIP1 protein and Ki-67 expression in aggressive fibromatosis (desmoid tumor).
Fibromatosis, Aggressive
The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report.
Fibrosarcoma
Cell cycle control with minimal participation of Cdk2 in a murine fibrosarcoma clone cultured in protein-free medium.
Fibrosarcoma
p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells.
Fragile X Syndrome
A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders.
Fragile X Syndrome
Lens GABA receptors are a target of GABA-related agonists that mitigate experimental myopia.
Fragile X Syndrome
Serotonin 5-HT7 receptors require cyclin-dependent kinase 5 to rescue hippocampal synaptic plasticity in a mouse model of Fragile X Syndrome.
Frontotemporal Dementia
Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39.
Frontotemporal Dementia
Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast.
Fuchs' Endothelial Dystrophy
Tissue Microarray Analysis of Cyclin-Dependent Kinase Inhibitors p21 and p16 in Fuchs Dystrophy.
Gallbladder Neoplasms
Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma.
Gallbladder Neoplasms
miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M.
Gallbladder Neoplasms
Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
Ganglioglioma
Mutational and expression analysis of the reelin pathway components CDK5 and doublecortin in gangliogliomas.
Gastrointestinal Neoplasms
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
Gastrointestinal Neoplasms
Cyclin-Dependent Kinase Inhibitors and the Treatment of Gastrointestinal Cancers.
Gastrointestinal Stromal Tumors
Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.
Genetic Diseases, Inborn
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Genetic Diseases, Inborn
Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
Genetic Diseases, Inborn
Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.
Genetic Diseases, Inborn
Impacts of caring for a child with the CDKL5 disorder on parental wellbeing and family quality of life.
Genetic Diseases, Inborn
Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.
Gestational Trophoblastic Disease
Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease.
Glaucoma
CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States.
Glaucoma
Elevation of p-NR2A(S1232) by Cdk5/p35 contributes to retinal ganglion cell apoptosis in a rat experimental glaucoma model.
Glaucoma
Overexpression of CDKN1B inhibits fibroblast proliferation in a rabbit model of experimental glaucoma filtration surgery.
Glaucoma, Open-Angle
Analysis of Cyclin-Dependent Kinase Inhibitor-2B rs1063192 Polymorphism in Saudi Patients with Primary Open-Angle Glaucoma.
Glaucoma, Open-Angle
Association of polymorphisms in APOE, p53, and p21 with primary open-angle glaucoma in Turkish patients.
Glaucoma, Open-Angle
CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States.
Glaucoma, Open-Angle
[Epidemiology of Bietti's keratopathy. Study of risk factors in Central Africa (Chad)]
Glioblastoma
Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Glioblastoma
Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway.
Glioblastoma
Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme.
Glioblastoma
Chromosomal abnormalities in human glioblastomas: gain in chromosome 7p correlating with loss in chromosome 10q.
Glioblastoma
Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression.
Glioblastoma
Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
Glioblastoma
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma.
Glioblastoma
Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models.
Glioblastoma
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Glioblastoma
Fluorescent Biosensor of CDK5 Kinase Activity in Glioblastoma Cell Extracts and Living Cells.
Glioblastoma
G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells.
Glioblastoma
Gap Junctions Enhance the Antiproliferative Effect of MicroRNA-124-3p in Glioblastoma Cells.
Glioblastoma
Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase.
Glioblastoma
Identification of Quinazolinone Analogs Targeting CDK5 Kinase Activity and Glioblastoma Cell Proliferation.
Glioblastoma
Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma.
Glioblastoma
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Glioblastoma
Inhibition of glioma growth by flavokawain B is mediated through endoplasmic reticulum stress induced autophagy.
Glioblastoma
Interferon-? sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02.
Glioblastoma
Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma.
Glioblastoma
Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.
Glioblastoma
MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Glioblastoma
MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6.
Glioblastoma
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
Glioblastoma
Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy.
Glioblastoma
N-(4-Hydroxyphenyl)retinamide induced differentiation with repression of telomerase and cell cycle to increase interferon-gamma sensitivity for apoptosis in human glioblastoma cells.
Glioblastoma
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Glioblastoma
p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway.
Glioblastoma
p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis.
Glioblastoma
Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Glioblastoma
Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.
Glioblastoma
Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.
Glioblastoma
Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines.
Glioblastoma
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Glioblastoma
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
Glioblastoma
TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma.
Glioma
Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway.
Glioma
Anti-proliferative effect of Zea mays L. cob extract on rat C6 glioma cells through regulation of glycolysis, mitochondrial ROS, and apoptosis.
Glioma
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.
Glioma
Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.
Glioma
Bioinformatical analysis of gene expression signatures of different glioma subtypes.
Glioma
CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.
Glioma
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
Glioma
CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway.
Glioma
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Glioma
Cell surface aggregation of elastin receptor molecules caused by suramin amplified signals leading to proliferation of human glioma cells.
Glioma
Chronic treatment with ginsenoside Rg3 induces Akt-dependent senescence in human glioma cells.
Glioma
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Glioma
Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27(kip1).
Glioma
Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications.
Glioma
Coordinate up-regulation of cyclin-dependent kinase 4 and its inhibitor p16(INK4) in human glioma cells following chloroethylnitrosourea-induced DNA damage.
Glioma
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Glioma
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA.
Glioma
Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-iota in human glioma cells.
Glioma
Cyclin?dependent kinase 10 prevents glioma metastasis via modulation of Snail expression.
Glioma
Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
Glioma
Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation.
Glioma
DNA methylation and leukemia susceptibility in China: Evidence from an updated meta-analysis.
Glioma
Effect of glutamine or glucose deprivation on the expression of cyclin and cyclin-dependent kinase genes in glioma cell line U87 and its subline with suppressed activity of signaling enzyme of endoplasmic reticulum-nuclei-1.
Glioma
Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
Glioma
Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells.
Glioma
Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes.
Glioma
Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation.
Glioma
Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Glioma
Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway.
Glioma
Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas.
Glioma
Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.
Glioma
Histone demethylase KDM6B regulates 1,25-dihydroxyvitamin D3-induced senescence in glioma cells.
Glioma
Human glioma PKC-iota and PKC-betaII phosphorylate cyclin-dependent kinase activating kinase during the cell cycle.
Glioma
Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.
Glioma
Inhibition of cell cycle progression by penta-acetyl geniposide in rat C6 glioma cells.
Glioma
Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study.
Glioma
Interaction of transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) in human glioma cells.
Glioma
Interferon-? sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02.
Glioma
Long noncoding RNA FOXD2-AS1 promotes glioma cell cycle progression and proliferation through the FOXD2-AS1/miR-31/CDK1 pathway.
Glioma
Magnolol and honokiol exert a synergistic anti-tumor effect through autophagy and apoptosis in human glioblastomas.
Glioma
MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6.
Glioma
MicroRNA-613 impedes the proliferation and invasion of glioma cells by targeting cyclin-dependent kinase 14.
Glioma
miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
Glioma
Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.
Glioma
Oroxyloside inhibits human glioma progression by suppressing proliferation, metastasis and inducing apoptosis related pathways.
Glioma
Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.
Glioma
Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.
Glioma
Proliferation arrest and induction of CDK inhibitors p21 and p27 by depleting the calcium store in cultured C6 glioma cells.
Glioma
Protein kinase translocation following beta-adrenergic receptor activation in C6 glioma cells.
Glioma
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Glioma
Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.
Glioma
Sirtuin 7 promotes glioma proliferation and invasion through activation of the ERK/STAT3 signaling pathway.
Glioma
Staurosporine-induced Growth Inhibition of Glioma Cells is Accompanied by Altered Expression of Cyclins, CDKs and CDK Inhibitors.
Glioma
Staurosporine-induced growth inhibition of glioma cells is accompanied by altered expression of cyclins, CDKs and CDK inhibitors.
Glioma
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Glioma
The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
Glioma
The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Glioma
The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells.
Glioma
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Glioma
Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma.
Glioma
[Expression of cyclin-dependent kinase CDC2 and its significance in malignant progression of gliomas]
Glomerulonephritis
Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
Glomerulonephritis
Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.
Glomerulonephritis
R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury.
Glomerulonephritis
The cyclin-dependent kinase inhibitor p21 limits murine mesangial proliferative glomerulonephritis.
Glomerulonephritis
The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis.
Glomerulonephritis
Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis.
Glomerulonephritis
[Nephroprotective role of early correction of impaired nutritional status in patients with chronic disease of the kidneys at a predialysis stage]
Glomerulonephritis, IGA
Role of differential and cell type-specific expression of cell cycle regulatory proteins in mediating progressive glomerular injury in human IgA nephropathy.
Glomerulonephritis, Membranous
Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Glomerulosclerosis, Focal Segmental
Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Glomerulosclerosis, Focal Segmental
Phenotypic characteristics and cyclin-dependent kinase inhibitors repression in hyperplastic epithelial pathology in idiopathic focal segmental glomerulosclerosis.
Graft vs Host Disease
p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes.
Granulosa Cell Tumor
Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
Graves Disease
p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma.
Growth Hormone-Secreting Pituitary Adenoma
CDKN2A (p16INK4A) affects the anti?tumor effect of CDK inhibitor in somatotroph adenomas.
Head and Neck Neoplasms
Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor.
Head and Neck Neoplasms
BAI, a novel cyclin-dependent kinase inhibitor induces apoptosis in A549 cells through activation of caspases and inactivation of Akt.
Head and Neck Neoplasms
Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells.
Head and Neck Neoplasms
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Head and Neck Neoplasms
Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer.
Head and Neck Neoplasms
Double Edge: CDK2AP1 in Cell-cycle Regulation and Epigenetic Regulation.
Head and Neck Neoplasms
Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1.
Head and Neck Neoplasms
Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.
Head and Neck Neoplasms
Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA.
Head and Neck Neoplasms
Selective antitumor activity of roscovitine in head and neck cancer.
Head and Neck Neoplasms
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
Hearing Loss
Inactivation of Cyclin-Dependent Kinase 5 in Hair Cells Causes Hearing Loss in Mice.
Hearing Loss
p19(Ink4d) and p21(Cip1) collaborate to maintain the postmitotic state of auditory hair cells, their codeletion leading to DNA damage and p53-mediated apoptosis.
Hearing Loss
Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor Ink4d.
Hearing Loss
Rescue from early-onset hearing loss in a mouse model lacking the cyclin-dependent kinase inhibitor p19(Ink4d).
Hearing Loss
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Hearing Loss, Noise-Induced
CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.
Heart Defects, Congenital
A set of consensus mammalian mediator subunits identified by multidimensional protein identification technology.
Heart Defects, Congenital
De novo variants in CDK13 associated with syndromic ID/DD; molecular and clinical delineation of 15 individuals and a further review.
Heart Defects, Congenital
Mouse Model of Congenital Heart Defects, Dysmorphic Facial Features and Intellectual Developmental Disorders as a Result of Non-functional CDK13.
Heart Defects, Congenital
Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders.
Heart Defects, Congenital
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Heart Diseases
Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: Three patients without cardiac defects.
Heart Failure
Activation of cyclins and cyclin-dependent kinases, DNA synthesis, and myocyte mitotic division in pacing-induced heart failure in dogs.
Heart Failure
Cyclin-Dependent Kinase Inhibitor 2b Controls Fibrosis and Functional Changes in Ischemia-Induced Heart Failure via the BMI1-p15-Rb Signalling Pathway.
Heart Failure
Cyclin-dependent kinase inhibitor expression in human heart failure. A comparison with fetal development.
Heart Failure
The protective effect of 1,25(OH)2D3 against cardiac hypertrophy is mediated by the cyclin-dependent kinase inhibitor p21.
Hemangioma
[Expression and clinical significance of cyclin H and CDK7 in human hemangiomas]
Hematologic Neoplasms
A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
Hematologic Neoplasms
Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.
Hematologic Neoplasms
CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients.
Hematologic Neoplasms
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Hematologic Neoplasms
Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies.
Hematologic Neoplasms
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Hematologic Neoplasms
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Hematologic Neoplasms
Discovery of N-(4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies.
Hematologic Neoplasms
Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia.
Hematologic Neoplasms
Hypermethylation of the cell cycle inhibitor p15INK4b 3'-untranslated region interferes with its transcriptional regulation in primary lymphomas.
Hematologic Neoplasms
Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Hematologic Neoplasms
Metabolomic Applications to the Characterization of the Mode-of-Action of CDK Inhibitors.
Hematologic Neoplasms
Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia.
Hematologic Neoplasms
Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia.
Hematologic Neoplasms
p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing.
Hematologic Neoplasms
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Hematologic Neoplasms
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Hematologic Neoplasms
Suppression of cyclin D1 but not cdk4 or cyclin A with induction of melanoma terminal differentiation.
Hematologic Neoplasms
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Hematologic Neoplasms
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Hepatitis
Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis.
Hepatitis B
Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein.
Hepatitis B
Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway.
Hepatitis B
Hepatitis B Virus Pre-S2 Mutant Surface Antigen Induces Degradation of Cyclin-Dependent Kinase Inhibitor p27Kip1 through c-Jun Activation Domain-Binding Protein 1.
Hepatitis B
Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene.
Hepatitis B
Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs.
Hepatitis B
Requirement of cyclin-dependent kinase function for hepatitis B virus cccDNA synthesis as measured by digital PCR.
Hepatitis B
[Mitotic cyclins--new possibilities for examining mechanisms of neoplasm growth]
Hepatitis C
Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein.
Hepatitis C
Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene.
Hepatitis C
Hepatitis C virus core protein expression leads to biphasic regulation of the p21 cdk inhibitor and modulation of hepatocyte cell cycle.
Hepatitis C
Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-beta pathway.
Hepatitis C
Hepatitis C Virus NS5B Protein Delays S Phase Progression in Human Hepatocyte-derived Cells by Relocalizing Cyclin-dependent Kinase 2-interacting Protein (CINP).
Hepatitis C
Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.
Hepatoblastoma
Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.
Herpes Simplex
Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.
Herpes Simplex
cdc2 cyclin-dependent kinase binds and phosphorylates herpes simplex virus 1 U(L)42 DNA synthesis processivity factor.
Herpes Simplex
Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs.
Herpes Simplex
Establishment and use of a cell line expressing HSV-1 thymidine kinase to characterize viral thymidine kinase-dependent drug-resistance.
Herpes Simplex
Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.
Herpes Simplex
Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis.
Herpes Simplex
Herpes Simplex Virus 1 (HSV-1) ICP22 protein directly interacts with cyclin-dependent kinase (CDK)9 to inhibit RNA polymerase II transcription elongation.
Herpes Simplex
Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions.
Herpes Simplex
Identification of homeodomain proteins, PBX1 and PREP1, involved in the transcription of murine leukemia virus.
Herpes Simplex
Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
Herpes Simplex
Role of a cdk5-associated protein, p35, in herpes simplex virus type 1 replication in vivo.
Herpes Simplex
The Cyclin-Dependent Kinase 5 Inhibitor Peptide Inhibits Herpes Simplex Virus Type 1 Replication.
Herpes Simplex
The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0.
Herpes Simplex
The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0.
Herpes Simplex
Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons.
Herpes Simplex
[The role of cyclin-dependent protein kinase 2 in the replication of herpes simplex virus]
Herpes Zoster
Are Atlantic cod in Store Lungegårdsvann, a seawater recipient in Bergen, affected by environmental contaminants? A qRT-PCR survey.
Herpes Zoster
Cellular and Molecular Impact of Vitrification Versus Slow Freezing on Ovarian Tissue.
Hodgkin Disease
Apoptosis of malignant cells in Hodgkin's disease is related to expression of the cdk inhibitor p27KIP1.
Hodgkin Disease
Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease.
Huntington Disease
Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors in Huntington's Disease by Altering the DARPP-32 Phosphorylation Status in the Nucleus Accumbens.
Hydatidiform Mole
Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping.
Hyperalgesia
Activation of cyclin-dependent kinase 5 (Cdk5) in primary sensory and dorsal horn neurons by peripheral inflammation contributes to heat hyperalgesia.
Hyperalgesia
Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia.
Hyperalgesia
Cdk5 contributes to inflammation-induced thermal hyperalgesia mediated by the p38 MAPK pathway in microglia.
Hyperalgesia
Cdk5-Dependent Phosphorylation of CaV3.2 T-Type Channels: Possible Role in Nerve Ligation-Induced Neuropathic Allodynia and the Compound Action Potential in Primary Afferent C Fibers.
Hyperalgesia
Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain.
Hyperalgesia
Increased synaptophysin is involved in inflammation-induced heat hyperalgesia mediated by cyclin-dependent kinase 5 in rats.
Hyperalgesia
Phosphorylation of TRPV1 by cyclin-dependent kinase 5 promotes TRPV1 surface localization, leading to inflammatory thermal hyperalgesia.
Hyperalgesia
The BDNF/TrkB Signaling Pathway Is Involved in Heat Hyperalgesia Mediated by Cdk5 in Rats.
Hyperalgesia
VGLUT2/Cdk5/p25 Signaling Pathway Contributed to Inflammatory Pain by Complete Freund's Adjuvant.
Hypercalcemia
Multiple Endocrine Neoplasia Type 1 (MEN1) Phenocopy Due to a Cell Cycle Division 73 (CDC73) Variant.
Hyperparathyroidism
Mutational analysis of CDKN1B, a candidate tumor-suppressor gene, in refractory secondary/tertiary hyperparathyroidism.
Hyperparathyroidism, Primary
Caspase 8 and menin expressions are not correlated in human parathyroid tumors.
Hyperparathyroidism, Secondary
Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27.
Hypersensitivity
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Hypersensitivity
Ethanol-hypersensitive and ethanol-dependent cdc- mutants in Schizosaccharomyces pombe.
Hypersensitivity
Maintenance of open chromatin and selective genomic occupancy at the cell cycle-regulated histone H4 promoter during differentiation of HL-60 promyelocytic leukemia cells.
Hypersensitivity
Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Hypersensitivity
p21 promotes error-free replication-coupled DNA double-strand break repair.
Hypersensitivity
Protein phosphatase 5 and the tumor suppressor P53 down-regulate each other's activities in mice.
Hypersensitivity
TORC1 kinase and the S-phase cyclin Clb5 collaborate to promote mitotic spindle assembly and DNA replication in S. cerevisiae.
Hypertension
Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs.
Hypertension
Inflammation and poor response to treatment with erythropoietin in chronic kidney disease.
Hypertension
Posterior Reversible Encephalopathy Occurring During Treatment With Palbociclib.
Hypertension
The genetics of hypertension modifies the renal cell replication response induced by experimental diabetes.
Hypertension, Pulmonary
Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice.
Hypertension, Pulmonary
Gene expression of cyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension.
Hyperthyroidism
Thyroid status affects rat liver regeneration after partial hepatectomy by regulating cell cycle and apoptosis.
Hypertrophy, Left Ventricular
Downregulation of cyclin-dependent kinase inhibitors p21 and p27 in pressure-overload hypertrophy.
Hypothyroidism
Thyroid status affects rat liver regeneration after partial hepatectomy by regulating cell cycle and apoptosis.
Hypoxia, Brain
Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
Infarction, Middle Cerebral Artery
Cell cycle-related gene expression in the adult rat brain: selective induction of cyclin G1 and p21WAF1/CIP1 in neurons following focal cerebral ischemia.
Infarction, Middle Cerebral Artery
Expression of cyclin-dependent kinase 5 and its activator p35 in rat brain after middle cerebral artery occlusion.
Infarction, Middle Cerebral Artery
Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity.
Infections
A protein encoded by the latency-related gene of bovine herpesvirus 1 is expressed in trigeminal ganglionic neurons of latently infected cattle and interacts with cyclin-dependent kinase 2 during productive infection.
Infections
Accumulation of human papillomavirus type 16 E7 protein bypasses G1 arrest induced by serum deprivation and by the cell cycle inhibitor p21.
Infections
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Infections
Adenovirus E1B 55-Kilodalton Protein Targets SMARCAL1 for Degradation during Infection and Modulates Cellular DNA Replication.
Infections
AG490 inhibits G1-S traverse in BALB/c-3T3 cells following either mitogenic stimulation or exogenous expression of E2F-1.
Infections
Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.
Infections
Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
Infections
BRD4 Couples NF-?B/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection.
Infections
CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21.
Infections
cdc2 cyclin-dependent kinase binds and phosphorylates herpes simplex virus 1 U(L)42 DNA synthesis processivity factor.
Infections
CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck.
Infections
CDK9-dependent transcriptional elongation in the innate interferon-stimulated gene response to respiratory syncytial virus infection in airway epithelial cells.
Infections
Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells.
Infections
Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.
Infections
Classical swine fever virus Shimen infection increases p53 signaling to promote cell cycle arrest in porcine alveolar macrophages.
Infections
Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles.
Infections
Cyclin-Dependent Kinase CRK9, Required for Spliced Leader trans Splicing of Pre-mRNA in Trypanosomes, Functions in a Complex with a New L-Type Cyclin and a Kinetoplastid-Specific Protein.
Infections
Disease and Carrier Isolates of Neisseria meningitidis Cause G1 Cell Cycle Arrest in Human Epithelial Cells.
Infections
Distinct cell cycle regulation during saprophytic and pathogenic growth in fungal pathogens.
Infections
Early life infection alters adult BALB/c hippocampal gene expression in a sex specific manner.
Infections
Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment.
Infections
Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment.
Infections
FgCDC14 regulates cytokinesis, morphogenesis, and pathogenesis in Fusarium graminearum.
Infections
Hepatitis C virus core protein expression leads to biphasic regulation of the p21 cdk inhibitor and modulation of hepatocyte cell cycle.
Infections
Herpes simplex virus type 1 infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells.
Infections
Host CDK-1 and formin mediate microvillar effacement induced by enterohemorrhagic Escherichia coli.
Infections
HSV-1 upregulates p35, alters CDK-5 localization, and stimulates CDK-5 kinase activity during acute infection in neurons.
Infections
Human cytomegalovirus (HCMV) IE1 plays role in resistance to apoptosis with etoposide in cancer cell line by Cdk2 accumulation.
Infections
Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation.
Infections
Human T-cell lymphotropic virus type 1 infection of CD34+ hematopoietic progenitor cells induces cell cycle arrest by modulation of p21(cip1/waf1) and survivin.
Infections
Impact of clean delivery-kit use on newborn umbilical cord and maternal puerperal infections in Egypt.
Infections
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase.
Infections
Loss of Cyclin-Dependent Kinase Inhibitor Alters Oncolytic Adenovirus Replication and Promotes More Efficient Virus Production.
Infections
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
Infections
Nuclear export of the human cytomegalovirus tegument protein pp65 requires cyclin-dependent kinase activity and the Crm1 exporter.
Infections
Oct-1 is posttranslationally modified and exhibits reduced capacity to bind cognate sites at late times after infection with herpes simplex virus 1.
Infections
Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.
Infections
Phosphoproteomics to characterize host response during influenza A virus infection of human macrophages.
Infections
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Infections
Prolonged activation of the mitogen-activated protein kinase pathway promotes DNA synthesis in primary hepatocytes from p21Cip-1/WAF1-null mice, but not in hepatocytes from p16INK4a-null mice.
Infections
Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription.
Infections
Regulation of Hepatitis B Virus Replication by Cyclin Docking Motifs in Core Protein.
Infections
RGNNV-induced cell cycle arrest at G1/S phase enhanced viral replication via p53-dependent pathway in GS cells.
Infections
Rotavirus infection induces G1 to S phase transition in MA104 cells via Ca(+2)/Calmodulin pathway.
Infections
The CDK inhibitor p21Cip1/WAF1 is induced by Fc{gamma}R activation and restricts the replication of HIV-1 and related primate lentiviruses in human macrophages.
Infections
The cyclin dependent kinase subunit Cks1 is required for infection-associated development of the rice blast fungus Magnaporthe oryzae.
Infections
The cytotoxic effect of E1B 55-kDa mutant adenovirus on human hepatocellular carcinoma cell lines.
Infections
The latency-related gene of bovine herpesvirus 1 inhibits programmed cell death.
Infections
The local environment orchestrates mucosal decidual macrophage differentiation and substantially inhibits HIV-1 replication.
Infections
The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic.
Infections
The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase.
Infections
Two Cdc2 Kinase Genes with Distinct Functions in Vegetative and Infectious Hyphae in Fusarium graminearum.
Infections
Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest.
Infections
[Voriconazole compromises renal function in an elderly CDK patient with Candida albicans infection]
Infertility, Male
Cyclin-Dependent Kinase Inhibitor Gene TaICK1 acts as a Potential Contributor to Wheat Male Sterility induced by a Chemical Hybridizing Agent.
Inflammatory Bowel Diseases
Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features.
Inflammatory Breast Neoplasms
Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer.
Influenza, Human
Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication.
Influenza, Human
Phosphoproteomics to characterize host response during influenza A virus infection of human macrophages.
Insulin Resistance
A novel non-agonist peroxisome proliferator-activated receptor ? (PPAR?) ligand UHC1 blocks PPAR? phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
Insulin Resistance
Cyclin-dependent kinase inhibitor, p21WAF1/CIP1, is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance.
Insulin Resistance
Distinct Hepatic PKA and CDK Signaling Pathways Control Activity-Independent Pyruvate Kinase Phosphorylation and Hepatic Glucose Production.
Insulin Resistance
Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) ? activators and pan-PPAR partial agonists.
Insulin Resistance
Molecular Recognition of PPAR? by Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations.
Insulin Resistance
Thrap3 docks on phosphoserine 273 of PPAR? and controls diabetic gene programming.
Insulinoma
Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
Intellectual Disability
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.
Intellectual Disability
A maternally inherited frameshift CDKL5 variant in a male with global developmental delay and late-onset generalized epilepsy.
Intellectual Disability
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
Intellectual Disability
Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
Intellectual Disability
Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
Intellectual Disability
Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity.
Intellectual Disability
AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
Intellectual Disability
Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients.
Intellectual Disability
CDKL5 deficiency augments inhibitory input into the dentate gyrus that can be reversed by deep brain stimulation.
Intellectual Disability
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
Intellectual Disability
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
Intellectual Disability
CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons.
Intellectual Disability
CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.
Intellectual Disability
CDKL5 Gene-Related Epileptic Encephalopathy in Estonia: Four Cases, One Novel Mutation Causing Severe Phenotype in a Boy, and Overview of the Literature.
Intellectual Disability
CDKL5 localizes at the centrosome and midbody and is required for faithful cell division.
Intellectual Disability
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
Intellectual Disability
CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
Intellectual Disability
CDKL5 PROTEIN SUBSTITUTION THERAPY RESCUES NEUROLOGICAL PHENOTYPES OF A MOUSE MODEL OF CDKL5 DISORDER.
Intellectual Disability
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
Intellectual Disability
CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.
Intellectual Disability
Characterization of interstitial Xp duplications in two families by tiling path array CGH.
Intellectual Disability
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Intellectual Disability
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Intellectual Disability
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Intellectual Disability
De novo variants in CDK13 associated with syndromic ID/DD; molecular and clinical delineation of 15 individuals and a further review.
Intellectual Disability
Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Intellectual Disability
Early onset seizures and Rett-like features associated with mutations in CDKL5.
Intellectual Disability
Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in single generation families.
Intellectual Disability
Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.
Intellectual Disability
Functional characterization of CDK5 and CDK5R1 mutations identified in patients with non-syndromic intellectual disability.
Intellectual Disability
Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.
Intellectual Disability
HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder.
Intellectual Disability
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.
Intellectual Disability
Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features.
Intellectual Disability
In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
Intellectual Disability
Inhibition of GSK3? rescues hippocampal development and learning in a mouse model of CDKL5 disorder.
Intellectual Disability
Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
Intellectual Disability
Lens GABA receptors are a target of GABA-related agonists that mitigate experimental myopia.
Intellectual Disability
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3? signaling.
Intellectual Disability
Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.
Intellectual Disability
Molecular and genetic insights into an infantile epileptic encephalopathy - CDKL5 disorder.
Intellectual Disability
Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression.
Intellectual Disability
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.
Intellectual Disability
Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.
Intellectual Disability
Novel Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) Gene in Indian Cases of Rett Syndrome.
Intellectual Disability
Pathogenic role of the X-linked cyclin-dependent kinase-like 5 and aristaless-related homeobox genes in epileptic encephalopathy of unknown etiology with onset in the first year of life.
Intellectual Disability
Pregnenolone and pregnenolone-methyl-ether rescue neuronal defects caused by dysfunctional CLIP170 in a neuronal model of CDKL5 Deficiency Disorder.
Intellectual Disability
Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: Three patients without cardiac defects.
Intellectual Disability
Sequential Elution Interactome Analysis of the Mind Bomb 1 Ubiquitin Ligase Reveals a Novel Role in Dendritic Spine Outgrowth.
Intellectual Disability
Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy.
Intellectual Disability
Structural Bases of Atypical Whisker Responses in a Mouse Model of CDKL5 Deficiency Disorder.
Intellectual Disability
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
Intellectual Disability
Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice.
Intellectual Disability
X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
Intellectual Disability
Xp22.33p22.12 Duplication in a Patient with Intellectual Disability and Dysmorphic Facial Features.
Intervertebral Disc Degeneration
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-?B Signaling Pathway.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Ischemic Attack, Transient
Down-regulation of cyclin-dependent kinase 5 attenuates p53-dependent apoptosis of hippocampal CA1 pyramidal neurons following transient cerebral ischemia.
Ischemic Stroke
Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells.
Ischemic Stroke
Cyclin-dependent kinase inhibition with roscovitine: neuroprotection in acute ischemic stroke.
Ischemic Stroke
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
Ischemic Stroke
Expression of cyclin-dependent kinase 5 mRNA and protein in the human brain following acute ischemic stroke.
Ischemic Stroke
Hypothermia treatment ameliorated cyclin-dependent kinase 5-mediated inflammation in ischemic stroke and improved outcomes in ischemic stroke patients.
Ischemic Stroke
Hypothermia treatment reduced cyclin-dependent kinase 5-mediated inflammation in ischemic stroke and improved outcomes in ischemic stroke patients.
Ischemic Stroke
Neuronal expression of cell cycle-related proteins after brain ischaemia in man.
Keloid
Effects of the circ_101238/miR-138-5p/CDK6 axis on proliferation and apoptosis keloid fibroblasts.
Keloid
Effects of the cyclin-dependent kinase 10 (CDK10) on the tamoxifen sensitivity of keloid samples.
Keratitis
Immunohistochemical localization of D-{beta}-aspartic acid-containing proteins in climatic droplet keratopathy.
Keratitis
Phototherapeutic keratectomy for climatic droplet keratopathy, KKESH Excimer Laser Study Group. King Khaled Eye Specialist Hospital.
Keratoacanthoma
Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma.
Keratoacanthoma
Expression of the cyclin-dependent kinase inhibitor p27 in keratoacanthoma.
Keratosis, Actinic
Expression of G1/S-cyclins and cyclin-dependent kinase inhibitors in actinic keratosis and squamous cell carcinoma.
Kidney Diseases
Novel Substituted 1,6-Naphthyridines as CDK 5 Inhibitors for Treating Kidney Diseases.
Kidney Diseases, Cystic
Role of cyclin-dependent kinase 2 in the progression of mouse juvenile cystic kidney disease.
Kidney Failure, Chronic
Association between Nrf2 and CDKN2A expression in patients with end-stage renal disease: a pilot study.
Kidney Failure, Chronic
Construction and Validation of Predictive Model to Identify Critical Genes Associated with Advanced Kidney Disease.
Kidney Failure, Chronic
Somatopsychic correlates and quality of life of the dialyzed patient: a cross-sectional study.
Kidney Failure, Chronic
The aftermath of acute kidney injury: a narrative review of long-term mortality and renal function.
Kidney Failure, Chronic
The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure.
Kidney Neoplasms
Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Kidney Neoplasms
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
Kyphosis
An algorithmic strategy of surgical intervention for cervical degenerative kyphosis.
Language Development Disorders
Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications.
Laryngeal Neoplasms
Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer.
Leiomyoma
An essential role of p27 down-regulation in Fenvalerate-induced cell growth in human uterine leiomyoma and smooth muscle cells.
Leiomyoma
CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue.
Leiomyoma
Cyclin-dependent kinase inhibitor p27Kip1 controls growth and cell cycle progression in human uterine leiomyoma.
Leiomyoma
Human Chorionic Gonadotrophin as a Possible Mediator of Leiomyoma Growth during Pregnancy: Molecular Mechanisms.
Leiomyoma
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Leiomyoma
Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Leiomyosarcoma
CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue.
Leiomyosarcoma
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.
Leiomyosarcoma
Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma.
Leiomyosarcoma
Expression of cyclin-dependent kinase subunit 2 in uterine leiomyosarcoma cells.
Leiomyosarcoma
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Leishmaniasis, Visceral
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.
Lennox Gastaut Syndrome
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Leukemia
7,8-dihydroxyflavone induces G1 arrest of the cell cycle in U937 human monocytic leukemia cells via induction of the Cdk inhibitor p27 and downregulation of pRB phosphorylation.
Leukemia
A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest.
Leukemia
A new aspect on glutathione-associated biological function of MRP/GS-X pump and its gene expression.
Leukemia
A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5): modulation of cAMP-induced apoptosis in rat leukemia cells.
Leukemia
Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model.
Leukemia
Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.
Leukemia
AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD.
Leukemia
Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias.
Leukemia
Ampelopsin Inhibits Cell Proliferation and Induces Apoptosis in HL60 and K562 Leukemia Cells by Downregulating AKT and NF-?B Signaling Pathways.
Leukemia
Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines.
Leukemia
Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells.
Leukemia
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Leukemia
AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Leukemia
Binary and ternary solid dispersions of an anticancer preclinical lead, IIIM-290: In vitro and in vivo studies.
Leukemia
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Leukemia
c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguard.
Leukemia
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
Leukemia
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
Leukemia
Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
Leukemia
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Leukemia
Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors.
Leukemia
Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation.
Leukemia
Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism.
Leukemia
DNA methylation and leukemia susceptibility in China: Evidence from an updated meta-analysis.
Leukemia
Downregulation of Mcl-1 has anti-inflammatory pro-resolution effects and enhances bacterial clearance from the lung.
Leukemia
Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.
Leukemia
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Leukemia
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
Leukemia
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine.
Leukemia
Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).
Leukemia
Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation.
Leukemia
Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Leukemia
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Leukemia
Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Leukemia
Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells.
Leukemia
Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Leukemia
Guided myeloid leukemia cell differentiation by blocking a specific cell cycle stage.
Leukemia
Hes6 controls cell proliferation via interaction with cAMP-response element-binding protein-binding protein in the promyelocytic leukemia nuclear body.
Leukemia
High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia.
Leukemia
Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome.
Leukemia
Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias.
Leukemia
Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias.
Leukemia
Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias.
Leukemia
Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer.
Leukemia
Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors.
Leukemia
Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.
Leukemia
Isolation, identification and screening of microorganisms for cytotoxic activities from deep sea sediments at different pacific stations
Leukemia
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Leukemia
KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1.
Leukemia
Linalool preferentially induces robust apoptosis of a variety of leukemia cells via upregulating p53 and cyclin-dependent kinase inhibitors.
Leukemia
Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis.
Leukemia
Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Leukemia
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Leukemia
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Leukemia
Meeting Report:The 7th ESPE Growth Plate Working Group Symposium - EUROGROP June 27th 2007, Helsinki, Finland.
Leukemia
MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells.
Leukemia
Momilactone B induces apoptosis and G1 arrest of the cell cycle in human monocytic leukemia U937 cells through downregulation of pRB phosphorylation and induction of the cyclin-dependent kinase inhibitor p21Waf1/Cip1.
Leukemia
Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest.
Leukemia
p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia.
Leukemia
p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
Leukemia
PDX1, a cellular homeoprotein, binds to and regulates the activity of human cytomegalovirus immediate early promoter.
Leukemia
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Leukemia
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Leukemia
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Leukemia
Promyelocytic leukemia zinc finger-retinoic acid receptor ? (PLZF-RAR?), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes.
Leukemia
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Leukemia
Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.
Leukemia
Recent progress in molecular mechanisms of leukemogenesis: the cyclin-dependent kinase 4-inhibitor gene in human leukemias.
Leukemia
Repression of CDKN2C caused by PML/RAR? binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.
Leukemia
Role of promyelocytic leukemia zinc finger (PLZF) in cell proliferation and cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) gene repression.
Leukemia
Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.
Leukemia
Roscovitine enhances All-trans retinoic acid (ATRA)-induced leukemia cell differentiation: Novel effects on signaling molecules for a putative Cdk2 inhibitor.
Leukemia
Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
Leukemia
Selection of a Water-Soluble Salt Form of a Preclinical Candidate, IIIM-290: Multiwell-Plate Salt Screening and Characterization.
Leukemia
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Leukemia
Specific association of increased cyclin-dependent kinase 5 expression with monocytic lineage of differentiation of human leukemia HL60 cells.
Leukemia
Specific nuclear binding of anti-cdc2 on p34cdc2 positive autonomously grown human leukemia cells induces differentiation.
Leukemia
Suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of Cdk inhibitor p16 and down-regulation of pRB phosphorylation.
Leukemia
Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors.
Leukemia
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Leukemia
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
Leukemia
Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma.
Leukemia
The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Leukemia
The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
Leukemia
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.
Leukemia
The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.
Leukemia
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Leukemia
The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.
Leukemia
The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression.
Leukemia
The prognostic potential of coilin in association with p27 expression in pediatric acute lymphoblastic leukemia for disease relapse.
Leukemia
The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase.
Leukemia
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Leukemia
Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5.
Leukemia
TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells.
Leukemia
TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner.
Leukemia
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Leukemia
Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4.
Leukemia
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Leukemia
Up-regulation of Egr1 by 1,25-dihydroxyvitamin D3 contributes to increased expression of p35 activator of cyclin-dependent kinase 5 and consequent onset of the terminal phase of HL60 cell differentiation.
Leukemia
Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Leukemia
[Effect of MLL-AF9 fusion gene silence of acute monocytic leukemia cell line THP-1 on cyclin-dependent kinase inhibitor p27 expression]
Leukemia, B-Cell
PDX1, a cellular homeoprotein, binds to and regulates the activity of human cytomegalovirus immediate early promoter.
Leukemia, Erythroblastic, Acute
CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells.
Leukemia, Erythroblastic, Acute
Changes in p34cdc2 kinase activity and cyclin A during induced differentiation of murine erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Differential modulation of G1-S-phase cyclin-dependent kinase 2/cyclin complexes occurs during the acquisition of a polyploid DNA content.
Leukemia, Erythroblastic, Acute
GATA-1 directly regulates p21 gene expression during erythroid differentiation.
Leukemia, Erythroblastic, Acute
Manipulating the onset of cell cycle withdrawal in differentiated erythroid cells with cyclin-dependent kinases and inhibitors.
Leukemia, Erythroblastic, Acute
Modulation of MDM2/p53 and cyclin-activating kinase during the megakaryocyte differentiation of human erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Leukemia, Lymphocytic, Chronic, B-Cell
Ability to downregulate the level of cyclin-dependent kinase inhibitor p27(Kip1) after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.
Leukemia, Lymphocytic, Chronic, B-Cell
Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism.
Leukemia, Lymphocytic, Chronic, B-Cell
Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma.
Leukemia, Lymphocytic, Chronic, B-Cell
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Emerging Drug Profile: Cyclin-Dependent Kinase Inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Flavopiridol-induced iNOS downregulation during apoptosis of chronic lymphocytic leukemia cells is caspase-dependent.
Leukemia, Lymphocytic, Chronic, B-Cell
High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
Leukemia, Lymphocytic, Chronic, B-Cell
Inhibition of NF-?B-mediated signaling by the CDK inhibitor CR8 overcomes pro-survival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16) gene in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Leukemia, Lymphocytic, Chronic, B-Cell
Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Leukemia, Lymphocytic, Chronic, B-Cell
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Leukemia, Lymphocytic, Chronic, B-Cell
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Leukemia, Lymphocytic, Chronic, B-Cell
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.
Leukemia, Lymphocytic, Chronic, B-Cell
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Leukemia, Lymphoid
Inhibitor of Cyclin-dependent Kinase (CDK) Interacting with Cyclin A1 (INCA1) Regulates Proliferation and Is Repressed by Oncogenic Signaling.
Leukemia, Lymphoid
Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Leukemia, Monocytic, Acute
[Effect of MLL-AF9 fusion gene silence of acute monocytic leukemia cell line THP-1 on cyclin-dependent kinase inhibitor p27 expression]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene therapy for BCR-ABL(+) human CML with dual phosphorylation resistant p27(Kip1) and stable RNA interference using an EBV vector.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Leukemia, Myeloid
1-beta-D-arabinofuranosylcytosine activates tyrosine phosphorylation of p34cdc2 and its association with the Src-like p56/p53lyn kinase in human myeloid leukemia cells.
Leukemia, Myeloid
Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
Leukemia, Myeloid
CDK2 destabilizes tumor suppressor C/EBP? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
Leukemia, Myeloid
Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.
Leukemia, Myeloid
Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.
Leukemia, Myeloid
Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.
Leukemia, Myeloid
The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Leukemia, Myeloid
Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor.
Leukemia, Myeloid, Acute
"Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease.
Leukemia, Myeloid, Acute
CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide.
Leukemia, Myeloid, Acute
CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism.
Leukemia, Myeloid, Acute
CDKN1B encoding the cyclin-dependent kinase inhibitor 1B (p27) is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Leukemia, Myeloid, Acute
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
Leukemia, Myeloid, Acute
Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.
Leukemia, Myeloid, Acute
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia.
Leukemia, Myeloid, Acute
miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6).
Leukemia, Myeloid, Acute
Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Leukemia, Myeloid, Acute
Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
Leukemia, Myeloid, Acute
Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression.
Leukemia, Myeloid, Acute
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Leukemia, Myeloid, Acute
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Leukemia, Myeloid, Acute
[Apoptosis of acute myeloid leukemia HL-60 cells induced by CDK inhibitor SNS-032 and its molecular mechanisms].
Leukemia, Myeloid, Acute
[Methylation of the genes in the 9P21 region in children with acute myeloid leukemia].
Leukemia, Plasma Cell
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma.
Leukemia, Promyelocytic, Acute
Repression of CDKN2C caused by PML/RAR? binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.
Leukemia, Promyelocytic, Acute
Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4.
Leukemia, T-Cell
A cooperative interaction of human T-cell leukemia virus type 1 Tax with the p21 cyclin-dependent kinase inhibitor activates the human immunodeficiency virus type 1 enhancer.
Leukemia, T-Cell
Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model.
Leukemia, T-Cell
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.
Leukemia, T-Cell
Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.
Leukemia, T-Cell
Human T-cell leukemia virus type 1 Tax activates cyclin-dependent kinase inhibitor p21/Waf1/Cip1 expression through a p53-independent mechanism: Inhibition of cdk2.
Leukemia, T-Cell
Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-? prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes.
Leukemia, T-Cell
p21WAF1 modulates NF-kappaB signaling and induces anti-apoptotic protein Bcl-2 in Tax-expressing rat fibroblast.
Leukemia, T-Cell
Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein.
Leukemia, T-Cell
PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.
Leukemia, T-Cell
Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells.
Leukemia-Lymphoma, Adult T-Cell
Alteration of p16 (CDKN2) gene is associated with interleukin-2-induced tumor cell growth in adult T-cell leukemia.
Leukemia-Lymphoma, Adult T-Cell
Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients.
Leukoencephalopathies
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Leukopenia
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Leukoplakia
Expression of apoptotic signaling proteins in leukoplakia and oral lichen planus: quantitative and topographical studies.
Lewy Body Disease
Cyclin-dependent kinase 5 (Cdk5) associated with Lewy bodies in diffuse Lewy body disease.
Lichen Planus, Oral
Study of P21 Expression in Oral Lichen Planus and Oral Squamous Cell Carcinoma by Immunohistochemical Technique.
Lichen Sclerosus et Atrophicus
Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions.
Lipoma
Cyclin-dependent kinase inhibitor 2A (p16) distinguishes well-differentiated liposarcoma from lipoma.
Liposarcoma
Application of molecular biology to individualize therapy for patients with liposarcoma.
Liposarcoma
Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Liposarcoma
Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.
Liposarcoma
Cyclin-dependent kinase inhibitor 2A (p16) distinguishes well-differentiated liposarcoma from lipoma.
Liposarcoma
Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
Liposarcoma
The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
Liver Cirrhosis
Proliferative capability of hepatocytes and expression of G1-related cell cycle molecules in the development of liver cirrhosis in rats.
Liver Cirrhosis, Biliary
miRNA-21 ablation protects against liver injury and necroptosis in cholestasis.
Liver Diseases
Cyclin and cyclin-dependent kinase 1 mRNA expression in models of regenerating liver and human liver diseases.
Liver Diseases
Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma.
Liver Diseases, Alcoholic
Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs.
Liver Neoplasms
A cyclin-dependent kinase inhibitor (p21(WAF1/CIP1)) affects thymidine incorporation in human liver cancer cells.
Liver Neoplasms
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
Liver Neoplasms
Alterations in specific gene expression and focal neoplastic growth during spontaneous hepatocarcinogenesis in albumin-SV40 T antigen transgenic rats.
Liver Neoplasms
Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells.
Liver Neoplasms
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.
Liver Neoplasms
Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer.
Liver Neoplasms
Kaempferol induces autophagy through AMPK and AKT signaling molecules and causes G2/M arrest via downregulation of CDK1/cyclin B in SK-HEP-1 human hepatic cancer cells.
Liver Neoplasms
Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
Liver Neoplasms
Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation.
Liver Neoplasms
miR372 Promotes Progression of Liver Cancer Cells by Upregulating erbB-2 through Enhancement of YB-1.
Liver Neoplasms
Overexpression of CMTM7 inhibits cell growth and migration in liver cancer.
Liver Neoplasms
[The effect of p21 on transcription of survivin in hepatocellular carcinoma HepG2 cells and its regulation mechanism]
Liver Neoplasms, Experimental
Maturation-promoting factor and the regulation of the cell cycle.
Lung Diseases, Interstitial
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
Lung Injury
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
Lung Injury
Ifenprodil and Flavopiridol Identified by Genomewide RNA Interference Screening as Effective Drugs To Ameliorate Murine Acute Lung Injury after Influenza A H5N1 Virus Infection.
Lung Injury
Induction of A- and D-type cyclins and cdc2 kinase activity during recovery from short-term hyperoxic lung injury.
Lung Injury
Long non-coding RNA CDKN2B-AS1 enhances LPS-induced apoptotic and inflammatory damages in human lung epithelial cells via regulating the miR-140-5p/TGFBR2/Smad3 signal network.
Lung Injury
Serial analysis of gene expression in mice with lipopolysaccharide-induced acute lung injury.
Lung Injury
The cyclin-dependent kinase inhibitor p21 protects the lung from oxidative stress.
Lung Neoplasms
?-Cyclodextrin Interacts Close to Vinblastine Site of Tubulin and Delivers Curcumin Preferentially to the Tubulin Surface of Cancer Cell.
Lung Neoplasms
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
Lung Neoplasms
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Lung Neoplasms
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Lung Neoplasms
A two kinase-gene signature model using CDK2 and PAK4 expression predicts poor outcome in non-small cell lung cancers.
Lung Neoplasms
Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling.
Lung Neoplasms
An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Lung Neoplasms
Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.
Lung Neoplasms
Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells.
Lung Neoplasms
Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
Lung Neoplasms
Circular RNA circDLGAP4 is involved in lung cancer development through modulating microRNA-143/CDK1 axis.
Lung Neoplasms
Cis-diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells.
Lung Neoplasms
CKS2 Promotes the Growth in Non-Small-Cell Lung Cancer by Downregulating Cyclin-Dependent Kinase Inhibitor.
Lung Neoplasms
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Lung Neoplasms
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Lung Neoplasms
Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer.
Lung Neoplasms
Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.
Lung Neoplasms
Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer.
Lung Neoplasms
Cyclin-dependent kinase 5 controls vasculogenic mimicry formation in non-small cell lung cancer via the FAK-AKT signaling pathway.
Lung Neoplasms
Cyclin-dependent kinase 5 regulates the proliferation, motility and invasiveness of lung cancer cells through its effects on cytoskeletal remodeling.
Lung Neoplasms
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Lung Neoplasms
Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin Dependent Kinases 1 and 2.
Lung Neoplasms
Distinct Molecular Mechanisms Analysis of Three Lung Cancer Subtypes Based on Gene Expression Profiles.
Lung Neoplasms
DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1).
Lung Neoplasms
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
Lung Neoplasms
Downregulation of XIAP and Induction of Apoptosis by the Synthetic Cyclin-Dependent Kinase Inhibitor GW8510 in Non-Small Cell Lung Cancer Cells.
Lung Neoplasms
Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment.
Lung Neoplasms
Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action.
Lung Neoplasms
Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
Lung Neoplasms
Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells.
Lung Neoplasms
Enolase 1 differentially contributes to cell transformation in lung cancer but not in esophageal cancer.
Lung Neoplasms
Establishment of two data mining models of lung cancer screening based on three gene promoter methylations combined with telomere damage.
Lung Neoplasms
Expression of cell cycle regulating factor mRNA in small cell lung cancer xenografts.
Lung Neoplasms
Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase.
Lung Neoplasms
Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
Lung Neoplasms
Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer.
Lung Neoplasms
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins.
Lung Neoplasms
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
Lung Neoplasms
In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.
Lung Neoplasms
Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
Lung Neoplasms
Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells.
Lung Neoplasms
Inhibition of PI-3K restores nuclear p27(Kip1) expression in a mouse model of Kras-driven lung cancer.
Lung Neoplasms
Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells.
Lung Neoplasms
Integrated Analysis of lncRNAs and mRNAs Identifies a Potential Driver lncRNA FENDRR in Lung Cancer in Xuanwei, China.
Lung Neoplasms
Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells.
Lung Neoplasms
Knockdown of PFTK1 Expression by RNAi Inhibits the Proliferation and Invasion of Human Non-Small Lung Adenocarcinoma Cells.
Lung Neoplasms
Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas.
Lung Neoplasms
Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC.
Lung Neoplasms
Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer.
Lung Neoplasms
Mechanistic insight of cyclin-dependent kinase 5 in modulating lung cancer growth.
Lung Neoplasms
Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
Lung Neoplasms
miR-377 inhibited tumorous behaviors of non-small cell lung cancer through directly targeting CDK6.
Lung Neoplasms
Mitotic cell death caused by follistatin-like 1 inhibition is associated with up-regulated Bim by inactivated Erk1/2 in human lung cancer cells.
Lung Neoplasms
Modulation of cell cycle regulatory protein expression and suppression of tumor growth by mimosine in nude mice.
Lung Neoplasms
Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small cell lung cancers.
Lung Neoplasms
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
Lung Neoplasms
Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Lung Neoplasms
P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
Lung Neoplasms
p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide in human lung cancer cells.
Lung Neoplasms
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Lung Neoplasms
Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells.
Lung Neoplasms
Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Lung Neoplasms
Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Lung Neoplasms
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.
Lung Neoplasms
Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments.
Lung Neoplasms
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Lung Neoplasms
Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer.
Lung Neoplasms
RNA silencing of Cks1 induced G2/M arrest and apoptosis in human lung cancer cells.
Lung Neoplasms
RNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growth.
Lung Neoplasms
Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer.
Lung Neoplasms
Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study.
Lung Neoplasms
Screening of gene mutations associated with bone metastasis in nonsmall cell lung cancer.
Lung Neoplasms
SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Lung Neoplasms
Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.
Lung Neoplasms
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Lung Neoplasms
Targeting cyclin-dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies.
Lung Neoplasms
The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens.
Lung Neoplasms
The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines.
Lung Neoplasms
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
Lung Neoplasms
The tumor-growth inhibitory activity of flavanone and 2'-OH flavanone in vitro and in vivo through induction of cell cycle arrest and suppression of cyclins and CDKs.
Lung Neoplasms
Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
Lung Neoplasms
Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer.
Lung Neoplasms
Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
Lupus Erythematosus, Systemic
Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
Lupus Erythematosus, Systemic
Identification of Cyclin-dependent Kinase 1 as a Novel Regulator of Type 1 Interferon Signaling in Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
Lupus susceptibility region containing CDKN1B rs34330 mechanistically influences expression and function of multiple target genes, also linked to proliferation and apoptosis.
Lymphatic Metastasis
Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
Lymphatic Metastasis
Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.
Lymphatic Metastasis
Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis.
Lymphatic Metastasis
Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1? and beclin1 in Breast Cancer Patients.
Lymphatic Metastasis
p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma.
Lymphatic Metastasis
Prognostic significance of p34cdc2 expression in tongue squamous cell carcinoma.
Lymphedema
Transcriptome analysis and functional identification of adipose-derived mesenchymal stem cells in secondary lymphedema.
Lymphocytosis
Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Lymphoma
3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
Lymphoma
53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells.
Lymphoma
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Lymphoma
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas.
Lymphoma
A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Lymphoma
Altered regulation of cyclic AMP-dependent protein kinase in a mouse lymphoma cell line.
Lymphoma
Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines.
Lymphoma
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Lymphoma
Cdc2 expression in primary thyroid lymphoma: its relationship with biological aggressiveness and G2 cyclins.
Lymphoma
Cellular kinetic differences between Hodgkin's and anaplastic large cell lymphomas: relation to the expression of p34cdc2 and cyclin B-1.
Lymphoma
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Lymphoma
Cyclamin, a natural 13,28-epoxy triterpenoid saponin, synergistically enhances the cytotoxicity of chemotherapeutic drugs in human liver cancer cells but not non-neoplastic liver cells.
Lymphoma
Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma.
Lymphoma
Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas.
Lymphoma
Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas.
Lymphoma
Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Lymphoma
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Lymphoma
Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease.
Lymphoma
Expression and subcellular localization of cyclin-dependent kinase inhibitor p27 does not correlate with proliferation pattern of mantle lymphoma cells.
Lymphoma
Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas.
Lymphoma
Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1.
Lymphoma
Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas.
Lymphoma
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma.
Lymphoma
Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis.
Lymphoma
Growth regulation by p27Kip1 is abrogated by multiple mechanisms in aggressive malignant lymphomas.
Lymphoma
Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21.
Lymphoma
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
Lymphoma
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lymphoma
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Lymphoma
Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines.
Lymphoma
Isolation, identification and screening of microorganisms for cytotoxic activities from deep sea sediments at different pacific stations
Lymphoma
Long-term arsenite exposure induces premature senescence in B cell lymphoma A20 cells.
Lymphoma
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
Lymphoma
Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.
Lymphoma
Methylation analysis of cyclin-dependent kinase inhibitor genes in primary gastrointestinal lymphomas.
Lymphoma
Mutation analysis of the pRb pathway in 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas.
Lymphoma
Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
Lymphoma
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Lymphoma
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Lymphoma
p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease.
Lymphoma
Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas.
Lymphoma
Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas.
Lymphoma
Protein expression of cell cycle regulator, p27Kip1, correlates with histopathological grade of non-Hodgkin's lymphoma.
Lymphoma
Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels.
Lymphoma
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 in feline lymphoma.
Lymphoma
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Lymphoma
Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.
Lymphoma
Roles of the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in receptor-mediated apoptosis of WEHI 231 B lymphoma cells.
Lymphoma
Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study.
Lymphoma
Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma.
Lymphoma
Steroid- and retinoid-mediated growth arrest and apoptosis in WEHI-231 cells: role of NF-kappaB, c-Myc and CKI p27(Kip1).
Lymphoma
Study on the role of G1 cyclins in Epstein-Barr virus-associated human lymphomas maintained in severe combined immune deficiency (SCID) mice.
Lymphoma
Subunit interaction in cyclic AMP-dependent protein kinase of mutant lymphoma cells.
Lymphoma
Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report.
Lymphoma
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Lymphoma
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Lymphoma
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Lymphoma
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
Lymphoma
The localization of p34cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity.
Lymphoma
Thyroid status modulates T lymphoma growth via cell cycle regulatory proteins and angiogenesis.
Lymphoma, B-Cell
53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells.
Lymphoma, B-Cell
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Lymphoma, B-Cell
A Sterol from Soft Coral Induces Apoptosis and Autophagy in MCF-7 Breast Cancer Cells.
Lymphoma, B-Cell
Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway.
Lymphoma, B-Cell
Are Atlantic cod in Store Lungegårdsvann, a seawater recipient in Bergen, affected by environmental contaminants? A qRT-PCR survey.
Lymphoma, B-Cell
CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis.
Lymphoma, B-Cell
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Lymphoma, B-Cell
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
Lymphoma, B-Cell
Dietary supplementation with essential amino acids boosts the beneficial effects of rosuvastatin on mouse kidney.
Lymphoma, B-Cell
Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.
Lymphoma, B-Cell
Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line.
Lymphoma, B-Cell
EPO Mediates Neurotrophic, Neuroprotective, Anti-Oxidant, and Anti-Apoptotic Effects via Downregulation of miR-451 and miR-885-5p in SH-SY5Y Neuron-Like Cells.
Lymphoma, B-Cell
Expressions of the CIP/KIP family of CDK inhibitor proteins in primary intestinal large B-cell lymphomas: correlation with clinical outcomes.
Lymphoma, B-Cell
EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Herbal Extracts Induce Dermal Papilla Cell Proliferation of Human Hair Follicles.
Lymphoma, B-Cell
Hsp90 inhibitor SY-016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian cancer cells.
Lymphoma, B-Cell
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
Lymphoma, B-Cell
In silico and in vitro investigation of anticancer effect of newly synthesized nonivamide-s-allyl cysteine ester.
Lymphoma, B-Cell
Increased expression of S100A6 promotes cell proliferation in gastric cancer cells.
Lymphoma, B-Cell
Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.
Lymphoma, B-Cell
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.
Lymphoma, B-Cell
LncRNA THUMPD3-AS1 enhances the proliferation and inflammatory response of chondrocytes in osteoarthritis.
Lymphoma, B-Cell
Loss of mitofusin 2 links beta-amyloid-mediated mitochondrial fragmentation and Cdk5-induced oxidative stress in neuron cells.
Lymphoma, B-Cell
Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.
Lymphoma, B-Cell
Magnolin Inhibits Proliferation and Invasion of Breast Cancer MDA-MB-231 Cells by Targeting the ERK1/2 Signaling Pathway.
Lymphoma, B-Cell
miR-636 represses cell survival by targeting CDK6/Bcl-2 in cervical cancer.
Lymphoma, B-Cell
Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets.
Lymphoma, B-Cell
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Lymphoma, B-Cell
Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-? activity in vitro.
Lymphoma, B-Cell
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Lymphoma, B-Cell
Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs.
Lymphoma, B-Cell
Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets.
Lymphoma, B-Cell
Synthesis and Evaluation of Novel Cholestanoheterocyclic Steroids as Anticancer Agents.
Lymphoma, B-Cell
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Lymphoma, B-Cell
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Lymphoma, B-Cell
The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression.
Lymphoma, Follicular
The effect of TGFbeta1 on the expression and phosphorylation of key cell-cycle regulators in malignant B cells.
Lymphoma, Large B-Cell, Diffuse
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Lymphoma, Large B-Cell, Diffuse
Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1.
Lymphoma, Large B-Cell, Diffuse
EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation.
Lymphoma, Large B-Cell, Diffuse
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Lymphoma, Large-Cell, Anaplastic
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
Lymphoma, Mantle-Cell
A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Lymphoma, Mantle-Cell
Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia.
Lymphoma, Mantle-Cell
Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
Lymphoma, Mantle-Cell
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
Lymphoma, Mantle-Cell
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Lymphoma, Mantle-Cell
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Lymphoma, Mantle-Cell
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Lymphoma, Non-Hodgkin
Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1.
Lymphoma, Non-Hodgkin
Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Expression of p16/INK4a in posttransplantation lymphoproliferative disorders.
Lymphoma, Non-Hodgkin
Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27.
Lymphoma, Non-Hodgkin
The effect of TGFbeta1 on the expression and phosphorylation of key cell-cycle regulators in malignant B cells.
Lymphoma, T-Cell
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma.
Lymphoma, T-Cell
Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas.
Lymphoma, T-Cell
Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma.
Lymphoma, T-Cell
Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas.
Lymphoproliferative Disorders
Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders.
Malaria
Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.
Malaria
In silico three-dimensional pharmacophores for aiding the discovery of the Pfmrk (Plasmodium cyclin-dependent protein kinases) specific inhibitors for the therapeutic treatment of malaria.
Malaria
Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization.
Malaria
Structural model of the Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics.
Malformations of Cortical Development
The potential role of cyclin-dependent kinase 5 in focal cortical dysplasia.
Medulloblastoma
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.
Medulloblastoma
Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
Medulloblastoma
DiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets.
Medulloblastoma
Expression of p27kip1 and p53 in medulloblastoma: relationship with cell proliferation and survival.
Medulloblastoma
Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma.
Medulloblastoma
Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
Medulloblastoma
Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.
Medulloblastoma
p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.
Medulloblastoma
Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
Medulloblastoma
Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma.
Medulloblastoma
Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Medulloblastoma
VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.
Melanoma
12-O-tetradecanoylphorbol-13-acetate induces transient cell cycle arrest in G1 and G2 in metastatic melanoma cells: inhibition of phosphorylation of p34cdc2.
Melanoma
A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.
Melanoma
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
Melanoma
An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation.
Melanoma
Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma.
Melanoma
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
Melanoma
CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.
Melanoma
CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds.
Melanoma
Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation.
Melanoma
Cell cycle transitions and Cdk inhibition in melanoma therapy: Cyclin' through the options.
Melanoma
Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor.
Melanoma
Characterization of the CDKN2A and ARF genes in UV-induced melanocytic hyperplasias and melanomas of an opossum (Monodelphis domestica).
Melanoma
Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.
Melanoma
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model.
Melanoma
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions.
Melanoma
Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions.
Melanoma
Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.
Melanoma
Cyclin-dependent kinase 5 regulates proliferation, migration, tyrosinase activity, and melanin production in B16-F10 melanoma cells via the essential regulator p-CREB.
Melanoma
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors.
Melanoma
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. Mouriaux F,*(1) Maurage CA, Labalette P, Sablonniere B, Malecaze F, Darbon JM. Inv Ophthalmol Vis Sci 2000;41:2837-2843.
Melanoma
Death-signal-induced relocalization of cyclin-dependent kinase 11 to mitochondria.
Melanoma
Dermal fibroblasts induce cell cycle arrest and block epithelial-mesenchymal transition to inhibit the early stage melanoma development.
Melanoma
Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
Melanoma
Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes.
Melanoma
Does the PITSLRE gene complex contribute to the pathogenesis of malignant melanoma of the skin? A study of patient-derived tumor samples?
Melanoma
Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.
Melanoma
Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine.
Melanoma
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Melanoma
Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells.
Melanoma
Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin.
Melanoma
Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.
Melanoma
Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins.
Melanoma
Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Melanoma
Familial Melanoma-Associated Mutations in p16 Uncouple its Tumor-Suppressor Functions.
Melanoma
Familial melanoma: Clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
Melanoma
Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases.
Melanoma
First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
Melanoma
Fluorescent Peptide Biosensor for Probing CDK6 Kinase Activity in Lung Cancer Cell Extracts.
Melanoma
Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Melanoma
Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Melanoma
Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Melanoma
Generation of knockout mouse models of cyclin-dependent kinase inhibitors by engineered nuclease-mediated genome editing.
Melanoma
Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion.
Melanoma
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.
Melanoma
Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.
Melanoma
Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma.
Melanoma
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Melanoma
High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas.
Melanoma
Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
Melanoma
Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells.
Melanoma
Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27.
Melanoma
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Melanoma
Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation.
Melanoma
Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations.
Melanoma
In vitro behavior and UV response of melanocytes derived from carriers of CDKN2A mutations and MC1R variants.
Melanoma
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Melanoma
Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Melanoma
Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine.
Melanoma
Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor.
Melanoma
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Melanoma
Interferon regulates expression of mda-6/WAF1/CIP1 and cyclin-dependent kinases independently from p53 in B16 murine melanoma cells.
Melanoma
Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
Melanoma
Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity.
Melanoma
Investigating DNA methylation as a potential mediator between pigmentation genes, pigmentary traits and skin cancer.
Melanoma
Lack of p21waf1 and p27kip1 protein induction by interferon-alpha2a in human melanoma cell lines.
Melanoma
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Melanoma
Lycorine hydrochloride inhibits melanoma cell proliferation, migration and invasion via down-regulating p21Cip1/WAF1.
Melanoma
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Melanoma
Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
Melanoma
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Melanoma
MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth.
Melanoma
Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.
Melanoma
Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN gamma.
Melanoma
Molecular pathogenesis of malignant melanoma: A different perspective from the studies of melanocytic nevus and acral melanoma.
Melanoma
Multiple neurofibromas as the presenting feature of familial atypical multiple malignant melanoma (FAMMM) syndrome.
Melanoma
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
Melanoma
Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
Melanoma
New established melanoma cell lines: genetic and biochemical characterization of cell division cycle.
Melanoma
Normal repair of ultraviolet radiation-induced DNA damage in familial melanoma without CDKN2A or CDK4 gene mutation.
Melanoma
Novel CDKN2A mutations detected in western Swedish families with hereditary malignant melanoma.
Melanoma
NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.
Melanoma
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Melanoma
Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma.
Melanoma
p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.
Melanoma
p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Melanoma
p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression.
Melanoma
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Melanoma
Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Melanoma
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
Melanoma
Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
Melanoma
Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis.
Melanoma
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
Melanoma
Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-?B Pathways.
Melanoma
Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.
Melanoma
Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
Melanoma
Reduced expression of SRY-box containing gene 17 correlates with an unfavorable melanoma patient survival.
Melanoma
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Melanoma
Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90.
Melanoma
Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity.
Melanoma
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Melanoma
Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma.
Melanoma
Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.
Melanoma
Sensitization of Melanoma Cells for Death Ligand TRAIL Is Based on Cell Cycle Arrest, ROS Production, and Activation of Proapoptotic Bcl-2 Proteins.
Melanoma
Silencing of astrocyte elevated gene-1 inhibits proliferation and migration of melanoma cells and induces apoptosis.
Melanoma
Some molecular and clinical aspects of genetic predisposition to malignant melanoma and tumours of various site of origin.
Melanoma
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
Melanoma
Structural organization, mapping, characterization and evolutionary relationships of CDKN2 gene family members in Xiphophorus fishes.
Melanoma
Suppression of cyclin D1 but not cdk4 or cyclin A with induction of melanoma terminal differentiation.
Melanoma
Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
Melanoma
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
Melanoma
The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling.
Melanoma
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Melanoma
The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest.
Melanoma
The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells.
Melanoma
Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
Melanoma
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells.
Melanoma
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Melanoma
WD repeat and SOCS box containing protein 2 in the proliferation, cycle progression, and migration of melanoma cells.
Melanoma
[Cyclin-dependent kinase inhibitory proteins in normal and transformed choroidal melanocytes]
Melanoma, Experimental
Cyclin-dependent kinase 2 and cyclin A interaction with E2F are targets for tyrosine induction of B16 melanoma terminal differentiation.
Melanoma, Experimental
G1 phase-specific suppression of the Cdk2 activity by ginsenoside Rh2 in cultured murine cells.
Memory Disorders
Cyclin-dependent kinase inhibitor flavopiridol promotes remyelination in a cuprizone induced demyelination model.
Memory Disorders
Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.
Memory Disorders
Tolfenamic acid inhibits GSK-3? and PP2A mediated tau hyperphosphorylation in Alzheimer's disease models.
Meningioma
Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02.
Mental Retardation, X-Linked
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Mental Retardation, X-Linked
Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.
Mesothelioma
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
Mesothelioma
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
Mesothelioma
Fluorescent Peptide Biosensor for Probing CDK6 Kinase Activity in Lung Cancer Cell Extracts.
Mesothelioma
Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
Mesothelioma
Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Mesothelioma, Malignant
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
Mesothelioma, Malignant
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
Mesothelioma, Malignant
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma.
Mesothelioma, Malignant
The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Mesothelioma, Malignant
Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Metabolic Syndrome
Association of a cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1 (CDKAL1) polymorphism with elevated hemoglobin A?(c) levels and the prevalence of metabolic syndrome in Japanese men: Interaction with dietary energy intake.
Metabolic Syndrome
Invited commentary: Gene x lifestyle interactions and complex disease traits--inferring cause and effect from observational data, sine qua non.
Microcephaly
CDK5RAP2 Expression During Murine and Human Brain Development Correlates with Pathology in Primary Autosomal Recessive Microcephaly.
Microcephaly
Revisiting the phenotype associated with FOXG1 mutations: two novel cases of congenital Rett variant.
Microphthalmos
Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Motor Neuron Disease
Alterations in cyclin-dependent protein kinase 5 (CDK5) protein levels, activity and immunocytochemistry in canine motor neuron disease.
Mouth Neoplasms
Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability.
Mouth Neoplasms
Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer.
Mouth Neoplasms
Helioxanthin suppresses the cross talk of COX-2/PGE2 and EGFR/ERK pathway to inhibit Arecoline-induced Oral Cancer Cell (T28) proliferation and blocks tumor growth in xenografted nude mice.
Mouth Neoplasms
Molecular docking analysis of piperine with CDK2,CDK4,Cyclin D and Cyclin T proteins.
Mouth Neoplasms
p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo.
Mouth Neoplasms
p21{Waf1/CIP1} is a poor diagnostic and prognostic marker for OSCC although its expression increases in patients with N1 regional metastasis.
Mouth Neoplasms
Role of p21WAF1 in green tea polyphenol-induced growth arrest and apoptosis of oral carcinoma cells.
Mouth Neoplasms
The curcumin analog (PAC) suppressed cell survival and induced apoptosis and autophagy in oral cancer cells.
Mouth Neoplasms
[Effect of long chain non-coding RNA H19 on the migration and invasion of oral cancer cells and its molecular mechanism].
Movement Disorders
Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
Movement Disorders
Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.
Multicystic Dysplastic Kidney
Novel CDK10 variants with multicystic dysplastic kidney, left ventricular non-compaction, and a solitary median maxillary central incisor.
Multiple Endocrine Neoplasia
Deficiency of the Cyclin-Dependent Kinase Inhibitor, CDKN1B, Results in Overgrowth and Neurodevelopmental Delay.
Multiple Endocrine Neoplasia
Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours.
Multiple Endocrine Neoplasia
Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4 (MEN4).
Multiple Endocrine Neoplasia
Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype.
Multiple Endocrine Neoplasia
Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid Adenomas.
Multiple Endocrine Neoplasia
Mutational analysis of CDKN1B, a candidate tumor-suppressor gene, in refractory secondary/tertiary hyperparathyroidism.
Multiple Endocrine Neoplasia
p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers.
Multiple Endocrine Neoplasia
p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors.
Multiple Endocrine Neoplasia
Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.
Multiple Endocrine Neoplasia
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Multiple Endocrine Neoplasia Type 1
Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours.
Multiple Endocrine Neoplasia Type 1
Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid Adenomas.
Multiple Endocrine Neoplasia Type 1
Molecular genetic advances in pituitary tumor development.
Multiple Endocrine Neoplasia Type 1
Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.
Multiple Myeloma
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Multiple Myeloma
Arylazopyrazole AAP1742 Inhibits CDKs and Induces Apoptosis in Multiple Myeloma Cells via Mcl-1 Downregulation.
Multiple Myeloma
Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
Multiple Myeloma
Cyclin D1 Overexpression Increases the Susceptibility of Human U266 Myeloma Cells to CDK Inhibitors Through a Process Involving p130-, p107- and E2F-Dependent S Phase Entry.
Multiple Myeloma
Cyclin D1 targets hexokinase 2 to control aerobic glycolysis in myeloma cells.
Multiple Myeloma
Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Multiple Myeloma
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.
Multiple Myeloma
EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma.
Multiple Myeloma
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
Multiple Myeloma
Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma.
Multiple Myeloma
Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.
Multiple Myeloma
Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.
Multiple Myeloma
Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma.
Multiple Myeloma
MicroRNA-26a inhibits multiple myeloma cell growth by suppressing cyclin-dependent kinase 6 expression.
Multiple Myeloma
MicroRNA-338-3p inhibits proliferation and promotes apoptosis of multiple myeloma cells through targeting Cyclin-dependent kinase 4.
Multiple Myeloma
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Multiple Myeloma
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Multiple Myeloma
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Multiple Myeloma
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Multiple Myeloma
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Multiple Myeloma
Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells.
Multiple Myeloma
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Multiple Myeloma
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Multiple Myeloma
The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.
Multiple Myeloma
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Multiple Myeloma
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Multiple System Atrophy
Cyclin-dependent kinase 5 and mitogen-activated protein kinase in glial cytoplasmic inclusions in multiple system atrophy.
Muscle Hypotonia
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Muscle Hypotonia
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
Muscle Hypotonia
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Muscle Hypotonia
What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.
Muscular Atrophy
Androgen depletion alters the diurnal patterns to signals that regulate autophagy in the limb skeletal muscle.
Muscular Atrophy
Spinal motor neuron loss occurs through a p53-and-p21-independent mechanism in the Smn2B/- mouse model of spinal muscular atrophy.
Muscular Atrophy, Spinal
Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.
Muscular Dystrophies
Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies.
Muscular Dystrophy, Duchenne
Antisense oligonucleotides and short interfering RNAs silencing the cyclin-dependent kinase inhibitor p21 improve proliferation of Duchenne muscular dystrophy patients' primary skeletal myoblasts.
Mycoses
IP7-SPX Domain Interaction Controls Fungal Virulence by Stabilizing Phosphate Signaling Machinery.
Mycosis Fungoides
MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.
Myelodysplastic Syndromes
Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors.
Myelodysplastic Syndromes
Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes.
Myelodysplastic Syndromes
Role of p15(INK4B) Methylation in Patients With Myelodysplastic Syndromes: A Systematic Meta-Analysis.
Myelodysplastic Syndromes
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Myeloproliferative Disorders
Kinases as drug discovery targets in hematologic malignancies.
Myocardial Infarction
Higher frequency of rs4977574 (the G Allele) on chromosome 9p21.3 in patients with myocardial infarction as revealed by PCR-RFLP analysis.
Myocardial Infarction
MTAP and CDKN2B genes are associated with myocardial infarction in Chinese Hans.
Myocardial Infarction
New findings in the roles of Cyclin-dependent Kinase inhibitors 2B Antisense RNA 1 (CDKN2B-AS1) rs1333049 G/C and rs4977574 A/G variants on the risk to coronary heart disease.
Myocarditis
Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy.
Myoepithelioma
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Myositis
Cyclin-dependent kinase 5 colocalizes with phosphorylated tau in human inclusion-body myositis paired-helical filaments and may play a role in tau phosphorylation.
Myositis, Inclusion Body
Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis.
Myotonic Dystrophy
CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model.
Myotonic Dystrophy
Reliable and versatile immortal muscle cell models from healthy and myotonic dystrophy type 1 primary human myoblasts.
Nasopharyngeal Carcinoma
CDK4 and miR-15a comprise an abnormal automodulatory feedback loop stimulating the pathogenesis and inducing chemotherapy resistance in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Cyclin-dependent kinase 4 overexpression is mostly independent of gene amplification and constitutes an independent prognosticator for nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Cyclin-dependent kinase inhibitor 3 promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting P27.
Nasopharyngeal Carcinoma
Decreased P27 protein expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
EBV-encoded LMP1 regulates Op18/stathmin signaling pathway by cdc2 mediation in nasopharyngeal carcinoma cells.
Nasopharyngeal Carcinoma
Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.
Nasopharyngeal Carcinoma
Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
miR-539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin-dependent kinase 4.
Nasopharyngeal Carcinoma
Nuclear expression of CDK4 correlates with disease progression and poor prognosis in human nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Nuclear p27 expression confers a favorable outcome for nasopharyngeal carcinoma patients.
Nasopharyngeal Carcinoma
Overexpression of CDC28 protein kinase regulatory subunit 1B confers an independent prognostic factor in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.
Nasopharyngeal Carcinoma
Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.
Nasopharyngeal Carcinoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Nasopharyngeal Carcinoma
Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.
Nematode Infections
Induction of cdc2a and cyc1At expression in Arabidopsis thaliana during early phases of nematode-induced feeding cell formation.
Nematode Infections
The Armadillo BTB Protein ABAP1 Is a Crucial Player in DNA Replication and Transcription of Nematode-Induced Galls.
Neoplasm Metastasis
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
Neoplasm Metastasis
Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells.
Neoplasm Metastasis
CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model.
Neoplasm Metastasis
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/? -catenin Signaling.
Neoplasm Metastasis
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
Neoplasm Metastasis
CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.
Neoplasm Metastasis
Characterization of a Candidate Tumor Suppressor Gene Uroplakin 1A in Esophageal Squamous Cell Carcinoma.
Neoplasm Metastasis
Chfr is linked to tumour metastasis through the downregulation of HDAC1.
Neoplasm Metastasis
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Neoplasm Metastasis
Codelivery of HIF-1? siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Neoplasm Metastasis
Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.
Neoplasm Metastasis
Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
Neoplasm Metastasis
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
Neoplasm Metastasis
Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser727 on STAT3 in prostate cancer cells.
Neoplasm Metastasis
Cyclin?dependent kinase 10 prevents glioma metastasis via modulation of Snail expression.
Neoplasm Metastasis
Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis.
Neoplasm Metastasis
Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.
Neoplasm Metastasis
Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis.
Neoplasm Metastasis
Downregulation of CDK-8 inhibits colon cancer hepatic metastasis by regulating Wnt/?-catenin pathway.
Neoplasm Metastasis
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
Neoplasm Metastasis
Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer.
Neoplasm Metastasis
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.
Neoplasm Metastasis
Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma.
Neoplasm Metastasis
Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1? and beclin1 in Breast Cancer Patients.
Neoplasm Metastasis
Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis.
Neoplasm Metastasis
Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma.
Neoplasm Metastasis
Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma.
Neoplasm Metastasis
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Neoplasm Metastasis
High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer.
Neoplasm Metastasis
Identification and characterization of a novel phosphoregulatory site on cyclin-dependent kinase 5.
Neoplasm Metastasis
Identification of hub genes associated with esophageal cancer progression using bioinformatics analysis.
Neoplasm Metastasis
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
Neoplasm Metastasis
Inhibitor of growth 4 suppresses colorectal cancer growth and invasion by inducing G1 arrest, inhibiting tumor angiogenesis and reversing epithelial-mesenchymal transition.
Neoplasm Metastasis
Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy.
Neoplasm Metastasis
Long noncoding RNA gastric cancer-related lncRNA1 mediates gastric malignancy through miRNA-885-3p and cyclin-dependent kinase 4.
Neoplasm Metastasis
Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis.
Neoplasm Metastasis
Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
Neoplasm Metastasis
MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
Neoplasm Metastasis
N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion.
Neoplasm Metastasis
p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription.
Neoplasm Metastasis
p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Neoplasm Metastasis
p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma.
Neoplasm Metastasis
Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling.
Neoplasm Metastasis
Polyketides from the marine-derived fungus Aspergillus falconensis: In silico and in vitro cytotoxicity studies.
Neoplasm Metastasis
Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
Neoplasm Metastasis
Prognostic significance of p34cdc2 expression in tongue squamous cell carcinoma.
Neoplasm Metastasis
Promoter-associated endogenous and exogenous small RNAs suppress human bladder cancer cell metastasis by activating p21 (CIP1/WAF1) expression.
Neoplasm Metastasis
Selective oestrogen receptor degraders in breast cancer: a review and perspectives.
Neoplasm Metastasis
Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression.
Neoplasm Metastasis
Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration.
Neoplasm Metastasis
Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma.
Neoplasm Metastasis
Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer.
Neoplasm Metastasis
The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.
Neoplasm Metastasis
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Neoplasm Metastasis
The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
Neoplasm Metastasis
Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis.
Neoplasm Metastasis
Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.
Neoplasm Metastasis
Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Neoplasm Metastasis
Up-regulated p27Kip1 reduces matrix metalloproteinase-9 and inhibits invasion of human breast cancer cells.
Neoplasm Metastasis
Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer.
Neoplasm, Residual
Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
Neoplasm, Residual
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.
Neoplasm, Residual
The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
Neoplasms
"Hedgehog pathway": a potential target of itraconazole in the treatment of cancer.
Neoplasms
2,4-bis (p-hydroxyphenyl)-2-butenal (HPB242) induces apoptosis via modulating E7 expression and inhibition of PI3K/Akt pathway in SiHa human cervical cancer cells.
Neoplasms
2-methoxyestradiol Prevents LNCaP Tumor Development in Nude Mice: Potential Role of G2/M Regulatory Proteins.
Neoplasms
3'-Hydroxypterostilbene Inhibits 7,12-Dimethylbenz[a]anthracene (DMBA)/12-O-Tetradecanoylphorbol-13-Acetate (TPA)-Induced Mouse Skin Carcinogenesis.
Neoplasms
3D Microenvironment Stiffness Regulates Tumor Spheroid Growth and Mechanics via p21 and ROCK.
Neoplasms
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Neoplasms
?-Cyclodextrin Interacts Close to Vinblastine Site of Tubulin and Delivers Curcumin Preferentially to the Tubulin Surface of Cancer Cell.
Neoplasms
A Bead-Based Microfluidic Approach to Integrated Single-Cell Gene Expression Analysis by Quantitative RT-PCR.
Neoplasms
A biomimetic assay platform for the interrogation of antigen-dependent anti-tumor T-cell function.
Neoplasms
A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence.
Neoplasms
A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
Neoplasms
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
Neoplasms
A conditional mouse mutant in the tumor suppressor SdhD gene unveils a link between p21(WAF1/Cip1) induction and mitochondrial dysfunction.
Neoplasms
A consensus cAMP-dependent protein kinase (PK-A) site in place of the CcN motif casein kinase II site simian virus 40 large T-antigen confers PK-A-mediated regulation of nuclear import.
Neoplasms
A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts.
Neoplasms
A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells.
Neoplasms
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
Neoplasms
A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers.
Neoplasms
A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors.
Neoplasms
A genomic approach to predict synergistic combinations for breast cancer treatment.
Neoplasms
A human tumour-derived mutant p53 protein induces a p34cdc2 reversible growth arrest in fission yeast.
Neoplasms
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis.
Neoplasms
A Mechanism Misregulating p27 in Tumors Discovered in a Functional Genomic Screen.
Neoplasms
A methoxyflavanone derivative from the Asian medicinal herb (Perilla frutescens) induces p53-mediated G2/M cell cycle arrest and apoptosis in A549 human lung adenocarcinoma.
Neoplasms
A naturally occurring mixture of tocotrienols inhibits the growth of human prostate tumor, associated with epigenetic modifications of cyclin-dependent kinase inhibitors p21 and p27.
Neoplasms
A new method for determining the status of p53 in tumor cell lines of different origin.
Neoplasms
A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
Neoplasms
A novel compound, ferulic acid-bound resveratrol, induces the tumor suppressor gene p15 and inhibits the three-dimensional proliferation of colorectal cancer cells.
Neoplasms
A novel cyclin-dependent kinase inhibitor down-regulates tumor necrosis factor-alpha (TNF-alpha)-induced expression of cell adhesion molecules by inhibition of NF-kappaB activation in human pulmonary epithelial cells.
Neoplasms
A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells.
Neoplasms
A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor.
Neoplasms
A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
Neoplasms
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
Neoplasms
A novel miRNA-mediated STOP sign in lung cancer: miR-340 inhibits the proliferation of lung cancer cells through p27(KIP1).
Neoplasms
A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype.
Neoplasms
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
Neoplasms
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Neoplasms
A Novel Tetranucleotide Repeat Polymorphism Within KCNQ1OT1 Confers Risk for Hepatocellular Carcinoma.
Neoplasms
A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts.
Neoplasms
A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases.
Neoplasms
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Neoplasms
A Phase 1 Study of Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Japanese Patients.
Neoplasms
A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
Neoplasms
A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers.
Neoplasms
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.
Neoplasms
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.
Neoplasms
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas.
Neoplasms
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Neoplasms
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.
Neoplasms
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Neoplasms
A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma.
Neoplasms
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Neoplasms
A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors.
Neoplasms
A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.
Neoplasms
A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer.
Neoplasms
A simple stochastic model for the feedback circuit between p16INK4a and p53 mediated by p38MAPK: implications for senescence and apoptosis.
Neoplasms
A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo.
Neoplasms
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
Neoplasms
A UNIQUE CDK4/6 INHIBITOR: CURRENT AND FUTURE THERAPEUTIC STRATEGIES OF ABEMACICLIB.
Neoplasms
A variable fork rate affects timing of origin firing and S phase dynamics in Saccharomyces cerevisiae.
Neoplasms
Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.
Neoplasms
Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype.
Neoplasms
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.
Neoplasms
Aberrant methylation in promoter regions of cyclin-dependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland.
Neoplasms
Aberrant methylation of hypermethylated-in-cancer-1 and exocyclic DNA adducts in tobacco smokers.
Neoplasms
Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China.
Neoplasms
Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
Neoplasms
Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation.
Neoplasms
Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines.
Neoplasms
Ablation of p21waf1cip1 expression enhances the capacity of p53-deficient human tumor cells to repair UVB-induced DNA damage.
Neoplasms
Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.
Neoplasms
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Neoplasms
Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification.
Neoplasms
Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.
Neoplasms
Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes.
Neoplasms
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
Neoplasms
Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
Neoplasms
Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway.
Neoplasms
Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
Neoplasms
Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
Neoplasms
Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Neoplasms
Activation of protein kinase C alpha is required for TPA-triggered ERK (MAPK) signaling and growth inhibition of human hepatoma cell HepG2.
Neoplasms
Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c).
Neoplasms
Activation of RB/E2F signaling pathway is required for the modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells.
Neoplasms
Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
Neoplasms
Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene.
Neoplasms
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Neoplasms
Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2.
Neoplasms
Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
Neoplasms
Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
Neoplasms
ACTL6A suppresses p21Cip1 expression to enhance the epidermal squamous cell carcinoma phenotype.
Neoplasms
Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma.
Neoplasms
Adenovirus expressing p27(Kip1) induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts.
Neoplasms
Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Neoplasms
Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Neoplasms
Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth.
Neoplasms
Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?
Neoplasms
Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia.
Neoplasms
Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain.
Neoplasms
Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization.
Neoplasms
Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Neoplasms
Alginate oligosaccharide alleviates enterotoxigenic Escherichia coli-induced intestinal mucosal disruption in weaned pigs.
Neoplasms
Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors.
Neoplasms
Alteration of G1 cell-cycle protein expression and induction of p53 but not p21/waf1 by the DNA-modifying carcinogen 2-acetylaminofluorene in growth-stimulated hepatocytes in vitro.
Neoplasms
Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling.
Neoplasms
Alterations in cytokine/antioncogene expression in skin lesions caused by "low-risk" types of human papillomaviruses.
Neoplasms
Alterations in Promoter Methylation Status of Tumor Suppressor HIC1, SFRP2, and DAPK1 Genes in Prostate Carcinomas.
Neoplasms
Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma.
Neoplasms
Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias.
Neoplasms
Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies.
Neoplasms
Alterations of the putative tumor suppressor gene p16/MTS1 in human hematological malignancies.
Neoplasms
Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma.
Neoplasms
Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis.
Neoplasms
Altered expression of GADD45 genes during the development of chemical-mediated liver hypertrophy and liver tumor promotion in rats.
Neoplasms
Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis.
Neoplasms
Alternative pathway of transcriptional induction of p21WAF1/Cip1 by cyclosporine A in p53-deficient human glioblastoma cells.
Neoplasms
Amniotic Membrane-Derived Cells Inhibit Proliferation of Cancer Cell Lines by Inducing Cell Cycle Arrest.
Neoplasms
An AC-repeat adjacent to mouse Cdkn2B allows the detection of specific allelic losses in the p15INK4b and p16INK4a tumor suppressor genes.
Neoplasms
An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks.
Neoplasms
An Antitumor 2-Hydroxyarylidene-4-cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor: Interaction Between TX-1123 Derivatives and Src Kinase.
Neoplasms
An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation.
Neoplasms
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence.
Neoplasms
An evaluation of palbociclib as a breast cancer treatment option: a current update.
Neoplasms
An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Neoplasms
An Indirubin Derivative, Indirubin-3'-Monoxime Suppresses Oral Cancer Tumorigenesis through the Downregulation of Survivin.
Neoplasms
An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridae.
Neoplasms
An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Neoplasms
An insight into the risk factors of brain tumors and their therapeutic interventions.
Neoplasms
An integrated chemical biology approach provides insight into cdk2 functional redundancy and inhibitor sensitivity.
Neoplasms
An opposite effect of the CDK inhibitor, p18(INK4c) on embryonic stem cells compared with tumor and adult stem cells.
Neoplasms
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Neoplasms
Analysis of location and integrity of the human PITSLRE (p58(cdc2L1)) genes in neuroblastoma cell genomes.
Neoplasms
Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias.
Neoplasms
Analysis of p27KIP1 protein and Ki-67 expression in aggressive fibromatosis (desmoid tumor).
Neoplasms
Analysis of promoter hypermethylation of death-associated protein kinase and p16 tumor suppressor genes in actinic keratoses and squamous cell carcinomas of the skin.
Neoplasms
Analysis of site-specific phosphorylation of the retinoblastoma protein during cell cycle progression.
Neoplasms
Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Neoplasms
Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Neoplasms
Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata.
Neoplasms
Annulus cells from more degenerated human discs show modified gene expression in 3D culture compared with expression in cells from healthier discs.
Neoplasms
Anti-angiogenic effects of novel cyclin-dependent kinase inhibitors with a pyrazolo[4,3-d]pyrimidine scaffold.
Neoplasms
Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway.
Neoplasms
Anti-proliferative effect of polysaccharides from Salicornia herbacea on induction of G2/M arrest and apoptosis in human colon cancer cells.
Neoplasms
Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro.
Neoplasms
Anticancer Activity of Ramalin, a Secondary Metabolite from the Antarctic Lichen Ramalina terebrata, against Colorectal Cancer Cells.
Neoplasms
Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS?032, on cervical cancer.
Neoplasms
Anticancer bioactive peptide (ACBP) inhibits gastric cancer cells by upregulating growth arrest and DNA damage-inducible gene 45A (GADD45A).
Neoplasms
Antineoplastic Activities, Apoptotic Mechanism of Action and Structural Properties of a Novel Silver(I) Chelate.
Neoplasms
Antiproliferative strategies for the treatment of vascular proliferative disease.
Neoplasms
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.
Neoplasms
Antitumor Activity of Ohmyungsamycin A through the Regulation of the Skp2-p27 Axis and MCM4 in Human Colorectal Cancer Cells.
Neoplasms
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Neoplasms
Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
Neoplasms
Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo.
Neoplasms
Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.
Neoplasms
AP4 directly downregulates p16 and p21 to suppress senescence and mediate transformation.
Neoplasms
Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.
Neoplasms
Apoptosis oxidative damage-mediated and antiproliferative effect of selenylated imidazo[1,2-a]pyridines on hepatocellular carcinoma HepG2 cells and in vivo.
Neoplasms
Apoptosis-related protein-1 acts as a tumor suppressor in cholangiocarcinoma cells by inducing cell cycle arrest via downregulation of cyclin-dependent kinase subunits.
Neoplasms
Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.
Neoplasms
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Neoplasms
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Neoplasms
Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells.
Neoplasms
Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27.
Neoplasms
Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas.
Neoplasms
Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene.
Neoplasms
Association between variations in cell cycle genes and idiopathic pulmonary fibrosis.
Neoplasms
Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women.
Neoplasms
Association of polymorphisms in APOE, p53, and p21 with primary open-angle glaucoma in Turkish patients.
Neoplasms
Atherosclerosis and cancer: common molecular pathways of disease development and progression.
Neoplasms
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers.
Neoplasms
ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor.
Neoplasms
Attenuation of Aluminum Chloride-Induced Neuroinflammation and Caspase Activation Through the AKT/GSK-3? Pathway by Hesperidin in Wistar Rats.
Neoplasms
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.
Neoplasms
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Neoplasms
AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells.
Neoplasms
Baffled by bafilomycin: an anticancer agent that induces hypoxia-inducible factor-1alpha expression.
Neoplasms
BAI, a novel Cdk inhibitor, enhances farnesyltransferase inhibitor LB42708-mediated apoptosis in renal carcinoma cells through the downregulation of Bcl-2 and c-FLIP (L).
Neoplasms
Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT.
Neoplasms
Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells.
Neoplasms
Basic Pan-Cancer Analysis of the Carcinogenic Effects of Cyclin-Dependent Kinase 4 (CDK4) in Human Surface Tumors.
Neoplasms
Bauerenol, a triterpenoid from Indian Suregada angustifolia: Induces reactive oxygen species-mediated P38MAPK activation and apoptosis in human hepatocellular carcinoma (HepG2) cells.
Neoplasms
Bax-mediated cell death by the Gax homeoprotein requires mitogen activation but is independent of cell cycle activity.
Neoplasms
Bear Bile Powder Inhibits Growth of Hepatocellular Carcinoma via Suppressing STAT3 Signaling Pathway in Mice.
Neoplasms
Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
Neoplasms
Binary and ternary solid dispersions of an anticancer preclinical lead, IIIM-290: In vitro and in vivo studies.
Neoplasms
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells.
Neoplasms
Bitter Melon (Momordica charantia) Extract Suppresses Adrenocortical Cancer Cell Proliferation Through Modulation of the Apoptotic Pathway, Steroidogenesis, and Insulin-Like Growth Factor Type 1 Receptor/RAC-? Serine/Threonine-Protein Kinase Signaling.
Neoplasms
Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy.
Neoplasms
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Neoplasms
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Neoplasms
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
Neoplasms
Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary gland.
Neoplasms
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.
Neoplasms
Breast Cancer Special Feature: Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins.
Neoplasms
c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition.
Neoplasms
Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3.
Neoplasms
CAMK1 Phosphoinositide Signal-Mediated Protein Sorting and Transport Network in Human Hepatocellular Carcinoma (HCC) by Biocomputation.
Neoplasms
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
Neoplasms
Cancer dormancy: role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM.
Neoplasms
Cancer epigenomics: implications of DNA methylation in personalized cancer therapy.
Neoplasms
Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol.
Neoplasms
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.
Neoplasms
cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization.
Neoplasms
CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker.
Neoplasms
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Neoplasms
CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide.
Neoplasms
Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.
Neoplasms
CDK Inhibitor Targets: a Hit or Miss Proposition?: Cyclin-Dependent Kinase Inhibitors Kill Tumor Cells by Downregulation of Anti-apoptotic Proteins.
Neoplasms
CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.
Neoplasms
CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model.
Neoplasms
Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Neoplasms
CDK phosphorylation of the discs large tumour suppressor controls its localisation and stability.
Neoplasms
CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
Neoplasms
CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Neoplasms
CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue.
Neoplasms
CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.
Neoplasms
CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner.
Neoplasms
CDK1 inhibitors antagonize the immediate apoptosis triggered by spindle disruption but promote apoptosis following the subsequent rereplication and abnormal mitosis.
Neoplasms
CDK1 stabilizes HIF-1? via direct phosphorylation of Ser668 to promote tumor growth.
Neoplasms
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
Neoplasms
CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells.
Neoplasms
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
Neoplasms
CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.
Neoplasms
CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target.
Neoplasms
CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
Neoplasms
CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes.
Neoplasms
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Neoplasms
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Neoplasms
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Neoplasms
CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation.
Neoplasms
CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability.
Neoplasms
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/? -catenin Signaling.
Neoplasms
CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
Neoplasms
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
Neoplasms
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Neoplasms
CDK12: cellular functions and therapeutic potential of versatile player in cancer.
Neoplasms
CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients.
Neoplasms
CDK13, a Kinase Involved in Pre-mRNA Splicing, Is a Component of the Perinucleolar Compartment.
Neoplasms
CDK16 overexpressed in non-small cell lung cancer and regulates cancer cell growth and apoptosis via a p27-dependent mechanism.
Neoplasms
Cdk2 is required for breast cancer mediated by the low molecular weight isoform of cyclin E.
Neoplasms
CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity in vivo and in vitro.
Neoplasms
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
Neoplasms
CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons.
Neoplasms
CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer.
Neoplasms
CDK4 regulates lysosomal function and mTORC1 activation to promote cancer cell survival.
Neoplasms
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Neoplasms
CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAFV600 Melanoma via a p53 Dependent Pathway.
Neoplasms
CDK4/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity.
Neoplasms
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.
Neoplasms
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
Neoplasms
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.
Neoplasms
CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis.
Neoplasms
CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
Neoplasms
Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity.
Neoplasms
CDK5RAP3 Inhibits the Translocation of MCM6 to Influence the Prognosis in Gastric Cancer.
Neoplasms
CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck.
Neoplasms
CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
Neoplasms
CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
Neoplasms
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38?/MYC/PD-L1 signaling in non-small cell lung cancer.
Neoplasms
CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism.
Neoplasms
CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
Neoplasms
Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Neoplasms
CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation.
Neoplasms
CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia.
Neoplasms
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
Neoplasms
CDKN1B encoding the cyclin-dependent kinase inhibitor 1B (p27) is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
Neoplasms
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
Neoplasms
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.
Neoplasms
CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.
Neoplasms
CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.
Neoplasms
CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia.
Neoplasms
Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis.
Neoplasms
CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis.
Neoplasms
CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1-Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion.
Neoplasms
CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
Neoplasms
CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.
Neoplasms
CDKN3 promotes cell proliferation, invasion and migration by activating the AKT signaling pathway in esophageal squamous cell carcinoma.
Neoplasms
Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway.
Neoplasms
Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.
Neoplasms
Cell cycle arrest mediated by a pyridopyrimidine is not abrogated by over-expression of Bcl-2 and cyclin D1.
Neoplasms
Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines.
Neoplasms
Cell cycle inhibitor p21/ WAF1/ CIP1 as a cofactor of MITF expression in melanoma cells.
Neoplasms
Cell Cycle Regulating Kinase Cdk4 as a Potential Target for Tumor Cell Treatment and Tumor Imaging.
Neoplasms
Cell cycle regulation by bevacizumab in ARPE-19 human retinal pigment epithelial cells.
Neoplasms
Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours.
Neoplasms
Cell cycle regulatory proteins in the liver in murine Trypanosoma cruzi infection.
Neoplasms
Cell cycle-dependent translation of p27 involves a responsive element in its 5'-UTR that overlaps with a uORF.
Neoplasms
Cell cyclins and cyclin-dependent kinase activities in mouse mammary tumor development.
Neoplasms
Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.
Neoplasms
Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
Neoplasms
Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers.
Neoplasms
Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix.
Neoplasms
Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor.
Neoplasms
Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line.
Neoplasms
Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations.
Neoplasms
Characterization of protein tyrosine kinase activity in murine Leydig tumor cells.
Neoplasms
Characterization of regulatory elements on the promoter region of p16(INK4a) that contribute to overexpression of p16 in senescent fibroblasts.
Neoplasms
Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Neoplasms
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.
Neoplasms
Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells.
Neoplasms
Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
Neoplasms
Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets.
Neoplasms
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Neoplasms
Chemoproteomic Profiling Uncovers CDK4-Mediated Phosphorylation of the Translational Suppressor 4E-BP1.
Neoplasms
Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
Neoplasms
ChIP-Seq analysis identifies p27(Kip1)-target genes involved in cell adhesion and cell signalling in mouse embryonic fibroblasts.
Neoplasms
Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer.
Neoplasms
Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation.
Neoplasms
Circular RNA CircCCNB1 sponges micro RNA-449a to inhibit cellular senescence by targeting CCNE2.
Neoplasms
Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas.
Neoplasms
Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
Neoplasms
Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway.
Neoplasms
Cisplatin's potential for type 2 diabetes repositioning by inhibiting CDKN1A, FAS, and SESN1.
Neoplasms
CKS protein overexpression renders tumors susceptible to a chemotherapeutic strategy that protects normal tissues.
Neoplasms
Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors.
Neoplasms
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Neoplasms
Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases.
Neoplasms
Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/CASP-3 during apoptosis induced by tumor necrosis factor.
Neoplasms
Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
Neoplasms
Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27(kip1).
Neoplasms
Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis.
Neoplasms
Clinicopathological features of atypical lipomatous tumors of the laryngopharynx.
Neoplasms
Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma.
Neoplasms
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Neoplasms
Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
Neoplasms
Co-purification of p34cdc2/p58cyclin A proline-directed protein kinase and the retinoblastoma tumor susceptibility gene product: interaction of an oncogenic serine/threonine protein kinase with a tumor-suppressor protein.
Neoplasms
Codelivery of HIF-1? siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Neoplasms
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Neoplasms
Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Neoplasms
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer.
Neoplasms
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Neoplasms
Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Neoplasms
Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity.
Neoplasms
Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
Neoplasms
Commentary on "A new cancer diagnostic system based on a CDK profiling technology" [Biochim. Biophys. Acta Molecular Basis of Disease 1741 (2005) 226-233].
Neoplasms
Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications.
Neoplasms
Comparative proteomic analysis of colon cancer cells in response to Oxaliplatin treatment.
Neoplasms
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Neoplasms
Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma.
Neoplasms
Comparison of p16INK4A and Hybrid Capture 2 human papillomavirus testing as adjunctive tests in liquid-based gynecologic SurePath preparations.
Neoplasms
Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Neoplasms
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model.
Neoplasms
Comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms' tumor.
Neoplasms
Computational experiments reveal the efficacy of targeting CDK2 and CKIs for significantly lowering cellular senescence bar for potential cancer treatment.
Neoplasms
Computational study to evaluate the potency of phytochemicals in Boerhavia diffusa and the impact of point mutation on cyclin-dependent kinase 2-associated protein 1.
Neoplasms
Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients.
Neoplasms
Consequences of p53 gene expression by adenovirus vector on cell cycle arrest and apoptosis in human aortic vascular smooth muscle cells.
Neoplasms
Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
Neoplasms
Constitutive CCND1/CDK2 activity substitutes for p53 loss, or MYC or oncogenic RAS expression in the transformation of human mammary epithelial cells.
Neoplasms
Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53.
Neoplasms
Contrasting behavior of the p18INK4c and p16INK4a tumor suppressors in both replicative and oncogene-induced senescence.
Neoplasms
Contribution of the dual coding capacity of the p16INK4a/MTS1/CDKN2 locus to human malignancies.
Neoplasms
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.
Neoplasms
Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.
Neoplasms
Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.
Neoplasms
Cooperative role between p21cip1/waf1 and p27kip1 in premature senescence in glandular proliferative lesions in mice.
Neoplasms
Correction: Combined Depletion of Cell Cycle and Transcriptional Cyclin-Dependent Kinase Activities Induces Apoptosis in Cancer Cells.
Neoplasms
Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Neoplasms
Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
Neoplasms
Correlation between TGF-beta1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas.
Neoplasms
Correlation of constitutive photomorphogenic 1 (COP1) and p27 tumor suppressor protein expression in ovarian cancer.
Neoplasms
Correlation of p16 immunohistochemistry in FNA biopsies with corresponding tissue specimens in HPV-related squamous cell carcinomas of the oropharynx.
Neoplasms
Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
Neoplasms
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Neoplasms
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Neoplasms
CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation.
Neoplasms
CRL4B(DCAF11) E3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells.
Neoplasms
CRM-1 knockdown inhibits extrahepatic cholangiocarcinoma tumor growth by blocking the nuclear export of p27Kip1.
Neoplasms
Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6.
Neoplasms
Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines.
Neoplasms
Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention.
Neoplasms
Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.
Neoplasms
Cyclin D1 overexpression in mouse epidermis increases cyclin-dependent kinase activity and cell proliferation in vivo but does not affect skin tumor development.
Neoplasms
Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases.
Neoplasms
Cyclin D3 deficiency inhibits skin tumor development, but does not affect normal keratinocyte proliferation.
Neoplasms
Cyclin E overexpression impairs progression through mitosis by inhibiting APC(Cdh1).
Neoplasms
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Neoplasms
Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
Neoplasms
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.
Neoplasms
Cyclin E: a potential treatment target to reverse cancer chemoresistance by regulating the cell cycle.
Neoplasms
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions.
Neoplasms
Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
Neoplasms
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials.
Neoplasms
Cyclin-dependent kinase 1 disruption inhibits angiogenesis by inducing cell cycle arrest and apoptosis.
Neoplasms
Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.
Neoplasms
Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Neoplasms
Cyclin-Dependent Kinase 14 Promotes Cell Proliferation, Migration and Invasion in Ovarian Cancer by Inhibiting Wnt Signaling Pathway.
Neoplasms
Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers.
Neoplasms
Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review.
Neoplasms
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
Neoplasms
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma.
Neoplasms
Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer.
Neoplasms
Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer.
Neoplasms
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Neoplasms
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Neoplasms
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.
Neoplasms
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.
Neoplasms
Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging.
Neoplasms
Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019).
Neoplasms
Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances.
Neoplasms
Cyclin-Dependent Kinase 5 (CDK5)-Mediated Phosphorylation of Upstream Stimulatory Factor 2 (USF2) Contributes to Carcinogenesis.
Neoplasms
Cyclin-dependent kinase 5 activates guanine nucleotide exchange factor GIV/Girdin to orchestrate migration-proliferation dichotomy.
Neoplasms
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA.
Neoplasms
Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Neoplasms
Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.
Neoplasms
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-?B Signaling Pathway.
Neoplasms
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Neoplasms
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Neoplasms
Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer.
Neoplasms
Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer.
Neoplasms
Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
Neoplasms
Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Neoplasms
Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.
Neoplasms
Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response.
Neoplasms
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1.
Neoplasms
Cyclin-Dependent Kinase Inhibitor 2b Controls Fibrosis and Functional Changes in Ischemia-Induced Heart Failure via the BMI1-p15-Rb Signalling Pathway.
Neoplasms
Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.
Neoplasms
Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling.
Neoplasms
Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation.
Neoplasms
Cyclin-dependent kinase inhibitor 3 promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting P27.
Neoplasms
Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice.
Neoplasms
Cyclin-dependent kinase inhibitor p27 as a prognostic biomarker and potential cancer therapeutic target.
Neoplasms
Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.
Neoplasms
Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells.
Neoplasms
Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer.
Neoplasms
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Neoplasms
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Neoplasms
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Neoplasms
Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Neoplasms
Cyclin-dependent kinase inhibitors uncouple cell cycle progression from mitochondrial apoptotic functions in DNA-damaged cancer cells.
Neoplasms
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors.
Neoplasms
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. Mouriaux F,*(1) Maurage CA, Labalette P, Sablonniere B, Malecaze F, Darbon JM. Inv Ophthalmol Vis Sci 2000;41:2837-2843.
Neoplasms
Cyclin-dependent kinase like 3 promotes triple-negative breast cancer progression via inhibiting the p53 signaling pathway.
Neoplasms
Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Neoplasms
Cyclin-Dependent Kinase Pathway Aberrations in Diverse Malignancies: Clinical and Molecular Characteristics.
Neoplasms
Cyclin-dependent kinase regulation of the replication functions of polyomavirus large T antigen.
Neoplasms
Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Neoplasms
Cyclin-dependent kinase site-regulated signal-dependent nuclear localization of the SW15 yeast transcription factor in mammalian cells.
Neoplasms
Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma.
Neoplasms
Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.
Neoplasms
Cyclin-dependent kinase-like function is shared by the beta- and gamma- subset of the conserved herpesvirus protein kinases.
Neoplasms
Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Neoplasms
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors.
Neoplasms
Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies.
Neoplasms
Cyclin-dependent kinases and P53 pathways are activated independently and mediate Bax activation in neurons after DNA damage.
Neoplasms
Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage.
Neoplasms
Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics.
Neoplasms
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Neoplasms
Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
Neoplasms
Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis.
Neoplasms
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Neoplasms
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
Neoplasms
Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer.
Neoplasms
Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1.
Neoplasms
Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.
Neoplasms
Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells.
Neoplasms
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
Neoplasms
Cytotoxic Effect of Portulaca Oleracea Extract on the Regulation of CDK1 and P53 Gene Expression in Pancreatic Cancer Cell Line.
Neoplasms
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Neoplasms
Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN?-dependent cell-cycle arrest.
Neoplasms
Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
Neoplasms
Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.
Neoplasms
Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
Neoplasms
Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma.
Neoplasms
Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma.
Neoplasms
Decreased expression of the INK4 family of cyclin-dependent kinase inhibitors in Wilms tumor.
Neoplasms
Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block.
Neoplasms
Decreasing CNPY2 Expression Diminishes Colorectal Tumor Growth and Development through Activation of p53 Pathway.
Neoplasms
Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Neoplasms
Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas.
Neoplasms
Deficiency of the Cyclin-Dependent Kinase Inhibitor, CDKN1B, Results in Overgrowth and Neurodevelopmental Delay.
Neoplasms
Definition of smad3 phosphorylation events that affect malignant and metastatic behaviors in breast cancer cells.
Neoplasms
Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors.
Neoplasms
Deletion mapping of a putative tumor suppressor gene on chromosome 4 in mouse lung tumors.
Neoplasms
Deletion of 1p36 in childhood endodermal sinus tumors by two-color fluorescence in situ hybridization: a pediatric oncology group study.
Neoplasms
Dephosphorylation of threonine-821 of the retinoblastoma tumor suppressor protein (Rb) is required for apoptosis induced by UV and Cdk inhibition.
Neoplasms
Depletion of the cdk inhibitor p16INK4a differentially affects proliferation of established cervical carcinoma cells.
Neoplasms
Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin.
Neoplasms
Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein.
Neoplasms
Dermal fibroblasts induce cell cycle arrest and block epithelial-mesenchymal transition to inhibit the early stage melanoma development.
Neoplasms
Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Neoplasms
Design and screening of FAK, CDK 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation.
Neoplasms
Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity.
Neoplasms
Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies.
Neoplasms
Design, Synthesis and Anticancer Activity of New Thiazole-Tetrazole or Triazole Hybrid Glycosides Targeting CDK-2 via Structure-Based Virtual Screening.
Neoplasms
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Neoplasms
Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors as Anti-Tumor Agents.
Neoplasms
Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
Neoplasms
Design, synthesis, and primary activity assays of baicalein derivatives as cyclin-dependent kinase 1 inhibitors.
Neoplasms
Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.
Neoplasms
Design, Synthesis, Molecular Modeling, Anticancer Studies, and Density Functional Theory Calculations of 4-(1,2,4-Triazol-3-ylsulfanylmethyl)-1,2,3-triazole Derivatives.
Neoplasms
Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.
Neoplasms
Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features.
Neoplasms
Detection of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma using droplet digital polymerase chain reaction.
Neoplasms
Detection of p16 gene alteration in cervical cancer using tissue microdissection and LOH study.
Neoplasms
Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry.
Neoplasms
Developing structure-activity relationships from an HTS hit for inhibition of the Cks1-Skp2 protein-protein interaction.
Neoplasms
Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium.
Neoplasms
Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors.
Neoplasms
Development of bioartificial renal tubule devices with lifespan-extended human renal proximal tubular epithelial cells.
Neoplasms
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Neoplasms
DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
Neoplasms
Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors.
Neoplasms
Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells, and mortality in obesity-resistant BALB/c mice.
Neoplasms
Dietary Mixed Cereal Grains Ameliorate the Azoxymethane and Dextran Sodium Sulfate-Induced Colonic Carcinogenesis in C57BL/6J Mice.
Neoplasms
Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells.
Neoplasms
Difference of cell cycle arrests induced by lidamycin in human breast cancer cells.
Neoplasms
Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Neoplasms
Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Neoplasms
Differential activities of E2F family members: unique functions in regulating transcription.
Neoplasms
Differential cyclin-dependent kinase expression and activation in human colon cancer.
Neoplasms
Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis.
Neoplasms
Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.
Neoplasms
Differential expression of forkhead box M1 and its downstream cyclin-dependent kinase inhibitors p27(kip1) and p21(waf1/cip1) in the diagnosis of pulmonary neuroendocrine tumours.
Neoplasms
Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping.
Neoplasms
Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Neoplasms
Differential gene expression of p27Kip1 and Rb knockout pituitary tumors associated with altered growth and angiogenesis.
Neoplasms
Differential modulation of G1-S-phase cyclin-dependent kinase 2/cyclin complexes occurs during the acquisition of a polyploid DNA content.
Neoplasms
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
Neoplasms
Differential regulation of cyclin-dependent kinase inhibitors in neuroblastoma cells.
Neoplasms
Differential regulation of p27kip1 levels and CDK activities by hypertrophic and hyperplastic agents in vascular smooth muscle cells.
Neoplasms
Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.
Neoplasms
Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.
Neoplasms
Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma.
Neoplasms
Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma.
Neoplasms
Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma.
Neoplasms
Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin Dependent Kinases 1 and 2.
Neoplasms
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
Neoplasms
Dinaciclib prolongs survival in the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma.
Neoplasms
Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Neoplasms
Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes.
Neoplasms
Direct current electrical fields induce apoptosis in oral mucosa cancer cells by NADPH oxidase-derived reactive oxygen species.
Neoplasms
Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication.
Neoplasms
Direct evidence from siRNA-directed "knock down" that p16(INK4a) is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation.
Neoplasms
Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein.
Neoplasms
Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21Waf1 cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) dosing to rats.
Neoplasms
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Neoplasms
Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Neoplasms
Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.
Neoplasms
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.
Neoplasms
Discovery of N-(4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies.
Neoplasms
Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer.
Neoplasms
Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Neoplasms
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Neoplasms
Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation.
Neoplasms
Disruption of G1-phase phospholipid turnover by inhibition of Ca2+-independent phospholipase A2 induces a p53-dependent cell-cycle arrest in G1 phase.
Neoplasms
Dissecting the contribution of p16(INK4A) and the Rb family to the Ras transformed phenotype.
Neoplasms
Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Neoplasms
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.
Neoplasms
Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors.
Neoplasms
DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression.
Neoplasms
DNA loop sequence as the determinant for chiral supramolecular compound G-quadruplex selectivity.
Neoplasms
DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1).
Neoplasms
DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications.
Neoplasms
Doenjang hexane fraction-induced G1 arrest is associated with the inhibition of pRB phosphorylation and induction of Cdk inhibitor p21 in human breast carcinoma MCF-7 cells.
Neoplasms
Does the PITSLRE gene complex contribute to the pathogenesis of malignant melanoma of the skin? A study of patient-derived tumor samples?
Neoplasms
Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species.
Neoplasms
Down-regulation of p21Waf-1 protein facilitates IR- and UV-induced apoptosis in human squamous carcinoma cells.
Neoplasms
Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases.
Neoplasms
Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
Neoplasms
Down-regulation of p27Kip1 expression is correlated with increased cell proliferation but not expression of p21waf1 and p53, and human papillomavirus infection in benign and malignant tumours of sinonasal regions.
Neoplasms
Down-regulation of S-phase kinase associated protein 2 (Skp2) induces apoptosis in oral cancer cells.
Neoplasms
Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis.
Neoplasms
Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Neoplasms
Downregulation of MSP58 inhibits growth of human colorectal cancer cells via regulation of the cyclin D1-cyclin-dependent kinase 4-p21 pathway.
Neoplasms
Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories.
Neoplasms
Downregulation of p57(kip2) promotes cell invasion via LIMK/cofilin pathway in human nasopharyngeal carcinoma cells.
Neoplasms
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
Neoplasms
DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation.
Neoplasms
Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Neoplasms
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.
Neoplasms
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Neoplasms
Dynamic Bcl-xL (S49) and (S62) Phosphorylation/Dephosphorylation during Mitosis Prevents Chromosome Instability and Aneuploidy in Normal Human Diploid Fibroblasts.
Neoplasms
Dynamic expression of the vertebrate-specific protein Nucks during rodent embryonic development.
Neoplasms
Dysregulation of the Urothelial Cancer Associated 1 Long Noncoding RNA Promotes Proliferation of Vascular Smooth Muscle Cells by Modulating Expression of P27KIP1/CDK2.
Neoplasms
E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis.
Neoplasms
Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
Neoplasms
Ectopic expression of human Cdk2 and its yeast homolog, Ime2, is deleterious to Saccharomyces cerevisiae.
Neoplasms
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Neoplasms
Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.
Neoplasms
Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer.
Neoplasms
Effect of p27Kip1 on the ability of invasion and metastasis of an oral cancer cell line.
Neoplasms
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Neoplasms
Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer.
Neoplasms
Effect of tumor suppressor gene cyclin-dependent kinase inhibitor 2A wild-type and A148T mutant on the cell cycle of human ovarian cancer cells.
Neoplasms
Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression.
Neoplasms
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Neoplasms
Effects of Beclin 1 overexpression on aggressive phenotypes of colon cancer cells.
Neoplasms
Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells.
Neoplasms
Effects of exogenous p16INK4a on growth of cells with various status of cell-cycle regulators.
Neoplasms
Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer.
Neoplasms
Effects of ionizing radiation and caffeine treatment on cyclin dependent kinase complexes in V79 hamster cells.
Neoplasms
Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication.
Neoplasms
Effects of quercetin on CDK4 mRNA and protein expression in A549 cells infected by H1N1.
Neoplasms
Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity.
Neoplasms
Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Neoplasms
Electro-hyperthermia up-regulates tumour suppressor Septin 4 to induce apoptotic cell death in hepatocellular carcinoma.
Neoplasms
Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.
Neoplasms
Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study.
Neoplasms
Elevated expression of SAG/ROC2/Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but antisense SAG transfection inhibits tumor cell growth.
Neoplasms
Elevated nuclear CDK6 is associated with an unfavorable prognosis in lung adenocarcinoma patients.
Neoplasms
Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6.
Neoplasms
Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers.
Neoplasms
Embryo arrest and reactivation: potential candidates controlling embryonic diapause in the tammar wallaby and mink1.
Neoplasms
Endothelial cells from umbilical cord of women affected by gestational diabetes: A suitable in vitro model to study mechanisms of early vascular senescence in diabetes.
Neoplasms
Endothelial p21(WAF1/CiP1) cell cycle inhibitor is down-regulated in breast cancer.
Neoplasms
Enhanced sensitivity to cis-diamminedichloroplatinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression.
Neoplasms
Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides.
Neoplasms
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Neoplasms
Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Neoplasms
Enzyme-linked immunosorbent assay for p16(INK4a) - a new triage test for the detection of cervical intraepithelial neoplasia?
Neoplasms
Epidermal growth factor and transforming growth factor-alpha-associated overexpression of cyclin D1, Cdk4, and c-Myc during hepatocarcinogenesis in Helicobacter hepaticus-infected A/JCr mice.
Neoplasms
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Neoplasms
Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours.
Neoplasms
Epigallocatechin-3-gallate and trichostatin A synergistically inhibit human lymphoma cell proliferation through epigenetic modification of p16INK4a.
Neoplasms
Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer.
Neoplasms
Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
Neoplasms
Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies.
Neoplasms
Epigenetic Targeting of TERT-Associated Gene Expression Signature in Human Neuroblastoma with TERT Overexpression.
Neoplasms
Epigenome-Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer.
Neoplasms
ERpS294 is a biomarker of ligand or mutational ER? activation and a breast cancer target for CDK2 inhibition.
Neoplasms
Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation.
Neoplasms
Estrogen regulated expression of the p21 Waf1/Cip1 gene in estrogen receptor positive human breast cancer cells.
Neoplasms
Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours.
Neoplasms
Evaluation of cyclin-dependent kinase-like 1 expression in breast cancer tissues and its regulation in cancer cell growth.
Neoplasms
Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas.
Neoplasms
Evaluation of the two polymorphisms rs1801133 in MTHFR and rs10811661 in CDKN2A/B in breast cancer.
Neoplasms
Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma.
Neoplasms
Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
Neoplasms
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Neoplasms
Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
Neoplasms
Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer.
Neoplasms
Expression and Prognostic Significance of CDK8 and ?-Catenin in Hepatocellular Carcinoma.
Neoplasms
Expression and prognostic significance of cyclin-dependent kinase inhibitor 1A in patients with resected gastric adenocarcinoma.
Neoplasms
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
Neoplasms
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
Neoplasms
Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells.
Neoplasms
Expression of apoptotic signaling proteins in leukoplakia and oral lichen planus: quantitative and topographical studies.
Neoplasms
Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1? and beclin1 in Breast Cancer Patients.
Neoplasms
Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions.
Neoplasms
Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.
Neoplasms
Expression of CK7 and CDKN2 in Cervical Intraepithelial Neoplasia and Correlation with Clinical Outcome.
Neoplasms
Expression of Concern: MicroRNA-505-5p functions as a tumor suppressor by targeting Cyclin-Dependent Kinase 5 in cervical cancer.
Neoplasms
Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.
Neoplasms
Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes.
Neoplasms
Expression of cyclin-dependent kinase inhibitor 2A 16, tumour protein 53 and epidermal growth factor receptor in salivary gland carcinomas is not associated with oncogenic virus infection.
Neoplasms
Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation.
Neoplasms
Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer.
Neoplasms
Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity.
Neoplasms
Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma.
Neoplasms
Expression of p15INK?b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.
Neoplasms
Expression of p16 and cyclin D1 in bladder cancer and correlation in cancer progression.
Neoplasms
Expression of p16 protein in gallbladder carcinoma and its precancerous conditions.
Neoplasms
Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Neoplasms
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Neoplasms
Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity.
Neoplasms
Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Neoplasms
Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression.
Neoplasms
Expression of p27kip1 and p53 in medulloblastoma: relationship with cell proliferation and survival.
Neoplasms
Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma.
Neoplasms
Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy.
Neoplasms
Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas.
Neoplasms
Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
Neoplasms
Expression of proline-directed protein kinase, (p34cdc2/p58cyclin A), a novel cell proliferation marker in childhood brain tumors.
Neoplasms
Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions.
Neoplasms
Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Neoplasms
Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?
Neoplasms
Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression.
Neoplasms
Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate.
Neoplasms
Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent cellular DNA damage response pathway.
Neoplasms
Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer.
Neoplasms
Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression.
Neoplasms
Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.
Neoplasms
Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Neoplasms
Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Neoplasms
Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy.
Neoplasms
Expression, Purification, and Identification of Associated Proteins of the Full-length hCDK12/CyclinK Complex.
Neoplasms
Expressions and clinical significance of factors related to giant cell tumor of bone.
Neoplasms
Extensive analysis of the retinoblastoma gene in adult T cell leukemia/lymphoma (ATL).
Neoplasms
Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.
Neoplasms
Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: a molecular dynamics approach.
Neoplasms
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Neoplasms
Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1? and Inhibition of VEGFR2 and TRKA.
Neoplasms
FBXL16 is a novel E2F1-regulated gene commonly upregulated in p16INK4A- and p14ARF-silenced HeLa cells.
Neoplasms
Feasibility of immunocytochemical detection of tumor markers (XIAP, phosphohistone H1 and p63) in FNA cellblock samples from head and neck squamous cell carcinoma.
Neoplasms
Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts.
Neoplasms
Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B.
Neoplasms
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Neoplasms
Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice.
Neoplasms
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy.
Neoplasms
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.
Neoplasms
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo.
Neoplasms
Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
Neoplasms
Flavopiridol inhibits lipopolysaccharide-induced TNF-? production through inactivation of nuclear factor-?B and mitogen-activated protein kinases in the MyD88-dependent pathway.
Neoplasms
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
Neoplasms
Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids.
Neoplasms
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Neoplasms
Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Neoplasms
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Neoplasms
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Neoplasms
Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin.
Neoplasms
Folic acid inhibits COLO-205 colon cancer cell proliferation through activating the FR?/c-SRC/ERK1/2/NF?B/TP53 pathway: in vitro and in vivo studies.
Neoplasms
Francisella tularensis Modulates a Distinct Subset of Regulatory Factors and Sustains Mitochondrial Integrity to Impair Human Neutrophil Apoptosis.
Neoplasms
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors.
Neoplasms
Frequent Amplification of CENPF, GMNN and CDK13 Genes in Hepatocellular Carcinomas.
Neoplasms
Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.
Neoplasms
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Neoplasms
Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Neoplasms
Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.
Neoplasms
Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Neoplasms
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer.
Neoplasms
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas.
Neoplasms
Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood.
Neoplasms
Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Neoplasms
Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer.
Neoplasms
Frogs and estivation: transcriptional insights into metabolism and cell survival in a natural model of extended muscle disuse.
Neoplasms
From simple to complex patterns of oscillatory behavior in a model for the mammalian cell cycle containing multiple oscillatory circuits.
Neoplasms
Functional Ablation of pRb Activates Cdk2 and Causes Antiestrogen Resistance in Human Breast Cancer Cells.
Neoplasms
Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway.
Neoplasms
Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4 (MEN4).
Neoplasms
Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype.
Neoplasms
Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.
Neoplasms
Functional conservation of the cell cycle-regulating transcription factor DRTF1/E2F and its pathway of control in Drosophila melanogaster.
Neoplasms
Functional Genetic Single-Nucleotide Polymorphisms (SNPs) in Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) Locus Are Associated with Risk and Prognosis of Osteosarcoma in Chinese Populations.
Neoplasms
Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Neoplasms
Functional inactivation of Rb sensitizes cancer cells to TSC2 inactivation induced cell death.
Neoplasms
G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta.
Neoplasms
G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
Neoplasms
G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer.
Neoplasms
Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110.
Neoplasms
Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.
Neoplasms
Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity.
Neoplasms
Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.
Neoplasms
Gene expression of cyclin-dependent kinase subunit Cks2 is repressed by the tumor suppressor p53 but not by the related proteins p63 or p73.
Neoplasms
Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays.
Neoplasms
Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
Neoplasms
Generation of knockout mouse models of cyclin-dependent kinase inhibitors by engineered nuclease-mediated genome editing.
Neoplasms
Genesis, a Winged Helix transcriptional repressor, has embryonic expression limited to the neural crest, and stimulates proliferation in vitro in a neural development model.
Neoplasms
Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Neoplasms
Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.
Neoplasms
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.
Neoplasms
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Neoplasms
Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion.
Neoplasms
Genetic association between the cyclin-dependent kinase inhibitor gene p27/Kip1 polymorphism (rs34330) and cancer susceptibility: a meta-analysis.
Neoplasms
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.
Neoplasms
Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, Zta.
Neoplasms
Genetic variants of p21 and p27 and hepatocellular cancer risk in a Chinese Han population: a case-control study.
Neoplasms
Genetic variants of p21 and p27 and pancreatic cancer risk in non-Hispanic Whites: a case-control study.
Neoplasms
Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer.
Neoplasms
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Neoplasms
Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report.
Neoplasms
Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation.
Neoplasms
Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.
Neoplasms
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
Neoplasms
Genomic Profiling of Prostate Cancers from Men with African and European Ancestry.
Neoplasms
Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer.
Neoplasms
Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma.
Neoplasms
Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid Adenomas.
Neoplasms
Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis.
Neoplasms
Green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle cells via activation of p53.
Neoplasms
Growth arrest of immortalized human keratinocytes and suppression of telomerase activity by p21WAF1 gene expression.
Neoplasms
Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.
Neoplasms
Growth inhibition of the pulmonary metastatic tumors by systemic delivery of the p27(kip1) gene using lyophilized lipid-polycation-DNA complexes.
Neoplasms
Growth stimulation versus induction of cell quiescence by hydrogen peroxide in prostate tumor spheroids is encoded by the duration of the Ca(2+) response.
Neoplasms
Guilu Erxian Glue () Inhibits Chemotherapy-Induced Bone Marrow Hematopoietic Stem Cell Senescence in Mice May via p16INK4a-Rb Signaling Pathway.
Neoplasms
Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice.
Neoplasms
Helicobacter pylori increases proteasome-mediated degradation of p27(kip1) in gastric epithelial cells.
Neoplasms
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Neoplasms
Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stress.
Neoplasms
Heme controls the expression of cell cycle regulators and cell growth in HeLa cells.
Neoplasms
Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling.
Neoplasms
Hepatitis B Virus Pre-S2 Mutant Surface Antigen Induces Degradation of Cyclin-Dependent Kinase Inhibitor p27Kip1 through c-Jun Activation Domain-Binding Protein 1.
Neoplasms
Hepatitis B virus X protein differentially regulates cell cycle progression in X-transforming versus nontransforming hepatocyte (AML12) cell lines.
Neoplasms
Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions.
Neoplasms
Heterogeneous EGFR, CDK4, MDM4, and PDGFRA Gene Expression Profiles in Primary GBM: No Association with Patient Survival.
Neoplasms
High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors.
Neoplasms
High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer.
Neoplasms
High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.
Neoplasms
High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas.
Neoplasms
High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.
Neoplasms
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Neoplasms
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers.
Neoplasms
High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.
Neoplasms
High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells.
Neoplasms
High-throughput sequencing-based analysis of gene expression of hepatitis B virus infection-associated human hepatocellular carcinoma.
Neoplasms
Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.
Neoplasms
Hinokitiol Exhibits Antitumor Properties through Induction of ROS-Mediated Apoptosis and p53-Driven Cell-Cycle Arrest in Endometrial Cancer Cell Lines (Ishikawa, HEC-1A, KLE).
Neoplasms
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Neoplasms
Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts.
Neoplasms
Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Neoplasms
Histone Deacetylase Inhibitors Reverse CpG Methylation by Regulating DNMT1 through ERK Signaling.
Neoplasms
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.
Neoplasms
Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome.
Neoplasms
Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors.
Neoplasms
Huanglian, A chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells.
Neoplasms
Human cytomegalovirus (HCMV) IE1 plays role in resistance to apoptosis with etoposide in cancer cell line by Cdk2 accumulation.
Neoplasms
Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins.
Neoplasms
Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways.
Neoplasms
Human papillomavirus dysregulates the cellular apparatus controlling the methylation status of H3K27 in different human cancers to consistently alter gene expression regardless of tissue of origin.
Neoplasms
Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents.
Neoplasms
Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin.
Neoplasms
Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.
Neoplasms
Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Neoplasms
Hypermethylation of CpG islands in the promoter region of the p15INK4B gene in childhood acute leukaemia.
Neoplasms
Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia.
Neoplasms
Hypermethylation of the cell cycle inhibitor p15INK4b 3'-untranslated region interferes with its transcriptional regulation in primary lymphomas.
Neoplasms
Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas.
Neoplasms
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Neoplasms
Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways.
Neoplasms
Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice.
Neoplasms
Identification and characterization of a novel phosphoregulatory site on cyclin-dependent kinase 5.
Neoplasms
Identification and Functional Characterization of FMN2, a Regulator of the Cyclin-Dependent Kinase Inhibitor p21.
Neoplasms
Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Neoplasms
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Neoplasms
Identification of dysregulated pathways associated with pancreatic cancer by survival analysis.
Neoplasms
Identification of key candidate genes for colorectal cancer by bioinformatics analysis.
Neoplasms
Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model.
Neoplasms
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Neoplasms
Identification of NUCKS1 as a putative oncogene and immunodiagnostic marker of hepatocellular carcinoma.
Neoplasms
Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis.
Neoplasms
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
Neoplasms
Identification of PFTAIRE protein kinase 1, a novel cell division cycle-2 related gene, in the motile phenotype of hepatocellular carcinoma cells.
Neoplasms
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Neoplasms
Identification of Quinazolinone Analogs Targeting CDK5 Kinase Activity and Glioblastoma Cell Proliferation.
Neoplasms
Identification of selective cyclin-dependent kinase 2 inhibitor from the library of pyrrolone-fused benzosuberene compounds: an in silico exploration.
Neoplasms
Identification of YPL014W (Cip1) as a novel negative regulator of cyclin-dependent kinase in Saccharomyces cerevisiae.
Neoplasms
IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential.
Neoplasms
IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours.
Neoplasms
Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome.
Neoplasms
Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis.
Neoplasms
Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Neoplasms
Immunohistochemical characterization of p57KIP2 expression in human esophageal squamous cell carcinoma.
Neoplasms
Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma.
Neoplasms
Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Neoplasms
Immunohistochemical determination of the P15 protein expression in cutaneous squamous cell carcinoma.
Neoplasms
Immunohistochemical evaluation of p27 (kip1) in pleomorphic adenomas and adenoid cystic carcinomas of the minor salivary glands.
Neoplasms
Immunohistochemical Expression of p16 and p21 in Pituitary Tissue Adjacent to Pituitary Adenoma versus Pituitary Tissue Obtained at Autopsy: Is There a Difference?
Neoplasms
Immunohistochemical investigation of F344/N rat islet cell tumors from national toxicology program studies.
Neoplasms
Immunolocalization of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human breast carcinoma.
Neoplasms
Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication.
Neoplasms
Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
Neoplasms
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.
Neoplasms
Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma.
Neoplasms
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents.
Neoplasms
Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations.
Neoplasms
Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma.
Neoplasms
Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction.
Neoplasms
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
Neoplasms
In silico and in vitro investigation of anticancer effect of newly synthesized nonivamide-s-allyl cysteine ester.
Neoplasms
In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug.
Neoplasms
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
Neoplasms
In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma.
Neoplasms
In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer.
Neoplasms
In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin.
Neoplasms
In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.
Neoplasms
In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer.
Neoplasms
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2.
Neoplasms
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Neoplasms
Inactivation of INK4a and ARF induces myocardial proliferation and improves cardiac repair following ischemia?reperfusion.
Neoplasms
Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies.
Neoplasms
Inactivation of p21WAF1/cip1 enhances intestinal tumor formation in Muc2-/- mice.
Neoplasms
Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors.
Neoplasms
Inactivation of TGF-? signaling and loss of PTEN cooperate to induce colon cancer in vivo.
Neoplasms
Inactivation of the kinase domain of CDK10 prevents tumor growth in a preclinical model of colorectal cancer, and is accompanied by downregulation of Bcl-2.
Neoplasms
Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays.
Neoplasms
Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function.
Neoplasms
Increased epithelial stem cell traits in advanced endometrial endometrioid carcinoma.
Neoplasms
Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
Neoplasms
Increased expression of cyclin D1, cyclin E and p21(Cip1) associated with decreased expression of p27(Kip1) in chemically induced rat mammary carcinogenesis.
Neoplasms
Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis.
Neoplasms
Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas.
Neoplasms
Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1.
Neoplasms
Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease.
Neoplasms
Increased proteasome activator 28 gamma (PA28?) levels are unspecific but correlate with disease activity in rheumatoid arthritis.
Neoplasms
Indirubin 3'-Oxime Inhibits Migration, Invasion, and Metastasis InVivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways.
Neoplasms
Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer.
Neoplasms
Induced expression of p16 and p21 proteins in UVB-irradiated human epidermis and cultured keratinocytes.
Neoplasms
Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug Ukrain.
Neoplasms
Inducible p27(Kip1) expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors.
Neoplasms
Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells.
Neoplasms
Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation.
Neoplasms
Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein.
Neoplasms
Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1).
Neoplasms
Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene.
Neoplasms
Induction of G0/G1 phase arrest and apoptosis by CRISPR/Cas9-mediated knockout of CDK2 in A375 melanocytes.
Neoplasms
Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner.
Neoplasms
Induction of transcriptionally active Jun proteins regulates drug-induced senescence.
Neoplasms
Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
Neoplasms
Inhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy.
Neoplasms
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
Neoplasms
Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms.
Neoplasms
Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.
Neoplasms
Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ER? expression in high-grade serous ovarian carcinoma.
Neoplasms
Inhibition of CDK2/CyclinE1 by xanthones from the mangosteen (Garcinia mangostana): a structure-activity relationship study.
Neoplasms
Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.
Neoplasms
Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
Neoplasms
Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
Neoplasms
Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells.
Neoplasms
Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1.
Neoplasms
Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Neoplasms
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells.
Neoplasms
Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product.
Neoplasms
Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Neoplasms
Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
Neoplasms
Inhibition of cyclin-dependent kinase activity and induction of apoptosis by preussin in human tumor cells.
Neoplasms
Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.
Neoplasms
Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
Neoplasms
Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
Neoplasms
Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Neoplasms
Inhibition of extracellular signal-regulated kinase potentiates the apoptotic and antimetastatic effects of cyclin-dependent kinase inhibitors on metastatic DU145 and PC3 prostate cancer cells.
Neoplasms
Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells.
Neoplasms
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Neoplasms
Inhibition of mitotic cyclin B and cdc2 kinase activity by selenomethionine in synchronized colon cancer cells.
Neoplasms
Inhibition of NF-?B-mediated signaling by the CDK inhibitor CR8 overcomes pro-survival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Neoplasms
Inhibition of ornithine decarboxylase alters the roscovitine-induced mitochondrial-mediated apoptosis in MCF-7 breast cancer cells.
Neoplasms
Inhibition of PI-3K restores nuclear p27(Kip1) expression in a mouse model of Kras-driven lung cancer.
Neoplasms
Inhibition of polyamine oxidase prevented cyclin-dependent kinase inhibitor-induced apoptosis in HCT 116 colon carcinoma cells.
Neoplasms
Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
Neoplasms
Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Neoplasms
Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer.
Neoplasms
Inhibition of UBE2N-dependent CDK6 protein degradation by miR-934 promotes human bladder cancer cell growth.
Neoplasms
Inhibitor of growth 4 suppresses colorectal cancer growth and invasion by inducing G1 arrest, inhibiting tumor angiogenesis and reversing epithelial-mesenchymal transition.
Neoplasms
Inhibitors of SCF-Skp2/Cks1 E3ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Neoplasms
Inhibitory effect of glycolic acid on ultraviolet-induced skin tumorigenesis in SKH-1 hairless mice and its mechanism of action.
Neoplasms
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.
Neoplasms
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.
Neoplasms
Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.
Neoplasms
Insufficient effect of p27(KIP1) to inhibit cyclin D1 in human esophageal cancer in vitro.
Neoplasms
Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
Neoplasms
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Neoplasms
Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cells.
Neoplasms
Interleukin-1alpha regulates G1 cell cycle progression and arrest in thyroid carcinoma cell lines NIM1 and NPA.
Neoplasms
Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression.
Neoplasms
Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells.
Neoplasms
Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors.
Neoplasms
Intratumoral Heterogeneity of Chromosome 9 Loss and CDKN2A (p16) Protein Expression in a Morphologically Challenging Spitzoid Melanoma.
Neoplasms
Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma.
Neoplasms
Investigating the Mechanism of Scutellariae barbata Herba in the Treatment of Colorectal Cancer by Network Pharmacology and Molecular Docking.
Neoplasms
Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines.
Neoplasms
Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Neoplasms
Involvement of cyclin-dependent kinases in doxorubicin-induced apoptosis in human tumor cells.
Neoplasms
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Neoplasms
Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia.
Neoplasms
Ironing out the role of the cyclin-dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity.
Neoplasms
Isolation and characterization of adult mammary stem cells from breast cancer-adjacent tissues.
Neoplasms
iTRAQ-based quantitative proteomic analysis provides insight for molecular mechanism of neuroticism.
Neoplasms
JAB1-STAT3 activation loop is associated with recurrence following 5-fluorouracil-based adjuvant chemotherapy in human colorectal cancer.
Neoplasms
Jinfukang induces cellular apoptosis through activation of Fas and DR4 in A549 cells.
Neoplasms
JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells.
Neoplasms
Karyopherin subunit-? 2 expression accelerates cell cycle progression by upregulating CCNB2 and CDK1 in hepatocellular carcinoma.
Neoplasms
Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
Neoplasms
Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice.
Neoplasms
KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner.
Neoplasms
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Neoplasms
Knockdown of CDK2AP1 by RNA interference inhibits cell growth and tumorigenesis of human glioma.
Neoplasms
Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis.
Neoplasms
Knockdown of PFTAIRE Protein Kinase 1 (PFTK1) Inhibits Proliferation, Invasion, and EMT in Colon Cancer Cells.
Neoplasms
Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer.
Neoplasms
Korean Scutellaria baicalensis water extract inhibits cell cycle G1/S transition by suppressing cyclin D1 expression and matrix-metalloproteinase-2 activity in human lung cancer cells.
Neoplasms
Kurarinone from Sophora Flavescens Roots Triggers ATF4 Activation and Cytostatic Effects Through PERK Phosphorylation.
Neoplasms
Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study.
Neoplasms
Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Neoplasms
Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis.
Neoplasms
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells.
Neoplasms
Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.
Neoplasms
Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21(WAF1/CIP1).
Neoplasms
Let-7a Functions as a Tumor Suppressor in Ewing's Sarcoma Cell Lines Partly by Targeting Cyclin-Dependent Kinase 6.
Neoplasms
Leydig-cell tumour in children: variable clinical presentation, diagnostic features, follow-up and genetic analysis of four cases.
Neoplasms
Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer.
Neoplasms
LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas.
Neoplasms
Lipid-Based Liquid Crystalline Nanoparticles Facilitate Cytosolic Delivery of siRNA via Structural Transformation.
Neoplasms
Lipophilic Grape Seed Proanthocyanidin Exert Anti-Proliferative and Pro-apoptotic Effects on PC3 Human Prostate Cancer Cells and Suppresses PC3 Xenograft Tumor Growth in Vivo.
Neoplasms
LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer.
Neoplasms
LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1.
Neoplasms
LncRNA THUMPD3-AS1 enhances the proliferation and inflammatory response of chondrocytes in osteoarthritis.
Neoplasms
Long non-coding RNA H19 regulates viability and metastasis, and is upregulated in retinoblastoma.
Neoplasms
Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Neoplasms
Long noncoding RNA gastric cancer-related lncRNA1 mediates gastric malignancy through miRNA-885-3p and cyclin-dependent kinase 4.
Neoplasms
Long Noncoding RNA GATA3-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Suppression of PTEN, CDKN1A, and TP53.
Neoplasms
Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Neoplasms
Loss of anchorage in checkpoint-deficient cells increases genomic instability and promotes oncogenic transformation.
Neoplasms
Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis.
Neoplasms
Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas.
Neoplasms
Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer.
Neoplasms
Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development.
Neoplasms
Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers.
Neoplasms
Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas.
Neoplasms
Loss of p27Kip1 leads to expansion of CD4+ effector memory T cells and accelerates colitis-associated colon cancer in mice with a T cell lineage restricted deletion of Smad4.
Neoplasms
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Neoplasms
Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Neoplasms
Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.
Neoplasms
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
Neoplasms
Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion.
Neoplasms
Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53.
Neoplasms
Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways.
Neoplasms
Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
Neoplasms
Low Expression of CyclinH and Cyclin-Dependent Kinase 7 Can Decrease the Proliferation of Human Esophageal Squamous Cell Carcinoma.
Neoplasms
Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia.
Neoplasms
Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.
Neoplasms
Low expression of p27(Kip1), a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma.
Neoplasms
Low incidence of genetic alterations of the p16CDKN2a in clear cell chondrosarcoma.
Neoplasms
Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas.
Neoplasms
Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.
Neoplasms
Low-grade central osteosarcoma of the metatarsal bone: a clinicopathological, immunohistochemical, cytogenetic and molecular cytogenetic analysis.
Neoplasms
Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway.
Neoplasms
MAGT1 is required for HeLa cell proliferation through regulating p21 expression, S-phase progress, and ERK/p38 MAPK MYC axis.
Neoplasms
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer.
Neoplasms
Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.
Neoplasms
MAPKAPK2 plays a crucial role in the progression of head and neck squamous cell carcinoma by regulating transcript stability.
Neoplasms
Marine guanidine alkaloids crambescidins inhibit tumor growth and activate intrinsic apoptotic signaling inducing tumor regression in a colorectal carcinoma zebrafish xenograft model.
Neoplasms
Markers for Sebaceoma Show a Spectrum of Cell Cycle Regulators, Tumor Suppressor Genes, and Oncogenes.
Neoplasms
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Neoplasms
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
Neoplasms
Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association.
Neoplasms
MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations.
Neoplasms
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors.
Neoplasms
Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c.
Neoplasms
Meta-analysis of the relationship between p21 Ser31Arg polymorphism and lung cancer susceptibility.
Neoplasms
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.
Neoplasms
Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma.
Neoplasms
Methylation analysis of cyclin-dependent kinase inhibitor genes in primary gastrointestinal lymphomas.
Neoplasms
Methylation of cyclin-dependent kinase inhibitors, XAF1, JUNB, CDH13 and soluble Wnt inhibitors in essential thrombocythaemia.
Neoplasms
Methylation of KvDMR1 involved in regulating the imprinting of CDKN1C gene in cattle.
Neoplasms
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Neoplasms
Methylation status of p16 (INK4A) tumor suppressor gene in Iranian patients with sporadic breast cancer.
Neoplasms
Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
Neoplasms
Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity.
Neoplasms
Mg2+/Mn2+-dependent phosphatase 1A is involved in regulating pregnane X receptor-mediated cytochrome p450 3A4 gene expression.
Neoplasms
Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation.
Neoplasms
Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.
Neoplasms
Microdissection-based allelotyping: a novel technique to determine the temporal sequence and biological aggressiveness of colorectal cancer.
Neoplasms
Microglia-derived IL-1? triggers p53-mediated cell cycle arrest and apoptosis in neural precursor cells.
Neoplasms
MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a.
Neoplasms
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
Neoplasms
MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.
Neoplasms
MicroRNA-1258 Inhibits the Proliferation and Migration of Human Colorectal Cancer Cells through Suppressing CKS1B Expression.
Neoplasms
MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer.
Neoplasms
MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
Neoplasms
microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs.
Neoplasms
MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
Neoplasms
MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC).
Neoplasms
microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6.
Neoplasms
MicroRNA-505-5p functions as a tumor suppressor by targeting cyclin-dependent kinase 5 in cervical cancer.
Neoplasms
MicroRNA-7 inhibits proliferation, migration and invasion of thyroid papillary cancer cells via targeting CKS2.
Neoplasms
microRNA-769 is downregulated in colorectal cancer and inhibits cancer progression by directly targeting cyclin-dependent kinase 1.
Neoplasms
MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1.
Neoplasms
MicroRNAs 221 and 222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1.
Neoplasms
microRNAs in the pathogenesis of non-obstructive azoospermia: the underlying mechanisms and therapeutic potentials.
Neoplasms
MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.
Neoplasms
Milk Oligosaccharides From Different Cattle Breeds Influence Growth-Related Characteristics of Intestinal Cells.
Neoplasms
miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells.
Neoplasms
miR-125a-3p inhibits ER? transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
Neoplasms
MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells.
Neoplasms
miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8.
Neoplasms
miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9.
Neoplasms
miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer.
Neoplasms
miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2.
Neoplasms
MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).
Neoplasms
miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.
Neoplasms
Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence.
Neoplasms
Mitoinhibitory effects of the tumor promoter 2-acetylaminofluorene in rat liver: loss of E2F-1 and E2F-3 expression and cdk 2 kinase activity in late G1.
Neoplasms
Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress.
Neoplasms
Modification of p27 with O-linked N-acetylglucosamine regulates cell proliferation in hepatocellular carcinoma.
Neoplasms
Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Neoplasms
Modulating cell cycle: current applications and prospects for future drug development.
Neoplasms
Modulation of glucocorticoid receptor transcriptional activation, phosphorylation, and growth inhibition by p27Kip1.
Neoplasms
Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors.
Neoplasms
Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice.
Neoplasms
Modulatory Effect of Indoles on the Expression of miRNAs Regulating G1/S Cell Cycle Phase in Breast Cancer Cells.
Neoplasms
Molecular analysis of H2O2-induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G1 arrest but not cell replication.
Neoplasms
Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.
Neoplasms
Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines.
Neoplasms
Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes.
Neoplasms
Molecular characterization of the cyclin-dependent protein kinase 6 in whitefish (Coregonus lavaretus) and its potential interplay with miR-34a.
Neoplasms
Molecular Determinants for the Inactivation of the Retinoblastoma Tumor Suppressor by the Viral Cyclin-dependent Kinase UL97.
Neoplasms
Molecular markers in dysplasia of the larynx: expression of cyclin-dependent kinase inhibitors p21, p27 and p53 tumour suppressor gene in predicting cancer risk.
Neoplasms
Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma.
Neoplasms
Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Neoplasms
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network.
Neoplasms
Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Neoplasms
Molecular systems biology of Sic1 in yeast cell cycle regulation through multiscale modeling.
Neoplasms
Monoclonal antibody specific for histone H1 phosphorylated by cyclin-dependent kinases: a novel immunohistochemical probe of proliferation and neoplasia.
Neoplasms
Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclins D1 and D2 binding to cdk4.
Neoplasms
MPT0B169, a New Tubulin Inhibitor, Inhibits Cell Growth and Induces G2/M Arrest in Nonresistant and Paclitaxel-Resistant Cancer Cells.
Neoplasms
Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells.
Neoplasms
Multiple Endocrine Neoplasia Type 1 (MEN1) Phenocopy Due to a Cell Cycle Division 73 (CDC73) Variant.
Neoplasms
Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.
Neoplasms
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Neoplasms
Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Neoplasms
Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region.
Neoplasms
Multiple neurofibromas as the presenting feature of familial atypical multiple malignant melanoma (FAMMM) syndrome.
Neoplasms
Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
Neoplasms
Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells.
Neoplasms
Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors.
Neoplasms
Mutation of the HEXIM1 gene results in defects during heart and vascular development partly through downregulation of vascular endothelial growth factor.
Neoplasms
Mutational alterations of the p16CDKN2A tumor suppressor gene have low incidence in mesenchymal chondrosarcoma.
Neoplasms
Mutational analysis of CDKN1B, a candidate tumor-suppressor gene, in refractory secondary/tertiary hyperparathyroidism.
Neoplasms
Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function.
Neoplasms
Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
Neoplasms
Mutational analysis of the P16-binding domain of cyclin-dependent kinase 4 in tumors in the head region of the pancreas.
Neoplasms
Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
Neoplasms
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
Neoplasms
Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.
Neoplasms
MYC up-regulation confers resistance to everolimus and establishes vulnerability to cyclin dependent kinase inhibitors in pancreatic neuroendocrine neoplasms cells.
Neoplasms
Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Neoplasms
Natural product (-)-gossypol inhibits colon cancer cell growth by targeting RNA-binding protein Musashi-1.
Neoplasms
NDR family of AGC kinases--essential regulators of the cell cycle and morphogenesis.
Neoplasms
Neisseria gonorrhoeae infection causes DNA damage and affects the expression of p21, p27 and p53 in non-tumor epithelial cells.
Neoplasms
Network Pharmacological Analysis through a Bioinformatics Approach of Novel NSC765600 and NSC765691 Compounds as Potential Inhibitors of CCND1/CDK4/PLK1/CD44 in Cancer Types.
Neoplasms
New concepts regarding focal adhesion kinase promotion of cell migration and proliferation.
Neoplasms
New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.
Neoplasms
New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?
Neoplasms
Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts.
Neoplasms
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
Neoplasms
Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.
Neoplasms
Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection.
Neoplasms
Nitric Oxide Donor DETA/NO Inhibits the Growth of Endometrial Cancer Cells by Upregulating the Expression of RASSF1 and CDKN1A.
Neoplasms
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
Neoplasms
Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
Neoplasms
No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
Neoplasms
Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.
Neoplasms
Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells.
Neoplasms
Novel Cdk inhibitors restore TGF-beta sensitivity in cdk4 overexpressing epithelial cells.
Neoplasms
Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.
Neoplasms
Novel Chemically Defined Approach To Produce Multipotent Cells from Terminally Differentiated Tissue Syncytia.
Neoplasms
Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Neoplasms
Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Neoplasms
Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors.
Neoplasms
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
Neoplasms
Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Neoplasms
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
Neoplasms
Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
Neoplasms
NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.
Neoplasms
NUCKS1 Acts as a Promising Novel Biomarker for the Prognosis of Patients with Hepatocellular Carcinoma.
Neoplasms
NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma.
Neoplasms
NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway.
Neoplasms
Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export.
Neoplasms
Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity.
Neoplasms
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
Neoplasms
Oleic Acid and Insulin as Key Characteristics of T2D Promote Colorectal Cancer Deterioration in Xenograft Mice Revealed by Functional Metabolomics.
Neoplasms
Oligosaccharides from human milk induce growth arrest via G2/M by influencing growth-related cell cycle genes in intestinal epithelial cells.
Neoplasms
Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.
Neoplasms
Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1).
Neoplasms
Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.
Neoplasms
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.
Neoplasms
Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
Neoplasms
One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element.
Neoplasms
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
Neoplasms
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Neoplasms
Optimization of luminescent assay for screening of cyclin-dependent kinase 2 inhibitors.
Neoplasms
Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
Neoplasms
Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agents.
Neoplasms
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy.
Neoplasms
Orphan nuclear receptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation.
Neoplasms
Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine.
Neoplasms
Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Neoplasms
Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Neoplasms
Over-expression of CDKIs p15INK4b, p16INK4a and p21CIP1/WAF1 genes mediate growth arrest in human osteosarcoma cell lines.
Neoplasms
Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27.
Neoplasms
Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.
Neoplasms
Overcoming Hypoxia-Induced Apoptotic Resistance through Combinatorial Inhibition of GSK-3{beta} and CDK1.
Neoplasms
Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials.
Neoplasms
Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
Neoplasms
Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells.
Neoplasms
Overexpression of CDC28 protein kinase regulatory subunit 1B confers an independent prognostic factor in nasopharyngeal carcinoma.
Neoplasms
Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma.
Neoplasms
Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells.
Neoplasms
Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability.
Neoplasms
Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features.
Neoplasms
Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma.
Neoplasms
Overexpression of p27 protein in human breast cancer correlates with in vitro resistance to doxorubicin and mitomycin C.
Neoplasms
Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.
Neoplasms
Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients.
Neoplasms
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Neoplasms
Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.
Neoplasms
Oxidized low density lipoprotein induces the cyclin-dependent kinase inhibitor p21(waf1) and the tumor suppressor Rb.
Neoplasms
p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck.
Neoplasms
p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis.
Neoplasms
p16 Controls p53 Protein Expression Through miR-dependent Destabilization of MDM2.
Neoplasms
p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription.
Neoplasms
p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis.
Neoplasms
P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling.
Neoplasms
p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.
Neoplasms
p16(INK4a) -mediated suppression of telomerase in normal and malignant human breast cells.
Neoplasms
p16(INK4a) immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities : A systematic review and meta-analysis.
Neoplasms
p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways.
Neoplasms
P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
Neoplasms
p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control.
Neoplasms
p185(HER-2/neu) and p21(CIP1/WAF1) expression in primary tumors and lymph node metastases in non-small cell lung cancer.
Neoplasms
p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers.
Neoplasms
p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors.
Neoplasms
p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma.
Neoplasms
p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids).
Neoplasms
p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury.
Neoplasms
p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression.
Neoplasms
p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA.
Neoplasms
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo.
Neoplasms
p21cip1/waf1 Coordinate Autophagy, Proliferation and Apoptosis in Response to Metabolic Stress.
Neoplasms
p21WAF1 protein expression determined by quantitative immunoassay in relation to non-small-cell lung cancer aggressiveness.
Neoplasms
p21WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression.
Neoplasms
p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer.
Neoplasms
P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest.
Neoplasms
p21WAF1/CIP1 mutants deficient in inhibiting cyclin-dependent kinases (CDKs) can promote assembly of active cyclin D/CDK4(6) complexes in human tumor cells.
Neoplasms
p27 inhibits CDK6/CCND1 complex formation resulting in cell cycle arrest and inhibition of cell proliferation.
Neoplasms
p27 Kip1 expression is reduced in pancreatic carcinoma but has limited prognostic value.
Neoplasms
p27 Labeling index and proliferation in gastrointestinal stromal tumors: correlations with clinicopathologic factors and recurrence.
Neoplasms
p27 suppresses cyclooxygenase-2 expression by inhibiting p38? and p38?-mediated CREB phosphorylation upon arsenite exposure.
Neoplasms
p27(kip1) and Other Cell-Cycle Protein Expression in Normal and Neoplastic Endocrine Tissues.
Neoplasms
p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up.
Neoplasms
p27(Kip1) loss does not predict survival in patients with advanced gastric carcinoma.
Neoplasms
p27(kip1) protein expression correlates with survival in myxoid and round-cell liposarcoma.
Neoplasms
p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase.
Neoplasms
p27Kip1 and p21Cip1 collaborate in the regulation of transcription by recruiting cyclin-Cdk complexes on the promoters of target genes.
Neoplasms
p27kip1 deficiency confers susceptibility to gastric carcinogenesis in Helicobacter pylori-infected mice.
Neoplasms
p27kip1 deficiency impairs G2/M arrest in response to DNA damage, leading to an increase in genetic instability.
Neoplasms
p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma.
Neoplasms
p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis.
Neoplasms
p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis.
Neoplasms
p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms.
Neoplasms
p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells.
Neoplasms
p27Kip1 is inactivated in human colorectal cancer by cytoplasmic localization associated with activation of Akt/PKB.
Neoplasms
p27Kip1 localizes to detergent-insoluble microdomains within lymphocyte membranes.
Neoplasms
p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/{beta}-Catenin Signaling.
Neoplasms
p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.
Neoplasms
p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression.
Neoplasms
p34cdc2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe.
Neoplasms
P53 and p21 (Waf1/Cip1) mRNA expression associated with DNA damage and repair in acute immune complex alveolitis in mice.
Neoplasms
p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.
Neoplasms
p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells.
Neoplasms
p53 Is Preferentially Recruited to the Promoters of Growth Arrest Genes p21 and GADD45 during Replicative Senescence of Normal Human Fibroblasts.
Neoplasms
P53 pathways involving G2 checkpoint regulators and the role of their subcellular localisation.
Neoplasms
p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein.
Neoplasms
p53-dependent induction of p21(Cip1/WAF1/Sdi1) protects against oxygen-induced toxicity.
Neoplasms
p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
Neoplasms
p53-independent expression of p21(CIP1/WAF1) in plasmacytic cells during G(2) cell cycle arrest induced by Actinobacillus actinomycetemcomitans cytolethal distending toxin.
Neoplasms
p53-independent inhibition of proliferation and p21(WAF1/Cip1)-modulated induction of cell death by the antioxidants N-acetylcysteine and vitamin E.
Neoplasms
p53-mediated accumulation of hypophosphorylated pRb after the G1 restriction point fails to halt cell cycle progression.
Neoplasms
p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.
Neoplasms
p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation.
Neoplasms
p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells.
Neoplasms
p57(KIP2) control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect.
Neoplasms
p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.
Neoplasms
p57(Kip2) regulates the proper development of labyrinthine and spongiotrophoblasts.
Neoplasms
p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
Neoplasms
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Neoplasms
Palbociclib induces cell senescence and apoptosis of gastric cancer cells by inhibiting the Notch pathway.
Neoplasms
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Neoplasms
Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
Neoplasms
Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors.
Neoplasms
Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models.
Neoplasms
Parathyroid tumor suppressor on 1p: analysis of the p18 cyclin-dependent kinase inhibitor gene as a candidate.
Neoplasms
Patient-derived xenografts: a promising resource for preclinical cancer research.
Neoplasms
PATZ1 (MAZR) Co-occupies Genomic Sites With p53 and Inhibits Liver Cancer Cell Proliferation via Regulating p27.
Neoplasms
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
Neoplasms
PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis.
Neoplasms
Pectenotoxin-2 induces G1 arrest of the cell cycle in synovial fibroblasts of patients with rheumatoid arthritis.
Neoplasms
Pediatric adrenocortical neoplasms: immunohistochemical expression of p57 identifies loss of heterozygosity and abnormal imprinting of the 11p15.5.
Neoplasms
PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression.
Neoplasms
PEP8-TAT2, a membrane-permeable peptide, inhibits cyclin-Cdk2 activity in HeLa cells.
Neoplasms
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.
Neoplasms
Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGI.
Neoplasms
Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors.
Neoplasms
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.
Neoplasms
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
Neoplasms
PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer.
Neoplasms
Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.
Neoplasms
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
Neoplasms
Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia.
Neoplasms
Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
Neoplasms
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Neoplasms
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Neoplasms
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Neoplasms
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
Neoplasms
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
Neoplasms
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Neoplasms
Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Neoplasms
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Neoplasms
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
Neoplasms
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Neoplasms
Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors.
Neoplasms
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
Neoplasms
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Neoplasms
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Neoplasms
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Neoplasms
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Neoplasms
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
Neoplasms
Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
Neoplasms
Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.
Neoplasms
Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells.
Neoplasms
Phosphorylated Platelet-Derived Growth Factor Receptor-Positive Cells With Anti-apoptotic Properties Accumulate in the Synovium of Patients With Rheumatoid Arthritis.
Neoplasms
Phosphorylation of OGFOD1 by Cell Cycle-Dependent Kinase 7/9 Enhances the Transcriptional Activity of RNA Polymerase II in Breast Cancer Cells.
Neoplasms
Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function.
Neoplasms
Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34.
Neoplasms
Physalin B inhibits cell proliferation and induces apoptosis in undifferentiated human gastric cancer HGC-27 cells.
Neoplasms
Phytoestrogens and breast cancer: In vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives.
Neoplasms
PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Neoplasms
Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Neoplasms
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
Neoplasms
Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).
Neoplasms
Plant cytokinin analogues with inhibitory activity on cyclin-dependent kinases exert their antiproliferative effect through induction of apoptosis initiated by the mitochondrial pathway: determination by a multiparametric flow cytometric analysis.
Neoplasms
Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.
Neoplasms
Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway.
Neoplasms
Polyamine depletion enhances the roscovitine-induced apoptosis through the activation of mitochondria in HCT116 colon carcinoma cells.
Neoplasms
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
Neoplasms
Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus.
Neoplasms
Polyketides from the marine-derived fungus Aspergillus falconensis: In silico and in vitro cytotoxicity studies.
Neoplasms
Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors.
Neoplasms
Positive tetracycline control of expression of p15INK4B from an Epstein-Barr autonomous plasmid in a human melanoma cell line.
Neoplasms
Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.
Neoplasms
Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor.
Neoplasms
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Neoplasms
Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer.
Neoplasms
Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
Neoplasms
Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.
Neoplasms
Potential therapeutic effect of targeting glycogen synthase kinase 3? in esophageal squamous cell carcinoma.
Neoplasms
Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.
Neoplasms
PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in Cancer.
Neoplasms
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.
Neoplasms
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Neoplasms
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
Neoplasms
Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Neoplasms
Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model.
Neoplasms
Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.
Neoplasms
Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis.
Neoplasms
Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy.
Neoplasms
Preliminary findings of chromosomal alterations and expression of cell cycle genes in head an neck tumors.
Neoplasms
Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells.
Neoplasms
Preparation and evaluation of 99mTc-labeled HYNIC-palbociclib analogs for cyclin-dependent kinase 4/6-positive tumor imaging.
Neoplasms
Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.
Neoplasms
PRMT4-mediated arginine methylation negatively regulates retinoblastoma tumor suppressor protein and promotes E2F-1 dissociation.
Neoplasms
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Neoplasms
Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
Neoplasms
Probing protein structure using biochemical and biophysical methods. Proteolysis, matrix-assisted laser desorption/ionization mass spectrometry, high-performance liquid chromatography and size-exclusion chromatography of p21Waf1/Cip1/Sdi1.
Neoplasms
Progesterone is Primary Regulator of Cdk2ap1 Gene Expression and Tissue-specific Expression in the Uterus.
Neoplasms
Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.
Neoplasms
Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor.
Neoplasms
Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1.
Neoplasms
Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas.
Neoplasms
Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
Neoplasms
Prognostic role of p27(Kip1) expression in oral squamous cell carcinoma in Taiwan.
Neoplasms
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.
Neoplasms
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.
Neoplasms
Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma.
Neoplasms
Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer.
Neoplasms
Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland.
Neoplasms
Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage.
Neoplasms
Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization.
Neoplasms
Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
Neoplasms
Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma.
Neoplasms
Prognostic value of p16 expression and alcohol consumption in Japanese patients with oropharyngeal squamous cell carcinoma.
Neoplasms
Prognostic value of p27 expression in adenocarcinoma of the pancreatic head region.
Neoplasms
Prognostic Value of p27 in Follicular Thyroid Carcinoma and its Relation to Radioactive Iodine Response: Does it Aid in the Modification of Risk Stratification?
Neoplasms
Prognostic value of p27Kip1 expression in Basaloid Squamous Cell Carcinoma of the larynx.
Neoplasms
Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1).
Neoplasms
Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
Neoplasms
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Neoplasms
Prolonged progestin treatment induces the promoter of CDK inhibitor p21 Cip1,Waf1 through activation of p53 in human breast and endometrial tumor cells.
Neoplasms
Prolyl oligopeptidase inhibition-induced growth arrest of human gastric cancer cells.
Neoplasms
Prolyl oligopeptidase participates in cell cycle progression in a human neuroblastoma cell line.
Neoplasms
Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.
Neoplasms
Promoter Hypermethylation of LATS1 Gene in Oral Squamous Cell Carcinoma (OSCC) among North Indian Population.
Neoplasms
Promoter-associated endogenous and exogenous small RNAs suppress human bladder cancer cell metastasis by activating p21 (CIP1/WAF1) expression.
Neoplasms
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Neoplasms
Promyelocytic leukemia zinc finger-retinoic acid receptor ? (PLZF-RAR?), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes.
Neoplasms
Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.
Neoplasms
Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
Neoplasms
Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments.
Neoplasms
Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.
Neoplasms
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
Neoplasms
Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
Neoplasms
Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.
Neoplasms
Protein phosphatase 2A-B55? enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Neoplasms
Protein phosphatase 5 and the tumor suppressor P53 down-regulate each other's activities in mice.
Neoplasms
Protein-protein interactions involved in the recognition of p27 by E3 ubiquitin ligase.
Neoplasms
Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
Neoplasms
PTEN/FOXO3/AKT pathway regulates cell death and mediates morphogenetic differentiation of Colorectal Cancer Cells under Simulated Microgravity.
Neoplasms
PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells.
Neoplasms
Pumilio directs deadenylation-associated translational repression of the cyclin-dependent kinase 1 activator RGC-32.
Neoplasms
Purvalanol A enhances cell killing by inhibiting up-regulation of CDC2 kinase activity in tumor cells irradiated with high doses of X rays.
Neoplasms
Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells.
Neoplasms
Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and autophagy in a time-dependent manner in HCT116 colon cancer cells.
Neoplasms
Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity.
Neoplasms
Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI.
Neoplasms
Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry.
Neoplasms
Quantitative Assessment the Relationship between p21 rs1059234 Polymorphism and Cancer Risk.
Neoplasms
Quantitative Phosphoproteomic Analysis Reveals Key Mechanisms of Cellular Proliferation in Liver Cancer Cells.
Neoplasms
Quercetin induces cell cycle G1 arrest through elevating Cdk inhibitors p21 and p27 in human hepatoma cell line (HepG2).
Neoplasms
RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors.
Neoplasms
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Neoplasms
Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells via Cell Cycle Perturbation.
Neoplasms
Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors.
Neoplasms
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Neoplasms
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.
Neoplasms
Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.
Neoplasms
Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
Neoplasms
RASSF1A Methylation is Predictive of Poor Prognosis in Female Breast Cancer in a Background of Overall Low Methylation Frequency.
Neoplasms
RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo.
Neoplasms
Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication.
Neoplasms
Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
Neoplasms
Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Neoplasms
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Neoplasms
Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
Neoplasms
Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents.
Neoplasms
Redox regulation of P-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids.
Neoplasms
Reduced expression of cyclin-dependent kinase inhibitor p27(Kip1) in oral malignant tumors.
Neoplasms
Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer.
Neoplasms
Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity.
Neoplasms
Reduction of plasma angiopoietin-like 2 after cardiac surgery is related to tissue inflammation and senescence status of patients.
Neoplasms
Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5.
Neoplasms
Regulation of CBP and Tip60 coordinates histone acetylation at local and global levels during Ras-induced transformation.
Neoplasms
Regulation of cell proliferation by induction of p21/WAF1 in rat bladder carcinoma cells using the Cre--loxP system.
Neoplasms
Regulation of cyclin-dependent kinase 5 and p53 by ERK1/2 pathway in the DNA damage-induced neuronal death.
Neoplasms
Regulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1 by protein kinase Cdelta-mediated phosphorylation.
Neoplasms
Regulation of p27 by ubiquitin ligases and its pathological significance in human lung carcinomas.
Neoplasms
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Neoplasms
Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90.
Neoplasms
Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor.
Neoplasms
Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer.
Neoplasms
Regulatory mechanisms of fluvastatin and lovastatin for the p21 induction in human cervical cancer HeLa cells.
Neoplasms
Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma.
Neoplasms
Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation.
Neoplasms
Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated PD-L1 attenuation and chemotherapeutics-induced immunogenic cell death.
Neoplasms
Responses of hela and chinese-hamster ovary p34(cdc2)/cyclin-B kinase in relation to cell-cycle perturbations induced by Etoposide.
Neoplasms
Restoration of p16INK4A protein induces myogenic differentiation in RD rhabdomyosarcoma cells.
Neoplasms
Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Neoplasms
Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.
Neoplasms
Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2.
Neoplasms
RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation.
Neoplasms
Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.
Neoplasms
Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
Neoplasms
Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior.
Neoplasms
Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins.
Neoplasms
Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase.
Neoplasms
Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1.
Neoplasms
Retinoic acid negatively regulates p34cdc2 expression during human neuroblastoma differentiation.
Neoplasms
Retraction notice to "Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines" [Biochem. Pharmacol. 73 (2007) 1024-1032].
Neoplasms
Retraction notice to Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines [Biochem. Pharmacol. 73 (2007) 10241032].
Neoplasms
Retraction: MicroRNA-505-5p functions as a tumor suppressor by targeting Cyclin-Dependent Kinase 5 in cervical cancer.
Neoplasms
Retroperitoneal lipomatous angiomyolipoma associated with amyloid deposition masquerading as well-differentiated liposarcoma.
Neoplasms
Revealing the molecular mechanism of gastric cancer marker annexin a4 in cancer cell proliferation using exon arrays.
Neoplasms
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
Neoplasms
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Neoplasms
Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics.
Neoplasms
Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation.
Neoplasms
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Neoplasms
Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Neoplasms
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Neoplasms
RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC.
Neoplasms
RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells.
Neoplasms
Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas.
Neoplasms
Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein.
Neoplasms
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Neoplasms
Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity.
Neoplasms
Role of p15(INK4B) Methylation in Patients With Myelodysplastic Syndromes: A Systematic Meta-Analysis.
Neoplasms
Role of p21WAF1 in green tea polyphenol-induced growth arrest and apoptosis of oral carcinoma cells.
Neoplasms
Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL).
Neoplasms
Roles of CDK/Cyclin complexes in transcription and pre-mRNA splicing: Cyclins L and CDK11 at the cross-roads of cell cycle and regulation of gene expression.
Neoplasms
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Neoplasms
Roles of estrogen receptor and p21WAF1 in bortezomib-induced growth inhibition in human breast cancer cells.
Neoplasms
Roles of the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in receptor-mediated apoptosis of WEHI 231 B lymphoma cells.
Neoplasms
Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9.
Neoplasms
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
Neoplasms
Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study.
Neoplasms
Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Neoplasms
Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Neoplasms
Roscovitine-treated HeLa cells finalize autophagy later than apoptosis by downregulating Bcl?2.
Neoplasms
RRS1 silencing suppresses colorectal cancer cell proliferation and tumorigenesis by inhibiting G2/M progression and angiogenesis.
Neoplasms
RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD.
Neoplasms
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase.
Neoplasms
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Neoplasms
Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer.
Neoplasms
Salivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancers.
Neoplasms
SCFFbl12 Increases p21Waf1/Cip1 Expression Level through Atypical Ubiquitin Chain Synthesis.
Neoplasms
Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis.
Neoplasms
Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.
Neoplasms
Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase.
Neoplasms
Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway.
Neoplasms
Selection of a Water-Soluble Salt Form of a Preclinical Candidate, IIIM-290: Multiwell-Plate Salt Screening and Characterization.
Neoplasms
Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Neoplasms
Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Neoplasms
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Neoplasms
Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.
Neoplasms
Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.
Neoplasms
Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.
Neoplasms
Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase.
Neoplasms
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Neoplasms
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
Neoplasms
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Neoplasms
Senescence and Telomere Homeostasis Might Be Involved in Placenta Percreta-Preliminary Investigation.
Neoplasms
Senescence delay of human diploid fibroblast induced by anti-sense p16INK4a expression.
Neoplasms
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.
Neoplasms
Sequestration of E12/E47 and suppression of p27KIP1 play a role in Id2-induced proliferation and tumorigenesis.
Neoplasms
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Neoplasms
SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
Neoplasms
Short Term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor Positive Breast Cancers.
Neoplasms
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Neoplasms
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
Neoplasms
Signaling pathways and intracellular targets of sulforaphane mediating cell cycle arrest and apoptosis.
Neoplasms
Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.
Neoplasms
Significance of immunohistochemical expression of p27 and involucrin as the marker of cellular differentiation of squamous cell carcinoma of the esophagus.
Neoplasms
Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study.
Neoplasms
Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.
Neoplasms
Silencing of circular RNA_0000326 inhibits cervical cancer cell proliferation, migration and invasion by boosting microRNA-338-3p-dependent down-regulation of CDK4.
Neoplasms
Silencing of the polyamine catabolic key enzyme SSAT prevents CDK inhibitor-induced apoptosis in Caco-2 colon cancer cells.
Neoplasms
Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling.
Neoplasms
Simulation of Different Truncated p16 Forms and In Silico Study of Interaction with Cdk4.
Neoplasms
Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis.
Neoplasms
Simultaneous evaluation of p53 and p21 expression level for early cancer diagnosis using SERS technique.
Neoplasms
Simultaneous Inactivation of the p16, p15 and p14 Genes Encoding Cyclin-Dependent Kinase Inhibitors in Canine T-Lymphoid Tumor Cells.
Neoplasms
Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells.
Neoplasms
Single chain antibodies as tools to study TGF-? regulated SMAD proteins in proximity ligation-based pharmacological screens.
Neoplasms
Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy.
Neoplasms
siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells.
Neoplasms
Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Neoplasms
Skp2 is an independent prognosticator of gallbladder carcinoma among p27(Kip1)-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray.
Neoplasms
Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas.
Neoplasms
Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression.
Neoplasms
Small-molecule targeting of brachyury transcription factor addiction in chordoma.
Neoplasms
Snail associates with EGR-1 and SP-1 to upregulate transcriptional activation of p15INK4b.
Neoplasms
SNP rs1059234 in CDKN1A Gene Correlates with Prognosis in Resected Gastric Adenocarcinoma.
Neoplasms
SOCS1 blocks G1-S transition in hepatocellular carcinoma by reducing the stability of the CyclinD1/CDK4 complex in the nucleus.
Neoplasms
Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q.
Neoplasms
Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors.
Neoplasms
Somatic Mutation and Germline Sequence Abnormalities in CDKN1B, Encoding p27Kip1, in Sporadic Parathyroid Adenomas.
Neoplasms
Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts.
Neoplasms
Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in The Biology of Cancer Progression.
Neoplasms
Sp1 phosphorylation by cyclin-dependent kinase 1/cyclin B1 represses its DNA-binding activity during mitosis in cancer cells.
Neoplasms
Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein.
Neoplasms
Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor.
Neoplasms
Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.
Neoplasms
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
Neoplasms
SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines.
Neoplasms
Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16INK4a-Negative Cancer.
Neoplasms
Stabilization of the retinoblastoma protein by A-type nuclear lamins is required for INK4A-mediated cell cycle arrest.
Neoplasms
Statin-induced depletion of geranylgeranyl pyrophosphate inhibits cell proliferation by a novel pathway of Skp2 degradation.
Neoplasms
Staurosporine resistance accompanies DNA tumor virus-induced immortalization and is independent of the expression and activities of ERK1, ERK2, cyclin A, cyclin-dependent kinase (cdk) 2, and cdk4.
Neoplasms
Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects.
Neoplasms
Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor.
Neoplasms
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.
Neoplasms
Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
Neoplasms
Structural basis of divergent cyclin-dependent kinase activation by Spy1/RINGO proteins.
Neoplasms
Structural characterization of As-MIF and hJAB1 during the inhibition of cell-cycle regulation.
Neoplasms
Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
Neoplasms
Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias.
Neoplasms
Structural organization, mapping, characterization and evolutionary relationships of CDKN2 gene family members in Xiphophorus fishes.
Neoplasms
Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Neoplasms
Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition.
Neoplasms
Studies on the in vitro phosphorylation of HSSB-p34 and -p107 by cyclin-dependent kinases. Cyclin-substrate interactions dictate the efficiency of phosphorylation.
Neoplasms
Study on Medication Rules of Traditional Chinese Medicine against Antineoplastic Drug-Induced Cardiotoxicity Based on Network Pharmacology and Data Mining.
Neoplasms
Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation.
Neoplasms
Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma.
Neoplasms
Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction.
Neoplasms
Suppression of CDK2 expression by siRNA induces cell cycle arrest and cell proliferation inhibition in human cancer cells.
Neoplasms
Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.
Neoplasms
Suppression of survival in human SKBR3 breast carcinoma in response to metal-chelator complexes is preferential for copper-dithiocarbamate.
Neoplasms
Sustained accumulation of the mitotic cyclins and tyrosine-phosphorylated p34cdc2 in human G1-S-arrested cancer cells but not untransformed cells.
Neoplasms
SV40 large tumor antigen nuclear import is regulated by the double-stranded DNA-dependent protein kinase site (serine 120) flanking the nuclear localization sequence.
Neoplasms
SV40 T antigen increases the expression and activities of p34cdc2, cyclin A, and cyclin B prior to immortalization of human diploid fibroblasts.
Neoplasms
SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Neoplasms
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Neoplasms
Synergistic antitumor effect of chemotherapy and antisense-mediated ablation of the cell cycle inhibitor p27KIP-1.
Neoplasms
Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells.
Neoplasms
Synergistic effects of multiple treatments, and both DNA and RNA direct bindings on, green tea catechins.
Neoplasms
Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
Neoplasms
Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors.
Neoplasms
Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
Neoplasms
Synthesis and Biological Evaluation of Novel 99mTc-Labeled Palbociclib Derivatives Targeting Cyclin-Dependent Kinase 4/6 (CDK4/6) as Potential Cancer Imaging Agents.
Neoplasms
Synthesis and evaluation of 3-ylideneoxindole acetamides as potent anticancer agents.
Neoplasms
Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine.
Neoplasms
Synthesis and Evaluation of Novel Cholestanoheterocyclic Steroids as Anticancer Agents.
Neoplasms
Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
Neoplasms
Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14.
Neoplasms
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
Neoplasms
Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.
Neoplasms
Synthesis, Docking Studies into CDK-2 and Anticancer Activity of New Derivatives Based Pyrimidine Scaffold and Their Derived Glycosides.
Neoplasms
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
Neoplasms
Synthesis, structure-activity relationship studies and biological evaluation of novel 2,5-disubstituted indole derivatives as anticancer agents.
Neoplasms
Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
Neoplasms
Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines.
Neoplasms
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Neoplasms
Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Neoplasms
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 1).
Neoplasms
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 2).
Neoplasms
Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration.
Neoplasms
Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
Neoplasms
Targeted overexpression of Tumor Necrosis Factor-? increases Cyclin-dependent kinase 5 activity and TRPV1-dependent Ca2+ influx in trigeminal neurons.
Neoplasms
Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
Neoplasms
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Neoplasms
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Neoplasms
Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.
Neoplasms
Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer.
Neoplasms
Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.
Neoplasms
Targeting cell cycle by ?-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer.
Neoplasms
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
Neoplasms
Targeting cyclin-dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies.
Neoplasms
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.
Neoplasms
Targeting Cyclins and Cyclin-Dependent Kinases in Cancer: Lessons from Mice, Hopes for Therapeutic Applications in Humans.
Neoplasms
Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
Neoplasms
Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition.
Neoplasms
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Neoplasms
Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Neoplasms
Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
Neoplasms
Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma.
Neoplasms
Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.
Neoplasms
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
Neoplasms
Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Neoplasms
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.
Neoplasms
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Neoplasms
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
Neoplasms
TCTP is essential for ?-cell proliferation and mass expansion during development and ?-cell adaptation in response to insulin resistance.
Neoplasms
Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer.
Neoplasms
Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Neoplasms
Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer.
Neoplasms
Testis-specific Arf promoter expression in a transposase-aided BAC transgenic mouse model.
Neoplasms
Tetrahydroanthraquinone Derivative (±)-4-Deoxyaustrocortilutein Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells via Upregulation of p21 and p53 and Downregulation of NF-kappaB.
Neoplasms
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.
Neoplasms
The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity.
Neoplasms
The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis.
Neoplasms
The atypical cell cycle regulator Spy1 suppresses differentiation of the neuroblastoma stem cell population.
Neoplasms
The Biflavonoid Amentoflavone Induces Apoptosis via Suppressing E7 Expression, Cell Cycle Arrest at Sub-G(1) Phase, and Mitochondria-Emanated Intrinsic Pathways in Human Cervical Cancer Cells.
Neoplasms
The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.
Neoplasms
The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report.
Neoplasms
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Neoplasms
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.
Neoplasms
The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics.
Neoplasms
The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
Neoplasms
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.
Neoplasms
The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway.
Neoplasms
The Cell Cycle Regulators P16INK4a, P15INK4b and Cyclin D1: Relationship to Clinicopathological Parameters and Disease-free Survival in Laryngeal Carcinoma Patients.
Neoplasms
The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor.
Neoplasms
The centrosomal protein Tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2.
Neoplasms
The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth.
Neoplasms
The clinicopathological and prognostic significance of P27kip in hepatocellular carcinoma patients: A systemic review and meta-analysis.
Neoplasms
The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients.
Neoplasms
The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
Neoplasms
The CtBP1-p300-FOXO3a transcriptional complex represses the expression of the apoptotic regulators Bax and Bim in human osteosarcoma cells.
Neoplasms
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Neoplasms
The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Neoplasms
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Neoplasms
The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Neoplasms
The cyclin-dependent kinase inhibitor p21 protects the lung from oxidative stress.
Neoplasms
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers.
Neoplasms
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Neoplasms
The cyclin-dependent kinase inhibitor, p21WAF1, promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells.
Neoplasms
The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest.
Neoplasms
The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway.
Neoplasms
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Neoplasms
The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner.
Neoplasms
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review.
Neoplasms
The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model.
Neoplasms
The effect of resveratrol supplementation on the expression levels of factors associated with cellular senescence and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomised clinical trial.
Neoplasms
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
Neoplasms
The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
Neoplasms
The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer.
Neoplasms
The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors.
Neoplasms
The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.
Neoplasms
The expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cells.
Neoplasms
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Neoplasms
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.
Neoplasms
The Flavonoid Metabolite 2,4,6-Trihydroxybenzoic Acid Is a CDK Inhibitor and an Anti-Proliferative Agent: A Potential Role in Cancer Prevention.
Neoplasms
The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: A hybrid model study.
Neoplasms
The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck.
Neoplasms
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
Neoplasms
The genomic repertoire for cell cycle control and DNA metabolism in S. purpuratus.
Neoplasms
The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter.
Neoplasms
The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
Neoplasms
The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design.
Neoplasms
The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.
Neoplasms
The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
Neoplasms
The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Neoplasms
The impacts of single nucleotide polymorphisms in genes of cell cycle and NF-kB pathways on the efficacy and acute toxicities of radiotherapy in patients with nasopharyngeal carcinoma.
Neoplasms
The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
Neoplasms
The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Neoplasms
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
Neoplasms
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.
Neoplasms
The level of DNA modification by (+)-syn-(11S,12R,13S,14R)- and (-)-anti-(11R,12S,13S,14R)-dihydrodiol epoxides of dibenzo[a,l]pyrene determined the effect on the proteins p53 and p21WAF1 in the human mammary carcinoma cell line MCF-7.
Neoplasms
The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired.
Neoplasms
The multi-target drug BAI induces apoptosis in various human cancer cells through modulation of Bcl-xL protein.
Neoplasms
The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Neoplasms
The natural sweetener metabolite steviol inhibits the proliferation of human osteosarcoma U2OS cell line.
Neoplasms
The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.
Neoplasms
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Neoplasms
The p16(INK4A) protein and flavopiridol restore yeast cell growth inhibited by Cdk4.
Neoplasms
The p16INK4a tumor suppressor controls p21WAF1 induction in response to ultraviolet light.
Neoplasms
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.
Neoplasms
The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers.
Neoplasms
The phenotype of a "Cdc2 kinase target site-deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control.
Neoplasms
The PI3K/Akt/FOXO3a pathway regulates regeneration following spinal cord injury in adult rats through TNF-? and p27kip1 expression.
Neoplasms
The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer.
Neoplasms
The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.
Neoplasms
The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
Neoplasms
The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
Neoplasms
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Neoplasms
The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.
Neoplasms
The Relevance of Women's Diseases, Jun Activation-domain Binding Protein 1 (JAB1) and p27(kip1).
Neoplasms
The role of cyclin D2 and p21/waf1 in human T-cell leukemia virus type 1 infected cells.
Neoplasms
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.
Neoplasms
The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
Neoplasms
The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine.
Neoplasms
The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.
Neoplasms
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
Neoplasms
The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer.
Neoplasms
The triage of low-grade cytological abnormalities by the immunocytological expression of cyclin-dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+.
Neoplasms
The tumor suppressor p16(INK4a) gene is a regulator of apoptosis induced by ultraviolet light and cisplatin.
Neoplasms
The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.
Neoplasms
The ubiquitous transcription factor NF-Y positively regulates the transcription of human p27Kip1 through a CCAAT box located in the 5-upstream region of the p27Kip1 gene.
Neoplasms
The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Neoplasms
The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression.
Neoplasms
Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Neoplasms
Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma.
Neoplasms
Thyroid status modulates T lymphoma growth via cell cycle regulatory proteins and angiogenesis.
Neoplasms
THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
Neoplasms
Time course comparison of cell-cycle protein expression following partial hepatectomy and WY14,643-induced hepatic cell proliferation in F344 rats.
Neoplasms
Time course of cell cycle-related protein expression in diethylnitrosamine-initiated rat liver.
Neoplasms
TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein.
Neoplasms
Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis.
Neoplasms
TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.
Neoplasms
Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Neoplasms
Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21waf1.
Neoplasms
Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53.
Neoplasms
Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
Neoplasms
Transcriptional activation of CBF? by CDK11p110 is necessary to promote osteosarcoma cell proliferation.
Neoplasms
Transcriptional activation of cyclin-dependent kinase inhibitor, p21waf1 gene by treatment with a differentiation inducing agent, vesnarinone in a human salivary gland cancer cell line.
Neoplasms
Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study.
Neoplasms
Transcriptional and epigenetic modulation of autophagy promotes EBV oncoprotein EBNA3C induced B-cell survival.
Neoplasms
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Neoplasms
Transcriptional modulation of apoptosis regulators by roscovitine and related compounds.
Neoplasms
Transfection of p27(Kip1) threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells.
Neoplasms
Transformation by v-Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors.
Neoplasms
Transforming growth factor beta 1 (TGF beta 1) reduces cellular levels of p34cdc2, and this effect is abrogated by adenovirus independently of the E1A-associated pRB binding activity.
Neoplasms
Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked.
Neoplasms
Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader.
Neoplasms
Triazole based isatin derivatives as potential inhibitor of key cancer promoting kinases- insight from electronic structure, docking and molecular dynamics simulations.
Neoplasms
Trichinella pseudospiralis infection is characterized by more continuous and diffuse myopathy than T. spiralis infection.
Neoplasms
Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Neoplasms
Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.
Neoplasms
Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients.
Neoplasms
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Neoplasms
Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway.
Neoplasms
Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35.
Neoplasms
Tumor necrosis factor-alpha-induced accumulation of tumor suppressor protein p53 and cyclin-dependent protein kinase inhibitory protein p21 is inhibited by insulin in ME-180S cells.
Neoplasms
Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Neoplasms
Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1.
Neoplasms
Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype.
Neoplasms
Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4.
Neoplasms
Tumor suppressor INK4: refinement of p16INK4A structure and determination of p15INK4B structure by comparative modeling and NMR data.
Neoplasms
Tumor suppressor p16INK4a inhibits cancer cell growth by down-regulating eEF1A2 through a direct interaction.
Neoplasms
Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.
Neoplasms
Tumor suppressor protein C53 antagonizes checkpoint kinases to promote cyclin-dependent kinase 1 activation.
Neoplasms
Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Neoplasms
Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways.
Neoplasms
Two loci controlling susceptibility to radiation-induced lymphomagenesis on mouse chromosome 4: cdkn2a, a candidate for one locus, and a novel locus distinct from cdkn2a.
Neoplasms
Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells.
Neoplasms
Ubiquitin-dependent signaling: the role of ubiquitination in the response of cells to their environment.
Neoplasms
UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction.
Neoplasms
UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.
Neoplasms
Ultraviolet B light induces G1 arrest in human melanocytes by prolonged inhibition of retinoblastoma protein phosphorylation associated with long-term expression of the p21Waf-1/SDI-1/Cip-1 protein.
Neoplasms
Uncovering the pharmacological response of novel sesquiterpene derivatives that differentially alter gene expression and modulate the cell cycle in cancer cells.
Neoplasms
Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas.
Neoplasms
Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
Neoplasms
Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization.
Neoplasms
Unraveling the complexity of endocrine resistance in breast cancer by functional genomics.
Neoplasms
Unusual deregulation of cell cycle components in early and frank estrogen-induced renal neoplasias in the Syrian hamster.
Neoplasms
Up-regulated p27Kip1 reduces matrix metalloproteinase-9 and inhibits invasion of human breast cancer cells.
Neoplasms
Up-regulation of cyclin B1 and cdc2 expression during 9-nitrocamptothecin-induced regression of DU145 prostate tumor.
Neoplasms
Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors.
Neoplasms
Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis.
Neoplasms
Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
Neoplasms
Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer.
Neoplasms
Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression.
Neoplasms
Upregulation of p21(WAF1/Cip1) precedes tumor necrosis factor-induced necrosis-like cell death.
Neoplasms
Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
Neoplasms
Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre.
Neoplasms
Vanadyl bisacetylacetonate induced G1/S cell cycle arrest via high-intensity ERK phosphorylation in HepG2 cells.
Neoplasms
Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women.
Neoplasms
Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity.
Neoplasms
Vitamin C Promotes Apoptosis and Cell Cycle Arrest in Oral Squamous Cell Carcinoma.
Neoplasms
Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells.
Neoplasms
Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
Neoplasms
Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner.
Neoplasms
Wild-type p16INK4a suppresses cell growth, telomerase activity and DNA repair in human breast cancer MCF-7 cells.
Neoplasms
XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.
Neoplasms
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Neoplasms
Yin-yang regulating effects of cancer-associated genes, proteins, and cells: An ancient Chinese concept in vogue in modern cancer research.
Neoplasms
ZAC, LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome.
Neoplasms
Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
Neoplasms
[A novel small molecule cyclin-dependent kinase inhibitor flavopiridol in cancer therapy]
Neoplasms
[Cancer and the cell cycle: a current merry-go-round in oncology of clinical relevance]
Neoplasms
[Coordination inhibition of the proliferation of MCF-7 by enhancing expression of p53,p21 and decreasing expression of c-myc]
Neoplasms
[Detection of expression of p53, p16, and cyclooxygenase 2 in pancreatic cancer by tissue microarray and correlation among these three genes]
Neoplasms
[Dual regulation of cell cycles by Shuanghuang Shengbai Granule in Lewis-bearing mice with chemotherapy-induced myelosuppression and its mechanism.]
Neoplasms
[Effect of phenelzine on the proliferation, apoptosis and histone methylation and acetylation of Molt-4 cells].
Neoplasms
[Expression of cyclin dependent kinase inhibitors of KIP family in gastric cancer]
Neoplasms
[Expression of p16 gene and protein in the evaluation of dynamics of laryngeal cancer growth]
Neoplasms
[Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Neoplasms
[Impact of p16INK4A and p15INK4B on human hepatocellular carcinoma cell proliferation and apoptosis]
Neoplasms
[Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology]
Neoplasms
[Pharmacological profile and clinical findings of palbociclib (IBRANCE® capsule 25?mg/125?mg)].
Neoplasms
[Prognostic significance of cyclin-dependent kinase inhibitor p27kip1 expression in human breast cancer]
Neoplasms
[The efficacy of p16, p53 and p21 genes on the proliferation of lung cancer cells in vitro]
Neoplasms, Germ Cell and Embryonal
Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours.
Neoplasms, Germ Cell and Embryonal
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Neoplasms, Germ Cell and Embryonal
Differential Akt signalling in non-seminomatous testicular germ cell tumors.
Neoplasms, Germ Cell and Embryonal
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Neoplasms, Germ Cell and Embryonal
Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors.
Neoplasms, Squamous Cell
CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck.
Neoplastic Cells, Circulating
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Neoplastic Cells, Circulating
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 1).
Neoplastic Cells, Circulating
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 2).
Nephritis
Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
Nephrosis, Lipoid
Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Nervous System Diseases
CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.
Nervous System Diseases
Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Nervous System Diseases
Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation.
Nervous System Diseases
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Nervous System Diseases
Elevation of p-NR2A(S1232) by Cdk5/p35 contributes to retinal ganglion cell apoptosis in a rat experimental glaucoma model.
Nervous System Diseases
Extra-cell cycle regulatory functions of cyclin-dependent kinases (CDK) and CDK inhibitor proteins contribute to brain development and neurological disorders.
Nervous System Diseases
Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis.
Nervous System Diseases
Inducible Knockout of the Cyclin-Dependent Kinase 5 Activator p35 Alters Hippocampal Spatial Coding and Neuronal Excitability.
Nervous System Diseases
Inhibition of Cdk5 rejuvenates inhibitory circuits and restores experience-dependent plasticity in adult visual cortex.
Nervous System Diseases
Regulation of hippocampal and behavioral excitability by cyclin-dependent kinase 5.
Nervous System Diseases
Role of Cell Cycle Re-Entry in Neurons: A Common Apoptotic Mechanism of Neuronal Cell Death.
Nervous System Diseases
The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.
Nervous System Diseases
The Ever-Changing Morphology of Hippocampal Granule Neurons in Physiology and Pathology.
Neural Tube Defects
Neural tube development requires the cooperation of p53- and Gadd45a-associated pathways.
Neuralgia
Crosstalk between Cdk5/p35 and ERK1/2 signalling mediates spinal astrocyte activity via the PPAR? pathway in a rat model of chronic constriction injury.
Neuralgia
Decreased Activity in Neuropathic Pain Form and Gene Expression of Cyclin-Dependent Kinase5 and Glycogen Synthase Kinase-3 Beta in Soleus Muscle of Wistar Male Rats.
Neuralgia
Differential expression of Cdk5-phosphorylated CRMP2 following a spared nerve injury.
Neuralgia
Long Noncoding RNA H19 Induces Neuropathic Pain by Upregulating Cyclin-Dependent Kinase 5-Mediated Phosphorylation of cAMP Response Element Binding Protein [Retraction].
Neuralgia
Long Noncoding RNA H19 Induces Neuropathic Pain by Upregulating Cyclin-Dependent Kinase 5-Mediated Phosphorylation of cAMP Response Element Binding Protein.
Neuroblastoma
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis.
Neuroblastoma
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Neuroblastoma
Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma.
Neuroblastoma
Analysis of location and integrity of the human PITSLRE (p58(cdc2L1)) genes in neuroblastoma cell genomes.
Neuroblastoma
Caspase 8/10 are not mediating apoptosis in neuroblastoma cells treated with CDK inhibitory drugs.
Neuroblastoma
CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model.
Neuroblastoma
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.
Neuroblastoma
CDK-5-mediated neurofilament phosphorylation in SHSY5Y human neuroblastoma cells.
Neuroblastoma
CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.
Neuroblastoma
CDK4 and CDK5 Inhibition Have Comparable Mild Hypothermia Effects in Preventing Drp1-Dependent Mitochondrial Fission and Neuron Death Induced by MPP
Neuroblastoma
CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
Neuroblastoma
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
Neuroblastoma
Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene.
Neuroblastoma
Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Neuroblastoma
Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
Neuroblastoma
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Neuroblastoma
Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells.
Neuroblastoma
Differential regulation of cyclin-dependent kinase inhibitors in neuroblastoma cells.
Neuroblastoma
Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma.
Neuroblastoma
DREAM target reactivation by core transcriptional regulators supports neuroblastoma growth.
Neuroblastoma
Epigenetic Targeting of TERT-Associated Gene Expression Signature in Human Neuroblastoma with TERT Overexpression.
Neuroblastoma
Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
Neuroblastoma
Gene replacement ameliorates deficits in mouse and human models of cyclin-dependent kinase-like 5 disorder.
Neuroblastoma
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
Neuroblastoma
Increase in the expression of the neuronal cyclin-dependent protein kinase cdk-5 during differentiation of N2A neuroblastoma cells.
Neuroblastoma
Increased expression of cdk5/p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins.
Neuroblastoma
Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells.
Neuroblastoma
Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells.
Neuroblastoma
Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents.
Neuroblastoma
Membrane depolarization stimulates the proliferation of SH-SY5Y human neuroblastoma cells by increasing retinoblastoma protein (RB) phosphorylation through the activation of cyclin-dependent kinase 2 (Cdk2).
Neuroblastoma
MicroRNA-H4-5p encoded by HSV-1 latency-associated transcript promotes cell proliferation, invasion and cell cycle progression via p16-mediated PI3K-Akt signaling pathway in SHSY5Y cells.
Neuroblastoma
Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas.
Neuroblastoma
Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Neuroblastoma
p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Neuroblastoma
p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation.
Neuroblastoma
Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Phosphorylation of endogenous proteins by adenosine 3':5'-monophosphate-dependent protein kinase in mouse neuroblastoma cells.
Neuroblastoma
Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation.
Neuroblastoma
Retinoic acid negatively regulates p34cdc2 expression during human neuroblastoma differentiation.
Neuroblastoma
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.
Neuroblastoma
Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma.
Neuroblastoma
Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).
Neuroblastoma
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Neuroblastoma
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.
Neuroblastoma
The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells.
Neuroblastoma
Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons.
Neurodegenerative Diseases
AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain.
Neurodegenerative Diseases
Acute and chronic stress differentially regulate cyclin-dependent kinase 5 in mouse brain: implications to glucocorticoid actions and major depression.
Neurodegenerative Diseases
Both N-methyl-D-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (cdk5) activator p35 in cultured rat hippocampal neurons.
Neurodegenerative Diseases
Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice.
Neurodegenerative Diseases
Callyspongisines A-D: bromopyrrole alkaloids from an Australian marine sponge, Callyspongia sp.
Neurodegenerative Diseases
Cdk1-FOXO1: a mitotic signal takes center stage in post-mitotic neurons.
Neurodegenerative Diseases
Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses.
Neurodegenerative Diseases
Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.
Neurodegenerative Diseases
Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease.
Neurodegenerative Diseases
Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration.
Neurodegenerative Diseases
Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1.
Neurodegenerative Diseases
Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells.
Neurodegenerative Diseases
Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Neurodegenerative Diseases
Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8.
Neurodegenerative Diseases
Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Neurodegenerative Diseases
Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus.
Neurodegenerative Diseases
Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis.
Neurodegenerative Diseases
Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress.
Neurodegenerative Diseases
Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor.
Neurodegenerative Diseases
Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons.
Neurodegenerative Diseases
Cyclin-Dependent Kinase 5 Regulates PSD-95 Ubiquitination in Neurons.
Neurodegenerative Diseases
Cyclin-dependent kinase 5 regulates steroidogenic acute regulatory protein and androgen production in mouse Leydig cells.
Neurodegenerative Diseases
Cyclin-dependent kinase 5 supports neuronal survival through phosphorylation of Bcl-2.
Neurodegenerative Diseases
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
Neurodegenerative Diseases
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
Neurodegenerative Diseases
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Neurodegenerative Diseases
Functional characterization of CDK5 and CDK5R1 mutations identified in patients with non-syndromic intellectual disability.
Neurodegenerative Diseases
Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.
Neurodegenerative Diseases
Identification of non-muscle myosin heavy chain as a substrate for Cdk5 and tool for drug screening.
Neurodegenerative Diseases
Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling.
Neurodegenerative Diseases
Identifying novel substrates for mouse Cdk5 kinase using the yeast Saccharomyces cerevisiae.
Neurodegenerative Diseases
Inactivation of CDK/pRb pathway normalizes survival pattern of lymphoblasts expressing the FTLD-progranulin mutation c.709-1G>A.
Neurodegenerative Diseases
Increased immunoreactivity of cdk5 activators in hippocampal sclerosis.
Neurodegenerative Diseases
Inhibition of ataxia telangiectasia-p53-E2F-1 pathway in neurons as a target for the prevention of neuronal apoptosis.
Neurodegenerative Diseases
Inhibition of cyclin-dependent kinase 5 activity alleviates diabetes-related cognitive deficits.
Neurodegenerative Diseases
Inhibition of p25/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia.
Neurodegenerative Diseases
Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease.
Neurodegenerative Diseases
Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action.
Neurodegenerative Diseases
Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors.
Neurodegenerative Diseases
Involvement of cyclin-dependent kinase-5 in the kainic acid-mediated degeneration of glutamatergic synapses in the rat hippocampus.
Neurodegenerative Diseases
Kinase inhibitor scaffolds against neurodegenerative diseases from a Southern Australian ascidian, Didemnum sp.
Neurodegenerative Diseases
Lithium treatment decreases activities of tau kinases in a murine model of senescence.
Neurodegenerative Diseases
Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases.
Neurodegenerative Diseases
Negative regulation of cyclin-dependent kinase 5 targets by protein kinase C.
Neurodegenerative Diseases
No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro.
Neurodegenerative Diseases
Novel potent pharmacological cyclin-dependent kinase inhibitors.
Neurodegenerative Diseases
Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory.
Neurodegenerative Diseases
p25/cyclin-dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum-stressed neurons.
Neurodegenerative Diseases
p53, Apaf-1, caspase-3, and -9 are dispensable for Cdk5 activation during cell death.
Neurodegenerative Diseases
Phosphorylation of CHIP at Ser20 by Cdk5 promotes tAIF-mediated neuronal death.
Neurodegenerative Diseases
Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function.
Neurodegenerative Diseases
Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review.
Neurodegenerative Diseases
Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora.
Neurodegenerative Diseases
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.
Neurodegenerative Diseases
Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid.
Neurodegenerative Diseases
Spiralisones A-D: acylphloroglucinol hemiketals from an Australian marine brown alga, Zonaria spiralis.
Neurodegenerative Diseases
Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.
Neurodegenerative Diseases
Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPAR? agonist improves neuronal loss and early lethality.
Neurodegenerative Diseases
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons.
Neurodegenerative Diseases
Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
Neurodegenerative Diseases
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
Neurodegenerative Diseases
The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.
Neurodegenerative Diseases
The mechanisms regulating cyclin-dependent kinase 5 in hippocampus during systemic inflammatory response: The effect on inflammatory gene expression.
Neurodegenerative Diseases
[Roles of cyclin-dependent kinase 5 in central nervous system development and neurodegenerative diseases.]
Neuroectodermal Tumors, Primitive
Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications.
Neuroectodermal Tumors, Primitive
Expression of proline-directed protein kinase, (p34cdc2/p58cyclin A), a novel cell proliferation marker in childhood brain tumors.
Neuroectodermal Tumors, Primitive
p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.
Neuroendocrine Tumors
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
Neuroendocrine Tumors
Differential expression of forkhead box M1 and its downstream cyclin-dependent kinase inhibitors p27(kip1) and p21(waf1/cip1) in the diagnosis of pulmonary neuroendocrine tumours.
Neuroendocrine Tumors
Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors.
Neuroendocrine Tumors
The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Neurofibroma, Plexiform
Combined CDK inhibition overcomes MEK inhibitor resistance in plexiform neurofibroma of neurofibromatosis type I.
Neurofibromatoses
Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells.
Neurofibromatoses
Combined CDK inhibition overcomes MEK inhibitor resistance in plexiform neurofibroma of neurofibromatosis type I.
Neurofibromatoses
Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas.
Neurofibromatosis 1
Combined CDK inhibition overcomes MEK inhibitor resistance in plexiform neurofibroma of neurofibromatosis type I.
Neurofibromatosis 2
Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells.
Neurofibromatosis 2
Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Neurofibromatosis 2
Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas.
Neurofibrosarcoma
RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors.
Neuroinflammatory Diseases
Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.
Neuroinflammatory Diseases
Cdk5 Inhibitory Peptide Prevents Loss of Neurons and Alleviates Behavioral Changes in p25 Transgenic Mice.
Neuroinflammatory Diseases
Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma.
Neuroinflammatory Diseases
Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo.
Neuroinflammatory Diseases
TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice.
Neurologic Manifestations
CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury.
Neurologic Manifestations
Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
Neurologic Manifestations
Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
Neuroma, Acoustic
MiR-205 Inhibits Sporadic Vestibular Schwannoma Cell Proliferation by Targeting Cyclin-Dependent Kinase 14.
Neutropenia
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
Neutropenia
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Neutropenia
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Neutropenia
Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer.
Neutropenia
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Neutropenia
Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances.
Neutropenia
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
Neutropenia
Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature.
Neutropenia
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
Neutropenia
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
Nevus
Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Nevus
Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins.
Nevus
Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.
Niemann-Pick Disease, Type C
p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
Niemann-Pick Disease, Type C
The neuroprotective effects of cyclin-dependent kinase-5 inhibition in mice with Niemann-Pick disease type C.
Niemann-Pick Diseases
The neuroprotective effects of cyclin-dependent kinase-5 inhibition in mice with Niemann-Pick disease type C.
Nijmegen Breakage Syndrome
Chemical genetics reveals a specific requirement for cdk2 activity in the DNA damage response and identifies nbs1 as a cdk2 substrate in human cells.
Nijmegen Breakage Syndrome
G2-phase radiation response in lymphoblastoid cell lines from Nijmegen breakage syndrome.
Obesity
Cyclin-dependent kinase 4/6 inhibitors require an arcuate to paraventricular hypothalamus melanocortin circuit to treat diet-induced obesity.
Obesity
Cyclin-dependent kinase inhibitor, p21WAF1/CIP1, is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance.
Obesity
Dissecting the nutrigenomics, diabetes, and gastrointestinal disease interface: from risk assessment to health intervention.
Obesity
Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease.
Obesity
Inflammation and poor response to treatment with erythropoietin in chronic kidney disease.
Obesity
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
Obesity
Molecular Recognition of PPAR? by Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations.
Obesity
PPM1A Controls Diabetic Gene Programming through Directly Dephosphorylating PPAR? at Ser273.
Obesity
Some cyclin-dependent kinase inhibitors-related genes are regulated by vitamin C in a model of diet-induced obesity.
Obesity
Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population.
Oligodendroglioma
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Oligodendroglioma
Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans.
Oligodendroglioma
Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.
Oligodendroglioma
Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome.
Oligodendroglioma
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
Oligodendroglioma
The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
Oncogene Addiction
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor ? and bcr-abl oncogene addiction in malignant hematologic cells.
Optic Nerve Injuries
Induction of CRMP-2 phosphorylation by CDK5 restricts the repair of damaged optic nerve.
Oral Submucous Fibrosis
The phosphorylation of survivin Thr34 by p34cdc2 in carcinogenesis of oral submucous fibrosis.
Osteoarthritis
An algorithmic strategy of surgical intervention for cervical degenerative kyphosis.
Osteoarthritis
Cellular Localization of Debromohymenialdisine and Hymenialdisine in the Marine Sponge Axinella sp. Using a Newly Developed Cell Purification Protocol.
Osteoarthritis
Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritis.
Osteoarthritis
Cyclin-Dependent Kinase Inhibitor-1-Deficient Mice Are Susceptible to Osteoarthritis Associated With Enhanced Inflammation.
Osteoarthritis
Susceptibility of cyclin-dependent kinase inhibitor 1-deficient mice to rheumatoid arthritis arising from interleukin-1?-induced inflammation.
Osteonecrosis
Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association.
Osteosarcoma
A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma.
Osteosarcoma
A p27(Kip1) mutant that does not inhibit CDK activity promotes centrosome amplification and micronucleation.
Osteosarcoma
Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.
Osteosarcoma
Antitumor and antimigration effects of Salvia clandestina L. extract on osteosarcoma cells.
Osteosarcoma
Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.
Osteosarcoma
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.
Osteosarcoma
BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.
Osteosarcoma
Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.
Osteosarcoma
CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Osteosarcoma
Circular RNA circ_001621 promotes osteosarcoma cells proliferation and migration by sponging miR-578 and regulating VEGF expression.
Osteosarcoma
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Osteosarcoma
Control of cell cycle gene expression in bone development and during c-Fos-induced osteosarcoma formation.
Osteosarcoma
Correction to: Transcriptional activation of CBF? by CDK11p110 is necessary to promote osteosarcoma cell proliferation.
Osteosarcoma
Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Osteosarcoma
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Osteosarcoma
Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells.
Osteosarcoma
Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis.
Osteosarcoma
Differential expression of degradome components in cutaneous squamous cell carcinomas.
Osteosarcoma
ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells.
Osteosarcoma
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.
Osteosarcoma
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
Osteosarcoma
FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line.
Osteosarcoma
Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase.
Osteosarcoma
Functional Genetic Single-Nucleotide Polymorphisms (SNPs) in Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) Locus Are Associated with Risk and Prognosis of Osteosarcoma in Chinese Populations.
Osteosarcoma
Giant cell-rich osteosarcoma of the vertebra with murine double minute chromosome 2- and cyclin-dependent kinase 4-positive and histone H3F3A mutant p.Gly34Trp-negative immunophenotypes.
Osteosarcoma
Inhibition of osteosarcoma cell progression by MacroH2A via the downregulation of cyclin D and cyclin?dependent kinase genes.
Osteosarcoma
MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
Osteosarcoma
MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
Osteosarcoma
microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6.
Osteosarcoma
MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma.
Osteosarcoma
Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells.
Osteosarcoma
Rhotekin 2 silencing inhibits proliferation and induces apoptosis in human osteosarcoma cells.
Osteosarcoma
Selected using bioinformatics and molecular docking analyses, PHA-793887 is effective against osteosarcoma.
Osteosarcoma
Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Osteosarcoma
Small molecule TSC01682 inhibits osteosarcoma cell growth by specifically disrupting the CUL4B-DDB1 interaction and decreasing the ubiquitination of CRL4B E3 ligase substrates.
Osteosarcoma
Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation.
Osteosarcoma
The CtBP1-p300-FOXO3a transcriptional complex represses the expression of the apoptotic regulators Bax and Bim in human osteosarcoma cells.
Osteosarcoma
The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.
Osteosarcoma
The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.
Osteosarcoma
Transcriptional activation of CBF? by CDK11p110 is necessary to promote osteosarcoma cell proliferation.
Osteosarcoma
Transcriptional repression of E2F gene by proteasome inhibitors in human osteosarcoma cells.
Osteosarcoma
Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked.
Osteosarcoma
Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein.
Osteosarcoma
Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
Ovarian Neoplasms
A Splice Site Variant of CDK12 and Breast Cancer in Three Eurasian Populations.
Ovarian Neoplasms
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Ovarian Neoplasms
Binding sites for adeno-associated virus Rep proteins within the human genome.
Ovarian Neoplasms
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
Ovarian Neoplasms
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Ovarian Neoplasms
Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53.
Ovarian Neoplasms
Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis.
Ovarian Neoplasms
Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Ovarian Neoplasms
Cyclin-Dependent Kinase 14 Promotes Cell Proliferation, Migration and Invasion in Ovarian Cancer by Inhibiting Wnt Signaling Pathway.
Ovarian Neoplasms
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Ovarian Neoplasms
Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Ovarian Neoplasms
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Ovarian Neoplasms
Dopamine and cAMP-regulated phosphoprotein 32kDa (DARPP-32), protein phosphatase-1 and cyclin-dependent kinase 5 expression in ovarian cancer.
Ovarian Neoplasms
Effect of tumor suppressor gene cyclin-dependent kinase inhibitor 2A wild-type and A148T mutant on the cell cycle of human ovarian cancer cells.
Ovarian Neoplasms
Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells.
Ovarian Neoplasms
Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas.
Ovarian Neoplasms
Expression, Purification, and Identification of Associated Proteins of the Full-length hCDK12/CyclinK Complex.
Ovarian Neoplasms
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Ovarian Neoplasms
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
Ovarian Neoplasms
Growth inhibitory effect of D-allose on human ovarian carcinoma cells in vitro.
Ovarian Neoplasms
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.
Ovarian Neoplasms
Identification of key genes for guiding chemotherapeutic management in ovarian cancer using translational bioinformatics.
Ovarian Neoplasms
Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis.
Ovarian Neoplasms
Inhibition of succinate dehydrogenase sensitizes cyclin E-driven ovarian cancer to CDK inhibition.
Ovarian Neoplasms
LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells.
Ovarian Neoplasms
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ovarian Neoplasms
Lysophosphatidic acid-induced p21Waf1 expression mediates the cytostatic response of breast and ovarian cancer cells to TGF?.
Ovarian Neoplasms
Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
Ovarian Neoplasms
MiR-498 regulated FOXO3 expression and inhibited the proliferation of human ovarian cancer cells.
Ovarian Neoplasms
NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.
Ovarian Neoplasms
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors.
Ovarian Neoplasms
Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Ovarian Neoplasms
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Ovarian Neoplasms
Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
Ovarian Neoplasms
PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer.
Ovarian Neoplasms
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Ovarian Neoplasms
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
Ovarian Neoplasms
Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.
Ovarian Neoplasms
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Ovarian Neoplasms
The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients.
Ovarian Neoplasms
The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
Ovarian Neoplasms
The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.
Ovarian Neoplasms
The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
Ovarian Neoplasms
The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells.
Ovarian Neoplasms
Why a Combination of WP 631 and Epo B is an Improvement on the Drugs Singly - Involvement in the Cell Cycle and Mitotic Slippage.
Ovarian Neoplasms
[Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol]
Paget Disease, Extramammary
Overexpression of cyclin-dependent kinase 4 protein in extramammary Paget's disease.
Pancreatic Diseases
Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.
Pancreatic Neoplasms
A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
Pancreatic Neoplasms
A Transcriptome-Wide Association Study (TWAS) Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer.
Pancreatic Neoplasms
Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
Pancreatic Neoplasms
An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells.
Pancreatic Neoplasms
Antiproliferative Effect of 1?,25-dihydroxyvitamin D3 Involves Upregulation of Cyclin-Dependent Kinase Inhibitor p21 in Human Pancreatic Cancer Cells.
Pancreatic Neoplasms
CDK14/?-catenin/TCF4/miR-26b positive feedback regulation modulating pancreatic cancer cell phenotypes in vitro and tumor growth in mice model in vivo.
Pancreatic Neoplasms
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
Pancreatic Neoplasms
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Pancreatic Neoplasms
Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Pancreatic Neoplasms
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Pancreatic Neoplasms
Ectopic Tbx2 expression results in polyploidy and cisplatin resistance.
Pancreatic Neoplasms
Epigenetic Silencing of MicroRNA miR-107 Regulates Cyclin-Dependent Kinase 6 Expression in Pancreatic Cancer.
Pancreatic Neoplasms
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Pancreatic Neoplasms
Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy.
Pancreatic Neoplasms
Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk.
Pancreatic Neoplasms
Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53.
Pancreatic Neoplasms
Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer.
Pancreatic Neoplasms
Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB.
Pancreatic Neoplasms
Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.
Pancreatic Neoplasms
Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer.
Pancreatic Neoplasms
Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Pancreatic Neoplasms
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
Pancreatic Neoplasms
Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin.
Pancreatic Neoplasms
Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer.
Pancreatic Neoplasms
Mechanism of T-oligo-induced cell cycle arrest in Mia-Paca pancreatic cancer cells.
Pancreatic Neoplasms
MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells.
Pancreatic Neoplasms
Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.
Pancreatic Neoplasms
NOVEL THIOSEMICARBAZONE IRON CHELATORS INDUCE UP-REGULATION AND PHOSPHORYLATION OF THE METASTASIS SUPPRESSOR, NDRG1: A NEW STRATEGY FOR THE TREATMENT OF PANCREATIC CANCER.
Pancreatic Neoplasms
Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer.
Pancreatic Neoplasms
P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation.
Pancreatic Neoplasms
p21 expression is induced by activation of nuclear nerve growth factor-induced Balpha (Nur77) in pancreatic cancer cells.
Pancreatic Neoplasms
Progression elevated gene-3 promoter (PEG-Prom) confers cancer cell selectivity to human polynucleotide phosphorylase (hPNPase(old-35))-mediated growth suppression.
Pancreatic Neoplasms
Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.
Pancreatic Neoplasms
Split Cyclin-Dependent Kinase 4/6-Retinoblastoma 1 Axis in Pancreatic Cancer.
Pancreatic Neoplasms
Synergistic antitumor effects of CDK inhibitor SNS?032 and an oncolytic adenovirus co?expressing TRAIL and Smac in pancreatic cancer.
Pancreatic Neoplasms
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
Pancreatic Neoplasms
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Pancreatic Neoplasms
Transient receptor potential channel TRPM8 is over-expressed and required for cellular proliferation in pancreatic adenocarcinoma.
Pancreatic Neoplasms
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Pancreatic Neoplasms
Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells.
Pancreatic Neoplasms
[Detection of expression of p53, p16, and cyclooxygenase 2 in pancreatic cancer by tissue microarray and correlation among these three genes]
Papilloma
Combinatorial expression of cell cycle regulators is more suitable for immortalization than oncogenic methods in dermal papilla cells.
Papilloma
Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes.
Papilloma
Oral Papillomas Associated With Felis catus Papillomavirus Type 1 in 2 Domestic Cats.
Papilloma
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Papilloma
Simultaneous human papilloma virus type 16 E7 and cdk inhibitor p21 expression induces apoptosis and cathepsin B activation.
Papillomavirus Infections
Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.
Papillomavirus Infections
Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA.
Papillomavirus Infections
Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer.
Papillomavirus Infections
Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents.
Papillomavirus Infections
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Papillomavirus Infections
Protein p 16INK4A expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of uterine cervix.
Papillomavirus Infections
The role of protein p16INK4a in non-oropharyngeal head and neck squamous cell carcinoma in Southern China.
Paralysis
An algorithmic strategy of surgical intervention for cervical degenerative kyphosis.
Parathyroid Neoplasms
Differential expression of kinase genes in primary hyperparathyroidism: adenoma versus normal and hyperplastic parathyroid tissue.
Parathyroid Neoplasms
Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid Adenomas.
Parathyroid Neoplasms
Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas.
Parathyroid Neoplasms
Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.
Parkinson Disease
A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease.
Parkinson Disease
Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNM1L-MAPK/ERK signaling are found in aged mutant Parkinsonian LRRK2R1441G mice.
Parkinson Disease
Abnormal Mitochondria in a Non-human Primate Model of MPTP-induced Parkinson's Disease: Drp1 and CDK5/p25 Signaling.
Parkinson Disease
Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease.
Parkinson Disease
Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration.
Parkinson Disease
Commitment of 1-methyl-4-phenylpyrinidinium ion-induced neuronal cell death by proteasome-mediated degradation of p35 cyclin-dependent kinase 5 activator.
Parkinson Disease
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease.
Parkinson Disease
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Parkinson Disease
Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease.
Parkinson Disease
Nucks1 gene polymorphism rs823114 is associated with the positive symptoms and neurocognitive function of patients with schizophrenia in parts of southern China.
Parkinson Disease
p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease.
Parkinson Disease
Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease.
Parkinsonian Disorders
Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast.
Perinatal Death
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors.
Perinatal Death
Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death.
Peripheral Nerve Injuries
Cdk5 Phosphorylation of STAT3 in Dorsal Root Ganglion Neurons Is Involved in Promoting Axonal Regeneration After Peripheral Nerve Injury.
Peripheral Nerve Injuries
Cdk5-Dependent Phosphorylation of CaV3.2 T-Type Channels: Possible Role in Nerve Ligation-Induced Neuropathic Allodynia and the Compound Action Potential in Primary Afferent C Fibers.
Persistent Hyperplastic Primary Vitreous
Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease.
Persistent Infection
Identification of key genes and pathways associated with different immune statuses of hepatitis B virus infection.
Peutz-Jeghers Syndrome
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.
Pheochromocytoma
A novel apoptotic cascade mediated by CDK4 in rat pheochromocytoma PC12 cells.
Pheochromocytoma
Constitutive overexpression of CDK2 inhibits neuronal differentiation of rat pheochromocytoma PC12 cells.
Pheochromocytoma
Extracellular ?-Synuclein Leads to Microtubule Destabilization via GSK-3?-Dependent Tau Phosphorylation in PC12 Cells.
Pheochromocytoma
Nerve growth factor regulates the expression and activity of p33cdk2 and p34cdc2 kinases in PC12 pheochromocytoma cells.
Pick Disease of the Brain
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Pituitary ACTH Hypersecretion
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Pituitary Neoplasms
Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
Pituitary Neoplasms
CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression.
Pituitary Neoplasms
Differential gene expression of p27Kip1 and Rb knockout pituitary tumors associated with altered growth and angiogenesis.
Pituitary Neoplasms
Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors.
Pituitary Neoplasms
Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Pituitary Neoplasms
Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1.
Pituitary Neoplasms
Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors.
Pituitary Neoplasms
p27 (Kip1) is required to maintain proliferative quiescence in the adult cochlea and pituitary.
Pituitary Neoplasms
Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas.
Pituitary Neoplasms
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Pituitary Neoplasms
The Expression of AIP-Related Molecules in Elucidation of Cellular Pathways in Pituitary Adenomas.
Plasmacytoma
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
Plasmacytoma
Resolution and general properties of different types of ribosomal protein kinases in mouse plasmocytoma.
Pleural Effusion
A genomic approach to predict synergistic combinations for breast cancer treatment.
Pleurisy
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
Pneumonia
Relationship between the Contents of Cyclins, Cyclin-Dependent Kinases, and Their Inhibitors in Whole Blood Mononuclear Leukocytes during the Postclinical Stage of Community-Acquired Pneumonia under the Influence of 1-GHz Microwaves.
Pneumonia
The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome.
Polycystic Kidney Diseases
Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Polycystic Kidney Diseases
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.
Polycystic Kidney, Autosomal Dominant
Ascofuranone: A Possible Therapeutic Tool for Autosomal Dominant Polycystic Kidney Disease? - Letter.
Polycystic Kidney, Autosomal Dominant
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD.
Polycystic Kidney, Autosomal Dominant
p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels.
Polycystic Kidney, Autosomal Dominant
Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease.
Polycystic Kidney, Autosomal Recessive
Early Cyst Growth Is Associated with the Increased Nuclear Expression of Cyclin D1/Rb Protein in an Autosomal-Recessive Polycystic Kidney Disease Rat Model.
Polycystic Ovary Syndrome
Genetic variants of cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1 and transcription factor 7-like 2 are not associated with polycystic ovary syndrome in Chinese women.
Polyomavirus Infections
JC polyomavirus infection in candidates for kidney transplantation living in the Brazilian Amazon region.
Porcine Reproductive and Respiratory Syndrome
Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methylation of CDKN2B CpG islands is associated with upregulated telomerase activity in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
p27KIP1 deletions in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The cell cycle inhibitor p16(INK4A) sensitizes lymphoblastic leukemia cells to apoptosis by physiologic glucocorticoid levels.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Effect of CDK Inhibitor LS-007 on Acute Lymphoblastic Leukemia and Its Mechanism].
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
LncRNA CDKN2B-AS1 contributes to tumorigenesis and chemoresistance in pediatric T-cell acute lymphoblastic leukemia through miR-335-3p/TRAF5 axis.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Relapsed T Cell ALL: Current Approaches and New Directions.
Primary Ovarian Insufficiency
Analysis of cyclin-dependent kinase inhibitor 1B mutation in Han Chinese women with premature ovarian failure.
Prostatic Neoplasms
2',4'-dihydroxychalcone, a flavonoid isolated from Herba oxytropis, suppresses PC-3 human prostate cancer cell growth by induction of apoptosis.
Prostatic Neoplasms
A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers.
Prostatic Neoplasms
A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells.
Prostatic Neoplasms
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
Prostatic Neoplasms
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer.
Prostatic Neoplasms
Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells.
Prostatic Neoplasms
Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers.
Prostatic Neoplasms
Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Prostatic Neoplasms
Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.
Prostatic Neoplasms
Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.
Prostatic Neoplasms
Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Prostatic Neoplasms
Antiproliferative activity of the dietary isothiocyanate erucin, a bioactive compound from cruciferous vegetables, on human prostate cancer cells.
Prostatic Neoplasms
Antiproliferative Effect of 1?,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation.
Prostatic Neoplasms
Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Prostatic Neoplasms
Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells.
Prostatic Neoplasms
Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis.
Prostatic Neoplasms
Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors.
Prostatic Neoplasms
Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.
Prostatic Neoplasms
Binding patterns and structure-activity relationship of CDK8 inhibitors.
Prostatic Neoplasms
Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
Prostatic Neoplasms
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.
Prostatic Neoplasms
Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines.
Prostatic Neoplasms
CDK Inhibitors Induce Mitochondria-Mediated Apoptosis Through The Activation Of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells.
Prostatic Neoplasms
CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?
Prostatic Neoplasms
CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
Prostatic Neoplasms
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
Prostatic Neoplasms
CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.
Prostatic Neoplasms
Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice.
Prostatic Neoplasms
Checkpoint kinase 1 regulates diallyl trisulfide-induced mitotic arrest in human prostate cancer cells.
Prostatic Neoplasms
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Prostatic Neoplasms
Costunolide Induces Apoptosis Through Nuclear Calcium(2+) Overload and DNA Damage Response in Human Prostate Cancer.
Prostatic Neoplasms
CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
Prostatic Neoplasms
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Prostatic Neoplasms
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
Prostatic Neoplasms
Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells.
Prostatic Neoplasms
Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser727 on STAT3 in prostate cancer cells.
Prostatic Neoplasms
Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells.
Prostatic Neoplasms
Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling.
Prostatic Neoplasms
Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1? and induces G2/M arrest under hypoxia in prostate cancer cells.
Prostatic Neoplasms
Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma.
Prostatic Neoplasms
Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer.
Prostatic Neoplasms
Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Prostatic Neoplasms
Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells.
Prostatic Neoplasms
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Prostatic Neoplasms
Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells.
Prostatic Neoplasms
Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
Prostatic Neoplasms
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
Prostatic Neoplasms
ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Prostatic Neoplasms
Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57(kip2a)).
Prostatic Neoplasms
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
Prostatic Neoplasms
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.
Prostatic Neoplasms
From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator.
Prostatic Neoplasms
Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications.
Prostatic Neoplasms
Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Prostatic Neoplasms
Human CDK12 and CDK13, multi-tasking CTD kinases for the new millennium.
Prostatic Neoplasms
Identification of distinctive patterns of USP19-mediated growth regulation in normal and malignant cells.
Prostatic Neoplasms
Identification of human male germ cell-associated kinase, a kinase transcriptionally activated by androgen in prostate cancer cells.
Prostatic Neoplasms
Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.
Prostatic Neoplasms
IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells.
Prostatic Neoplasms
In silico 3D structure modeling and inhibitor binding studies of human male germ cell-associated kinase.
Prostatic Neoplasms
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Prostatic Neoplasms
Indole-3-carbinol mediated cell cycle arrest of LNCaP human prostate cancer cells requires the induced production of activated p53 tumor suppressor protein.
Prostatic Neoplasms
Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the beta-lapachone-induced apoptosis of human prostate cancer cells.
Prostatic Neoplasms
Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1.
Prostatic Neoplasms
Inhibition of extracellular signal-regulated kinase potentiates the apoptotic and antimetastatic effects of cyclin-dependent kinase inhibitors on metastatic DU145 and PC3 prostate cancer cells.
Prostatic Neoplasms
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Prostatic Neoplasms
Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis.
Prostatic Neoplasms
Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer.
Prostatic Neoplasms
Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis.
Prostatic Neoplasms
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
Prostatic Neoplasms
Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells.
Prostatic Neoplasms
Male germ cell-associated kinase is overexpressed in prostate cancer cells and causes mitotic defects via deregulation of APC/C(CDH1).
Prostatic Neoplasms
Male Germ Cell-Associated Kinase, a Male-Specific Kinase Regulated by Androgen, Is a Coactivator of Androgen Receptor in Prostate Cancer Cells.
Prostatic Neoplasms
Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
Prostatic Neoplasms
MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL.
Prostatic Neoplasms
Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
Prostatic Neoplasms
mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Prostatic Neoplasms
Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
Prostatic Neoplasms
Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition.
Prostatic Neoplasms
Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
Prostatic Neoplasms
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Prostatic Neoplasms
p16 Is upregulated in proliferative inflammatory atrophy of the prostate.
Prostatic Neoplasms
p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer.
Prostatic Neoplasms
p27 Protein and cancers of the gastrointestinal tract and liver: an overview.
Prostatic Neoplasms
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Prostatic Neoplasms
Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
Prostatic Neoplasms
Persistent P21Cip1 Induction Mediates G(1) Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells.
Prostatic Neoplasms
Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity.
Prostatic Neoplasms
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Prostatic Neoplasms
Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer.
Prostatic Neoplasms
Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells.
Prostatic Neoplasms
PUM1 represses CDKN1B translation and contributes to prostate cancer progression.
Prostatic Neoplasms
Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions.
Prostatic Neoplasms
RB independent G1-phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor and histone deacetylase inhibitor.
Prostatic Neoplasms
Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5.
Prostatic Neoplasms
Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.
Prostatic Neoplasms
Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression.
Prostatic Neoplasms
Suppression of human prostate cancer cell growth by beta-lapachone via down-regulation of pRB phosphorylation and induction of Cdk inhibitor p21(WAF1/CIP1).
Prostatic Neoplasms
Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.
Prostatic Neoplasms
Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
Prostatic Neoplasms
The effects of natural ligands of hormone receptors and their antagonists on telomerase activity in the androgen sensitive prostatic cancer cell line LNCaP.
Prostatic Neoplasms
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.
Prostatic Neoplasms
The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.
Prostatic Neoplasms
Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.
Prostatic Neoplasms
TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.
Prostatic Neoplasms
TNF receptor 1 is involved in the induction of apoptosis by the cyclin dependent kinase inhibitor p27Kip1 in the prostate cancer cell line PC-3.
Prostatic Neoplasms
Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells.
Prostatic Neoplasms
Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
Prostatic Neoplasms
Upregulation of MircoRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1.
Prostatic Neoplasms
Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm.
Prostatic Neoplasms, Castration-Resistant
Enhanced expression of cyclin-dependent kinase inhibitor in apoptosis of androgen-independent prostatic cancer cell line induced by calcium ionophore.
Prostatic Neoplasms, Castration-Resistant
Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
Proteinuria
Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration.
Proteinuria
Detecting and managing patients with type 2 diabetic kidney disease: proteinuria and cardiovascular disease.
Proteinuria
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus.
Proteinuria
Proteinuria 1 year after renal transplantation is associated with impaired graft survival in children.
Pseudohypoaldosteronism
One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature.
Psoriasis
Cyclin-Dependent Kinase 7 Promotes Th17/Th1 Cell Differentiation in Psoriasis by Modulating Glycolytic Metabolism.
Psychomotor Disorders
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
Puerperal Infection
Impact of clean delivery-kit use on newborn umbilical cord and maternal puerperal infections in Egypt.
Pulmonary Disease, Chronic Obstructive
Genetic Ablation of p16(Ink4a) Does Not Protect Against Cellular Senescence in Mouse Models of COPD/Emphysema.
Pulmonary Disease, Chronic Obstructive
Suppressed expression of T-box transcription factors is involved in senescence in chronic obstructive pulmonary disease.
Pulmonary Fibrosis
Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis.
receptor protein-tyrosine kinase deficiency
c-Met signalling is required for efficient postnatal thymic regeneration and repair.
Rectal Neoplasms
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.
Rectal Neoplasms
p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance?
Renal Insufficiency
[Nephroprotective role of early correction of impaired nutritional status in patients with chronic disease of the kidneys at a predialysis stage]
Renal Insufficiency, Chronic
Proteinuria 1 year after renal transplantation is associated with impaired graft survival in children.
Reoviridae Infections
Reovirus-induced alterations in gene expression related to cell cycle regulation.
Reperfusion Injury
Acetyl salicylic acid augments functional recovery following sciatic nerve crush in mice.
Reperfusion Injury
Evaluating the Effects of CDK Inhibitors in Ischemia-Reperfusion Injury Models.
Reperfusion Injury
Inhibited histone deacetylase 3 ameliorates myocardial ischemia-reperfusion injury in a rat model by elevating microRNA-19a-3p and reducing cyclin-dependent kinase 2.
Reperfusion Injury
Inhibition of Cyclin-dependent Kinase 2 Signaling Prevents Liver Ischemia and Reperfusion Injury.
Reperfusion Injury
Neuroprotective effect of Buyang Huanwu Decoction on spinal ischemia-reperfusion injury in rats is linked with inhibition of cyclin-dependent kinase 5.
Reperfusion Injury
p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury.
Reperfusion Injury
Small Molecule Cyclin-Dependent Kinase Inhibitors Protect Against Neuronal Cell Death in the Ischemic-Reperfused Rat Retina.
Reperfusion Injury
The neuroprotective mechanism of puerarin in the treatment of acute spinal ischemia-reperfusion injury is linked to cyclin-dependent kinase 5.
Respiratory Distress Syndrome
The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome.
Retinal Degeneration
High-resolution Imaging in Male Germ Cell-Associated Kinase (MAK)-related Retinal Degeneration.
Retinitis Pigmentosa
Exome sequencing and analysis of induced pluripotent stem cells identify the cilia-related gene male germ cell-associated kinase (MAK) as a cause of retinitis pigmentosa.
Retinitis Pigmentosa
Intraretinal cystoid spaces in a patient with retinitis pigmentosa due to mutation in the MAK gene.
Retinitis Pigmentosa
Slowly progressive retinitis pigmentosa caused by two novel mutations in the MAK gene.
Retinoblastoma
1-(2-Hydroxy-5-methylphenyl)-3-phenyl-1,3-propanedione Induces G1 Cell Cycle Arrest and Autophagy in HeLa Cervical Cancer Cells.
Retinoblastoma
17 beta-Estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects.
Retinoblastoma
2,3,4',5-Tetrahydroxystilbene-2-0-beta-D-glucoside inhibits platelet-derived growth factor-induced proliferation of vascular smooth muscle cells by regulating cell cycle.
Retinoblastoma
2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle.
Retinoblastoma
25-Methoxyhispidol A, a novel triterpenoid of Poncirus trifoliata, inhibits cell growth via the modulation of EGFR/c-Src signaling pathway in MDA-MB-231 human breast cancer cells.
Retinoblastoma
3-Deazaadenosine Prevents Smooth Muscle Cell Proliferation and Neointima Formation by Interfering With Ras Signaling.
Retinoblastoma
5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.
Retinoblastoma
5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines.
Retinoblastoma
7,3',4'-trihydroxyisoflavone inhibits epidermal growth factor-induced proliferation and transformation of JB6 P+ mouse epidermal cells by suppressing cyclin-dependent kinases and phosphatidylinositol 3- kinase.
Retinoblastoma
7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism.
Retinoblastoma
A clinical evaluation of treatments that target cell cycle machinery in breast cancer.
Retinoblastoma
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
Retinoblastoma
A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S?Phase by Up-regulating p27(KIP1).
Retinoblastoma
A Fas-associated death domain protein/caspase-8-signaling axis promotes S-phase entry and maintains S6 kinase activity in T cells responding to IL-2.
Retinoblastoma
A General G1/S-Phase Cell-Cycle Control Module in the Flowering Plant Arabidopsis thaliana.
Retinoblastoma
A high-content, high-throughput siRNA screen identifies cyclin D2 as a potent regulator of muscle progenitor cell fusion and a target to enhance muscle regeneration.
Retinoblastoma
A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
Retinoblastoma
A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells.
Retinoblastoma
A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27(Kip1).
Retinoblastoma
A novel polyacetylene significantly inhibits angiogenesis and promotes apoptosis in human endothelial cells through activation of the CDK inhibitors and caspase-7.
Retinoblastoma
A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma.
Retinoblastoma
A novel synthetic oleanolic acid derivative with amino acid conjugate suppresses tumour growth by inducing cell cycle arrest.
Retinoblastoma
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas.
Retinoblastoma
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
Retinoblastoma
A pipecolic acid-rich branched cyclic depsipeptide ulleungamide C from a Streptomyces species induces G0/G1 cell cycle arrest in promyelocytic leukemia cells.
Retinoblastoma
A population genomics study of the Arabidopsis core cell cycle genes shows the signature of natural selection.
Retinoblastoma
A proliferation control network model: the simulation of two-dimensional epithelial homeostasis.
Retinoblastoma
A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer.
Retinoblastoma
A secreted low-molecular-weight protein from Helicobacter pylori induces cell-cycle arrest of T cells.
Retinoblastoma
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model.
Retinoblastoma
AA-PMe, a novel asiatic acid derivative, induces apoptosis and suppresses proliferation, migration, and invasion of gastric cancer cells.
Retinoblastoma
Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas.
Retinoblastoma
Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon.
Retinoblastoma
Aberrant methylation-induced dysfunction of p16 is associated with osteoblast activation caused by fluoride.
Retinoblastoma
Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation.
Retinoblastoma
Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Retinoblastoma
Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model.
Retinoblastoma
Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Retinoblastoma
Activation of Cdk2-pRB-E2F1 cell cycle pathway by repeated electroconvulsive shock in the rat frontal cortex.
Retinoblastoma
Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c).
Retinoblastoma
Activation of RB/E2F signaling pathway is required for the modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells.
Retinoblastoma
Activation of the p53-p21(Cip1) pathway is required for CDK2 activation and S-phase entry in primary rat hepatocytes.
Retinoblastoma
Activin A induction of cell-cycle arrest involves modulation of cyclin D2 and p21CIP1/WAF1 in plasmacytic cells.
Retinoblastoma
Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells.
Retinoblastoma
Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression.
Retinoblastoma
Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes.
Retinoblastoma
Adipogenic Differentiation Is Impaired in Replicative Senescent Human Subcutaneous Adipose-Derived Stromal/Progenitor Cells.
Retinoblastoma
Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
Retinoblastoma
Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia.
Retinoblastoma
Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients.
Retinoblastoma
Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor.
Retinoblastoma
Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer.
Retinoblastoma
Analysis of site-specific phosphorylation of the retinoblastoma protein during cell cycle progression.
Retinoblastoma
Anchorage dependence of mitogen-induced G1 to S transition in primary T lymphocytes.
Retinoblastoma
Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression.
Retinoblastoma
Angiotensin II regulates activation of Bim via Rb/E2F1 during apoptosis: involvement of interaction between AMPK?1/2 and Cdk4.
Retinoblastoma
Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
Retinoblastoma
Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest.
Retinoblastoma
Anti-proliferation effect on human breast cancer cells via inhibition of pRb phosphorylation by taiwanin E isolated from Eleutherococcus trifoliatus.
Retinoblastoma
Anti-proliferative effects of the novel squamosamide derivative (FLZ) on HepG2 human hepatoma cells by regulating the cell cycle-related proteins are associated with decreased Ca(2+)/ROS levels.
Retinoblastoma
Anticancer properties of extracts from Opuntia humifusa against human cervical carcinoma cells.
Retinoblastoma
Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
Retinoblastoma
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Retinoblastoma
Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition ?-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines.
Retinoblastoma
Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways.
Retinoblastoma
Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Retinoblastoma
Antiproliferative effects of a new ?-lipoic acid derivative, DHL-HisZnNa, in HT29 human colon cancer cells in vitro.
Retinoblastoma
Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.
Retinoblastoma
Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Retinoblastoma
Antitumor effects of a novel benzonaphthofurandione derivative (8e) on the human colon cancer cells in vitro and in vivo through cell cycle arrest accompanied with the modulation of EGFR and mTOR signaling.
Retinoblastoma
AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
Retinoblastoma
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Retinoblastoma
Arctigenin, a natural lignan compound, induces G0/G1 cell cycle arrest and apoptosis in human glioma cells.
Retinoblastoma
Arotinoid mofarotene (RO40-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines.
Retinoblastoma
Aryl hydrocarbon receptor mediates laminar fluid shear stress-induced CYP1A1 activation and cell cycle arrest in vascular endothelial cells.
Retinoblastoma
Astragaloside IV ameliorates radiation-induced senescence via antioxidative mechanism.
Retinoblastoma
Autophagy Inhibition Sensitizes Renal Tubular Epithelial Cell to G1 Arrest Induced by Transforming Growth Factor beta (TGF-?).
Retinoblastoma
B55alpha PP2A holoenzymes modulate the phosphorylation status of the retinoblastoma-related protein p107 and its activation.
Retinoblastoma
BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application.
Retinoblastoma
Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells.
Retinoblastoma
BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1).
Retinoblastoma
Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3.
Retinoblastoma
Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells.
Retinoblastoma
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
Retinoblastoma
BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.
Retinoblastoma
Bruton's tyrosine-kinase-deficient murine B lymphocytes fail to enter S phase when stimulated with anti-immunoglobulin plus interleukin-4.
Retinoblastoma
Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells.
Retinoblastoma
Ca(2+)-dependent stimulation of retinoblastoma gene product phosphorylation and p34cdc2 kinase activation in serum-stimulated human fibroblasts.
Retinoblastoma
Calmodulin is essential for cyclin-dependent kinase 4 (Cdk4) activity and nuclear accumulation of cyclin D1-Cdk4 during G1.
Retinoblastoma
Calpain modulates cyclin-dependent kinase inhibitor 1B (p27(Kip1)) in cells of the osteoblast lineage.
Retinoblastoma
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas.
Retinoblastoma
CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G0 growth arrest and apoptosis.
Retinoblastoma
Cdc37 facilitates cell survival of colorectal carcinoma via activating the CDK4 signaling pathway.
Retinoblastoma
CDK4 has the ability to regulate Aurora B and Cenpp expression in mouse keratinocytes.
Retinoblastoma
Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis.
Retinoblastoma
Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway.
Retinoblastoma
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.
Retinoblastoma
Cell cycle arrest in G0/G1 phase by contact inhibition and TGF-beta 1 in mink Mv1Lu lung epithelial cells.
Retinoblastoma
Cell cycle deregulation and xeroderma pigmentosum group C cell transformation.
Retinoblastoma
Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Retinoblastoma
Cell cycle function of a Medicago sativa A2-type cyclin interacting with a PSTAIRE-type cyclin-dependent kinase and a retinoblastoma protein.
Retinoblastoma
Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines.
Retinoblastoma
Cell cycle in alveolar epithelial type II cells: integration of Matrigel and KGF.
Retinoblastoma
Cell cycle regulation by bevacizumab in ARPE-19 human retinal pigment epithelial cells.
Retinoblastoma
Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Retinoblastoma
Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1.
Retinoblastoma
Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds.
Retinoblastoma
Cell-cycle control in Caenorhabditis elegans: how the worm moves from G1 to S.
Retinoblastoma
Cell-cycle regulators are involved in transient cerebral ischemia induced neuronal apoptosis in female rats.
Retinoblastoma
Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
Retinoblastoma
Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice.
Retinoblastoma
Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets.
Retinoblastoma
Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.
Retinoblastoma
Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
Retinoblastoma
Cloning of murine CDK9/PITALRE and its tissue-specific expression in development.
Retinoblastoma
Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo.
Retinoblastoma
Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro.
Retinoblastoma
Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
Retinoblastoma
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
Retinoblastoma
Contragestazol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo.
Retinoblastoma
Control of cell cycle progression in human natural killer cells through redox regulation of expression and phosphorylation of retinoblastoma gene product protein.
Retinoblastoma
Control of cell cycle regulatory proteins and modulation of STAT1 proteins by IFN-gamma in human prostatic JCA-1 cells.
Retinoblastoma
Cotylenin A inhibits cell proliferation and induces apoptosis and PAX6 mRNA transcripts in retinoblastoma cell lines.
Retinoblastoma
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Retinoblastoma
Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6.
Retinoblastoma
Curcuma wenyujin extract induces apoptosis and inhibits proliferation of human cervical cancer cells in vitro and in vivo.
Retinoblastoma
Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines.
Retinoblastoma
Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.
Retinoblastoma
Cyclin D1 fine-tunes the neurogenic output of embryonic retinal progenitor cells.
Retinoblastoma
Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients.
Retinoblastoma
Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism.
Retinoblastoma
Cyclin D1, p16, and retinoblastoma gene regulate mitogenic signaling of endothelin in rat mesangial cells.
Retinoblastoma
Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.
Retinoblastoma
Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells.
Retinoblastoma
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.
Retinoblastoma
Cyclin-dependent kinase 2 signaling regulates myocardial ischemia/reperfusion injury.
Retinoblastoma
Cyclin-dependent kinase 2-associating protein 1 commits murine embryonic stem cell differentiation through retinoblastoma protein regulation.
Retinoblastoma
Cyclin-dependent kinase 4/6 inhibitors require an arcuate to paraventricular hypothalamus melanocortin circuit to treat diet-induced obesity.
Retinoblastoma
Cyclin-dependent kinase inhibitor p16INK4A inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH.
Retinoblastoma
Cyclin-dependent kinase-like function is shared by the beta- and gamma- subset of the conserved herpesvirus protein kinases.
Retinoblastoma
Cycling to and from a stem cell niche: the temporal and spatial odyssey of mitotic male germ cells.
Retinoblastoma
Cyclins B1, T1 and H differ in their molecular mode of interaction with cytomegalovirus protein kinase pUL97.
Retinoblastoma
Cytosolic nucleic acid sensors of the innate immune system promote liver regeneration after partial hepatectomy.
Retinoblastoma
Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells.
Retinoblastoma
Dephosphorylation of threonine-821 of the retinoblastoma tumor suppressor protein (Rb) is required for apoptosis induced by UV and Cdk inhibition.
Retinoblastoma
Deregulation of the G1/S-phase control in human testicular germ cell tumours.
Retinoblastoma
Deregulation of the p16-cyclin D1/cyclin-dependent kinase 4-retinoblastoma pathway involved in the rat bladder carcinogenesis induced by terephthalic acid-calculi.
Retinoblastoma
Development of a Novel Nonradioisotopic Assay and Cdc25B Overexpression Cell Lines for Use in Screening for Cdc25B Inhibitors.
Retinoblastoma
Difference of cell cycle arrests induced by lidamycin in human breast cancer cells.
Retinoblastoma
Differences in stability of repressor complexes at promoters underlie distinct roles for Rb family members.
Retinoblastoma
Different roles of ERK and p38 MAP kinases during tube formation from endothelial cells cultured in 3-dimensional collagen matrices.
Retinoblastoma
Differential activities of E2F family members: unique functions in regulating transcription.
Retinoblastoma
Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4.
Retinoblastoma
Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis.
Retinoblastoma
Differential regulation of p27kip1 levels and CDK activities by hypertrophic and hyperplastic agents in vascular smooth muscle cells.
Retinoblastoma
Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites.
Retinoblastoma
Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.
Retinoblastoma
Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.
Retinoblastoma
Differentiation-inducing factor-1, a morphogen of dictyostelium, induces G(1) arrest and differentiation of vascular smooth muscle cells.
Retinoblastoma
Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes.
Retinoblastoma
Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein.
Retinoblastoma
Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6.
Retinoblastoma
Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb.
Retinoblastoma
Distinct action of the retinoblastoma pathway on the DNA replication machinery defines specific roles for cyclin-dependent kinase complexes in prereplication complex assembly and S-phase progression.
Retinoblastoma
Docosahexaenoic acid inhibits cancer cell growth via p27Kip1, CDK2, ERK1/ERK2, and retinoblastoma phosphorylation.
Retinoblastoma
Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?
Retinoblastoma
Down-regulation and decreased activity of cyclin-dependent kinase 2 in H2O2-induced premature senescence.
Retinoblastoma
Downregulation of Cdc2/CDK1 kinase activity induces the synthesis of noninfectious human papillomavirus type 31b virions in organotypic tissues exposed to benzo[a]pyrene.
Retinoblastoma
Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.
Retinoblastoma
Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells.
Retinoblastoma
Downregulation of P16 promotes cigarette smoke extract-induced vascular smooth muscle cell proliferation via preventing G1/S phase transition.
Retinoblastoma
Downregulation of Pin1 in human atherosclerosis and its association with vascular smooth muscle cell senescence.
Retinoblastoma
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.
Retinoblastoma
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).
Retinoblastoma
E2F proteins are posttranslationally modified concomitantly with a reduction in nuclear binding activity in cells infected with herpes simplex virus 1.
Retinoblastoma
E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis.
Retinoblastoma
E2F-1 regulates the expression of a subset of target genes during skeletal myoblast hypertrophy.
Retinoblastoma
E2f1, E2f2, and E2f3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop.
Retinoblastoma
EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.
Retinoblastoma
Effect of cyclin E overexpression on lovastatin-induced G1 arrest and RhoA inactivation in NIH3T3 cells.
Retinoblastoma
Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats.
Retinoblastoma
Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression.
Retinoblastoma
Effect of Yanggan Jiedu Sanjie formula on human hepatocellular carcinoma Bel-7402 cells.
Retinoblastoma
Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60).
Retinoblastoma
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
Retinoblastoma
Electroacupuncture promotes chondrocyte proliferation via accelerated G1/S transition in the cell cycle.
Retinoblastoma
Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade.
Retinoblastoma
Enhancement of radiation response with combined Ganoderma lucidum and Duchesnea chrysantha extracts in human leukemia HL-60 cells.
Retinoblastoma
Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway.
Retinoblastoma
Epothilone B inhibits neointimal formation after rat carotid injury through the regulation of cell cycle-related proteins.
Retinoblastoma
Epothilone D, a microtubule-stabilizing compound, inhibits neointimal hyperplasia after rat carotid artery injury by cell cycle arrest via regulation of G1-checkpoint proteins.
Retinoblastoma
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7.
Retinoblastoma
Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
Retinoblastoma
Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation.
Retinoblastoma
Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells.
Retinoblastoma
Evidence for a novel anti-apoptotic pathway in human keratinocytes involving the aryl hydrocarbon receptor, E2F1, and checkpoint kinase 1.
Retinoblastoma
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
Retinoblastoma
Expression and modulation of p42/p44 MAPKs and cell cycle regulatory proteins in rat pancreas regeneration.
Retinoblastoma
Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells.
Retinoblastoma
Expression of certain antiproliferative and growth-related genes in isolated mouse pancreatic islets: analysis by polymerase chain reaction.
Retinoblastoma
Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression.
Retinoblastoma
Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent cellular DNA damage response pathway.
Retinoblastoma
Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions.
Retinoblastoma
Expressions and activities of cell cycle regulatory molecules during the transition from myocyte hyperplasia to hypertrophy.
Retinoblastoma
Fgf15-mediated control of neurogenic and proneural gene expression regulates dorsal midbrain neurogenesis.
Retinoblastoma
Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody.
Retinoblastoma
FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor.
Retinoblastoma
Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry.
Retinoblastoma
Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1.
Retinoblastoma
Function of cell-cycle regulators in predicting silent pituitary adenoma progression following surgical resection.
Retinoblastoma
Functional conservation of the cell cycle-regulating transcription factor DRTF1/E2F and its pathway of control in Drosophila melanogaster.
Retinoblastoma
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Retinoblastoma
G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
Retinoblastoma
G1/S cell cycle regulators mediate effects of circadian dysregulation on tumor growth and provide targets for timed anticancer treatment.
Retinoblastoma
Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo.
Retinoblastoma
Garcinia cambogia suppresses adipogenesis in 3T3-L1 cells by inhibiting p90RSK and Stat3 activation during mitotic clonal expansion.
Retinoblastoma
Gene expression profile of butyrate-inhibited vascular smooth muscle cell proliferation.
Retinoblastoma
Genistein inhibits rat aortic smooth muscle cell proliferation through the induction of p27kip1.
Retinoblastoma
Ghrelin augments murine T-cell proliferation by activation of the phosphatidylinositol-3-kinase, extracellular signal-regulated kinase and protein kinase C signaling pathways.
Retinoblastoma
GL331 induces down-regulation of cyclin D1 expression via enhanced proteolysis and repressed transcription.
Retinoblastoma
Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells.
Retinoblastoma
Glycogen serves as an energy source that maintains astrocyte cell proliferation in the neonatal telencephalon.
Retinoblastoma
Growth induction of rat primary hepatocytes using antisense oligonucleotides.
Retinoblastoma
Growth inhibition and cell cycle arrest effects of epigallocatechin gallate in the NBT-II bladder tumour cell line.
Retinoblastoma
Growth inhibition and G1 cell cycle arrest mediated by 25-methoxyhispidol A, a novel triterpenoid, isolated from the fruit of Poncirus trifoliata in human hepatocellular carcinoma cells.
Retinoblastoma
Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
Retinoblastoma
Guilu Erxian Glue () Inhibits Chemotherapy-Induced Bone Marrow Hematopoietic Stem Cell Senescence in Mice May via p16INK4a-Rb Signaling Pathway.
Retinoblastoma
Heat shock protein B8, a cyclin-dependent kinase-independent cyclin D1 target gene, contributes to its effects on radiation sensitivity.
Retinoblastoma
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Retinoblastoma
Hepatitis B Virus Pre-S2 Mutant Surface Antigen Induces Degradation of Cyclin-Dependent Kinase Inhibitor p27Kip1 through c-Jun Activation Domain-Binding Protein 1.
Retinoblastoma
Hepatitis C virus core functions as a suppressor of cyclin-dependent kinase-activating kinase and impairs cell cycle progression.
Retinoblastoma
Hepatoprotective effects of hydroxysafflor yellow A in D-galactose-treated aging mice.
Retinoblastoma
Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3.
Retinoblastoma
Hesperetin, a bioflavonoid, inhibits rat aortic vascular smooth muscle cells proliferation by arresting cell cycle.
Retinoblastoma
High trefoil factor 1 (TFF1) expression in human retinoblastoma cells correlates with low growth kinetics, increased cyclin-dependent kinase (CDK) inhibitor levels and a selective down-regulation of CDK6.
Retinoblastoma
Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.
Retinoblastoma
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Retinoblastoma
Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells.
Retinoblastoma
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.
Retinoblastoma
HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects.
Retinoblastoma
How can food extracts consumed in the Mediterranean and East Asia suppress prostate cancer proliferation?
Retinoblastoma
Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells.
Retinoblastoma
Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins.
Retinoblastoma
Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase.
Retinoblastoma
Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis.
Retinoblastoma
Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin.
Retinoblastoma
Human retinoblastoma protein (Rb) is phosphorylated by cdc2 kinase and MAP kinase in Xenopus maturing oocytes.
Retinoblastoma
Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Retinoblastoma
Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein.
Retinoblastoma
Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia.
Retinoblastoma
Hypoxia-ischemia induces DNA synthesis without cell proliferation in dying neurons in adult rodent brain.
Retinoblastoma
Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer.
Retinoblastoma
Identification of the E2A gene products as regulatory targets of the G1 cyclin-dependent kinases.
Retinoblastoma
IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells.
Retinoblastoma
Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas.
Retinoblastoma
Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16INK4A/pRb.
Retinoblastoma
Immunohistochemical analysis for cell regulatory proteins in bladder carcinogenesis induced by N-methyl-N-nitrosourea-terephthalic acid.
Retinoblastoma
Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Retinoblastoma
Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Retinoblastoma
Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions.
Retinoblastoma
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Retinoblastoma
Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma.
Retinoblastoma
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
Retinoblastoma
In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase.
Retinoblastoma
In vivo expression patterns of MyoD, p21, and Rb proteins in myonuclei and satellite cells of denervated rat skeletal muscle.
Retinoblastoma
Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function.
Retinoblastoma
Increased expression of the P27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1.
Retinoblastoma
Increased histone H1 phosphorylation and relaxed chromatin structure in Rb-deficient fibroblasts.
Retinoblastoma
Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action?
Retinoblastoma
Induced expression of p16 and p21 proteins in UVB-irradiated human epidermis and cultured keratinocytes.
Retinoblastoma
Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation.
Retinoblastoma
Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.
Retinoblastoma
Induction of beta-cell proliferation and retinoblastoma protein phosphorylation in rat and human islets using adenovirus-mediated transfer of cyclin-dependent kinase-4 and cyclin D1.
Retinoblastoma
Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin.
Retinoblastoma
Induction of G1 arrest and apoptosis by schisandrin C isolated from Schizandra chinensis Baill in human leukemia U937 cells.
Retinoblastoma
Induction of G1 arrest and apoptosis by Scutellaria barbata in the human promyelocytic leukemia HL-60 cell line.
Retinoblastoma
Induction of G1 cell cycle arrest in human umbilical vein endothelial cells by flavone's inhibition of the extracellular signal regulated kinase cascade.
Retinoblastoma
Induction of G?/M Arrest by Berberine via Activation of PI3K/Akt and p38 in Human Chondrosarcoma Cell Line.
Retinoblastoma
Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation.
Retinoblastoma
Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells.
Retinoblastoma
ING1a expression increases during replicative senescence and induces a senescent phenotype.
Retinoblastoma
Inhibition of cell-cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor.
Retinoblastoma
Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.
Retinoblastoma
Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic.
Retinoblastoma
Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1.
Retinoblastoma
Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation.
Retinoblastoma
Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells.
Retinoblastoma
Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat.
Retinoblastoma
Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein.
Retinoblastoma
Inhibition of myogenesis by depletion of the glycogen-associated regulatory subunit of protein phosphatase-1 in rat skeletal muscle cells.
Retinoblastoma
Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors.
Retinoblastoma
Inhibition of retinoblastoma protein phosphorylation by myogenesis-induced changes in the subunit composition of the cyclin-dependent kinase 4 complex.
Retinoblastoma
Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.
Retinoblastoma
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
Retinoblastoma
Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation.
Retinoblastoma
Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation.
Retinoblastoma
Inhibitory Effect of Human Breast Cancer Cell Proliferation via p21-Mediated G1 Cell Cycle Arrest by Araliadiol Isolated from Aralia cordata Thunb.
Retinoblastoma
Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery.
Retinoblastoma
Inhibitory effects of docetaxel on platelet-derived growth factor (PDGF)-BB-induced proliferation of vascular smooth muscle cells through blocking PDGF-receptor ? phosphorylation.
Retinoblastoma
Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells.
Retinoblastoma
Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
Retinoblastoma
Interaction between high glucose and TGF-beta in cell cycle protein regulations in MDCK cells.
Retinoblastoma
Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Retinoblastoma
Interactions of the human papillomavirus E7 protein with cell cycle regulators.
Retinoblastoma
Intercellular adhesion molecule 1 discriminates functionally different populations of human osteoblasts: characteristic involvement of cell cycle regulators.
Retinoblastoma
Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway.
Retinoblastoma
Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK).
Retinoblastoma
Interleukin-1 receptor antagonist (IL-1ra) modulates endothelial cell proliferation.
Retinoblastoma
Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells.
Retinoblastoma
Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity.
Retinoblastoma
Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein.
Retinoblastoma
Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation.
Retinoblastoma
Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs.
Retinoblastoma
Involvement of E2F1 transcriptional activity in cadmium-induced cell-cycle arrest at G1 in human lung fibroblasts.
Retinoblastoma
Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.
Retinoblastoma
Involvement of p21cip-1 and p27kip-1 in the molecular mechanisms of steel factor-induced proliferative synergy in vitro and of p21cip-1 in the maintenance of stem/progenitor cells in vivo.
Retinoblastoma
Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells.
Retinoblastoma
Ionizing radiation-induced chromosomal rearrangements occur in transcriptionally active regions of the genome.
Retinoblastoma
KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway.
Retinoblastoma
Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
Retinoblastoma
KCl cotransport is an important modulator of human cervical cancer growth and invasion.
Retinoblastoma
KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis.
Retinoblastoma
Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Retinoblastoma
Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis.
Retinoblastoma
Laminar shear stress inhibits vascular endothelial cell proliferation by inducing cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1)
Retinoblastoma
Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.
Retinoblastoma
Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1).
Retinoblastoma
Long intergenic noncoding RNA 00908 promotes proliferation and inhibits apoptosis of colorectal cancer cells by regulating KLF5 expression.
Retinoblastoma
Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3? Signaling Pathway.
Retinoblastoma
Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts.
Retinoblastoma
Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer.
Retinoblastoma
LRP1 Regulates Retinal Angiogenesis by Inhibiting PARP-1 Activity and Endothelial Cell Proliferation.
Retinoblastoma
Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway.
Retinoblastoma
Lyn is activated during late G1 of stem-cell-factor-induced cell cycle progression in haemopoietic cells.
Retinoblastoma
Mechanosensitive p27Kip1 regulation and cell cycle entry in vascular smooth muscle cells.
Retinoblastoma
Membrane depolarization stimulates the proliferation of SH-SY5Y human neuroblastoma cells by increasing retinoblastoma protein (RB) phosphorylation through the activation of cyclin-dependent kinase 2 (Cdk2).
Retinoblastoma
Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma.
Retinoblastoma
microRNAs in the pathogenesis of non-obstructive azoospermia: the underlying mechanisms and therapeutic potentials.
Retinoblastoma
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
Retinoblastoma
MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells.
Retinoblastoma
Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells.
Retinoblastoma
Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence.
Retinoblastoma
Molecular characterisation of breast cancer patients at high and low recurrence risk.
Retinoblastoma
Molecular cloning and characterization of the human p19(INK4d) gene promoter.
Retinoblastoma
Molecular Determinants for the Inactivation of the Retinoblastoma Tumor Suppressor by the Viral Cyclin-dependent Kinase UL97.
Retinoblastoma
Molecular mechanisms of cellular senescence and immortalization of human cells.
Retinoblastoma
Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.
Retinoblastoma
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Retinoblastoma
mRNA Expression of CDK2AP1 in Human Breast Cancer: Correlation with Clinical and Pathological Parameters.
Retinoblastoma
Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.
Retinoblastoma
Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Retinoblastoma
Murine coronavirus nonstructural protein p28 arrests cell cycle in G0/G1 phase.
Retinoblastoma
Murrayafoline A Induces a G0/G1-Phase Arrest in Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cells.
Retinoblastoma
Mutant p53 can delay growth arrest and loss of CDK2 activity in senescing human fibroblasts without reducing p21(WAF1) expression.
Retinoblastoma
Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
Retinoblastoma
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Retinoblastoma
Natriuretic peptide receptor-C agonist attenuates the expression of cell cycle proteins and proliferation of vascular smooth muscle cells from spontaneously hypertensive rats: role of Gi proteins and MAPkinase/PI3kinase signaling.
Retinoblastoma
NGF regulates the PC12 cell cycle machinery through specific inhibition of the Cdk kinases and induction of cyclin D1.
Retinoblastoma
Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.
Retinoblastoma
Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest.
Retinoblastoma
Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells.
Retinoblastoma
Novel SIRT Inhibitor, MHY2256, Induces Cell Cycle Arrest, Apoptosis, and Autophagic Cell Death in HCT116 Human Colorectal Cancer Cells.
Retinoblastoma
Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export.
Retinoblastoma
Occurrence of molecular abnormalities of cell cycle in L132 cells after in vitro short-term exposure to air pollution PM(2.5).
Retinoblastoma
Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis.
Retinoblastoma
Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia.
Retinoblastoma
Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.
Retinoblastoma
Overexpression of the signaling adapter FRS2 reconstitutes the cell cycle deficit of a nerve growth factor non-responsive TrkA receptor mutant.
Retinoblastoma
p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck.
Retinoblastoma
p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis.
Retinoblastoma
P16 protein abnormality in Epstein-Barr virus-associated gastric carcinomas.
Retinoblastoma
P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
Retinoblastoma
p21 and retinoblastoma protein control the absence of DNA replication in terminally differentiated muscle cells.
Retinoblastoma
p27 (Kip1) is required to maintain proliferative quiescence in the adult cochlea and pituitary.
Retinoblastoma
p27(Kip1) is important in modulating pulmonary artery smooth muscle cell proliferation.
Retinoblastoma
p34cdc2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe.
Retinoblastoma
p53 family members in myogenic differentiation and rhabdomyosarcoma development.
Retinoblastoma
p53/p21 Pathway involved in mediating cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients.
Retinoblastoma
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Retinoblastoma
Panaxydol Derived from Panax ginseng Inhibits G1 Cell Cycle Progression in Non-small Cell Lung Cancer via Upregulation of Intracellular Ca2+ Levels.
Retinoblastoma
PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis.
Retinoblastoma
Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Retinoblastoma
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Retinoblastoma
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Retinoblastoma
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
Retinoblastoma
Phosphatase 2A associated with polyomavirus small-T or middle-T antigen is an okadaic acid-sensitive tyrosyl phosphatase.
Retinoblastoma
Phosphorylation of Drosophila Brahma on CDK-phosphorylation sites is important for cell cycle regulation and differentiation.
Retinoblastoma
Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function.
Retinoblastoma
Phosphorylation of transcriptional regulators in the retinoblastoma protein pathway by UL97, the viral cyclin-dependent kinase encoded by human cytomegalovirus.
Retinoblastoma
Physalin B inhibits cell proliferation and induces apoptosis in undifferentiated human gastric cancer HGC-27 cells.
Retinoblastoma
Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein.
Retinoblastoma
Physiological cyclic stretch causes cell cycle arrest in cultured vascular smooth muscle cells.
Retinoblastoma
Piperlongumine decreases cell proliferation and the expression of cell cycle-associated proteins by inhibiting Akt pathway in human lung cancer cells.
Retinoblastoma
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro.
Retinoblastoma
Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway.
Retinoblastoma
Pocket protein p130/Rb2 is required for efficient herpes simplex virus type 1 gene expression and viral replication.
Retinoblastoma
Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells.
Retinoblastoma
PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates.
Retinoblastoma
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.
Retinoblastoma
Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.
Retinoblastoma
Primary endobronchial liposarcoma successfully resected via bronchoscopy: A rare case report with genetic analysis.
Retinoblastoma
PRMT4-mediated arginine methylation negatively regulates retinoblastoma tumor suppressor protein and promotes E2F-1 dissociation.
Retinoblastoma
Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101.
Retinoblastoma
Progesterone receptor isoforms and proliferation in the rat mammary gland during development.
Retinoblastoma
Proliferating cell nuclear antigen as the cell cycle sensor for an HLA-derived peptide blocking T cell proliferation.
Retinoblastoma
Proliferation of intimal smooth muscle cells. Attenuation of basic fibroblast growth factor 2-stimulated proliferation is associated with increased expression of cell cycle inhibitors.
Retinoblastoma
Prolyl oligopeptidase participates in cell cycle progression in a human neuroblastoma cell line.
Retinoblastoma
Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G1 phase arrest in A549 lung adenocarcinoma cells.
Retinoblastoma
Prostaglandin A2 blocks the activation of G1 phase cyclin-dependent kinase without altering mitogen-activated protein kinase stimulation.
Retinoblastoma
PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Retinoblastoma
Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
Retinoblastoma
Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest.
Retinoblastoma
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Retinoblastoma
Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21(waf1/cip1) and p27(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells.
Retinoblastoma
Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
Retinoblastoma
Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway.
Retinoblastoma
Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
Retinoblastoma
Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity.
Retinoblastoma
RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors.
Retinoblastoma
Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression.
Retinoblastoma
Rare mutations of the growth suppressor genes involved in negative regulation of the cell cycle.
Retinoblastoma
Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer.
Retinoblastoma
Regulation of CBP and Tip60 coordinates histone acetylation at local and global levels during Ras-induced transformation.
Retinoblastoma
Regulation of cyclin and cyclin-dependent kinase gene expression during lens differentiation requires the retinoblastoma protein.
Retinoblastoma
Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling.
Retinoblastoma
Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas.
Retinoblastoma
Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.
Retinoblastoma
Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
Retinoblastoma
Retinoblastoma protein phosphorylation does not require activation of p34CDC2 protein kinase.
Retinoblastoma
Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase.
Retinoblastoma
Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas.
Retinoblastoma
Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion.
Retinoblastoma
Retraction for Braden et al., "Distinct Action of the Retinoblastoma Pathway on the DNA Replication Machinery Defines Specific Roles for Cyclin-Dependent Kinase Complexes in Prereplication Complex Assembly and S-Phase Progression".
Retinoblastoma
Revealing the Anti-Tumor Effect of Artificial miRNA p-27-5p on Human Breast Carcinoma Cell Line T-47D.
Retinoblastoma
Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity.
Retinoblastoma
RNA interference against mixed lineage leukemia 5 resulted in cell cycle arrest.
Retinoblastoma
Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas.
Retinoblastoma
Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity.
Retinoblastoma
Role of key regulators of the cell cycle in maintenance of hematopoietic stem cells.
Retinoblastoma
Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.
Retinoblastoma
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Retinoblastoma
Roxithromycin is an inhibitor of human coronary artery smooth muscle cells proliferation: a potential ability to prevent coronary heart disease.
Retinoblastoma
S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation.
Retinoblastoma
Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials.
Retinoblastoma
Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Retinoblastoma
Selective inhibition of HTLV-1-infected cell proliferation by a novel tetramethylnaphthalene derivative.
Retinoblastoma
Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Retinoblastoma
Serine/arginine-rich splicing factor 7 regulates p21-dependent growth arrest in colon cancer cells.
Retinoblastoma
SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27.
Retinoblastoma
Signalling In The Epidermis: The E2f Cell Cycle Regulatory Pathway In Epidermal Morphogenesis, Regeneration And Transformation.
Retinoblastoma
Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q.
Retinoblastoma
Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol 3-kinase. Involvement of RhoA and cyclin E x cyclin-dependent kinase 2 complexes.
Retinoblastoma
Specificity of the polycation-stimulated (type-2A) and ATP,Mg-dependent (type-1) protein phosphatases toward substrates phosphorylated by P34cdc2 kinase.
Retinoblastoma
Stable SREBP-1a knockdown decreases the cell proliferation rate in human preadipocyte cells without inducing senescence.
Retinoblastoma
Stem-cell factor regulates the expression of cyclin A and retinoblastoma gene product in the growth and differentiation pathway of human megakaryocytic cells.
Retinoblastoma
Steroid- and retinoid-mediated growth arrest and apoptosis in WEHI-231 cells: role of NF-kappaB, c-Myc and CKI p27(Kip1).
Retinoblastoma
Structures of inactive retinoblastoma protein reveal multiple mechanisms for cell cycle control.
Retinoblastoma
Study of a novel brain relatively specific gene LRRC4 involved in glioma tumorigenesis suppression using the Tet-on system.
Retinoblastoma
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Retinoblastoma
Suppression of Src/ERK and GSK-3/?-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells.
Retinoblastoma
Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1.
Retinoblastoma
T-cell apoptosis induced by granulocyte colony-stimulating factor is associated with retinoblastoma protein phosphorylation and reduced expression of cyclin-dependent kinase inhibitors.
Retinoblastoma
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Retinoblastoma
TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression.
Retinoblastoma
Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer.
Retinoblastoma
The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.
Retinoblastoma
The antiproliferative effect of beta-carotene requires p21waf1/cip1 in normal human fibroblasts.
Retinoblastoma
The Biflavonoid Amentoflavone Induces Apoptosis via Suppressing E7 Expression, Cell Cycle Arrest at Sub-G(1) Phase, and Mitochondria-Emanated Intrinsic Pathways in Human Cervical Cancer Cells.
Retinoblastoma
The biochemical basis of CDK phosphorylation-independent regulation of E2F1 by the retinoblastoma protein.
Retinoblastoma
The CDC2-related kinase PITALRE is the catalytic subunit of active multimeric protein complexes.
Retinoblastoma
The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.
Retinoblastoma
The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
Retinoblastoma
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Retinoblastoma
The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Retinoblastoma
The cyclin-dependent kinase inhibitory domain of the yeast Sic1 protein is contained within the C-terminal 70 amino acids.
Retinoblastoma
The cyclopentenone 15-deoxy-delta(12,14)-prostaglandin J2 inhibits G1/S transition and retinoblastoma protein phosphorylation in immortalized lymphocytes from Alzheimer's disease patients.
Retinoblastoma
The E2FC-DPB Transcription Factor Controls Cell Division, Endoreplication and Lateral Root Formation in a SCF-Dependent Manner.
Retinoblastoma
The effect of miR-340 over-expression on cell-cycle-related genes in triple-negative breast cancer cells.
Retinoblastoma
The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer.
Retinoblastoma
The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors.
Retinoblastoma
The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity.
Retinoblastoma
The human melanocyte: a model system to study the complexity of cellular aging and transformation in non-fibroblastic cells.
Retinoblastoma
The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer.
Retinoblastoma
The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
Retinoblastoma
The interplay between p16 serine phosphorylation and arginine methylation determines its function in modulating cellular apoptosis and senescence.
Retinoblastoma
The kinase inhibitor staurosporine induces G1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells.
Retinoblastoma
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Retinoblastoma
The multifaceted role of cell cycle regulators in the coordination of growth and metabolism.
Retinoblastoma
The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
Retinoblastoma
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Retinoblastoma
The role of activin type I receptors in activin A-induced growth arrest and apoptosis in mouse B-cell hybridoma cells.
Retinoblastoma
The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.
Retinoblastoma
The soybean-derived peptide lunasin inhibits non-small cell lung cancer cell proliferation by suppressing phosphorylation of the retinoblastoma protein.
Retinoblastoma
The structure of CDK4/cyclin D3 has implications for models of CDK activation.
Retinoblastoma
The tumor suppressor gene p53 can mediate transforming growth [corrected] factor beta1-induced differentiation of leukemic cells independently of activation of the retinoblastoma protein.
Retinoblastoma
The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B.
Retinoblastoma
Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.
Retinoblastoma
Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.
Retinoblastoma
Thyrotropin and serum regulate thyroid cell proliferation through differential effects on p27 expression and localization.
Retinoblastoma
TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein.
Retinoblastoma
Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Retinoblastoma
TRANSCRIPTIONAL DOWNREGULATION OF p27KIP1 THROUGH REGULATION OF E2F FUNCTION DURING LMP1-MEDIATED TRANSFORMATION.
Retinoblastoma
Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb.
Retinoblastoma
Transformation by v-Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors.
Retinoblastoma
Transforming growth factor beta 1 (TGF beta 1) reduces cellular levels of p34cdc2, and this effect is abrogated by adenovirus independently of the E1A-associated pRB binding activity.
Retinoblastoma
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Retinoblastoma
Transforming Growth Factor-? Regulates the Growth of Valve Interstitial Cells in Vitro.
Retinoblastoma
Transforming growth factor-beta antagonizes alveolar type II cell proliferation induced by keratinocyte growth factor.
Retinoblastoma
Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium.
Retinoblastoma
Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Retinoblastoma
Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1.
Retinoblastoma
Type V collagen is an epithelial cell cycle inhibitor that is induced by and mimics the effects of transforming growth factor beta1.
Retinoblastoma
Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest.
Retinoblastoma
UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction.
Retinoblastoma
Unliganded thyroid hormone receptor beta1 inhibits proliferation of murine fibroblasts by delaying the onset of the G1 cell-cycle signals.
Retinoblastoma
Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate.
Retinoblastoma
V3 loop of human immunodeficiency virus type 1 reduces cyclin E expression and induces G1 arrest in interleukin 2-dependent T cells.
Retinoblastoma
Vanadyl bisacetylacetonate induced G1/S cell cycle arrest via high-intensity ERK phosphorylation in HepG2 cells.
Retinoblastoma
Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm.
Retinoblastoma
Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules.
Retinoblastoma
WD repeat and SOCS box containing protein 2 in the proliferation, cycle progression, and migration of melanoma cells.
Retinoblastoma
Widdrol induces cell cycle arrest, associated with MCM down-regulation, in human colon adenocarcinoma cells.
Retinoblastoma
Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
Retinoblastoma
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]
Rett Syndrome
14q12 microdeletions excluding FOXG1 give rise to a congenital variant Rett syndrome-like phenotype.
Rett Syndrome
A missense mutation within the fork-head domain of the forkhead box G1 Gene (FOXG1) affects its nuclear localization.
Rett Syndrome
A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders.
Rett Syndrome
A novel CDKL5 mutation in a 47,XXY boy with the early-onset seizure variant of Rett syndrome.
Rett Syndrome
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
Rett Syndrome
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
Rett Syndrome
Alteration of serum lipid profile, SRB1 loss, and impaired Nrf2 activation in CDKL5 disorder.
Rett Syndrome
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
Rett Syndrome
An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain.
Rett Syndrome
Analysis of FOXG1 Is Highly Recommended in Male and Female Patients with Rett Syndrome.
Rett Syndrome
Analysis of Hungarian patients with Rett syndrome phenotype for MECP2, CDKL5 and FOXG1 gene mutations.
Rett Syndrome
CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary Function.
Rett Syndrome
CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome.
Rett Syndrome
CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons.
Rett Syndrome
CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.
Rett Syndrome
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
Rett Syndrome
CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery.
Rett Syndrome
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
Rett Syndrome
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
Rett Syndrome
CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling.
Rett Syndrome
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Rett Syndrome
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Rett Syndrome
Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.
Rett Syndrome
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Rett Syndrome
Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
Rett Syndrome
Cyclin-dependent kinase-like 5 binds and phosphorylates DNA methyltransferase 1.
Rett Syndrome
Cytokine Dysregulation in MECP2- and CDKL5-Related Rett Syndrome: Relationships with Aberrant Redox Homeostasis, Inflammation, and ?-3 PUFAs.
Rett Syndrome
Dendritic Spine Instability in a Mouse Model of CDKL5 Disorder Is Rescued by Insulin-like Growth Factor 1.
Rett Syndrome
Early onset seizures and Rett-like features associated with mutations in CDKL5.
Rett Syndrome
Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.
Rett Syndrome
Enrichment of mutations in chromatin regulators in people with Rett syndrome lacking mutations in MECP2.
Rett Syndrome
Epigenetic mechanisms of gene expression regulation in neurological diseases.
Rett Syndrome
Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in single generation families.
Rett Syndrome
Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.
Rett Syndrome
Epileptic encephalopathy and atypical Rett syndrome with mutations in CDKL5: clinical and molecular characterization of two Brazilian patients.
Rett Syndrome
Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 gene.
Rett Syndrome
Evoked Potentials and EEG Analysis in Rett Syndrome and Related Developmental Encephalopathies: Towards a Biomarker for Translational Research.
Rett Syndrome
Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.
Rett Syndrome
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
Rett Syndrome
Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.
Rett Syndrome
GluD1 is a common altered player in neuronal differentiation from both MECP2-mutated and CDKL5-mutated iPS cells.
Rett Syndrome
HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder.
Rett Syndrome
Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder.
Rett Syndrome
Imbalance of excitatory/inhibitory synaptic protein expression in iPSC-derived neurons from FOXG1(+/-) patients and in foxg1(+/-) mice.
Rett Syndrome
Immune dysfunction in Rett syndrome patients revealed by high levels of serum anti-N(Glc) IgM antibody fraction.
Rett Syndrome
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
Rett Syndrome
In Silico Study of Rett Syndrome Treatment-Related Genes, MECP2, CDKL5, and FOXG1, by Evolutionary Classification and Disordered Region Assessment.
Rett Syndrome
Inactivation of the CDKL3 gene at 5q31.1 by a balanced t(X;5) translocation associated with nonspecific mild mental retardation.
Rett Syndrome
Inflammatory protein response in CDKL5-Rett syndrome: evidence of a subclinical smouldering inflammation.
Rett Syndrome
Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario.
Rett Syndrome
Lack of Cdkl5 Disrupts the Organization of Excitatory and Inhibitory Synapses and Parvalbumin Interneurons in the Primary Visual Cortex.
Rett Syndrome
Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice.
Rett Syndrome
Maternal origin of a novel C-terminal truncation mutation in CDKL5 causing a severe atypical form of Rett syndrome.
Rett Syndrome
MECP2 and CDKL5 gene mutation analysis in Chinese patients with Rett syndrome.
Rett Syndrome
Mutation analysis of the HDAC 1, 2, 8 and CDKL5 genes in Rett syndrome patients without mutations in MECP2.
Rett Syndrome
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Rett Syndrome
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.
Rett Syndrome
Neurobehavioral phenotype in cyclin-dependent kinase-like 5 syndrome: Case report and review of literature.
Rett Syndrome
Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy.
Rett Syndrome
Novel Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) Gene in Indian Cases of Rett Syndrome.
Rett Syndrome
Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes.
Rett Syndrome
Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development.
Rett Syndrome
Phenotypes in adult patients with Rett syndrome: results of a 13-year experience and insights into healthcare transition.
Rett Syndrome
Phenotypic manifestations between male and female children with CDKL5 mutations.
Rett Syndrome
Potentially Treatable Disorder Diagnosed Post Mortem by Exome Analysis in a Boy with Respiratory Distress.
Rett Syndrome
Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.
Rett Syndrome
Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene.
Rett Syndrome
Seizures and electroencephalographic findings in CDKL5 mutations: case report and review.
Rett Syndrome
Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).
Rett Syndrome
Synaptic Synthesis, Dephosphorylation, and Degradation: A NOVEL PARADIGM FOR AN ACTIVITY-DEPENDENT NEURONAL CONTROL OF CDKL5.
Rett Syndrome
The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.
Rett Syndrome
Transcription Factor 4 and Myocyte Enhancer Factor 2C mutations are not common causes of Rett syndrome.
Rett Syndrome
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Rett Syndrome
Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 cases.
Rett Syndrome
Variation in novel exons (RACEfrags) of the MECP2 gene in Rett syndrome patients and controls.
Rett Syndrome
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
Rett Syndrome
[Methyl-CpG-binding protein 2 gene and CDKL5 gene mutation in patients with Rett syndrome: analysis of 177 Chinese pediatric patients]
Rhabdoid Tumor
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Rhabdoid Tumor
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Rhabdomyosarcoma
Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma.
Rhabdomyosarcoma
Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD.
Rhabdomyosarcoma
Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma.
Rhabdomyosarcoma
FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor.
Rhabdomyosarcoma
Immunohistochemical expression of cyclin-dependent kinase inhibitors p16 and p57 in rhabdomyosarcoma.
Rhabdomyosarcoma
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2.
Rhabdomyosarcoma
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
Rhabdomyosarcoma
Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells.
Rhabdomyosarcoma, Alveolar
Cyclin-Dependent Kinase 4 Phosphorylates and Positively Regulates PAX3-FOXO1 in Human Alveolar Rhabdomyosarcoma Cells.
Rhabdomyosarcoma, Alveolar
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rhabdomyosarcoma, Embryonal
Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma.
Rheumatic Diseases
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
Salivary Gland Neoplasms
Expression of cyclin-dependent kinase inhibitor 2A 16, tumour protein 53 and epidermal growth factor receptor in salivary gland carcinomas is not associated with oncogenic virus infection.
Salivary Gland Neoplasms
Transcriptional activation of cyclin-dependent kinase inhibitor, p21waf1 gene by treatment with a differentiation inducing agent, vesnarinone in a human salivary gland cancer cell line.
Sarcoma
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Sarcoma
Association between methylation of DNA damage response-related genes and DNA damage in hepatocytes of rats following subchronic exposure to vinyl chloride.
Sarcoma
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.
Sarcoma
DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.
Sarcoma
G1 phase-specific suppression of the Cdk2 activity by ginsenoside Rh2 in cultured murine cells.
Sarcoma
Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.
Sarcoma
Generation of knockout mouse models of cyclin-dependent kinase inhibitors by engineered nuclease-mediated genome editing.
Sarcoma
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Sarcoma
Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma.
Sarcoma
Identification of dysregulated pathways associated with pancreatic cancer by survival analysis.
Sarcoma
Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
Sarcoma
Novel mutation of the cyclin-dependent kinase 4 gene in a Chinese patient with intimal sarcoma of the pulmonary artery.
Sarcoma
Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells.
Sarcoma
Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Sarcoma
Supernumerary ring chromosomes derived from the long arm of chromosome 12 as the primary cytogenetic anomaly in a rare soft tissue chondroma.
Sarcoma
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
Sarcoma
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and phase I clinical trial.
Sarcoma
The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Sarcoma
The prognosis in spindle-cell sarcoma depends on the expression of cyclin-dependent kinase inhibitor p27(Kip1) and cyclin E.
Sarcoma
Use of 5'-?-Ferrocenyl Adenosine Triphosphate (Fc-ATP) Bioconjugates Having Poly(ethylene glycol) Spacers in Kinase-Catalyzed Phosphorylations.
Sarcoma
Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
Sarcoma
Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.
Sarcoma
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Sarcoma, Avian
Cytosolic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus.
Sarcoma, Avian
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Sarcoma, Ewing
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Sarcoma, Ewing
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Sarcoma, Ewing
Let-7a Functions as a Tumor Suppressor in Ewing's Sarcoma Cell Lines Partly by Targeting Cyclin-Dependent Kinase 6.
Sarcoma, Ewing
Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein.
Sarcoma, Kaposi
Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex.
Sarcoma, Kaposi
Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6.
Sarcoma, Kaposi
KSHV vCyclin counters the senescence/G1 arrest response triggered by NF-?B hyperactivation.
Sarcoma, Kaposi
The Regulatory Effects of CDKN1A on Relevant Genes in Kaposi's Sarcoma Cells.
Sarcoma, Synovial
Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Sarcoma, Synovial
Low expression of p27(Kip1), a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma.
Sarcopenia
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
Scleroderma, Systemic
The non-neuronal cyclin-dependent kinase 5 is a fibrotic mediator potentially implicated in systemic sclerosis and a novel therapeutic target.
Scoliosis
Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.
Seizures
14q12 microdeletions excluding FOXG1 give rise to a congenital variant Rett syndrome-like phenotype.
Seizures
A case of CDKL5 disorder: improved ADL by simple treatment strategy for intractable epileptic seizures.
Seizures
A distinctive seizure type in patients with CDKL5 mutations: Hypermotor-tonic-spasms sequence.
Seizures
A girl with early-onset epileptic encephalopathy associated with microdeletion involving CDKL5.
Seizures
A maternally inherited frameshift CDKL5 variant in a male with global developmental delay and late-onset generalized epilepsy.
Seizures
A novel CDKL5 mutation in a 47,XXY boy with the early-onset seizure variant of Rett syndrome.
Seizures
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
Seizures
A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain.
Seizures
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
Seizures
Altered network and rescue of human neurons derived from individuals with early-onset genetic epilepsy.
Seizures
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
Seizures
AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
Seizures
An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain.
Seizures
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
Seizures
CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.
Seizures
CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome.
Seizures
CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility.
Seizures
CDKL5 deficiency augments inhibitory input into the dentate gyrus that can be reversed by deep brain stimulation.
Seizures
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
Seizures
CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.
Seizures
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
Seizures
CDKL5 Gene-Related Epileptic Encephalopathy in Estonia: Four Cases, One Novel Mutation Causing Severe Phenotype in a Boy, and Overview of the Literature.
Seizures
CDKL5 localizes at the centrosome and midbody and is required for faithful cell division.
Seizures
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
Seizures
CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
Seizures
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
Seizures
CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.
Seizures
Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
Seizures
Clinical and electroencephalographic features in patients with CDKL5 mutations: two new Italian cases and review of the literature.
Seizures
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Seizures
Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.
Seizures
Content Validation of Clinician-Reported Items for a Severity Measure for CDKL5 Deficiency Disorder.
Seizures
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Seizures
Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Seizures
Early-onset seizure variant of Rett syndrome: Definition of the clinical diagnostic criteria.
Seizures
Early-onset seizures due to mosaic exonic deletions of CDKL5 in a male and two females.
Seizures
Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.
Seizures
Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 gene.
Seizures
Exploring genotype-phenotype relationships in the CDKL5 deficiency disorder using an international dataset.
Seizures
Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
Seizures
Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.
Seizures
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
Seizures
Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.
Seizures
Gene mutation analysis of 175 Chinese patients with early-onset epileptic encephalopathy.
Seizures
Genetic interactions among cortical malformation genes that influence susceptibility to convulsions in C. elegans.
Seizures
Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience.
Seizures
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.
Seizures
Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features.
Seizures
Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: role of [Delta]FosB.
Seizures
Inhibition of GSK3? rescues hippocampal development and learning in a mouse model of CDKL5 disorder.
Seizures
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3? signaling.
Seizures
Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.
Seizures
Molecular and genetic insights into an infantile epileptic encephalopathy - CDKL5 disorder.
Seizures
Mutation in an alternative transcript of CDKL5 in a boy with early onset seizures.
Seizures
Mutation screening of the CDKL5 gene in cryptogenic infantile intractable epilepsy and review of clinical sensitivity.
Seizures
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Seizures
Neurobehavioral phenotype in cyclin-dependent kinase-like 5 syndrome: Case report and review of literature.
Seizures
Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy.
Seizures
Novel Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) Gene in Indian Cases of Rett Syndrome.
Seizures
Potentially Treatable Disorder Diagnosed Post Mortem by Exome Analysis in a Boy with Respiratory Distress.
Seizures
Pregnenolone and pregnenolone-methyl-ether rescue neuronal defects caused by dysfunctional CLIP170 in a neuronal model of CDKL5 Deficiency Disorder.
Seizures
Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.
Seizures
Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene.
Seizures
Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy.
Seizures
Rett-like phenotypes: expanding the genetic heterogeneity to the KCNA2 gene and first familial case of CDKL5-related disease.
Seizures
Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder.
Seizures
Seizures and electroencephalographic findings in CDKL5 mutations: case report and review.
Seizures
Site-specific abnormalities in the visual system of a mouse model of CDKL5 deficiency disorder.
Seizures
Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy.
Seizures
Structural Bases of Atypical Whisker Responses in a Mouse Model of CDKL5 Deficiency Disorder.
Seizures
The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.
Seizures
The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.
Seizures
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
Seizures
The perceived effects of cannabis products in the management of seizures in CDKL5 Deficiency Disorder.
Seizures
Treatment with a GSK-3?/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder.
Seizures
Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice.
Seizures
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Seizures
Validation of high-resolution DNA melting analysis for mutation scanning of the CDKL5 gene: identification of novel mutations.
Seizures
Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 cases.
Seizures
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Seizures
X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
Seizures
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
Seminoma
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Seminoma
Identification of nuclear structural protein alterations associated with seminomas.
Sepsis
Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis.
Sepsis
Impact of clean delivery-kit use on newborn umbilical cord and maternal puerperal infections in Egypt.
Sertoli Cell-Only Syndrome
microRNAs in the pathogenesis of non-obstructive azoospermia: the underlying mechanisms and therapeutic potentials.
Skin Diseases
Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer.
Skin Neoplasms
Growth arrest of immortalized human keratinocytes and suppression of telomerase activity by p21WAF1 gene expression.
Skin Neoplasms
Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer.
Skin Neoplasms
Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation.
Skin Neoplasms
Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
Sleep Wake Disorders
Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene.
Small Cell Lung Carcinoma
An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Small Cell Lung Carcinoma
Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
Small Cell Lung Carcinoma
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Small Cell Lung Carcinoma
Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action.
Small Cell Lung Carcinoma
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
Small Cell Lung Carcinoma
Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer.
Small Cell Lung Carcinoma
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Smooth Muscle Tumor
Atypical uterine leiomyoma: a case report and review of the literature.
Smooth Muscle Tumor
CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue.
Smooth Muscle Tumor
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Spasm
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Spasms, Infantile
A 1.1 million base pair X-chromosomal deletion covering the PDHA1 and CDKL5 genes in a female patient with west syndrome and pyruvate oxidation deficiency.
Spasms, Infantile
A novel C-terminal truncated mutation in hCDKL5 protein causing a severe West syndrome: Comparison with previous truncated mutations and genotype/phenotype correlation.
Spasms, Infantile
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
Spasms, Infantile
A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain.
Spasms, Infantile
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
Spasms, Infantile
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
Spasms, Infantile
An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain.
Spasms, Infantile
CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.
Spasms, Infantile
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
Spasms, Infantile
CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery.
Spasms, Infantile
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
Spasms, Infantile
CDKL5 truncation due to a t(X;2)(p22.1;p25.3) in a girl with X-linked infantile spasm syndrome.
Spasms, Infantile
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
Spasms, Infantile
CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling.
Spasms, Infantile
CDKL5-Related Disorders: From Clinical Description to Molecular Genetics.
Spasms, Infantile
CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.
Spasms, Infantile
Cell cloning-based transcriptome analysis in cyclin-dependent kinase-like 5 mutation patients with severe epileptic encephalopathy.
Spasms, Infantile
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Spasms, Infantile
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Spasms, Infantile
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
Spasms, Infantile
Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.
Spasms, Infantile
Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience.
Spasms, Infantile
High prevalence of genetic alterations in early-onset epileptic encephalopathies associated with infantile movement disorders.
Spasms, Infantile
Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder.
Spasms, Infantile
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
Spasms, Infantile
Inactivation of the CDKL3 gene at 5q31.1 by a balanced t(X;5) translocation associated with nonspecific mild mental retardation.
Spasms, Infantile
Maternal origin of a novel C-terminal truncation mutation in CDKL5 causing a severe atypical form of Rett syndrome.
Spasms, Infantile
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Spasms, Infantile
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.
Spasms, Infantile
Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.
Spasms, Infantile
Novel Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) Gene in Indian Cases of Rett Syndrome.
Spasms, Infantile
Novel mutations in the CDKL5 gene in complex genotypes associated with West syndrome with variable phenotype: First description of somatic mosaic state.
Spasms, Infantile
Phenotypic manifestations between male and female children with CDKL5 mutations.
Spasms, Infantile
Seizures and electroencephalographic findings in CDKL5 mutations: case report and review.
Spasms, Infantile
Validation of high-resolution DNA melting analysis for mutation scanning of the CDKL5 gene: identification of novel mutations.
Spasms, Infantile
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
Spinal Cord Injuries
An algorithmic strategy of surgical intervention for cervical degenerative kyphosis.
Spinal Cord Injuries
Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats.
Spinal Cord Injuries
Increased expression of CDK11(p58 )and cyclin D3 following spinal cord injury in rats.
Spinal Cord Injuries
The PI3K/Akt/FOXO3a pathway regulates regeneration following spinal cord injury in adult rats through TNF-? and p27kip1 expression.
Spondylitis, Ankylosing
Hsa_circ_0056558 regulates cyclin-dependent kinase 6 by sponging microRNA-1290 to suppress the proliferation and differentiation in ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Squamous Cell Carcinoma of Head and Neck
CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line.
Squamous Cell Carcinoma of Head and Neck
Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Diagnostic value of cyclin-dependent kinase/cyclin-dependent kinase inhibitor expression ratios as biomarkers of locoregional and hematogenous dissemination risks in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity.
Squamous Cell Carcinoma of Head and Neck
Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy.
Squamous Cell Carcinoma of Head and Neck
Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Expression of Skp2 and p27(kip1) proteins in hypopharyngeal squamous cell carcinoma and its clinical significance.
Squamous Cell Carcinoma of Head and Neck
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Squamous Cell Carcinoma of Head and Neck
Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo.
Squamous Cell Carcinoma of Head and Neck
Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.
Squamous Cell Carcinoma of Head and Neck
High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors.
Squamous Cell Carcinoma of Head and Neck
Hypermethylation of Promoter Region of LATS1 - a CDK Interacting Protein in Oral Squamous Cell Carcinomas - a Pilot Study in India.
Squamous Cell Carcinoma of Head and Neck
Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx.
Squamous Cell Carcinoma of Head and Neck
Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas.
Squamous Cell Carcinoma of Head and Neck
Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/?-catenin signaling pathway.
Squamous Cell Carcinoma of Head and Neck
Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
miR-204 enhances p27 mRNA stability by targeting Brd4 in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway.
Squamous Cell Carcinoma of Head and Neck
Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy.
Squamous Cell Carcinoma of Head and Neck
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Squamous Cell Carcinoma of Head and Neck
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Squamous Cell Carcinoma of Head and Neck
The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
Squamous Cell Carcinoma of Head and Neck
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The clinical significance of CDK1 expression in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
Squamous Cell Carcinoma of Head and Neck
The localization of p34cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity.
Squamous Cell Carcinoma of Head and Neck
The Opioid Growth Factor (OGF) OGF Receptor Axis Uses the p16 Pathway to Inhibit Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
Transfection of p27(Kip1) threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells.
Starvation
A role for cell cycle proteins in the serum-starvation resistance of Epstein-Barr virus immortalized B lymphocytes.
Starvation
Autophosphorylation-induced degradation of the Pho85 cyclin Pcl5 is essential for response to amino acid limitation.
Starvation
CDK-dependent Hsp70 Phosphorylation controls G1 cyclin abundance and cell-cycle progression.
Starvation
Chemical inhibition of the Pho85 cyclin-dependent kinase reveals a role in the environmental stress response.
Starvation
Common regulation of growth arrest and differentiation of osteoblasts by helix-loop-helix factors.
Starvation
DAF-16/FOXO regulates transcription of cki-1/Cip/Kip and repression of lin-4 during C. elegans L1 arrest.
Starvation
Different domains of the essential GTPase Cdc42p required for growth and development of Saccharomyces cerevisiae.
Starvation
Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control.
Starvation
Functional characterization of the Cdc42p binding domain of yeast Ste20p protein kinase.
Starvation
Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse.
Starvation
Interaction of yeast Rvs167 and Pho85 cyclin-dependent kinase complexes may link the cell cycle to the actin cytoskeleton.
Starvation
Mcm1p binding sites in ARG1 positively regulate Gcn4p binding and SWI/SNF recruitment.
Starvation
Mcm1p binding sites in the ARG1 promoter positively regulate ARG1 transcription and S. cerevisiae growth in the absence of arginine and Gcn4p.
Starvation
Nutrient-regulated antisense and intragenic RNAs modulate a signal transduction pathway in yeast.
Starvation
Oct1 is required for mTOR-induced G1 cell cycle arrest via the control of p27(Kip1) expression.
Starvation
Polyglutamine repeats of spinocerebellar ataxia 6 impair the cell-death-preventing effect of CaV2.1 Ca2+ channel--loss-of-function cellular model of SCA6.
Starvation
Pop2 phosphorylation at S39 contributes to the glucose repression of stress response genes, HSP12 and HSP26.
Starvation
Quantitative proteomics identifies unanticipated regulators of nitrogen- and glucose starvation.
Starvation
Requirement of PP2A-B56Par1 for the Stabilization of the CDK Inhibitor Rum1 and Activation of APC/CSte9 during Pre-Start G1 in S. pombe.
Starvation
Sensitization of Melanoma Cells for Death Ligand TRAIL Is Based on Cell Cycle Arrest, ROS Production, and Activation of Proapoptotic Bcl-2 Proteins.
Starvation
Sphingolipids and Inositol Phosphates Regulate the Tau Protein Phosphorylation Status in Humanized Yeast.
Starvation
The geranyl acetophenone tHGA attenuates human bronchial smooth muscle proliferation via inhibition of AKT phosphorylation.
Starvation
[Function of an inhibitor of cyclin-dependent kinase p27/Kip in cells transformed by E1A + E1B19 kDa + E1A + cHa-Ras, differing in their ability to realize a G1-block during serum starvation]
Stomach Neoplasms
Analysis of Cyclin-Dependent Kinase 1 as an Independent Prognostic Factor for Gastric Cancer Based on Statistical Methods.
Stomach Neoplasms
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
Stomach Neoplasms
CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells.
Stomach Neoplasms
CDK5RAP3 Inhibits the Translocation of MCM6 to Influence the Prognosis in Gastric Cancer.
Stomach Neoplasms
Clinicopathological and biological significance of CDC28 protein kinase regulatory subunit 2 overexpression in human gastric cancer.
Stomach Neoplasms
Constitutive activation of glycogen synthase kinase-3beta correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer.
Stomach Neoplasms
Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis.
Stomach Neoplasms
Cyclin-Dependent Kinase 1 (CDK1) is Co-Expressed with CDCA5: Their Functions in Gastric Cancer Cell Line MGC-803.
Stomach Neoplasms
Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis.
Stomach Neoplasms
Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo.
Stomach Neoplasms
Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Stomach Neoplasms
Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis.
Stomach Neoplasms
Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer.
Stomach Neoplasms
Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis.
Stomach Neoplasms
E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIs.
Stomach Neoplasms
Expression of CRM1 and CDK5 shows high prognostic accuracy for gastric cancer.
Stomach Neoplasms
Expression of NUAK2 in gastric cancer tissue and its effects on the proliferation of gastric cancer cells.
Stomach Neoplasms
Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer.
Stomach Neoplasms
Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression.
Stomach Neoplasms
Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer.
Stomach Neoplasms
Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis.
Stomach Neoplasms
Genetic and epigenetic alterations in multistep carcinogenesis of the stomach.
Stomach Neoplasms
Growth inhibition of cultured human gastric cancer cells by 9-cis-retinoic acid with induction of cdk inhibitor Waf1/Cip1/Sdi1/p21 protein.
Stomach Neoplasms
Intracellular chloride regulates cell proliferation through the activation of stress-activated protein kinases in MKN28 human gastric cancer cells.
Stomach Neoplasms
Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Stomach Neoplasms
Knockdown of long noncoding RNA GHET1 inhibits cell?cycle progression and invasion of gastric cancer cells.
Stomach Neoplasms
Liquiritin induces apoptosis and autophagy in cisplatin (DDP)-resistant gastric cancer cells in vitro and xenograft nude mice in vivo.
Stomach Neoplasms
Loss of cyclin-dependent kinase-like 2 predicts poor prognosis in gastric cancer, and its overexpression suppresses cells growth and invasion.
Stomach Neoplasms
Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma.
Stomach Neoplasms
Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
Stomach Neoplasms
Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells.
Stomach Neoplasms
miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells.
Stomach Neoplasms
Oleanolic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells.
Stomach Neoplasms
Overexpressed CISD2 has prognostic value in human gastric cancer and promotes gastric cancer cell proliferation and tumorigenesis via AKT signaling pathway.
Stomach Neoplasms
p27kip1 expression is inversely related to the grade of gastric MALT lymphoma.
Stomach Neoplasms
Palbociclib induces cell senescence and apoptosis of gastric cancer cells by inhibiting the Notch pathway.
Stomach Neoplasms
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
Stomach Neoplasms
Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.
Stomach Neoplasms
Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers.
Stomach Neoplasms
Prognostic value of the cyclin-dependent kinase inhibitor p27Kip1 in gastric cancer.
Stomach Neoplasms
RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells.
Stomach Neoplasms
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Stomach Neoplasms
The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Stomach Neoplasms
The novel protective role of P27 in MLN4924-treated gastric cancer cells.
Stomach Neoplasms
The prognostic value of Cyclin-Dependent Kinase 5 and Protein Phosphatase 2A in Gastric Cancer.
Stomach Neoplasms
The Role and Clinical Implications of the Retinoblastoma (RB)-E2F Pathway in Gastric Cancer.
Stomach Neoplasms
Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.
Stomach Neoplasms
Upregulation of cyclin-dependent kinase 7 and matrix metalloproteinase-14 expression contribute to metastatic properties of gastric cancer.
Stomach Neoplasms
Upregulation of miR-370 contributes to the progression of gastric carcinoma via suppression of FOXO1.
Stomach Neoplasms
[Correlation between cyclin-dependent kinase inhibitor p27kip1 and trastuzumab-resistance in gastric cancer].
Stomach Ulcer
Role of basic fibroblast growth factor in the suppression of apoptotic caspase-3 during chronic gastric ulcer healing.
Stomatitis
Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Stomatitis
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
Stroke
Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.
Stroke
Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo.
Stroke
Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
Stroke
N-Methyl-D-Aspartate Receptor Signaling-Protein Kinases Crosstalk in Cerebral Ischemia.
Superinfection
Adeno-associated virus type 2 increases proteosome-dependent degradation of p21WAF1 in a human papillomavirus type 31b-positive cervical carcinoma line.
Tauopathies
Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice.
Tauopathies
Cell-Cycle Markers in a Transgenic Mouse Model of Human Tauopathy: Increased Levels of Cyclin-Dependent Kinase Inhibitors p21Cip1 and p27Kip1.
Tauopathies
Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach.
Tauopathies
Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.
Tauopathies
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Tauopathies
Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.
Tauopathies
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.
Tauopathies
RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation.
Tauopathies
Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation.
Tauopathies
Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity.
Telangiectasia, Hereditary Hemorrhagic
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
Domain within the helicase subunit Mcm4 integrates multiple kinase signals to control DNA replication initiation and fork progression.
Telangiectasis
Middle infrared radiation induces G2/M cell cycle arrest in A549 lung cancer cells.
Tendinopathy
Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells.
Teratocarcinoma
Correlation of ploidy and cyclin B1, P34cdc2 and PCNA expression in F9 teratocarcinoma cells.
Teratoma
Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study.
Teratoma
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Testicular Neoplasms
Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours.
Thrombosis
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
Thymoma
Analysis of salivary microRNA expression profiles and identification of novel biomarkers in esophageal cancer.
Thymoma
Cyclin-dependent kinase inhibitors, p16 and p27, demonstrate different expression patterns in thymoma and thymic carcinoma.
Thymoma
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Thymoma
Loss of p16(INK4A) Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas.
Thymoma
Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.
Thymoma
miR-144/451 Promote Cell Proliferation via Targeting PTEN/AKT Pathway in Insulinomas.
Thymoma
Transcriptome sequencing combined with bioinformatics predicts potential genes and pathways associated with bupivacaine-induced apoptosis.
Thymoma
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Thyroid Cancer, Papillary
Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications.
Thyroid Cancer, Papillary
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
Thyroid Cancer, Papillary
Cyclin-dependent kinase 7 is a potential therapeutic target in papillary thyroid carcinoma.
Thyroid Cancer, Papillary
Downregulation of cyclin-dependent kinase 8 by microRNA-148a suppresses proliferation and invasiveness of papillary thyroid carcinomas.
Thyroid Cancer, Papillary
Expression of p21(cip1), p27 (kip1), and p16 (INk4a) Cyclin-Dependent Kinase Inhibitors in Papillary Thyroid Carcinoma: Correlation with Clinicopathological Factors.
Thyroid Cancer, Papillary
Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis.
Thyroid Carcinoma, Anaplastic
BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1).
Thyroid Carcinoma, Anaplastic
Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.
Thyroid Carcinoma, Anaplastic
Effects of roniciclib in preclinical models of anaplastic thyroid cancer.
Thyroid Carcinoma, Anaplastic
Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Thyroid Neoplasms
A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Thyroid Neoplasms
A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
Thyroid Neoplasms
An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks.
Thyroid Neoplasms
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
Thyroid Neoplasms
Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.
Thyroid Neoplasms
Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
Thyroid Neoplasms
Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Thyroid Neoplasms
Interleukin-1alpha regulates G1 cell cycle progression and arrest in thyroid carcinoma cell lines NIM1 and NPA.
Thyroid Neoplasms
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma.
Thyroid Neoplasms
Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells.
Thyroid Neoplasms
Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer.
Thyroid Neoplasms
Prognostic Value of p27 in Follicular Thyroid Carcinoma and its Relation to Radioactive Iodine Response: Does it Aid in the Modification of Risk Stratification?
Thyroid Neoplasms
PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1.
Trichothiodystrophy Syndromes
ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and transcription activities.
Triple Negative Breast Neoplasms
A clinical evaluation of treatments that target cell cycle machinery in breast cancer.
Triple Negative Breast Neoplasms
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
Triple Negative Breast Neoplasms
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.
Triple Negative Breast Neoplasms
Cyclin-dependent kinase like 3 promotes triple-negative breast cancer progression via inhibiting the p53 signaling pathway.
Triple Negative Breast Neoplasms
G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells.
Triple Negative Breast Neoplasms
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Triple Negative Breast Neoplasms
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
Triple Negative Breast Neoplasms
No driver behind the wheel? Targeting transcription in cancer.
Triple Negative Breast Neoplasms
Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.
Triple Negative Breast Neoplasms
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Thioridazine hydrochloride: an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0/G1 arrest and apoptosis.
Trophoblastic Neoplasms
[The expressions of p16, CDK4 and PCNA proteins in trophoblastic tumors]
Trypanosomiasis
Identification and Functional Characterisation of CRK12:CYC9, a Novel Cyclin-Dependent Kinase (CDK)-Cyclin Complex in Trypanosoma brucei.
Tuberous Sclerosis
Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B.
Tuberous Sclerosis
Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.
Tuberous Sclerosis
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Tuberous Sclerosis
The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27.
Tuberous Sclerosis
Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.
Tumor Lysis Syndrome
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Tumor Lysis Syndrome
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Urinary Bladder Neck Obstruction
The physiological significance of p27(KIP1) expression in detrusor function.
Urinary Bladder Neoplasms
Analysis of the cyclin-dependent kinase inhibitor p27Kip1 in muscle invasive bladder cancer.
Urinary Bladder Neoplasms
CDK12 inactivation across solid tumors: an actionable genetic subtype.
Urinary Bladder Neoplasms
Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Urinary Bladder Neoplasms
Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells.
Urinary Bladder Neoplasms
Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma.
Urinary Bladder Neoplasms
Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53.
Urinary Bladder Neoplasms
Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?
Urinary Bladder Neoplasms
Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Urinary Bladder Neoplasms
Growth inhibition and cell cycle arrest effects of epigallocatechin gallate in the NBT-II bladder tumour cell line.
Urinary Bladder Neoplasms
High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
Urinary Bladder Neoplasms
Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B.
Urinary Bladder Neoplasms
Increased cyclin-dependent kinase 6 expression in bladder cancer.
Urinary Bladder Neoplasms
Isoliquiritigenin induces apoptosis of human bladder cancer T24 cells via a cyclin-dependent kinase-independent mechanism.
Urinary Bladder Neoplasms
Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
Urinary Bladder Neoplasms
MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6.
Urinary Bladder Neoplasms
MiR-124 retards bladder cancer growth by directly targeting CDK4.
Urinary Bladder Neoplasms
Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
Urinary Bladder Neoplasms
Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.
Urologic Diseases
Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer.
Urologic Diseases
Prognostic significance of p27(Kip 1) expression in renal cell carcinoma.
Uterine Cervical Neoplasms
2,4-bis (p-hydroxyphenyl)-2-butenal (HPB242) induces apoptosis via modulating E7 expression and inhibition of PI3K/Akt pathway in SiHa human cervical cancer cells.
Uterine Cervical Neoplasms
Absence of High-Risk Human Papillomavirus (HPV) Detection in Endocervical Adenocarcinoma with Gastric Morphology and Phenotype.
Uterine Cervical Neoplasms
Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway.
Uterine Cervical Neoplasms
Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS?032, on cervical cancer.
Uterine Cervical Neoplasms
CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
Uterine Cervical Neoplasms
CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia.
Uterine Cervical Neoplasms
CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer.
Uterine Cervical Neoplasms
Comparison of p16INK4A and Hybrid Capture 2 human papillomavirus testing as adjunctive tests in liquid-based gynecologic SurePath preparations.
Uterine Cervical Neoplasms
Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Uterine Cervical Neoplasms
Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells.
Uterine Cervical Neoplasms
Expression of Concern: MicroRNA-505-5p functions as a tumor suppressor by targeting Cyclin-Dependent Kinase 5 in cervical cancer.
Uterine Cervical Neoplasms
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis.
Uterine Cervical Neoplasms
Hsa_circ_0000520 overexpression increases CDK2 expression via miR-1296 to facilitate cervical cancer cell proliferation.
Uterine Cervical Neoplasms
KCl cotransport is an important modulator of human cervical cancer growth and invasion.
Uterine Cervical Neoplasms
Low P16INK4A Expression Associated with High Expression of Cancer Stem Cell Markers Predicts Poor Prognosis in Cervical Cancer after Radiotherapy.
Uterine Cervical Neoplasms
MicroRNA-150 suppresses p27Kip1 expression and promotes cell proliferation in HeLa human cervical cancer cells.
Uterine Cervical Neoplasms
MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis.
Uterine Cervical Neoplasms
MicroRNA-505-5p functions as a tumor suppressor by targeting cyclin-dependent kinase 5 in cervical cancer.
Uterine Cervical Neoplasms
MiR-495-3p and miR-143-3p co-target CDK1 to inhibit the development of cervical cancer.
Uterine Cervical Neoplasms
Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer.
Uterine Cervical Neoplasms
p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis.
Uterine Cervical Neoplasms
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia.
Uterine Cervical Neoplasms
PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Uterine Cervical Neoplasms
Retraction: MicroRNA-505-5p functions as a tumor suppressor by targeting Cyclin-Dependent Kinase 5 in cervical cancer.
Uterine Cervical Neoplasms
Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Uterine Cervical Neoplasms
Roscovitine-treated HeLa cells finalize autophagy later than apoptosis by downregulating Bcl?2.
Uterine Cervical Neoplasms
Silencing of circular RNA_0000326 inhibits cervical cancer cell proliferation, migration and invasion by boosting microRNA-338-3p-dependent down-regulation of CDK4.
Uterine Cervical Neoplasms
The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis.
Uterine Cervical Neoplasms
The Biflavonoid Amentoflavone Induces Apoptosis via Suppressing E7 Expression, Cell Cycle Arrest at Sub-G(1) Phase, and Mitochondria-Emanated Intrinsic Pathways in Human Cervical Cancer Cells.
Uterine Cervical Neoplasms
The histone demethylase RBP2 is over-expressed in gastric cancer and its inhibition triggers senescence of cancer cells.
Uterine Cervical Neoplasms
Ultrasensitive electrochemical immunosensor based on dual signal amplification process for p16(INK4a) cervical cancer detection in clinical samples.
Uterine Neoplasms
Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.
Vaccinia
Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses.
Vaccinia
The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase.
Vascular Calcification
The CDK 9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP.
Vascular Diseases
A meta-analysis on associations of CDKN2B-AS variants with atherosclerotic cardio-cerebral vascular diseases.
Vascular Diseases
Deletion of chromosome 9p21 noncoding cardiovascular risk interval in mice alters Smad2 signaling and promotes vascular aneurysm.
Vascular Diseases
Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
Vascular Diseases
p27kip1-838C>A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity.
Vascular Diseases
Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells.
Vascular Diseases
Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury.
Vascular System Injuries
Induction of apoptosis after stent implantation in canine portal vein.
Vascular System Injuries
Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.
Vascular System Injuries
Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Vascular System Injuries
The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury.
Venous Thromboembolism
Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
Venous Thromboembolism
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Ventilator-Induced Lung Injury
Cyclin-dependent kinase inhibition reduces lung damage in a mouse model of ventilator-induced lung injury.
Virus Diseases
Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics.
Virus Diseases
Direct Substrate Identification with an Analog Sensitive (AS) Viral Cyclin-Dependent Kinase (v-Cdk).
Virus Diseases
Expression of cyclin-dependent kinase inhibitor 2A 16, tumour protein 53 and epidermal growth factor receptor in salivary gland carcinomas is not associated with oncogenic virus infection.
Virus Diseases
Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis.
Virus Diseases
Regulation of memory CD8 T-cell differentiation by cyclin-dependent kinase inhibitor p27Kip1.
Virus Diseases
Roles of Arabidopsis cyclin-dependent kinase C complexes in cauliflower mosaic virus infection, plant growth, and development.
Virus Diseases
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.
Virus Diseases
Simian virus 40 activates ATR-Delta p53 signaling to override cell cycle and DNA replication control.
Virus Diseases
Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity.
Vision Disorders
CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
Vision Disorders
Cerebral visual impairment in CDKL5 deficiency disorder: vision as an outcome measure.
Vision Disorders
Searching for biomarkers of CDKL5 disorder: early-onset visual impairment in CDKL5 mutant mice.
Vision Disorders
Treatment with a GSK-3?/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder.
Vitiligo
Integrative Analysis of Omics Data Reveals Regulatory Network of CDK10 in Vitiligo Risk.
von Hippel-Lindau Disease
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Warts
Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts.
Warts
Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts.
Whooping Cough
Responses of pertussis toxin-treated microvascular endothelial cells to transforming growth factor beta 1. No evidence for pertussis-sensitive G-protein involvement in TGF-beta signal transduction.
Whooping Cough
The GTP-binding protein G(ialpha) translocates to kinetochores and regulates the M-G(1) cell cycle transition of Swiss 3T3 cells.
Wilms Tumor
1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat.
Wilms Tumor
Cell-cycle mechanisms involved in podocyte proliferation in cellular lesion of focal segmental glomerulosclerosis.
Wilms Tumor
Decreased expression of the INK4 family of cyclin-dependent kinase inhibitors in Wilms tumor.
Wilms Tumor
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Wilms Tumor
MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma.
Wilms Tumor
Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition.
Wilms Tumor
Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms' tumor.
Wiskott-Aldrich Syndrome
Close encounters of the third kind: disordered domains and the interactions of proteins.
Wiskott-Aldrich Syndrome
How signaling proteins integrate multiple inputs: a comparison of N-WASP and Cdk2.
Xeroderma Pigmentosum
Neural tube development requires the cooperation of p53- and Gadd45a-associated pathways.
Xeroderma Pigmentosum
Spironolactone-induced XPB degradation requires TFIIH integrity and ubiquitin-selective segregase VCP/p97.
Xeroderma Pigmentosum
TFIIH action in transcription initiation and promoter escape requires distinct regions of downstream promoter DNA.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00021
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(4-[[3-(1,3-oxazetidin-3-yl)propyl]sulfonyl]phenyl)pyrimidin-2-amine
Homo sapiens
with CDK4
0.00045
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
Homo sapiens
with isozyme CDK4
0.00053
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl]pyrimidin-2-amine
Homo sapiens
with CDK4
0.0056
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with isozyme CDK4
0.009
4-[[4-(1-cyclopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with CDK4, IC50 above 0.009 mM
0.0013
4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with CDK4
0.0002
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
Homo sapiens
with CDK4
0.0086
N-(2-methoxyethyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
Homo sapiens
with CDK4, IC50 above 0.0086 mM
0.00014
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
Homo sapiens
with CDK4
0.0015
N-[4-(benzylsulfonyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
Homo sapiens
with CDK4
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). CDK4_HUMAN
303
0
33730
Swiss-Prot
other Location (Reliability: 2)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
additional information
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Hanks, S.K.
Homology probing: identification of cDNA clones encoding members of the protein-serine kinase family
Proc. Natl. Acad. Sci. USA
84
388-392
1987
Homo sapiens (P11802)
brenda
Soufir, N.; Avril, M.F.; Chompret, A.; Demenais, F.; Bombled, J.; Spatz, A.; Stoppa-Lyonnet, D.; Benard, J.; Bressac-de Paillerets, B.
Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group
Hum. Mol. Genet.
7
209-216
1998
Homo sapiens (P11802)
brenda
Elkahloun, A.G.; Krizman, D.B.; Wang, Z.; Hofmann, T.A.; Roe, B.; Meltzer, P.S.
Transcript mapping in a 46-kb sequenced region at the core of 12q13.3 amplification in human cancers
Genomics
42
295-301
1997
Homo sapiens (P11802)
brenda
Zuo, L.; Weger, J.; Yang, Q.; Goldstein, A.M.; Tucker, M.A.; Walker, G.J.; Hayward, N.; Dracopoli, N.C.
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Nat. Genet.
12
97-99
1996
Homo sapiens (P11802)
brenda
Wolfel, T.; Hauer, M.; Schneider, J.; Serrano, M.; Wolfel, C.; Klehmann-Hieb, E.; De Plaen, E.; Hankeln, T.; Meyer zum Buschenfelde, K.H.; Beach, D.
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
Science
269
1281-1284
1995
Homo sapiens (P11802), Homo sapiens
brenda
Khatib, Z.A.; Matsushime, H.; Valentine, M.; Shapiro, D.N.; Sherr, C.J.; Look, A.T.
Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas
Cancer Res.
53
5535-5541
1993
Homo sapiens (P11802), Homo sapiens
brenda
Anderson, M.; Andrews, D.M.; Barker, A.J.; Brassington, C.A.; Breed, J.; Byth, K.F.; Culshaw, J.D.; Finlay, M.R.; Fisher, E.; McMiken, H.H.; Green, C.P.; Heaton, D.W.; Nash, I.A.; Newcombe, N.J.; Oakes, S.E.; Pauptit, R.A.; Roberts, A.; Stanway, J.J.; Thomas, A.P.; Tucker, J.A.; Walker, M.; Weir, H.M.
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors
Bioorg. Med. Chem. Lett.
18
5487-5492
2008
Homo sapiens (P11802), Homo sapiens (P24941)
brenda
EXTERNAL LINKS (specific for EC-Number 2.7.11.22)
Transporter Classification Database (TCDB): 1.I.1.1.3
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
